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ABSTRACTS

Proceedings of the American Radium
Society®’s 103rd Annual Meeting
ORAL ABSTRACTS
(OA01) Interleukin-15 Rescues Radiation Related Lymphopenia and Improves Tumor Control Outcomes in Pancreatic Cancer
Bhanu Prasad Venkatesulu, MD1, Cheng Cheng-En Hsieh, MD2,
Byung Kyu Kim, PhD2, Keith L. Sanders, BS2, Amrish Sharma, PhD2,
Pankaj Kumar Singh, PhD3, Sunil Krishnan, MD4; 1Loyola University
Chicago,2 MD Anderson Cancer Centre,3 Mayo Clinic, Jacksonville,
4
Mayo Clinic, Jacksonville
Background: There have been recent reports on the association
between radiation related lymphopenia and survival outcomes in solid
tumors. Depletion of the circulating lymphocytes during the course of
radiation has been reported to cause inferior overall survival outcomes
in gliomas, head and neck squamous cell carcinoma, nasopharyngeal
cancer, lung cancer, esophagus, hepatocellular carcinoma, pancreatic
cancer as well as cervical cancer. The radiation dose to the circulating
lymphocyte population when the lymphocytes traverse the radiation
portal as well as unintended dose to primary and secondary lymphoid
organs were postulated as the reasons for the lymphocyte depletion.
This RT related lymphocyte depletion not only mitigates the beneﬁcial
effect of RT but as well as reduces the effectiveness of T cell based
immunotherapeutic agents like checkpoint inhibitors and adoptive T
cell transfer.
Objectives: 1. To understand the alterations in the lymphocyte and
cytokine kinetics in peripheral blood samples of patients with locally
advanced pancreatic cancer who underwent deﬁnitive chemoradiation
as part of a prospective phase 2 trial 2. Create radiation related lymphopenia murine pancreatic cancer models 3. Devise rescue agents of
radiation related lymphopenia and assess if tumor control outcomes are
improved with enhancing lymphocyte population 4. Assess which
subgroup of lymphocyte populations are responsible for improvement
in tumor control outcomes.
Methods: We analyzed the severity of lymphopenia, mean splenic dose,
lymphocyte subpopulations (CD3, CD45, CD4, CD8, PD-1, Foxp3, Ki67, CTLA-4 and the level of cytokines (IL-2, IL-6, IL-10, IL-7, IL-15,
and TNF-alpha) in a cohort of 20 pancreatic cancer patients undergoing
conventional 50.4 Gy in 28 fractions intensity modulated radiation
therapy (IMRT) for locally advanced pancreatic (LPAC) as part of a
phase 2 clinical trial. Based on our clinical ﬁndings, we also designed a
model of radiation induced lymphopenia through splenic irradiation in
mice and assessed the lymphocyte subpopulation dynamics in peripheral blood and its impact on murine xenograft pancreatic tumors. We
also devised potential rescue strategies to see if T lymphocyte
homeostatic cytokines Interleukin-15 (IL-15) 7.5 ug for 7 days and
Interleukin-7 (IL-7) 10 ug for 7 days supplemented to mice that had
radiation related lymphopenia could have its lymphopenia rescued and
the tumor outcomes could improve. In addition, we tested the efﬁcacy
of IL-15 super agonist which has a longer half-life than IL-15 as
lymphorepletion agent and its impact on primary tumor as well as
secondary non-irradiated tumor in murine pancreatic cancer models.

Results: Twenty patients with locally advanced pancreatic cancer were
enrolled as part of a single arm phase 2 clinical trial. All patients
received 50.4 Gy in 28 fractions of IMRT with concurrent daily capecitabine and weekly nab-paclitaxel on days 1, 8, 15, 22, and 29 for a
total duration of 5-6 weeks. The mean splenic dose for severe lymphopenia (grade 3, 4) was 4.92 Gy compared with 1.52 Gy in mild
lymphopenia arm (grade 1, 2). The following cytokines IL-2, IL-6, IL7, IL-15 and TNF-alpha were analyzed and homeostatic T cell cytokines IL-7, IL-15 fail to increase in patients with severe lymphopenia
compared with elevation of IL-7 in patients with mild lymphopenia.
Analyses of the frequencies of T cells from the peripheral blood shows
that the patients who had higher mean splenic doses (4.92 Gy) compared with lower splenic doses (1.52 Gy) had signiﬁcant depletion (P
value < 0.05) of CD3+ T cells (17.30% vs 40.80%), CD4+ T cells
(11.87% vs 27.88%), CD8+ T cells (0.16% vs 0.52%) at week 1; CD3+
T cells (19.28% vs 29.84%), CD4+ T cells (13.87% vs 27.86%), CD8+
T cells (0.23% vs 0.98%) at week 5. We tested IL-7 and IL-15 in
C57BL6 murine pancreatic cancer models. The tumors were irradiated
to a dose of 10 Gy in 5 fractions over 5 days and the spleen was
irradiated to 5 Gy in 5 fractions over 5 days with Philips 250 Kv
orthovoltage irradiator. Splenic irradiation compromises the tumor
control outcomes provided by radiation. IL-15 was administered intraperitoneally 24 hours post radiation 7.5 ug per day for 7 days IP and IL7 was administered intra-peritoneally 24 hours post radiation 10 ug per
day for 7 days. Treatment with IL-15 induced complete primary tumor
regression in 75% of the treatment group whereas IL-7 did not induce
complete primary tumor regression in any mice. IL-15 increased cytotoxic CD8 T cell and natural killer cell inﬁltration into tumors and
peripheral blood. IL-15 rescued the lymphopenia induced by radiation
by increasing the circulating lymphocyte populations as well as by
enhancing lymphocyte inﬁltration into the tumor as well as the residential lymphocytes in the spleen. IL-15 super agonist which has a
longer half-life and ease of administration was tested. IL-15 super
agonist 4 ug per mice was administered 24 hours after radiation delivery
for 2 doses one week apart. IL-15 super agonist supplementation in
lymphodepleted mice enhances the tumor control at the primary site as
well as the secondary non-irradiated abscopal site.
Conclusions: Our results show that lymphopenia is a common
accompaniment of pancreatic cancer treatment with radiation being the
prime contributor and lymphopenia correlates with suboptimal tumor
control outcomes. The mean splenic dose correlates with the severity of
lymphopenia and the main lymphocyte subpopulations that are depleted
are CD3, CD4, CD8 lymphocyte populations. Though IL-7 supplementation rescued CD4 counts, the reconstitution did not have a tangible effect on the tumor control outcomes in murine pancreatic cancer
models. These results add further strength to the notion that CD8 T cells
play an important role in immunological cell death of pancreatic tumor
and the reconstitution of the CD8 cells with IL-15 not only increases the
lymphocyte count but improves tumor control outcomes. Our experiments provide impetus for design of clinical trials for use of IL-15 or
IL-15 super agonist as an adjuvant therapy to rescue T cells and to
further augment the beneﬁt of radiation in pancreatic cancer (Figs. 1–3).
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FIGURE 1. Radiation of 50.4 Gray in 28 fractions given over 5.5 weeks in combination with capecitabine 825 mg/m2 (Monday to Friday)
and nab-paclitaxel IV over 30 minutes on days 1, 8, 15, 22, and 29 in locally advanced pancreatic cancer leads to lymphopenia and
causes distinct alterations in the cytokine levels in peripheral blood at baseline, week 1, week 3, week 5 and follow up after completion of
one month of treatment. (A) Illustrative summary of the design of the phase I clinical trial. The figures show the cytokine levels IL-2, IL-6,
IL-7, IL-15, TNF-alpha in mild lymphopenia group (B) and severe lymphopenia group (C), percentage of CD3+ T cells (D), percentage of
CD4+ T cells (E), percentage of FOXp3+ cells (F), percentage of CD8+ T cells (G), percentage of CD19+ cells (H), percentage of CD11b11C+ cells (I). Data are represented as means ± SEM (n = 20 patients). Statistical significance was assessed by unpaired T test; *, P < 0.05;
**, P < 0.005; ***P < 0.0005; ns-not significant.
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FIGURE 2. Interleukin-15 rescues radiation induced lymphopenia and enhances tumor control outcomes in murine Pancreatic cancer
xenograft models. (A) Experimental schema (B) shows the tumor growth delay curves when spleen is irradiated (C) shows that Interleukin-7 doesn’t improve tumor control outcomes (D) shows that IL-15 rescues the inferior tumor control that occurs with incidental
splenic radiation (E) shows mean tumor weights. Unpaired T test with Welch’s correction was used to assess significance between the
tumor growth delay groups; *, P < 0.05; **, P < 0.005; ***P < 0.0005; ns-not significant. (Each group had mice n = 8-10 per group).
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FIGURE 3. Serial assessment of the peripheral blood lymphocyte subpopulations in mice bearing Panco2 xenograft tumor models in right thigh
show that Interleukin-15 (A) and (C) increases circulating CD3+ T cells and CD8+ T cells with no impact on (B) CD4+ T cells. (D) representative
flow cytometry figures that show alterations in CD3 and CD19 populations during the course of radiation from day 1-to day 5 and after IL-15
rescue from day 6 to day 13 and follow up till day 32. (E) representative flow cytometry figures that show alterations in CD8 and CD4 populations
during the course of radiation from day 1-to day 5 and after IL-15 rescue from day 6 to day 13 and follow up till day 32. Tumors and spleen were
harvested on day 15 and the isolated tumor infiltrating lymphocytes and splenocytes were characterized by flow cytometry. The figures show
percentage of CD3+ T cells in tumor (F), percentage of CD4+ T cells in tumor (G), percentage of CD8+ T cells in tumor (H), percentage of NK cells
in tumor (I), percentage of CD3+ T cells in spleen (J), percentage of CD8+ T cells in spleen (K). Data are represented as means ± SEM (n = 6-8
mice/group) statistical significance was assessed by unpaired T test; *, P < 0.05; **, P < 0.005; ***P < 0.0005; ns-not significant.
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(OA02) Long-term Pathologic and Survival Outcomes with
Chemotherapy and Stereotactic Body Radiotherapy in
Localized Pancreatic Adenocarcinoma
Colin Hill1, Shuchi Sehgal, BS2, Jeffrey Meyer, MS, MD1, Joseph
Herman, MD3, Amol Narang, MD1; 1Johns Hopkins University School
of Medicine, Department of Radiation Oncology and Molecular Radiation
Sciences, 2Philadelphia College of Osteopathic Medicine, 3Northwell
Health
Background: Borderline resectable (BRPC) or locally advanced pancreatic cancer (LAPC) patients are at high risk of margin positive
resection. Neoadjuvant stereotactic body radiation therapy (SBRT) may
help increase the proportion of patients that are surgically explored and
resected with negative margins. We report long-term outcomes of
BRPC/LAPC patients after neoadjuvant CT (nCT) followed by
5-fraction SBRT (nCT-SBRT) with a high proportion of patients
receiving multi-agent (MA)-CT and surgically explored.
Objectives: Consecutive BRPC/LAPC patients diagnosed from 20112019 who underwent resection following nCT-SBRT were retrospectively reviewed to determine survival outcomes, pathological
endpoints, and patterns of failure.
Methods: One-sided and two-sided T-Test was used to compare
covariates of interest with P-value ≤ 0.05. Pathological endpoints and
patterns of failure are descriptively reported, and Kaplan-Meier method
was used to analyze survival outcomes.
Results: Of 274 patients, 156 patients (57%) were BRPC and 118
patients (43%) were LAPC. The median follow-up was 25.3 months
(range: 6.6–88.4) from diagnosis and 18.9 months (1.5–81.9) from
SBRT. The median age at diagnosis was 65.3 years of age (range: 39.7–
84.1 y) and the tumor was more frequently located in the head/neck/
uncinate regions (n = 192, 71%). For nCT, FOLFIRINOX (FFX) was
administered in 203 patients (74%) and gemcitabine and nab-paciltaxel
(GnP) was utilized in 91 patients (33%). 29 patients (11%) received a
different regimen which included single agent gemcitabine, a combination of gemcitabine, docetaxel, capecitabine, or gemcitabine and
cisplatin. 45 patients (16%) received more than 1 line of CT before
SBRT. The median total duration of nCT was 4.2 months (range: 0.518.0). SBRT median dose was 33 Gy (range: 25-40). At baseline,
median cancer antigen (CA) 19-9 was 192.6 U/mL (range: 0–14,004.2)
with 63% of cases ≥ 90 U/mL, but after neoadjuvant chemotherapy, the
median CA 19-9 was 41.3 U/mL (range: 0–3264.0) with only 28% of
cases ≥ 90 U/mL. In 31% of patients, the CA 19-9 reduction was
greater than 80%. After SBRT, 250 patients (91%) were surgically
explored, and 226 patients (83%) were surgically resected. In resected
patients with available pathology, 190 (91.3%) had negative margins,
137 (61%) were node-negative, and 17 (8%) had a pathological complete response (pCR). Of the 156 BRPC patients, 112 (72%) were
explored with 104 (67%) completing a resection and 98 (94%) were
margin-negative. Of the 118 LAPC patients, 138 (89%) were surgically
explored with 122 (78%) completing a resection and 110 (90%) were
margin-negative. In all resected patients, vascular reconstruction was
required in 84 cases (37%) with LAPC patients more frequently
requiring reconstruction (n = 47, 41%) compared with BRPC patients
(n = 37, 24%). Only 81 patients (30%) received adjuvant chemotherapy.
The median overall survival (OS) for all patients from SBRT was
24.4 months (mo) and 30.7 mo from diagnosis. The median OS from
SBRT for BRPC (23.3 mo) and LAPC (26.17 mo) from SBRT were
similar (P = 0.743). The 1- and 2-year probability for OS from SBRT
was 75.2% (95% CI: 70.0-80.4%) and 50.9% (95% CI: 44.7-57.1%).
The 1- and 2-year probability for OS from diagnosis was 93.7% (95%
CI 90.8-96.6%) and 59.9% (95% CI: 54.0-66.0%). Patients who were
taken to surgery had a signiﬁcantly better median survival if they were
resected at 28.0 mo vs. 10.0 months for those explored (HR 3.14,
P < 0.001) and vs. 10.1 mo (HR 3.35, P < 0.001) for those aborted.
When comparing covariates in patients surviving longer (n = 82, 30%)
or less than 36 mo (n = 192, 70%) after diagnosis, there was a signiﬁcant difference in duration of neoadjuvant chemotherapy (median:
4.9 vs. 4.0 mo, P = 0.005), successful resection (96% vs 77%,
P < 0.001), (pCR (13% vs. 10%, P = 0.015), and node-negative status
(76% vs. 52%, P < 0.001). From SBRT, the 3-year OS probability for
resected patients was 44.8% (95% CI: 37.7-51.9%) versus 9.0% (95%
CI: 0.0-18.3%) in non-resected patients. From SBRT, the median
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progression-free survival was 11.4 mo, local (LPFS) was 24.8 mo, and
distant metastasis-free survival (DMFS) was 13.32 mo. The most
common pattern of ﬁrst failure was distant in 100 patients (47%) followed by synchronous in 57 (27%) and local in 45 (21%) patients. In
BRPC patients, local failure occurred ﬁrst in 15 (7%), distant in 43
(20%), and synchronous in 31 (15%) whereas in LAPC patients, local
failure was ﬁrst in 30 (14%), distant in 57 (27%), and synchronous in 26
(12%). Margin-negative patients had better LPFS with median LPFS of
36.4 mo versus 16 mo in margin-positive patients (HR 0.51, P = 0.029).
Conclusions: In a large cohort of BRPC/LAPC patients treated at a
single high-volume institution with SBRT following multi-agent chemotherapy, a high proportion of patients underwent successful resection
of their cancer ( > 80%), of which a high proportion of resections were
margin negative ( > 90%). Patients who underwent resection experienced signiﬁcantly improved median and long-term survival. Despite
aggressive local therapy with SBRT and resection, local failure
remained not insigniﬁcant, highlighting opportunity to continue to
reﬁne radiation therapy for this disease.

(OA03) Detection of Minimal Residual Disease in Localized
Bladder Cancer Patients Based on Single Nucleotide Variants and Copy Number Alterations in Urine Tumor DNA
Kevin Chen, BS1, Pradeep Chauhan, PhD1, Ramandeep Babbra, MD1,
Wenjia Feng, MS1, Jeffrey Szymanski, MD, PhD2, Peter Harris, PhD1,
Katherine Dienstbach, MPH3, Andrew Atkocius, BS3, Lenon Maguire,
BS3, Faridi Qaium, BS1, Yi Huang, MS1, Brian Baumann, MD1, Li
Ding, PhD4, Dengfeng Cao, MD5, Melissa Reimers, MD3, Eric Kim,
MD6, Vivek Arora, MD, PhD3, Zachary Smith, MD6, Aadel Chaudhuri,
MD, PhD2; 1Department of Radiation Oncology, Washington University School of Medicine in St. Louis, 2Washington University School
of Medicine in St. Louis, 3Department of Medicine, Washington University School of Medicine in St. Louis, 4McDonnell Genome Institute,
Washington University School of Medicine in St. Louis, 5Department of
Pathology and Immunology, Washington University School of Medicine
in St. Louis, 6Department of Surgery, Washington University School of
Medicine in St. Louis
Background: Standard-of-care for treating muscle-invasive bladder
cancer involves radical cystectomy, which is a morbid procedure.
Nonoperative treatment with chemoradiation is the alternative but
requires frequent invasive monitoring to assess for response and
recurrence.
Objectives: We sought to develop a noninvasive liquid biopsy
approach by detecting single nucleotide variants (SNVs) and copy
number alterations (CNAs) in urine tumor DNA (utDNA) obtained

FIGURE 1. Scatterplot of highest utDNA variant allele fraction
(vAF), shown as the square-root value, among non-silent, duplexsupported driver mutations detected in the urine of localized
bladder cancer patients (pCR vs. no pCR) and healthy adults. P
values were calculated using Mann-Whitney U test with an α of
0.017 after Bonferroni correction.
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FIGURE 2. Representative genome-wide comparisons of copy number alterations among a patient with no pCR, a patient with pCR, and
a healthy adult. Y-axis indicates log2 copy number ratio. Color legend also indicates genomic locus-specific copy number levels.
pre-operatively from localized bladder cancer patients. These results
were correlated with pathologic complete response (pCR) assessed by
surgery.
Methods: We acquired urine samples from 42 localized bladder cancer
patients with an indication for radical cystectomy, often following
neoadjuvant chemotherapy. SNV-calling with Cancer Personalized
Proﬁling by deep Sequencing (CAPP-Seq) was performed without
tumor mutational knowledge using a 145 kb panel of 49 consensus
driver genes. For each patient, we identiﬁed the non-silent, duplexsupported driver mutation with the highest variant allele fraction (vAF)
after removing germline variants. Minimal residual disease (MRD)
detection was deﬁned using the optimal threshold of highest vAF that
classiﬁed patients with residual disease in their cystectomy specimens
(no pCR) against 15 healthy adults. Accuracy of pCR prediction based
on MRD was assessed by applying leave-one-out cross-validation to a
logistic regression controlling for age and sex. Low-pass whole genome
sequencing (LP-WGS) was performed on a subset of urine samples to
correlate pCR with genome-wide CNAs.
Results: The median difference in highest vAF between patients with
no pCR (n = 26) and those who achieved pCR (n = 16) was 4.3% (4.3%
vs. 0%; P = 0.002), while there was no median difference between pCR
and healthy adults (0% vs 0%, P = 0.23) (Fig. 1). Using highest vAF to
deﬁne MRD and predict pCR in a logistic regression, 81% of cases in
our cohort were correctly classiﬁed by cross-validation with 81% sensitivity and 81% speciﬁcity. Positive MRD correlated with worse progression-free survival (HR = 7.4; P = 0.03) with a median follow-up
time of 183 days. Median utDNA fractions derived from genome-wide
CNAs in patients who achieved pCR (n = 4) were also signiﬁcantly

lower than those with no pCR (n = 4) by 12% (1% vs. 13%; P = 0.03)
but not signiﬁcantly different compared with four healthy adults (1% vs
0%; P = 0.43). Representative genome-wide comparisons among two
patients and a healthy adult are shown in Figure 2.
Conclusions: utDNA analysis of MRD in localized bladder cancer
patients signiﬁcantly predicted pCR in the cystectomy specimen with
81% sensitivity and 81% speciﬁcity. Patients who achieved pCR also
demonstrated genomic copy number stability similar to healthy adults,
while those with no pCR did not. In the future, this work could pave the
way toward more precise and noninvasive response assessment in
bladder-sparing chemoradiation patients.

(OA04) Benchmarking Outcomes After Ablative Radiotherapy for Molecularly Characterized Unresectable
Intrahepatic Cholangiocarcinoma
Brian De, MD1, Ibrahim Abu-Gheida, MD1, Aashini Patel, BS1, Sylvia
Ng, MD PhD MSc1, Mohamed Zaid, MD1, Connor Thunshelle, BA1,
Dalia Elganainy, MD1, Milind Javle, MD1, Kanwal Raghav, MD
MBBS1, Sunyoung Lee, MD1, Jean-Nicolas Vauthey, MD1, Ching-Wei
Tzeng, MD1, Hop Tran Cao, MD1, Ethan Ludmir, MD1, Bruce Minsky,
MD1, Grace Smith, MD MPH1, Emma Holliday, MD1, Cullen Taniguchi, MD PhD2, Albert Koong, MD, PhD1, Prajnan Das, MD MS
MPH2, Eugene Koay, MD PhD2; 1MD Anderson Cancer Center, 2MD
Anderson
Background: We previously showed that ablative radiotherapy (A-RT)
with biologically effective dose (BED10) ≥ 80.5 Gy is associated with
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TABLE 1. Time-to-event Outcomes of Patients Stratified by the Most Commonly Mutated Genes

longer survival for patients with unresectable intrahepatic cholangiocarcinoma (ICC). Despite recent large-scale sequencing efforts in
ICC, RT outcomes based on genetic alterations have not been described.
Objectives: To identify clinical and pathologic characteristics associated with disease control and survival after RT for ICC, and to
benchmark RT outcomes based on commonly mutated genes.
Methods: We reviewed records of 156 consecutive patients (54%
female) treated with A-RT for unresectable ICC from 2008-2020. For
114 patients (73%), next generation sequencing using solid tumor tissue
and/or cell-free DNA provided molecular proﬁles. The Kaplan-Meier
method was used to estimate overall survival (OS), local control (LC),
and both intrahepatic and extrahepatic distant metastasis-free survival
(DMFS). Univariable Cox analysis was used to determine associations
with outcomes. Median age at RT was 66 years (range, 31-89 y).
Median number of liver tumors was 1 (range, 1-5) and 51% had satellitosis. Median tumor size was 7.3 cm (range, 2.2-18.2). American
Joint Committee on Cancer 8th Edition stages were I, II, III, and IV in
12%, 22%, 38%, and 29%, respectively. Portal vein thrombus (PVT)
was present in 10%. Systemic therapy before, concurrently with, and
after RT were delivered to 81%, 63%, and 58%, respectively. RT
technique was photon in 73% and proton in 27%. RT median dose was
67.5 Gy (range, 58.05-100) in a median 15 fractions (range, 10-28) for a
median BED10 of 98 Gy (range, 81-144 Gy).

Results: Median [95% conﬁdence interval] follow-up was 50 [37-92]
months from diagnosis and 35 [29-62] months from RT. Median OS
was 32 [29-37] months after diagnosis and 21 [17-25] months after
RT. One-year OS, LC, and intrahepatic DMFS were 73% [65-80%],
81% [72-87%], and 35% [27-43%]. Among 111 (71%) patients with
M0 disease at RT, 1-year extrahepatic DMFS was 60% [50-69%].
Most common mutations were in IDH1 (24%), TP53 (21%), ARID1A
(21%), FGFR2 (13%), BAP1 (12%), IDH2 (12%), and PIK3CA
(11%). Sixteen (14%) patients had no somatic mutations identiﬁed.
Outcomes stratiﬁed by the most commonly mutated genes are shown
in Table 1. On univariable analysis, factors commonly associated
with death were worse performance status, higher CA 19-9 levels,
male sex, metastatic disease, PVT, satellitosis, D90% to gross tumor
volume, and IDH1 mutation. Factors associated with progression
included satellitosis, PVT, higher CA 19-9 levels, and IDH1 and
TP53 mutations. Signiﬁcant results for time-to-event endpoints are
shown in Table 2.
Conclusions: IDH1 mutations may be associated with poorer disease
control and survival for patients with ICC receiving A-RT. However,
favorable outcomes with A-RT were observed regardless of molecular
proﬁle. Further investigation into the prognostic value and therapeutic
implications of individual mutations and combinations thereof is
warranted.

TABLE 2. Univariable Cox Analysis of Factors Associated With Time-to-event Outcomes
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(OA05) Economic Evaluation of Total Neoadjuvant Therapy in Rectal Cancer: Short-course Radiation Therapy vs.
Long-course Chemoradiation
Re-I Chin, MD1, Ebun Otegbeye, MD1, Kylie Kang, MD2, Su-Hsin
Chang, PhD1, Scott McHenry, MD1, Amit Roy, MD3, Shahed Badiyan,
MD1, William Chapman Jr, MD1, Sean Glasgow, MD1, Lauren Henke,
MD, MSCI4, Steven Hunt, MD1, Katrina Pedersen, MD1, Pamela
Samson, MD, MPHS2, Matthew Silviera, MD1, Benjamin Tan, MD1,
Paul Wise, MD1, Matthew Mutch, MD1, Hyun Kim, MD1; 1Washington
University School of Medicine, 2Department of Radiation Oncology,
Washington University School of Medicine in St. Louis, 3Washington
University in St. Louis, 4henke.lauren@wustl.edu
Background: Distant recurrence risk is high in patients treated for
locally advanced rectal cancer (LARC). Total neoadjuvant therapy
(TNT) with either short-course radiation therapy (SC-TNT) or longcourse chemoradiation (LC-TNT) has been proposed to lower this risk,
but the economic implications of these two approaches are unknown.
Objectives: To evaluate the cost-effectiveness of SC-TNT vs. LC-TNT
in conjunction with total mesorectal excision for patients with
resectable LARC.
Methods: A decision analytic model with a 5-year time horizon was
constructed. Markov modeling was used to model disease progression and patient survival after treatment in 3-month cycles. Data
on probabilities and utilities were extracted from the literature. Costs
were evaluated from Medicare payer’s perspective in 2020 US dollars (2020$). Sensitivity analyses were performed for key variables.
Quality-adjusted life-years (QALYs) and total costs (2020$) were
computed and discounted at 3% annually. Cost-effectiveness was
evaluated using the net-monetary beneﬁt (NMB), QALYs × willingness-to-pay per QALY (WTP) - total costs, where WTP was set at
$50,000.
Results: Over the 5-year horizon, QALYs accrued were 2.20 for SCTNT and 2.35 for LC-TNT. The total cost was $44,010 for SC-TNT and
$53,463 for LC-TNT. The NMB was $66,134 for SC-TNT versus
$64,165 for LC-TNT. The sensitivity analyses using WTP at $100,000
and $150,000 demonstrated the same conclusion.
Conclusions: SC-TNT is an economically preferred treatment strategy
with a greater net-monetary beneﬁt compared with LC-TNT.
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Methods: The multi-institutional cohort comprised 1,863 patients
treated at 15 tertiary referral centers between 1995-2018 with high- and
very high-risk prostate cancer treated with deﬁnitive radiotherapy, with
or without androgen deprivation therapy (ADT). Patients were stratiﬁed
by risk of pelvic nodal upstaging by PSMA PET/CT ( ≤ 25% vs > 25%)
using a nomogram built using logistic regression on four variables:
initial PSA, biopsy Gleason grade group, percent positive cores, and
clinical T category. Time-to-event outcomes were compared using
Gray’s test (for biochemical recurrence [BCR], distant metastasis [DM],
prostate cancer-speciﬁc mortality [PCSM]) and the log-rank test (for
OS), allowing for competing risks and censoring. Multivariable analyses were performed using Fine-Gray regression (for BCR, DM, PCSM)
and Cox regression (for OS) controlling for patient age, initial PSA,
clinical T stage, Gleason grade group, percent positive cores, brachytherapy boost, and ADT.
Results: 69% (1,287/1,863) of patients in the high-risk multi-institutional cohort received WPRT. Median follow-up was 6.1 years. On
unadjusted analysis, WPRT was associated with signiﬁcantly higher
8-year freedom from BCR versus no WPRT in patients at high (71% vs
58%, P = 0.007) and low risk (84% vs 78%, P = 0.02) of pelvic nodal
upstaging; there were no differences in DM, PCSM, or OS. After
adjustment for clinical features and brachytherapy, the BCR beneﬁt of
WPRT persisted in high but not in low nodal risk patients. However,
after additionally adjusting for ADT, the beneﬁt of WPRT disappeared
from all groups. This ﬁnding was unchanged in subgroup and interaction analyses according to the status of brachytherapy or ADT.
Conclusions: For PSA screen-detected patients without upfront PSMA
screening, the value of WPRT requires further study. Individualized and
shared decision making is crucial (Figs. 1–3).

(OA06) The Beneﬁt of Whole Pelvis Radiation Therapy
in Patients with High-Risk Prostate Cancer Relative to
the Risk of Nodal Metastases in a Multi-Institutional
Cohort
Luca Valle, MD1, Michael Xiang, MD, PhD2, Amar Kishan, MD2,
Tahmineh Romero, MS2, Jessica Wong3, Bradley Stish, MD4, Daniel
Spratt, MD5, Avinash Pilar, MD6, Jay Ciezki, MD7, Trude Wedde,
MD8, Gregory Merrick, MD9, Richard Stock, MD10, Brian Moran,
MD11, Phuoc Tran, MD12, Rafael Martinez-Monge, MD13, Daniel
Krauss, MD14, Ashley Ross, MD, PhD15, Derya Tilki, MD16, Jonathan
Tward, MD, PhD17, Brian Davis, MD, PhD18, Michael Steinberg, MD2;
1
University of California, Los Angeles, 2UCLA, 3Fox Chase Cancer
Center, 4Mayo Clinic Rochester, 5University of Michigan Department
of Radiation Oncology, 6Princess Margaret Hospital, 7Cleveland
Clinic, 8iMaria Sklodowska-Curie Memorial Cancer Center, 9Wheeling
Jesuit University, 10Icahn School of Medicine at Mount Sinai, 11Prostate Cancer Foundation of Chicago, 12Johns Hopkins University School
of Medicine, 13University of Navarra, 14Oakland University William
Beaumont School of Medicine, 15Northwestern University Feinberg
School of Medicine, 16University Hospital Hamburg-Eppendorf,
17
Huntsman Cancer Institute at the University of Utah, 18Mayo Clinic
Background: The optimal selection of men with prostate cancer for
whole-pelvis radiation (WPRT) is controversial, although emerging
data suggest a beneﬁt in very high-risk patients.
Objectives: We evaluated the beneﬁt of WPRT in a large, contemporary, prostate-speciﬁc antigen (PSA) screen-detected multi-institutional cohort of high-risk patients, stratiﬁed by risk of nodal upstaging
on prostate-speciﬁc membrane antigen (PSMA) PET/CT.

FIGURE 1. Chemical Structures and Binding Sites for Molecular
PET-Tracers. The molecular structures for the three evaluated PET
tracers are shown above, along with their relevant binding sites for
prostate cancer imaging. 18F-FACBC is a fluorinated synthetic
amino acid analog that is transported into prostate cancer cells by
amino acid transporters that are upregulated in prostate cancer.
18F-DCFPyl and 68Ga-PSMA-11 are both radiolabeled ligands
that bind to the extracellular component of the prostate specific
membrane antigen (PSMA) transmembrane glycoprotein, which is
overexpressed in prostate cancer cells. Graphic created with BioRender.com.
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FIGURE 2. PRISMA Diagram. PRISMA diagram depicting studies included in our systematic review.

FIGURE 3. Potential Management Changes Resulting from Molecular PET Findings. Schematic of potential changes to radiation dose
(Red), radiation volume (green), or ADT use and duration (blue) as findings from molecular PET/CT are incorporated into patient
management. Potential revisions in treatment considerations are organized by anatomic region of PET-detected disease.
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(OA07) Radiosensitivity, Microenvironment Inﬂammation,
and Mutational Frequency of Non-Small Cell Lung Cancer
Metastases Across Host Tissue Types
Austin Sim, MD, JD1, Prithvi Shetty, BS2, Eric Welsh, PhD3, Jamie
Teer, PhD3, Steven Eschrich, PhD3, James Mule, PhD4, Javier TorresRoca, MD1, Kamran Ahmed, MD1, G. Daniel Grass, MD, PhD1;
1
Department of Radiation Oncology, H. Lee Mofﬁtt Cancer Center &
Research Institute, 2University of South Florida Morsani College of
Medicine, 3Department of Biostatistics and Bioinformatics, H. Lee
Mofﬁtt Cancer Center & Research Institute, 4Department of Immunology, H. Lee Mofﬁtt Cancer Center & Research Institute
Background: Therapies for non-small cell lung cancer (NSCLC)
metastases are minimally personalized, especially if a targetable mutation is lacking. Additionally, the inﬂuence of the metastasis host tissue
type is unknown.
Objectives: To explore differences in radiosensitivity, tumor microenvironment inﬂammation (TMI), and mutational frequency (MF)
among NSCLC metastases by host tissue.
Methods: Metastatic NSCLC samples across 6 tissues (adrenal, bone,
brain, liver, lymph node [LN], soft tissue [ST]) underwent microarray
gene expression proﬁling. A previously described signature was used to
estimate radiosensitivity (scale 0-1), known as the radiosensitivity index
(RSI). Higher RSI values are associated with greater radioresistance
(cutpoint 0.375). An additional 12-gene chemokine signature (12CK)
was used to estimate the magnitude of TMI, where a higher score
indicates greater inﬂammation. A subset of samples (n = 24) additionally underwent targeted exome sequencing of 1,327 known cancerassociated genes. The number of somatic mutations (MF) was calculated and ﬁltered for known germline/silent mutations and artifacts for
enrichment. Differences across these metrics were compared across
tissue types using the Kruskal-Wallis H test. RSI, 12CK, and MF were
then correlated using Spearman’s rho.
Results: From 1998 to 2011, 154 metastatic samples were identiﬁed
from unique patients. Median age at diagnosis was 62 (range 36-82).
With a median follow-up of 168.3 months (95%CI 146.3-190.3),
median survival was 28.5 months (95%CI 24.0-33.0). Median values
for RSI, 12CK, and MB were 0.420 (interquartile range [IQR] 0.3190.491), 7.58 (IQR 6.28-8.92), and 90 (IQR 80.5-111), respectively.
Signiﬁcant differences existed among tissues for both RSI (P < 0.001)
and 12CK (P < 0.001), but not for MF (P = 0.442). After Bonferroni
correction, RSI pairwise comparisons were signiﬁcant for LN-Brain
(P = 0.006), Adrenal-Brain (P = 0.020), and ST-Brain (P = 0.021).
12CK pairwise comparisons remained signiﬁcant for Liver-LN
(P = 0.026), Liver-Adrenal (P = 0.026), Brain-ST (P = 0.003), BrainLN (P < 0.001), Brain-Adrenal (P < 0.001). Signiﬁcant correlation
between RSI and 12CK was noted (rho = -0.420, P < 0.001). However,
no signiﬁcant correlation was found between MF and RSI or 12CK. No
signiﬁcant differences were found for RSI or 12CK when stratiﬁed by
presence of ALK, EGFR, or KRAS mutations.
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Conclusions: In this novel composite gene expression analysis of
NSCLC metastases, adrenal and LN metastases appear relatively radiosensitive, while brain and liver metastases appear resistant, warranting
dose escalation. The concomitant low TMI scores of brain, liver, and
bone metastases may reﬁne patient selection for immunotherapy. More
inﬂamed metastases appear to be more radiosensitive, except for in
bone. Better elucidation of the effects of host tissue on the tumor
microenvironment may provide the opportunity for further treatment
personalization through therapy selection and sequencing (Table 1).

(OA08) Pulmonary Function Test Results of a Multiinstitutional Phase II Clinical Trial for 4DCT-ventilation
Functional Avoidance Thoracic Radiotherapy
Brian Kavanagh1, Yevgeniy Vinogradskiy2; 1University of Colorado,
2
Thomas Jefferson University
Background: A novel form of lung function imaging has been proposed that uses 4DCT data along with image processing techniques to
generate 4DCT-based ventilation images (4DCT-ventilation). 4DCTventilation-based functional avoidance radiotherapy proposes to reduce
dose to functional portions of the lung (as measured by 4DCT-ventilation) with the hypothesis that reduced doses to functional lung will
lead to reduced rates of pulmonary toxicity.
Objectives: A phase II, multi-center, prospective study was initiated to
evaluate 4DCT-ventilaiton functional avoidance radiotherapy. As part
of the study, pulmonary function tests (PFTs) were collected at baseline
and 3 months post radiotherapy. We report on a secondary trial endpoint of PFT changes; speciﬁcally changes in Diffusing capacity for
carbon monoxide (DLCO), which have been shown to predict for
clinical pulmonary toxicity (Guerra et al, IJROBP, 2012) are reported.
Methods: Lung cancer patients receiving curative intent radiotherapy
(prescription doses of 45-75 Gy) and planned curative intent chemotherapy were accrued from 2 institutions. Each patient’s 4DCT images
along with image processing techniques (Guerrero et al, PMB, 2006) were
used to generate 4DCT-ventilation maps. Using favorable arc geometry
and optimization techniques the 4DCT-ventilation images were used to
generate functional avoidance plans. The functional avoidance plans
aimed to reduce doses to functional portions of the lung while delivering
the prescribed tumor dose and respecting tolerances of organs-at-risk.
Standard PFTs were acquired at baseline and 3 months post radiotherapy
(median 3.4 mo, range 2.4–8.3 mo). We report on changes in DLCO as a
percentage of predicted level (determined by sex, height, and weight).
Results: 50 patients enrolled on the study with pre and post-treatment PFTs
were evaluable for the current analysis. The majority (74%) of study patient’s
had stage III disease. The median prescription dose was 60 Gy (range
45–66 Gy) delivered in 30 fractions (range 15–33 fractions). Median DLCO
values at baseline were 62% (range 32-100%) and 52% (27-106%) post
chemo-radiation for a median difference of 10% (range -50% to +44%).

TABLE 1. Radiosensitivity Index Scores, 12-Chemokine Scores, and Mutational Frequencies by Tissue

Number of samples, median values, and interquartile range of Radiosensitivity Index scores, 12-Chemokine scores, and mutational frequencies of metastatic samples
stratiﬁed by host tissue type. RSI: Radiosensitivity Index, 12CK: 12-Chemokine score, MF: mutational frequency, IQR: interquartile range.
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Conclusions: DLCO changes from pre- to post-treatment have been shown
to be a predictor of pulmonary toxicity. For patients treated with standard
thoracic chemo-radiation, DLCO values decrease by 20% on average
(Guerra et al, IJROBP, 2012). Our results indicate DLCO reductions of
10% with functional avoidance, providing evidence that functional avoidance results in improved preservation of clinically signiﬁcant pulmonary
function when compared with standard thoracic radiotherapy.

(OA09) The Inﬂuence of Dosimetric Parameters on Quality
of Life for Early Stage Non-small Cell Lung Cancer
Patients Treated with Stereotactic Body Radiation Therapy
Suneetha Devpura, PhD1, Aharon Feldman, MD1, Samuel Rusu, MSc1,
Stephen Brown, PhD1, Andrew Cook, MD2, Avielle Movsas, MD1,
Zhen Sun, MSc1, Sean Vance, MD1, Michael Simoff, MD1, Munther
Ajlouni, MD1, M. Salim Siddiqui, MD, PhD1, Benjamin Movsas, MD2,
Indrin Chetty, PhD1; 1Henry Ford Cancer Institute, HFHS, 2Department of Radiation Oncology, Henry Ford Cancer Institute
Background: Lung stereotactic body radiotherapy (SBRT) has become a
standard treatment option for early stage non-small cell lung cancer
(NSCLC) patients who are medically inoperable. The inﬂuence of radiation dose/volume parameters on quality of life is not known. Our
hypothesis is that clinically meaningful declines in quality of life over time
will be associated with increased radiation lung dose/volume parameters.
Objectives: To investigate clinical toxicity and quality of life (QOL)
outcomes of stage I NSCLC patients after SBRT as a function of
radiation dose/volume parameters.
Methods: In this IRB-approved study, 55 stage I NSCLC patients who
received SBRT (12 Gy x 4) and completed QOL forms were analyzed.
Clinical symptoms and QOL were measured at baseline and at 3, 6, 12, 18,
24, and 36 months post-SBRT. Clinical toxicity was graded using the
common terminology criteria for adverse effects (CTCAE v4.0). Quality of
life was followed using the validated Functional Assessment of Cancer
Therapy-Trial Outcome Index (FACT-TOI) instrument. Dosimetric
parameters, including the mean lung radiation dose (MLD), and the volume
of normal lung receiving > 5, 10, 13 or 20 Gy (V5, V10, V13, and V20)
were measured from the radiation treatment plan. Student’s t-test and
Pearson correlation analyses were used to examine the relationships
between radiation lung metrics and clinically meaningful changes in QOL
and/or clinical toxicities. Kaplan-Meier method was used to estimate rates
of local control (LC), disease free survival (DFS), and overall survival (OS).
Results: With a median follow-up of 24 months, the 3 year LC, DFS, and
OS were 93%, 65% and 84%, respectively, with 5.5% grade 3 toxicity and no
grade 4 or 5 toxicities. Clinically meaningful declines in patient reported QOL
(FACT-TOI, lung cancer subscale, physical well-being, and/or functional
well-being) post-treatment signiﬁcantly correlated with increased dosimetric
parameters, such as V10, V13, and V20.
Conclusions: While lung SBRT is associated with excellent LC and minimal
clinical toxicity for early stage NSCLC, clinically meaningful declines in QOL
signiﬁcantly correlated with increasing lung dose/volume parameters. This suggests
that further improvements in the techniques of lung SBRT have the potential to
further enhance patients’ QOL following this treatment.

(OA10) Feasibility and Phase I/II Trial of Preoperative
Proton Beam Radiotherapy with Concurrent Chemotherapy
for Resectable Stage IIIA Non-Small Cell Lung Cancer
Nikhil Yegya-Raman, MD1, Charles Simone, MD, FACRO2, Shwetha
Manjunath, MD1, Jacob Shabason, MD, MTR1, Abigail Berman, MD,
MSCE1, Vivek Verma, MD3, Lee Xu, MS1, Keith Cengel, MD, PhD1,
William Levin, MD1, John Christodouleas, MD, MPH1, Roger Cohen,
MD1, Corey Langer, MD1, Charu Aggarwal, MD, MPH1, Joshua
Bauml, MD1, Taine Pechet, MD1, Sunil Singhal, MD1, John
Kucharczuk, MD1, Ramesh Rengan, MD, PhD4, Steven Feigenberg,
MD1; 1University of Pennsylvania, 2New York Proton Center, 3University of Texas M.D. Anderson Cancer Center, Department of Radiation Oncology, 4University of Washington
Background: Neoadjuvant chemoradiotherapy (CRT) followed by
surgical resection represents one treatment approach for patients with
locally advanced non-small cell lung cancer (LA-NSCLC). Beneﬁts in
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progression-free survival with trimodality therapy have been offset by
signiﬁcant treatment-related morbidity, necessitating strategies to
enhance the safety of this approach. Due to its characteristic Bragg
peak, proton beam therapy (PBT) can potentially minimize dose to
normal structures while facilitating full or escalated doses to target
volumes.
Objectives: To assess feasibility (ﬁrst portion), followed by maximum
tolerated dose (MTD) and pathologic complete response (pCR) (phase
I/II portion), of a trimodality approach with PBT.
Methods: Patients with NSCLC (potentially resectable stage IIIA or
superior sulcus tumors) were enrolled on this prospective trial
(NCT01076231). Patients received neoadjuvant concurrent CRT with
PBT, followed by restaging and surgical resection. For each patient,
both a PBT plan and a photon therapy (IMRT) clinical backup plan
were generated. The starting radiotherapy dose level was 50.4 Gy
(feasibility phase), followed by sequential dose escalation to 59.4 Gy
and 66.6 Gy in 1.8 Gy daily fractions to determine MTD based on doselimiting toxicity. Primary outcomes were feasibility, MTD, and pCR.
Additional outcomes included post-operative toxicity, late toxicity,
progression-free survival (PFS), and overall survival (OS).
Results: From 2011-2018, 21 patients were enrolled, of whom 19
underwent surgical resection and were included in the ﬁnal analysis. The
trial was closed early before reaching MTD due to poor accrual. Median
age was 64 years. Radiotherapy doses were 50.4 Gy (n = 13, 68%) and
59.4 Gy (n = 6, 32%). Concurrent chemotherapy consisted of cisplatin/
etoposide (n = 15, 79%), carboplatin/paclitaxel (n = 3, 16%), and carboplatin/pemetrexed (n = 1, 5%). Most patients (n = 16, 84%) underwent
lobectomy. Primary endpoint of feasibility was met, as no patient
received photon therapy for > 30% of their total treatment, all patients
completed treatment within 10 days of planned completion date, no
treatment breaks > 5 days were required, and no patient experienced an
acute grade 3+ non-hematologic toxicity from PBT. pCR occurred in 5
patients (26%), including 2/13 patients (15%) who received 50.4 Gy and
3/6 patients (50%) who received 59.4 Gy (P = 0.26). Nodal pCR
occurred in 8/18 patients (44%) who were clinically node positive. There
were no post-operative grade 4-5 toxicities or deaths within 30 days.
One patient (5%) experienced late grade 4 toxicity (aspiration). Median
follow-up was 85.7 months (95% CI 38.6-105 mo). Median PFS was
22.3 months and median OS was 40.7 months.
Conclusions: The ﬁrst prospective report of neoadjuvant CRT with
PBT for LA-NSCLC demonstrated this approach as feasible, with an
acceptable toxicity proﬁle and favorable nodal pCR and survival rates.

(OA11) Sustained Lung Cancer Radiotherapy Quality
Improvement in a Statewide Collaborative Radiation
Oncology Quality Consortium
Shruti Jolly, MD1, Melissa Mietzel, MS1, Peter Paximadis, MD2, James
Hayman, MD, MBA1, Robert Dess, MD1, Reshma Jagsi, MD, DPhil1,
Kent Grifﬁth, MS1, Jean Moran, PhD1, Lori Pierce, MD1, Matthew
Schipper, PhD1, Martha Matuszak, PhD1; 1University of Michigan,
2
Spectrum Health
Background: Advancements in imaging and radiation therapy delivery
have made it possible to provide more targeted treatment with less
toxicity. With improved precision, the quality parameters required to
deliver high level radiation become even more important. In 2011, a
statewide collaborative quality initiative (CQI) was created focused on
lung and breast cancer patients (later expanded to other select patient
populations) to establish and disseminate best practice guidelines that
enable radiation oncology practitioners to optimize the delivery of costeffective care. Using an incentive participation program, various quality
measures and targets were utilized to drive improvements.
Objectives: To report the impact of a statewide CQI on the quality of
lung cancer radiotherapy delivered.
Methods: Using educational forums, in-person as well as virtual
meetings, and establishment of a lung cancer speciﬁc working group,
four time-limited measures for lung cancer radiation therapy quality
improvement have been developed over the course of the CQI. These
measures focused on 1]evaluation of lung tumor motion management,
2] tumor volume (GTV/ITV) deﬁnition as deﬁned by the consortium, 3]
TG-263 nomenclature compliance for heart and lungs, and 4] cardiac
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FIGURE 1. Change in lung motion assessment measure over time.
dose reduction (mean heart dose <20 Gy while keeping target coverage
> 95%). The rate of compliance of these measures was evaluated before
initiation of the measure and then annually. When consistent
improvement in the measure is noted, it is no longer tied to the incentive
participation program. Additional quality measures have been adopted
over time.
Results: To date, 3846 lung cancer patients from 27 radiation treatment
centers (academic and community practices) and over 125 members
participate in the collaborative by enrolling patients to this prospective
observational database. Adoption of lung motion assessment increased
from 57% to 93%. Even after removal of the incentive component of
this measure in 2018, the rate of compliance did not decrease. See ﬁgure
below. Target volume contouring per guidelines increased from 83% to
96%. The current rate of implementation of nomenclature standardization per TG-263 is 98%. The cardiac dose reduction and tumor
coverage measure increased from 44% to 85%.
Conclusions: Across a statewide consortium, we have seen a substantial improvement in lung cancer delivery and treatment. The long
term clinical impact of these improvements are being assessed by collection of cardiac and pulmonary toxicity outcomes (Fig. 1).

(OA12) Utility of Prophylactic Cranial Irradiation for
Limited Stage Small Cell Lung Cancer in the Modern Era
with Magnetic Resonance Imaging Surveillance
Siddharth Ghanta1, Andrew Keller, MD2, Joshua Rodríguez-López,
MD3, Ankur Patel, MD2, Sushil Beriwal, MD, MBA2; 1University of
Pittsburgh School of Medicine, 2UPMC Hillman Cancer Center,
3
Department of Radiation Oncology, UPMC Hillman Cancer Center,
University of Pittsburgh School of Medicine

Background: Limited stage small cell lung cancer (LS-SCLC) is
generally treated with local radiation or surgery and chemotherapy.
Since systemic therapy does not adequately cross the blood-brain barrier, brain metastases are common and prophylactic cranial irradiation
(PCI) has been utilized to reduce the risk of brain metastases. Multiple
meta-analyses of prospective trials and retrospective reviews demonstrated the utility of PCI in patients with LS-SCLC who responded to
upfront treatment (Aupérin et al NEJM 1999 and Meert et al BMC
Cancer 2001). However, all available prospective data includes patients
treated before 1998 before widespread MRI screening for brain metastases. The utility of PCI in patients with LS-SCLC in the modern era of
widespread MRI screening has not yet been examined in published
prospective trials and recent retrospective analyses have demonstrated
conﬂicting data.
Objectives: To retrospectively analyze the impact of prophylactic cranial irradiation (PCI) on survival and intracranial progression in patients
with limited stage small cell lung cancer (LS-SCLC) in the modern era
of widespread MRI brain screening.
Methods: Patients with LS-SCLC treated within our network between
2009-2020 who responded to initial therapy were stratiﬁed by receipt of
PCI and stage of disease. Propensity score match analysis was performed for stage II-III patients. Overall survival (OS) and neurologic
survival (NS) were deﬁned as time to death and presumed death due to
uncontrolled intracranial disease, respectively. Brain metastasis freesurvival (BMFS) and symptomatic brain metastasis free-survival
(SBMFS) were deﬁned as freedom from intracranial progression and
symptomatic intracranial progression, respectively. The effect of PCI on
these outcomes was assessed using Kaplan-Meier and Cox-proportional
hazards models.
Results: 243 (69.6%) of 349 patients received PCI. On multivariate
analysis (MVA) in the propensity matched stage II-III cohort, PCI was a

FIGURE 1. Kaplan-Meier plots of Overall Survival in entire cohort (1A), stage I cohorts (1B), and stage II-III cohorts (1C), stratified by use of PCI.
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FIGURE 2. Kaplan-Meier plots of Overall Survival (2A), Neurologic Survival (2B), Brain Metastasis Free-Survival (2C), and Symptomatic
Brain Metastasis-Free Survival (2D) within the propensity matched stage II-II cohort, stratified by use of PCI.
signiﬁcant predictor of improved NS (HR: 0.23, 95% CI: 0.08-0.65;
P = 0.01), BMFS (HR: 0.25, 95% CI: 0.12-0.51; P < 0.01) and SBMFS
(HR: 0.21, 95% CI: 0.08-0.55; P < 0.01), but not improved OS. 2-year
NS estimates within the propensity matched cohort were 96.8% (95%
CI: 87.6-99.2%) with PCI and 77.2% (95% CI: 63.0-86.4%) without
PCI and 1- and 2-year estimates of incidence of brain metastases were
3.9% (95% CI: 1.3-11.7%) and 11.7% (95% CI: 5.6-23.5%) in the PCI
group and 31.6% (95% CI: 22.1-43.9%) and 40.4% (95% CI: 29.254.0%) in the no PCI group, respectively.
Conclusions: In the modern era of MRI screening, PCI was associated
with reduced incidence of intracranial progression in patients with stage
II-III LS-SCLC who respond to initial therapy. This, importantly,
translated to a decreased risk of neurologic death within our propensity
matched cohort, without signiﬁcant improvement in overall survival
(Figs. 1 and 2).

(OA13) Phase II Trial Evaluating Efﬁcacy of a Fitbit Program for Improving the Health of Endometrial Cancer
Survivors
Elham Rahimy, MD1, Melissa Usoz, BS2, Rie von Eyben, MS1, Dylann
Fujimoto, BS3, Darla Watanabe, RN1, Amer Karam, MD1, Arati
Jairam-Thodla, NP1, Margaret Mills, NP1, Oliver Dorigo, MD PhD1,
Elisabeth Diver, MD1, Nelson Teng, MD PhD1, Diana English, MD4,
Elizabeth Kidd, MD1; 1Stanford University, 2Duke University School of
Medicine, 3University of California, Irvine, School of Medicine, 4University of South Florida
Background: Endometrial cancer has a strong association with obesity
and low physical activity. Despite the favorable prognosis of early stage
disease, mortality from cardiovascular disease in this patient demographic is high.
Objectives: We aimed to evaluate the efﬁcacy of a Fitbit program to
improve physical activity in endometrial cancer survivors.
Methods: Eligible patients were diagnosed with stage IA-IIIA endometrioid endometrial adenocarcinoma, at least three months out from
treatment, and English- or Spanish-speaking. All participants received a
Fitbit Alta and initial exercise consultation and were randomized to
receive reminders/goal-setting counseling via telephone or electronic

methods (email/text). Communication was every two weeks for two
months, then once during months four and ﬁve. Average daily steps
were assessed weekly for nine months. BMI and quality of life were
assessed at baseline and at three, six, and nine months follow-up.
Changes in activity and health/quality of life metrics were evaluated
with repeated measures models. Quality of life was evaluated with the
FACT-G questionnaire which consists of four domains (physical,
social, emotional, and functional well-being), each measured on a 24-28
point scale.
Results: The 46 analyzable patients demonstrated a baseline of 5,641
median daily average steps. Average steps increased by 22% at 6 months
but decreased to baseline by nine months. Baseline activity level (daily
steps and walks per week) was the greatest predictor of activity level.
Only the telephone intervention participants demonstrated increased
activity level at several timepoints, although not maintained by nine
months (Fig. 1). BMI was unchanged. There was mild improvement in
physical and social well-being in those with low baseline well-being
(P = 0.009 and 0.014, respectively), regardless of intervention group.
Emotional well-being correlated with step count (P = 0.005).
Conclusions: Activity level was low and mildly improved on the Fitbit
program with the telephone intervention, but effects did not persist by
study completion. The program had the greatest impact on a select
group of telephone intervention patients with high baseline walking
frequency and low baseline step count. Others may require more intense
intervention to promote more robust/persistent lifestyle changes.

(OA14) Survival Outcomes and Patterns of Recurrence
After Adjuvant Vaginal Cuff Brachytherapy and Chemotherapy in Early-Stage Uterine Serous Carcinoma
Andrew Cook, MD1, Ahmed Ghanem, MD PhD2, Miriana Hijaz, MD2,
Charlotte Burmeister, MS3, Mohamed Elshaikh, MD2; 1Department of
Radiation Oncology, Henry Ford Cancer Institute, 2Henry Ford Cancer
Institute, 3Henry Ford Health System
Background: Uterine serous carcinoma (USC) is a relatively rare histology that portends a poor prognosis. The optimal adjuvant therapy for
early-stage USC remains controversial; however, adjuvant vaginal cuff
brachytherapy (VB) and chemotherapy is a commonly utilized strategy.

FIGURE 1. Trends in daily steps overall and by intervention group. Average daily steps during the study for the whole cohort (left) and
stratified by intervention groups (right). Predicted mean trend lines are shown in bold. Tudor-Locke classification of steps is shown along
the y-axis.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

www.amjclinicaloncology.com

Copyright r 2021 Wolters Kluwer Health, Inc. All rights reserved.

| S13

Abstracts

American Journal of Clinical Oncology

Objectives: We sought to characterize predictors of survival endpoints
and determine recurrence patterns in women with early-stage USC who
received adjuvant VB and chemotherapy.
Methods: We queried our prospectively maintained database for patients
with 2009 FIGO stages I-II USC who underwent adequate surgical
staging at our institution and received adjuvant chemotherapy with carboplatin and paclitaxel along with VB. We excluded women with synchronous malignancies. Overall survival (OS), disease-speciﬁc survival
(DSS), and recurrence-free survival (RFS) were assessed by Kaplan-Meier
and log-rank tests. Univariate (UVA) and multivariate analyses (MVA)
were performed to identify statistically signiﬁcant predictors of survival
endpoints. Variables with P < 0.1 on UVA were included in a MVA and
any variable with P < 0.05 was considered statistically signiﬁcant.
Results: We identiﬁed 77 women who met our inclusion criteria who
underwent surgical staging between 1991 and 2018. The median followup time was 36 months (range 6-125). The median age was 66 years. Of
the cohort, 70% were FIGO stage IA, 17% were stage IB, and 13% were
stage II. The median number of dissected lymph nodes (LN) was 22.
There were 10 women (13%) diagnosed with a recurrence with a median
time to recurrence of 12.0 months. The main site of initial recurrence
was distant in seven patients (70%) with the remaining recurrences being
pelvic/para-aortic. The 5-year RFS for patients who experienced a distant recurrence was 87% (95% Conﬁdence Interval [CI] 0.75-0.94). For
the entire cohort, 5-year OS, DSS, and RFS were 83% (95% CI 0.680.91), 92% (95% CI 0.78-0.97), and 83% (95% CI 0.71-0.91), respectively. The sole predictor of 5-year OS on UVA was receipt of omentectomy (P = 0.09). The predictors of 5-year DSS on UVA were presence of positive peritoneal cytology (P = 0.03), number of LN examined
(Hazard Ratio [HR] 1.10, 95% CI 1.00-1.21, P = 0.05), and number of
para-aortic LN examined (HR 1.16 [95% CI 1.01-1.32], P = 0.03). The
sole independent predictor of DSS was the presence of positive peritoneal cytology (HR 0.03 [95% CI 0.00-0.72], P = 0.03). Predictors of
ﬁve-year RFS on UVA were robotic vs open surgery technique
(P = 0.06), presence of positive peritoneal cytology (P = 0.01), percent
myometrial invasion (HR 5.59 [95% CI 0.84-37.46], P = 0.08), and
presence of lymphovascular space invasion (LVSI) (P = 0.05).
Conclusions: Five-year survival outcomes were promising in this cohort
of women with early-stage USC treated with adjuvant chemotherapy and
VB; however, this study shows that the predominant pattern of relapse in
this population is distant, suggesting the need to optimize systemic therapy. Possible predictors of worse outcomes include positive peritoneal
cytology, deep myometrial invasion, and presence of LVSI. Multi-institutional pooled analyses are warranted to conﬁrm our study results.

(OA15) A Report on the Unique Secondary Malignancy Risk
Proﬁles for Uterine Cancer Patients Stratiﬁed by Treatment
Received: A SEER Database Study Spanning 40 Years
Ryan Kraus, MD1, Matthew Parsons, MD1, Christopher Weil, MD1,
Johnathan Chipman, PhD2, Gita Suneja, MD1, Lindsay Burt, MD1,
Melissa Brackmann, MD3, David Gaffney, MD/PhD4; 1University of
Utah Huntsman Cancer Institute, 2University of Utah, 3University of
Utah Huntsman Cancer Institute TRIAL, 4Huntsman Cancer Institute at
the University of Utah
Background: As treatment outcomes for uterine cancer improve, the
late side effects of treatment gain increasing importance.
Objectives: With this in mind, we sought to characterize the risk of
secondary malignancies (SM) in patients with uterine cancer based on
treatment modality rendered.
Methods: Patients diagnosed with uterine cancer between 1975 and
2016 were identiﬁed using the National Cancer Institute’s Surveillance,
Epidemiology and End Results Program database. Standardized incidence ratios (deﬁned as observed-to-expected [O/E] relative to the
endemic population), which account for patient years at risk, and
absolute excess risk of SM were assessed and quantiﬁed based on
treatment received. Given the standard removal of the ovaries and
cervix at the time of uterine cancer surgical staging, we did not include
malignancies of these sites in our analysis; nor did we include nonmelanoma skin cancers.
Results: We identiﬁed 117,283 patients with uterine cancer accounting
for 1,323,710 patient years at risk. In this population, 33,566 were treated
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with radiotherapy (RT) and 11,019 were treated with chemotherapy (CT).
17,062 SM were observed in 14,744 (13%) patients which was similar to
endemic rates (O/E 1.01, CI 1-1.03). Uterine cancer patients had higher
rates of colon, rectal, breast, vaginal, vulvar, bladder, renal, and thyroid
cancer compared with endemic rates (all P < 0.05). Bladder cancer was
identiﬁed as a late occurring SM with signiﬁcantly higher rates (O/E 1.94)
occurring > 20 years after diagnosis. There was an increased rate of SM
in patients treated with CT (O/E 1.27, CI 1.18-1.37), as well as RT (O/E
1.16, CI 1.13-1.19). There was no signiﬁcant difference in the rate of SM
between these two types of treatment. However, each form of treatment
was associated with a unique risk proﬁle of SM. When compared with
patients who received no therapy, patients treated with CT had higher
rates of SM of the colon, lung/mediastinum, bladder, thyroid, and leukemia while treatment with RT was associated with a higher rate of SM of
the colon, bone/joint, soft tissue, vulva, bladder, Non-Hodgkin lymphoma,
and leukemia (all P < 0.05). When evaluating the timing of SM, patients
treated with CT had signiﬁcantly higher rates of secondary leukemia (O/E
2.70, CI 1.69-4.09) within the ﬁrst ﬁve years of therapy than patients
treated with no therapy (O/E 0.92, CI 0.76-1.11) or RT (O/E 1.22, CI
0.89-1.62). When stratifying the associated site speciﬁc SM risk of different RT modalities, we found there was a numerically higher rate of any
SM in patients treated with larger volumes or higher doses of RT: brachytherapy (BT) 9.6% (O/E 1.11, CI 1.03-1.20), external bream radiotherapy (EBRT) 16.6% (O/E 1.14, CI 1.10-1.18), or combined EBRT and
BT 17.9% (O/E 1.23, CI 1.17-1.29).
Conclusions: In the largest population of uterine cancer patients
reported to date, we found that chemotherapy and RT were each
associated with a unique proﬁle of SM risks. This information may help
facilitate targeted SM screenings in uterine cancer patients based on the
treatment received.

(OA16) Limited Time Penalty for Improved Dosimetry:
Simpliﬁed Needle Insertion in Combined Tandem and
Ovoid + Interstitial Cases with Custom Templates
Thomas Niedermayr, PhD1, Elizabeth Kidd, MD1; 1Stanford University
Background: In cervical brachytherapy the addition of interstitial (IS)
needles to intra-cavitary (IC) applicators can signiﬁcantly enhance
dosimetry by improving target coverage without increasing normal tissues doses. Accurate placement of interstitial needles requires signiﬁcant
skill, time and imaging guidance proﬁciency, thereby limiting the beneﬁts to a subset of practitioners and patients. Available commercial
solutions lead to unsatisfactory needle locations for optimized dosimetry.
Objectives: We developed supplemental templates that attach to the
tandem applicator and guide needles to optimized positions for different
tumor topologies. This TARGIT (Tandem Anchored Radially Guiding
Interstitial Template, patent 63/124,784) is 3D printed from sterilizable
and biocompatible materials. We compared the dosimetry between
tandem and ovoid (TO) implants with no needles (NN), freehand needles (FH) or using TARGIT guided needles (TN) as well as the associated procedure length.
Methods: From Feb 2017-Jan 2021, 302 implants from 70 patients (4-5
implants per patient) were treated with TO only (n = 133), combined
TO/IS using either free-hand needles (n = 101) or TARGIT (Fig. 1)
guided needles (n = 68). Interstitial needles were inserted to a predeﬁned depth using the pre-procedure MRI and/or from previous
fractions. Varian TO Fletcher titanium applicators were inserted with
either no, freehand, or TARGIT-guided needles. Post implant CT was
used for planning along with MR for clinical target volume (CTV)
contouring. CTV, normal tissue metrics and procedure times were
compared between three groups: NN, FN or TN.
Results: The average CTV volume for the NN, FN, TN groups was
24.0 cc, 39.5 cc and 28.5 cc. The mean CTV V100% for the NN-FNTN groups was 87.2%, 84.1% and 90.2% whereas the combined
external beam + HDR normal tissue mean EQD2 doses were 79.9 Gy,
81.0 Gy and 82.0 Gy (Bladder); 62.3 Gy, 63.9 Gy and 64.7 Gy (Rectum); 66.3 Gy, 66.0 Gy and 68.2 Gy (Bowel). The difference between
the FN and TN groups was signiﬁcant for the V100% (P < 0.00003) but
not for any OAR doses (P > 0.13), which shows the beneﬁt of TARGIT-guided needles in improving the CTV coverage while preserving
normal tissue sparing. This improvement between FN and TN groups is
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FIGURE 1. TARGIT templates with needles directed sideways towards hard-to-reach regions of the tumor.
maintained for CTV volumes larger than 25cc with V100% of 83.7%
and 89.9% (P < 0.0006) while having a signiﬁcant (P = 0.07) dose
difference only for the bladder, increasing from 81.6 Gy to 84.8 Gy),
still below the 85 Gy limit. The mean procedure time for the NN-FNTN groups was 21 min (range, 7-58), 25 min (10-62) and 29 min (1056), which in the TN group includes a non-negligible ultrasound
imaging component for design feedback purposes.
Conclusions: The addition of TARGIT-guided needles improves CTV
coverage while maintaining normal tissue sparing, in particular for CTV
larger than 25cc. The simpliﬁed and optimized needle positioning with
TARGIT offers an effective, economical and time-efﬁcient solution.

(OA17) Is Substantial Lymphovascular Space Invasion Prognostic for Clinical Outcomes in Type II Endometrial Cancer?
Sushil Beriwal, MD, MBA1, Phillip Pifer, MD,PhD2, Sruthi Jaishankar2, Rohit Bhargava, MD3, Andrew Keller, MD1, Hima Bindu
Musunuru, MD2, Ankur Patel, MD1, Paniti Sukumvanich, MD4,
Madeleine Courtney-Brooks, MD4, Michelle Boisen, MD4, Jessica
Berger, MD4, Sarah Taylor, MD4, Alexander Olawaiye, MD4, Jamie
Lesnock, MD4, Robert Edwards, MD4, John Vargo, MD2; 1UPMC
Hillman Cancer Center, 2Department of Radiation Oncology, Hillman
Cancer Center, University of Pittsburgh Medical Center, 3Department
of Pathology, Magee-Women’s Hospital, University of Pittsburgh
Medical Center, 4Department of Gynecologic Oncology, MageeWomen’s Hospital, University of Pittsburgh Medical Center
Background: Analysis of PORTEC 1&2 demonstrated substantial
lymphovascular space invasion (LVSI) compared with none or focal
LSVI was predictive for pelvic recurrence, distant metastasis, and
overall survival (OS) in Type I endometrial cancer (Bosse T, et al Eur J
Cancer, 2015). Subsequently, substantial LVSI has been associated with
lymph node (LN) involvement in this histologic subtype (Pifer PM, et al
Gyn Onc 2020). Although LVSI has been associated with worse outcomes in Type II (clear cell and serous) endometrial cancer, the effect of
substantial LVSI has not been investigated.
Objectives: We aimed to quantify the relationship of substantial LSVI
on Type II endometrial cancer histologic subtypes and to correlate
extent of LVSI with LN involvement, loco-regional disease-free survival (LRDFS), distant metastasis-free survival (DMFS) and OS.
Methods: A retrospective review was conducted on patients with Type II
endometrial cancer (serous and/or clear cell histology with or without
endometrioid component) who underwent surgical staging from July 2017
to December 2019. Patients were excluded if they received neoadjuvant
therapy or had synchronous cancers. χ2 was used to assess the correlation
between the extent of LVSI and clinical/pathological factors. For univariate and multivariable analysis, LVSI was deﬁned as none/focal versus

substantial. Binary logistic regression was used for univariate analysis. For
the multivariate analysis with forward conditional selection, all variables
with P < 0.05 on univariate analysis were entered into the model. LRDFS,
DMFS and OS were analyzed using the Kaplan-Meier method.
Results: After surgical staging, 79 patients with Type II endometrial
carcinomas were identiﬁed (41 pure serous histology, 11 pure clear cell
histology and the remainder being of mixed histology). No LVSI was
present in 48.1%, focal LVSI was present in 15.2%, and substantial LVSI
was present in 36.7% of samples. In patients with LN evaluation (72 out
of 79), lymph nodes were involved in 0.0% without LVSI, 20.0% with
focal LVSI, and 60.0% with substantial LVSI (P < 0.001). On univariate
analysis, myometrial invasion > 50% (OR 33.8, 95% CI 6.6-171.7),
tumor size > 3.6 cm (OR 10.5, 95% CI 2.91-37.83), and substantial LVSI
versus none/focal LVSI (OR 10.5, 95% CI 2.91-37.83) were signiﬁcant
predictors for LN involvement. On multivariable analysis, myometrial
invasion > 50% and substantial LVSI versus none/focal LVSI remained
signiﬁcant predictors of LN involvement (P = 0.002 and P = 0.002). With
a median follow-up of 22.2 months, the 2-year LRDFS, DMFS, and OS
was 91.5% vs 71.4% (P = 0.01), 90.2% vs 63.8% (P = 0.005), and 95.4%
vs 72.3% (P = 0.072) for none/focal versus substantial LVSI.
Conclusions: Incidence of substantial LVSI is higher in Type 2
endometrial pathologies compared with Type I disease. Substantial
LVSI is associated with higher risk of LN involvement and worse
clinical outcomes in Type II endometrial cancer.

(OA18) Creation of Appropriate Use Criteria for Management of Uterine Clear Cell and Serous Carcinomas
Tracy Sherertz, MD1, Catheryn Yashar, MD2, Anuja Jhingran, MD3,
Andrew Wahl, MD4, Mohamed Elshaikh, MD5, Robert Coleman, MD3,
Matthew Biagioli, MD6, Elizabeth Kidd, MD7, David Gaffney, MD/
PhD8, Matthew Harkenrider, MD9, Aradhana Venkatesan, MD3, Shruti
Jolly, MD10, Lorraine Portelance, MD11, Karen Heskett, MSI12, William
Small, MD, FACRO, FACR, FASTRO13; 1Kaiser Permanente Washington, 2UCSD, 3MD Anderson Cancer Center, 4University of Nebraska
Medical Center, 5Henry Ford Cancer Institute, 6Advent Health, 7Stanford University, 8Huntsman Cancer Institute at the University of Utah,
9
Loyola University Chicago, 10University of Michigan Department of
Radiation Oncology, 11University of Miami Health System, 12University
of California San Diego, 13Loyola University Chicago, Stritch School of
Medicine, Cardinal Bernardin Cancer Center
Background: Uterine serous carcinomas (USC) and uterine clear cell
carcinomas (UCCC) represent a subset of endometrial cancers that have
a high propensity for peritoneal, lymphatic and distant spread, tend to
be more advanced at presentation, and carry a higher risk of recurrence
and death compared with most estrogen-mediated endometrioid
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carcinomas. Both USC and UCCC have typically been pooled into
studies that include other high-risk uterine cancers, but neither histology
has been exclusively studied in large prospective clinical trials. Thus,
the optimal treatment paradigm for each individual histology remains
somewhat undeﬁned, especially in early stage disease limited to the
uterus. Adjuvant treatment options include chemotherapy, vaginal cuff
brachytherapy (VBT) and pelvic +/- para-aortic external beam radiotherapy (EBRT), or both, with multimodality therapy typically considered for these aggressive tumors.
Objectives: We sought to rate the appropriateness of treatment procedures for a variety of USC and UCCC cases by a multidisciplinary
expert panel including gynecological oncologists and radiation oncologists with expertise in the treatment of uterine cancer.
Methods: An extensive and updated analysis of current medical literature
from peer-reviewed journals was conducted from 1/1/1996-1/28/2020 using
the Preferred Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines to search the PubMed, Embase and Web of Science
databases to retrieve a comprehensive set of relevant articles. We developed
strategies using subject and combinations of keywords search terms. We
reviewed the bibliographies of full articles for a comprehensive survey, and
relevant studies were included. The literature was reviewed for quality of
study design, cohort size, selection bias, variability of evaluation of participants in regard to time from exposure, and methods of assessments. In
addition, two signiﬁcant studies published in 12/20 and 2/21 were selectively
included during writing of the manuscript. A well-established consensus
methodology (modiﬁed Delphi) was used to rate the appropriateness of
treatment procedures by the expert panel.
Results: The panel recommends strongly vaginal cuff brachytherapy
(VBT) alone or systemic therapy + VBT as adjuvant treatment for a noninvasive surgically staged FIGO stage IA UCCC or USC. The panel
recommends strongly that adjuvant chemotherapy and radiation therapy
is usually appropriate for a typical case of FIGO stage IB UCS and
UCCC; an exception is the option for pelvic EBRT alone for a surgically
staged IB UCCC with minimal risk features. The panel recommends
strongly that tumor volume-directed radiation treatment is usually
appropriate in the adjuvant setting of patients with advanced stage USC
or UCCC. IMRT is the recommended treatment technique when EBRT
is recommended. For patients who undergo pelvic and para-aortic lymph
node sampling and are pN0, the panel recommends strongly omitting the
para-aortics from the external beam ﬁeld, while there was some disagreement on whether to target para-aortic lymph nodes when the pelvic
lymph nodes are known to be involved yet the para-aortic sampling was
negative. The panel strongly recommends against the routine use of
adjuvant WART outside of a clinical trial setting.
Conclusions: Due to the rarity of uterine clear cell and serous carcinomas, there is a paucity of prospective trials focusing exclusively on
management of these aggressive histologies and hence there is no
standard consensus for treatment strategy in patients with uterine clear
cell and serous carcinoma. Given the aggressive nature of these
malignancies, and until further research determines the most appropriate
adjuvant therapy, it may be reasonable to counsel patients about combined modality treatment with systemic chemotherapy and RT. Further
prospective studies or multi-institutional retrospective studies are warranted to determine optimal sequencing of therapy and appropriate
management of patients based on their unique risk factors.

(OA19) An Open-Label, Phase II, Multicenter, Single-Arm
Study of Induction and Concurrent Vismodegib Combined
with Curative-Intent Radiation Therapy for Locally
Advanced Basal Cell Carcinoma
Sue Yom, MD, PhD, MAS1, Sarah Arron, MD, PhD1, Alan Ho, MD,
PhD2, Alain Algazi, MD1, Lara Dunn, MD2, C. Jillian Tsai, MD, PhD,
MS2, Audrey Humphries, BS1, Carter Hultman, BS3, Roy Grekin, MD3, P.
Daniel Knott, MD3, Christopher Barker, MD2; 1University of California,
San Francisco, 2Memorial Sloan Kettering Cancer Center, 3UCSF
Background: Vismodegib is effective for basal cell carcinoma (BCC)
that cannot be removed with surgery. Its feasibility and efﬁcacy combined with deﬁnitive-intent radiation therapy (RT) have not been previously established. This phase II, multicenter clinical trial assessed the
disease response and toxicity resulting from a combined-modality
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course of vismodegib 150 mg daily before and concurrent with curativeintent RT to 66-70 Gy.
Objectives: To assess the primary endpoint of local-regional control (LRC)
rate at 12 months from completion of the protocol as well as the secondary
endpoints of rates of adverse events (AEs), overall response rate (ORR), and
rates of progression-free survival (PFS) and overall survival (OS).
Methods: Eligible patients were required to have inoperable BCC due
to surgical futility, functional morbidity or medical contraindication.
Ineligibility criteria included prior RT overlapping planned RT, presence of distant metastasis, Gorlin syndrome, administration of any
competing therapies, or malignancy or HIV with life expectancy of
<1 year such that the patient would not complete the trial endpoint.
Patients received 12-14 weeks of vismodegib followed by 6.5-7 weeks
of RT with concurrent vismodegib. The primary endpoint of LRC rate
at 12 months from end of treatment (EOT) was deﬁned as no evidence
of progression within the RT volume. A sample size of 24 yielded 81%
power to detect an increase in LRC from 60% to 80%, assuming a
directional level of signiﬁcance of 0.10 based upon a one-sample exact
binomial test. Secondary endpoints were AEs, ORR, PFS, and OS.
Results: 24 patients, including 18 men and 6 women having a median
age of 68 years (range, 50-98), were enrolled. During induction, 1
patient withdrew consent due to travel and 4 discontinued vismodegib
due to AEs. 1 discontinued vismodegib during RT due to AEs. 1
expired just after EOT from pre-existing aortic aneurysm. Thus 17/24
patients were evaluable for the primary endpoint. During the study, 1
patient had grade 4 eye disorder, and 9 (38%) patients had grade 3 AEs
including hyponatremia (13%), oral mucositis (8%), gastrointestinal
(8%) or dermatologic (8%) disorder, liver function (4%), anemia (4%),
and hypertension (4%). 19 (79.2%) patients had grade 2 AEs including
dermatitis (33%), dysgeusia (33%), myalgia (25%), fatigue (21%), oral
mucositis (21%), and weight loss (17%). At end-of-induction, the ORR
among 19 evaluable patients was 74%, while at 3 months post-EOT,
among 17 evaluable it was 88%. At 12 months post-EOT, all 17 were
alive with LRC. For all 24 patients, the median followup was 33 months
(range, 0-62), and the estimated 3-year PFS and OS were 82% (95% CI,
59-93%) and 91% (95% CI, 68-98%), respectively. Among 17 evaluable patients, the median followup was 31 months (range, 16-62), and
the 3-year PFS and OS were 88% (95% CI, 61-97%) and 100%,
respectively. No patient developed distant metastasis.
Conclusions: Vismodegib-RT was efﬁcacious with an expected toxicity
proﬁle. The potential advantages of this strategy are wound healing and
contracture of subclinical disease before RT as well as radiosensitization
during RT. Concurrent vismodegib did not affect completion of deﬁnitiveintent RT. This is the ﬁrst clinical trial reporting a novel strategy of combining targeted therapy with RT for unresectable, locally advanced BCC.

(OA20) Predictors of Pathologic Lymph Node Positivity in
Clinically Node Negative Oral Cavity Cancer Patients
Eric Anderson, MD1, Michael Luu, MPH1, Diana Lu, MD1, Eric
Chung, MD1, Christopher Gay, MD1, Kevin Scher, MD1, Alain Mita,
MD1, Jon Mallen-St. Clair, MD1, Allen Ho, MD1, Zachary Zumsteg,
MD1; 1Cedars-Sinai Medical Center
Background: Most patients undergoing surgery for clinically nodenegative (cN0) oral cavity cancer (OCC) require elective neck dissection (END) based on randomized controlled trials showing improved
survival with END versus observation. Prior retrospective studies have
suggested that primary tumor depth of invasion (DOI) is the dominant
predictor of occult lymph node involvement and can be used to select
patients for omission of END. However, these studies primarily focused
on oral tongue cancers, and it is unclear if the importance of DOI is
applicable to other oral cavity cancers. Moreover, the independent
predictive value of DOI in comparison with other correlated factors like
T-stage, grade, and lymphovascular invasion is not well established.
Objectives: We sought to systematically examine predictors of pN+ for
cN0 oral cavity cancers of various sites.
Methods: Patients with cN0 oral cavity cancers with at least 2 mm DOI
diagnosed from 2010-2015 and undergoing primary surgery were
identiﬁed in the National Cancer Data Base. Patients with missing
pathologic variable data were excluded. Multivariable logistic regression was performed to assess predictors of pN+.
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Benjamin Smith, MD1, Julius Weng, MD2, Xiudong Lei, PhD2, Pamela
Schlembach, MD2, Elizabeth Bloom, MD2, Simona Shaitelman, MD,

MEd3, Isidora Arzu, MD, PhD2, Daniel Buchholz, MD4, Gregory
Chronowski, MD2, Tomas Dvorak, MD4, Emily Grade, MD5, Karen
Hoffman, MD, MPH2, George Perkins, MD, MBA6, Valerie Reed,
MD2, Shalin Shah, MD2, Michael Stauder, MD2, Eric Strom, MD2,
Welela Tereffe, MD2, Wendy Woodward, MD PhD1, Gabriel Hortobagyi, MD2, Kelly Hunt, MD2, Thomas Buchholz, MD7; 1University of
Texas MD Anderson Cancer Center, 2MD Anderson Cancer Center,
3
Department of Radiation Oncology, The University of Texas MD
Anderson Cancer Center, 4Orlando Health UF Health Cancer Center,
5
Banner MD Anderson Cancer Center, 6smoulder@mdanderson.org,
7
Scripps MD Anderson Cancer Center
Background: Whole-breast irradiation (WBI) is well-tolerated by the
majority of women with early breast cancer, however, a signiﬁcant
minority experience persistent treatment-related toxicity and suboptimal
cosmetic results. There is little data on clinically relevant predictors of
patient- and physician-reported outcomes after WBI plus a boost, and
whether unique subsets of patients experience better outcomes after
hypofractionation compared with conventional fractionation.
Objectives: To characterize longitudinal PROs and cosmesis obtained
in a prospective, randomized trial comparing conventionally fractionated (CF) vs hypofractionated (HF) WBI plus boost.
Methods: From 2011 to 2014, women age ≥ 40 years with Tis-T2,
N0-N1a, M0 breast cancer who underwent lumpectomy with negative
margins were randomized to CF-WBI (50 Gy/25 fractions plus boost)
vs HF-WBI (42.56 Gy/16 fractions plus boost). At baseline (pre-radiation), 6 months, and yearly thereafter through 5 years, PROs included
the Breast Cancer Treatment Outcome Scale (BCTOS), Functional
Assessment of Cancer Therapy-Breast (FACT-B), and Body Image

FIGURE 1. BCTOS longitudinal multivariable mixed-effects growth
curve models. A lower score indicates a better outcome. a indicates
referent group, * indicates P-value < 0.05, *** indicates P value <
0.001, 95% CI = 95% confidence interval, HF = hypofractionated,
CF = conventionally fractionated, WBI = whole-breast irradiation.

FIGURE 2. FACT-B longitudinal multivariable mixed-effects
growth curve models. A higher score indicates a better outcome.
a indicates referent group, * indicates P-value < 0.05, *** indicates
P value < 0.001, 95% CI = 95% confidence interval, HF =
hypofractionated, CF = conventionally fractionated, WBI = wholebreast irradiation.

Results: 5060 cN0 patients met inclusion criteria, including 1127 (22.3%) pN
+ patients. pN+ rates varied by OCC subsites (oral tongue: 25.6%; ﬂoor of
mouth: 19.4%; other sites: 19.3%). In multivariable logistic regression, the
presence of lymphovascular invasion (LVI) was the strongest predictor of pN+
(odds ratio [OR] = 4.28, 95% conﬁdence interval [CI] 3.34-5.44, P < 0.001).
Histologic grade also strongly predicted pN+ (high- vs. low-grade: OR 3.18,
95% CI 2.24-4.55, P < 0.001; intermediate- vs. low-grade: OR 2.20, 95% CI
1.64-2.98, P < 0.001). Other predictors of pN+ were higher pT-stage and oral
tongue primary site. DOI was not a predictor of pN+ among the full cohort of
OCC patients. However, DOI did independently correlate with pN+ in the oral
tongue subgroup ( ≥ 20 mm, OR 2.04, 95% CI 1.08-3.82, P = 0.027; 1019.99 mm, OR 1.67, 95% CI 1.10-2.57, P = 0.018), although LVI and grade
remained the strongest predictors of pN+ in this anatomic site.
Conclusions: LVI and histologic grade are the strongest predictors of
pN+ among patients with cN0 OCC. DOI predicts pN+ in patients with
oral tongue cancer, but not for patients with OCCs of other anatomic
subsites. Even for oral tongue cancer, DOI was found to be a weaker
predictor than LVI or histologic grade. These factors should be given
greater consideration when determining which patients require END.

(OA21) 5-Year Longitudinal Analysis of Patient-Reported
Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated versus Hypofractionated WholeBreast Irradiation
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FIGURE 3. Body Image Scale (BIS) longitudinal multivariable
mixed-effects growth curve model. A lower score indicates a
better outcome. a indicates referent group, * indicates P-value <
0.05, *** indicates P value < 0.001, 95% CI = 95% confidence
interval, HF = hypofractionated, CF = conventionally fractionated,
WBI = whole-breast irradiation.
Scale; cosmesis was reported by the treating physician using Radiation
Therapy Oncology Group cosmesis. Multivariable mixed effects growth
curve models evaluated associations of treatment arm and patient factors with outcomes and tested for relevant interactions with
treatment arm.
Results: A total of 287 patients were randomized, completing a total of
14,801 PRO assessments. Median age was 60 years, median follow up
was 48.3 months, 37% had bra cup size ≥ D, 44% were obese, and 30%
received chemotherapy. Patient, tumor, and treatment characteristics
were well-balanced between the two treatment arms. Through 5 years,
there were no signiﬁcant differences in PROs or cosmesis by treatment
arm. Bra cup size ≥ D was associated with worse BCTOS cosmesis
(P < 0.001), BCTOS pain (P = 0.001), FACT-B Trial Outcome Index
(P = 0.03), FACT-B Emotional Well-Being (P = 0.03), and Body Image
Scale (P = 0.003). Chemotherapy receipt was associated with worse
BCTOS pain (P = 0.02). Physician-rated cosmesis was worse in patients
who were overweight (P = 0.02) or obese (P < 0.001), relative to those
with a normal weight. No patient subsets experienced better PROs or
cosmesis with CF-WBI.
Conclusions: Both CF-WBI and HF-WBI confer similar longitudinal
PROs and physician-rated cosmesis through ﬁve years follow up, with
no relevant subsets that fared better with CF-WBI. The associations of
large breast size and obesity with adverse outcomes across multiple
domains highlights the opportunity to engage at-risk patients in lifestyle
intervention strategies, as well as consideration of alternative radiation
treatment regimens, such as partial breast irradiation (Figs. 1–3).

(OA22) Surgical Drain Fluid Liquid Biopsy Analysis of
Locoregional Residual Disease After Surgery in HPV+
Oropharyngeal Cancer for Adjuvant Radiotherapy Risk
Stratiﬁcation
Noah Earland, BS1, Ricardo Ramirez, MD2, Peter Harris, PhD3, Sophie
Gerndt, MD2, Jeffrey Szymanski, MD, PhD4, Benjamin Wahle, MD2,
Katherine Chang, MD2, Jose Zevallos, M.D., MPH, FACS2, Aadel
Chaudhuri, MD, PhD4; 1Washington University in St. Louis School of
Medicine, 2Washington University School of Medicine, 3Department of
Radiation Oncology, Washington University School of Medicine in St.
Louis, 4Washington University School of Medicine in St. Louis
Background: In the current era of treatment de-intensiﬁcation for HPV
+ oropharyngeal squamous cell carcinoma (OPSCC), we urgently need
to improve adjuvant treatment risk stratiﬁcation after surgery.
Objectives: We present a novel, objective, proximal, and quantiﬁable
biomarker of locoregional residual disease (LRD): surgical drain ﬂuid
(SDF). We hypothesize that elevated HPV viral load in SDF correlates
directly with high-risk surgical pathology and can help risk-stratify
adjuvant chemo/radiotherapy.
Methods: Eighty-four SDF neck dissection specimens were collected
postoperatively at 24 hours from 58 HPV+ OPSCC patients. We
measured SDF blood content using the NanoDrop Oxy-hemoglobin
method. Limit of detection (LOD) of Taqman quantitative PCR (qPCR)

FIGURE 1. HPV levels in postoperative surgical drain fluid versus
surgical pathology. All 84 SDF samples were categorized according
to the local pathological diagnosis of the neck from which they
were extracted; ENE+ N1 or N2, ENE- N1 or N2, and N0. ENE+
N1/N2 had the significantly highest HPV levels in SDF (median
145 copies/uL), followed by ENE- N1/N2 (median 7 copies/uL),
and lastly, the N0 necks (median ND). ND = not detected.

was compared with digital droplet PCR (ddPCR) by analyzing 10-fold
dilutions of the HPV16 E6T2aE7 plasmid. HPV copies/uL in DNA
eluted from SDF were then compared with pathological features (ENE,
number of positive nodes). HPV detection was also performed in paired
plasma samples from 25 node+ patients. Statistical analyses included
Wilcoxon, Kruskal-Wallis, Fisher’s exact testing, and Spearman correlation. AJCC 8th edition was used for staging.
Results: LOD was 5 HPV copies using Taqman qPCR with 24 replicates and > 95% conﬁdence. This was similar to the LOD attained by
ddPCR, so we used Taqman qPCR for further analyses. Hemoglobin
concentration had no correlation to HPV levels (ρ = -0.07, P = 0.53).
The proportion of N1-N2 necks with HPV levels above LOD was 6-fold
higher than N0 necks (P < 0.0001; Fig. 1). Furthermore, median HPV
copies were 20-fold higher in ENE+ N1-N2 compared with ENEN1-N2 necks (P = 0.015; Fig. 1). These data suggest that post-operative
SDF HPV detection levels reﬂect invasive nodal disease and serve as a
proxy for LRD. As adjuvant therapy escalation occurs in patients with
higher-risk disease, stratifying SDF by eventual adjuvant therapy type–
radiation alone (XRT), chemoradiation (CRT), or none (No Tx)–
revealed that median HPV load was higher in CRT and XRT than in No
Tx (P = 0.044; Fig. 2). Strikingly, 15 (33%) patients treated with XRT
or CRT had undetectable HPV in their SDF, suggesting these patients
could potentially have safely undergone treatment de-escalation. Also, 3
of 18 (17%) patients treated with adjuvant CRT with detectable HPV in
SDF experienced suspicious or conﬁrmed recurrence, suggesting they
could have potentially beneﬁted from further or orthogonal treatment
escalation (i.e. immunotherapy). Lastly, only 4 (16%) post-operative
paired plasma samples had detectable HPV, implying inferior sensitivity for detecting LRD compared with SDF.
Conclusions: Postoperative qPCR of SDF enables LRD detection in
HPV+ OPSCC. SDF is highly enriched for HPV compared with plasma
and correlates signiﬁcantly with aggressive pathologic features (nodal
stage, ENE) and adjuvant treatment escalation. If conﬁrmed, postoperative SDF analysis could someday aid traditional pathology to
personalize adjuvant therapy for surgically treated HPV+ OPSCC.
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FIGURE 2. HPV levels in postoperative surgical drain fluid by
adjuvant treatment type. SDF was collected postoperatively (the
SDF with the higher HPV copies was used for patients with
bilateral neck dissections). There was a non-significant elevation in
SDF HPV levels from patients who went on to receive chemoradiation therapy (CRT) compared with only radiation therapy
(XRT) (median 263 vs. 18 copies/uL; P = 0.56). SDF from patients
in the CRT group was significantly enriched for HPV compared
with no treatment (No Tx) (median 263 copies/uL vs. ND;
P = 0.026). The single patient that recurred in the No Tx group
was deemed to be high-risk but declined adjuvant radiotherapy.
ND = not detected.

(OA23) DNA Damage Response Inhibitors Potentiate
Immunogenic Cell Death and Radiotherapy in Merkel Cell
Carcinoma
Peter Goff, MD, PhD1, Rashmi Bhakuni, PhD1, Thomas Pulliam1,
Ramesh Rengan, MD, PhD1, Paul Nghiem, MD, PhD1; 1University of
Washington
Background: Metastatic cancer with primary or acquired resistance to
immune checkpoint inhibitors requires novel management strategies.
Merkel cell carcinoma (MCC) is immunogenic with the highest
response rate to PD-1 pathway blockade among solid tumors such that
approximately 50% of patients with advanced MCC attain durable
disease control. Cell cycle checkpoint and DNA damage response
(DDR) proteins, including ATR, ATM & DNA-PK, have been recognized as promising therapeutic targets for decades. However, it is only
recently described in preclinical studies that targeting the DDR may
stimulate anti-tumor immunity and augment existing immunotherapies.
Importantly, speciﬁc and potent DRR inhibitors (DDRi) are in earlyphase clinical investigation. The rapid growth of MCC is driven by
deregulation of early cell cycle components (e.g. p53 & Rb inactivation
paired with Myc protein upregulation), suggesting high replication
stress and susceptibility to DDRi or DNA damaging agents. MCC
tumors are particularly radiosensitive. The mechanisms governing how
DDRi may interact with radiation to promote antitumor immunity are
not well understood; however, they may potentiate immunogenic cell
death (ICD) to recruit and activate antigen presenting cells.
Objectives: We assessed if several classes of DDRi, alone or in combination with radiation, potentiated ICD and quantiﬁed their potencies
as radiosensitizers in MCC cell lines. These preclinical studies are an
early test of our hypothesis that DDRi could play a role in the treatment
of PD-1 pathway blockade-refractory MCC.
Methods: Representative Merkel cell polyomavirus positive (VP) and
negative (VN) MCC cell lines were treated with various doses of single
fraction radiation (0, 2, 4, 8, 16 Gray; 160 kV x-rays) +/- inhibitors of
ATR, ATM or DNA-PK (ATRi, ATMi and DNA-PKi). Cells were
assessed for viability and hallmarks of ICD including extracellular ATP
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release (luciferase assay) and HSP70 secretion (ELISA) at 1 - 5 days
post-treatment.
Results: Inhibitors of ATR, ATM and DNA-PK are all effective radiosensitizers of MCC, and DNA-PKi proved the most potent with an
enhancement ratio of ∼5-fold compared with ∼2-fold or less for ATMi
or ATRi across cell lines. ATRi and ATMi induced extracellular release
of ATP or HSP70 alone or in combination with low dose radiation (2 4 Gy) more effectively than when combined with radiation doses of
≥ 8 Gy in VP and VN cell lines. DNA-PKi, however, had limited ability
to potentiate these ICD markers alone and, in fact, abrogated extracellular ATP release compared with radiation alone in a VP cell line.
Conclusions: Either alone or in combination with low-dose radiation (1
fraction of 2-4 Gy), ATRi and ATMi more effectively induced canonical markers of ICD in MCC cell lines compared with DNA-PKi. DNAPKi was superior as a radiosensitizer; however, it apparently enhanced a
non-immunogenic mechanism of cell death. Elucidating the cell death
pathways induced by radiation and DDRi in MCC is underway.
Understanding why relatively lower radiation doses appear more
immunogenic when combined with ATRi and ATMi is of particular
interest. Given its inherent immunogenicity, cell cycle checkpoint
deﬁciencies and radiosensitivity, MCC is relevant for the preclinical and
clinical evaluation of DDRi as novel agents to overcome PD-1 pathway
blockade resistance.

(OA24) What Is Reasonably Achievable? Evaluation of Left
Breast Mean Heart Dose Distributions to Improve the Peer
Review Process
Amit Sood, MD1, Rachel Hackett, CMD, RTT1, Mark Farrugia, MD,
PhD1, Varun Chowdhry, MD1; 1Roswell Park Comprehensive Cancer
Center
Background: To improve the peer review process, our Radiation
Oncology department deﬁned disease site speciﬁc dose constraints for
organs at risk (OARs) based on QUANTEC and national protocols.
However, there is opportunity to improve on these existing dose
constraints.
Objectives: For patients undergoing radiotherapy to the left breast, our
departmental mean heart dose constraint is 3 Gy. However, in our
experience this constraint is achievable in virtually all circumstances.
To improve the process of peer review, we wanted to understand the
distribution of mean heart dose (MHD) for patients treated at our center
to identify plans that are potential outliers.
Methods: We retrospectively reviewed aggregate data from peer
reviewed treatment plans for patients treated at our center from 2019 to
2020 utilizing Radiologica software (Radiologica LLC, St. Louis,
MO). We analyzed MHD in patients being treated with hypofractionated radiotherapy (HFx, 40 Gy/15fx) +/- boost for left whole breast as
well as patients treated with conventional fractionated radiotherapy
(CFx, 50 Gy/25fx) in patients undergoing regional nodal irradiation
(RNI) +/- boost. All patients underwent deep inspiratory breath hold
(DIBH).
Results: A total of 191 patients were identiﬁed, including 162 in the
HFx group and 29 in the CFx group. Using a student’s t-test, the use of
a boost did not impact the mean heart dose (P = 0.44). In both the HFx
and CFx group, there were no patients who exceeded 3 Gy MHD. In the
HFx group, MHD was 0.82 Gy (95% CI ,0.37 -1.72), and there were 7/
162 (4.3%) of cases identiﬁed with the MHD exceeding two-standard
deviations ( > 1.72 Gy). In the CFx group, MHD was 1.46 Gy (95%CI
0.34-2.58), and there were 0/29 (0%) of cases identiﬁed with mean heart
dose exceeding two-standard deviations ( > 2.58 Gy).
Conclusions: For patients undergoing radiotherapy for left sided
breast cancer, a MHD of 3 Gy is not helpful to stratify cases that need
more detailed peer review. Based on our results, we recommend an
additional physician and dosimetrist review of contours and treatment
plan where mean heart dose falls two standard deviations outside the
mean ( > 1.72 Gy). This standard will serve for a future quality
improvement project. Understanding the distribution of doses to a
particular OAR can be helpful in identifying plans that could beneﬁt
from more careful peer review. This process can be used for other
OARs and disease sites.
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FIGURE 1. Proportion of each race/ethnicity and sex for radiation
oncology pipeline in 2019.

(OA25) Intersection of Race or Ethnicity and Sex on Senior
Faculty Representation in Radiation Oncology: Mixed
Changes from 2000 to 2019
James Janopaul-Naylor, MD1, Lauren Beck2, Sanford Roberts, MD3,
Jeffrey Switchenko, PhD, MS1, Mylin Torres, MD1; 1Winship Cancer
Institute at Emory University, 2University of Pennsylvania, 3University
of Pennsylvania Department of Surgery
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Background: Radiation Oncology (RO) is a small, specialized ﬁeld of
medicine traditionally included in Radiology (R) Departments until the 1980s.
Given work hours primarily conﬁned to the busines week with few emergencies, the opportunity to care for cancer patients, and favorable compensation, RO is a potentially attractive career. Advantages of a diverse physician
workforce include higher patient satisfaction, patient compliance with physician recommendations, and increased participation of under-represented
minority (URM) patients in clinical research (Cooper-Patrick et al, JAMA
1999; Branson et al, Am J Surg 2007). However, data from 2000 to 2020
indicate that URM and female representation in RO continues to be poor, with
the ﬁeld having less diversity than in medical schools and even other oncology
specialties (Chapman et al IJROBP 2013; Deville et al, IJROBP 2020).
Objectives: The goal of this study was to determine the proportion of
women and URMs senior faculty over the last two decades in RO
relative to other departments. We compared RO to Internal Medicine
(IM), General Surgery (GS) and R given the large number of physicians
in IM and GS and the historical relationship RO has with R.
Methods: AAMC data were used to determine the proportion of women
and URMs in senior faculty positions (Full or Associate Professors) in RO
relative to IM, GS, and R. Comparisons were assessed using the CochranArmitage trend test and multivariable linear regression models using SAS.
Results: From 2000 to 2019, the proportion of women and Asian male
senior faculty increased among RO, IM, GS, and R Departments
(P < 0.001). The proportion of senior faculty who were women
increased faster in RO than GS or R (P < 0.001) but slower than in IM
(P < 0.001). While the proportion of senior faculty that were non-White
increased fastest in RO (1.00% per year, P < 0.001), this change in
representation was largely due to the increase in Asian males. The
increase in proportion of non-white/non-Asian faculty who became
senior faculty over time was signiﬁcantly lower in RO (0.04% per year)
than in GS (0.16% per year, P < 0.001), IM (0.24% per year, P < 0.001)
or R (0.12% per year, P < 0.001). The proportion of Black male senior
faculty in RO decreased 70% (Fig. 1) since 2000, while remaining
stable in other departments. Full, Associate, or Assistant Professors who
identiﬁed as American Indians, Alaskan Natives, Native Hawaiians, or

FIGURE 2. Proportion of each race/ethnicity and sex for professors in radiation oncology from 2000 to 2019.
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FIGURE 3. Proportion of each race/ethnicity and sex for full professors in all departments in 2019.
other Paciﬁc Islanders decreased 20% in RO, while increasing in IM,
GS, and R from 2000-2019. Among all clinical departments, RO was
among lowest in representation of White or Hispanic women and
Hispanic men in senior faculty positions.
Conclusions: Our ﬁndings indicate that sex and URM disparities in RO
are large and improving at slower rate than in IM, GS, and R. Emphasis
on improving these gaps in representation is needed in our ﬁeld to
address the needs of our diverse patient population and reﬂect the
increasing diversity of medical students (Figs. 2 and 3).

Methods: A principal component analysis (PCA) of differentially
methylated immune synapse genes in 8,186 solid tumors and 745 normal
adjacent tissues from TCGA database was performed. Subsequently, the
dysregulated methylation pattern of immune synapse genes was validated
in two independent cohorts (GSE120878 and GSE86355 datasets). Lastly,
the capacity of PC1 to predict response to immunotherapy in melanoma
was investigated. Pearson’s, Spearman’s and t-SNE correlation statistics,
and the 2-sided Student’s t tests were performed as appropriate. The

(OA26) Epigenetic Methylation of Immune Synapse Genes
in Primary and Metastatic Melanoma Tumors
Matthew Mills, MD1, Anders Berglund, PhD2, Ryan Putney, PhD2, Imene
Hamaidi, PhD2, James Mule, PhD3, Sungjune Kim, MD PhD2; 1H. Lee
Mofﬁtt Cancer Center and Research Institute, Department of Radiation
Oncology, 2H. Lee Mofﬁtt Cancer Center and Research Institute, 3Department of Immunology, H. Lee Mofﬁtt Cancer Center & Research Institute
Background: Tumor cells often express immune synapse proteins to
evade the immune system, which are frequently regulated by epigenetic
mechanisms. Our prior work (Berglund, A., JCI, 2020, 10.1172/
JCI131234) demonstrated that the methylation status of immune synapse genes in multiple tumor types was associated with functional T cell
recruitment and associated with survival.
Objectives: To assess whether the methylation status of immune synapse genes predicts response to immunotherapy in metastatic melanoma.

FIGURE 1. A demonstrates response to immunotherapy by PC1
status. B is a Kaplan Meier curve of overall survival stratified by
PC1 status.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

www.amjclinicaloncology.com

Copyright r 2021 Wolters Kluwer Health, Inc. All rights reserved.

| S21

Abstracts

American Journal of Clinical Oncology

Kaplan-Meier method was utilized for overall survival (OS), with log-rank
testing to identify associated with methylation status.
Results: The PCA has revealed two main components: PC1 and PC2.
PC1 was mainly driven by co-stimulatory genes (i.e. CD40), frequently
hypermethylated in tumor in comparison with normal adjacent tissue.
Conversely, PC2 was characterized by immune checkpoint genes (i.e.
HHLA2), which are often hypomethylated in melanoma. Such dysregulated methylation was validated in the independent cohorts,
GSE120878 and GSE863, as costimulatory genes were hypermethylated and immune checkpoint genes were hypomethylated in
melanoma compared with nevi. Importantly, a pilot analysis of a melanoma patient cohort who were treated with immunotherapy (N = 29)
demonstrated a trend for superior response to immunotherapy
(P = 0.15) and survival (HR 2.32, P = 0.15) in patients with low
PC1, which is characterized by relative hypomethylation of costimulatory genes.
Conclusions: The selective hypomethylation of immune checkpoint
genes and hypermethylation of co-stimulatory genes by melanoma
represents a crucial epigenetic mechanism of immune evasion, and the
relative methylation levels of these genes may predict response to
immunotherapy and survival (Fig. 1).

(OA27) Circulating Tumor Cells, Isolated Using the Graphene Oxide Microﬂuidic Chip, Predict Shorter Progression
Free Survival in Stage III Non-Small Cell Lung Cancer
Patients
Emma Purcell1, Zeqi Niu1, Shruti Jolly, MD2, Sunitha Nagrath, PhD1;
1
University of Michigan, 2University of Michigan Department of
Radiation Oncology
Background: Stage III non-small cell lung cancer (NSCLC) patients
commonly undergo radiation therapy, with imaging scans being the
standard of care for determining disease progression both during and
after radiation. Imaging technologies only detect progression after it
has occurred, which may be well after tumor growth or disease
progression has begun. We suggest that the molecular characterization of circulating tumor cells (CTCs) found in the bloodstream
can identify or predict disease progression before it is currently
diagnosable.
Objectives: The objective of this work is to determine whether CTC
metrics, including the number of CTCs, change in the number of
CTCs during treatment, and PD-L1 expression on CTCs, can be used
as a blood-based biomarker to predict patient outcomes in stage
III NSCLC.
Methods: Blood from 26 stage III NSLC patients was processed for
CTC isolation and analysis using the graphene oxide (GO) microﬂuidic
chip. The GO chip isolates CTCs using immunoafﬁnity capture, taking
advantage of EPCAM, EGFR, and CD133 expression on CTCs for
speciﬁc isolation. CTCs were quantiﬁed by protein expression at six
timepoints as being DAPI+/CK+, CD45- cells with two subpopulations

FIGURE 1. A, PFS curve for percent decrease in CTCs between
pre-treatment and mid-radiation. B, PFS curve for percent PD-L1+
CTCs at pre-treatment.
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deﬁned as PD-L1+/- CTCs. The number of CTCs, percent change in the
number of CTCs, and the number of PD-L1+ CTCs were correlated to
clinical metrics including progression free survival (PFS) time. The
primary endpoint was disease progression, either locoregional, distant,
or death.
Results: CTCs were present in 100% of patients (n = 26/26), and at
93% of timepoints (n = 102/110). The number of CTCs decreased
signiﬁcantly from pre-treatment to mid-radiation (P = 0.02), after
radiation (P = 0.04), and mid-immunotherapy (P = 0.02) timepoints.
By calculating the percent decrease in CTCs from pre-treatment to
mid-radiation therapy, it was found that patients who had a large
decrease in CTCs had sustained stability. Conversely, patients who
had an increase in CTCs during radiation therapy were likely to have
progression. Patients were split in two even groups, deﬁned by a 75%
change in CTCs between pre-treatment and mid-radiation. A decrease
in CTCs of less than 75% precluded a signiﬁcantly shorter PFS time,
7 months vs 21 months average monitoring time with no progression
(P = 0.005), Fig. 1A. Secondarily, the number of PD-L1+ CTCs were
quantiﬁed and found to decrease from pre-treatment to the ﬁrst week
of radiation therapy (P = 0.045). It was found that the three patients
who had progression while receiving anti-PD-L1 immunotherapy had
a quantity of PD-L1+ CTCs greater than the median at all time points.
Survival analysis shows that having > 50% PD-L1+ CTCs at pretreatment potentially predicts a shorter PFS, Fig. 1B.
Conclusions: CTCs isolated using the GO chip are a potential bloodbased biomarker to predict patient outcomes in stage III NSCLC
undergoing chemoradiation. Increase in the number of CTCs during
radiation treatment and the percent of PD-L1+ CTCs at pre-treatment
may indicate shorter PFS time.

(OA28) Biological Guided Carbon-ion Microporous Radiation to Tumor Hypoxia Area Triggers Robust Abscopal
Effects as Open Field Radiation
Jiade Lu, MD1, Qingting Huang, MSc1, Yun Sun, PhD1, Lin Kong,
MD1, Weiwei Wang, MSc1, Lien-Chun Lin, MSc1, Yangle Huang,
PhD2, Jing Yang, MD1, Xiaodong Wu, PhD1; 1Shanghai Proton and
Heavy Ion Center, 2Fudan University Shanghai Cancer Center
Background: Recently, a growing number of studies focus on partial
tumor irradiation to induce the stronger non-target effects. However, the
value of partial volume carbon ion radiotherapy (CIRT) targeting
hypoxic region of a tumor under imaging guidance as well as its effect
of inducing radiation induced abscopal effects (RIAEs) have not been
well investigated.

FIGURE 1. 18F-FMISO PET/CT imaging was performed before
irradiation treatment for evaluating the hypoxia status of tumors.
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FIGURE 2. Mouse irradiation and dose profile. (A and B) The radiation area and dose profile of CI-MPR group. (C) The radiation area and
dose profile of CI-OFR group.

Objectives: To investigate the differences in abscopal effects induced
by CIRT to the entire tumor versus partial volume CIRT using the
newly developed Carbon Ion Microporous Radiation (CI-MPR) guided
by 18F-FMISO PET/CT targeting the tumor hypoxia region.
Methods: We developed a technique of CI-MPR, guided by 18FFMISO PET/CT, for partial volume irradiation targeting the hypoxia
area of a tumor and investigated its capability of inducing abscopal
effects. Tumor-bearing mice were inoculated subcutaneously with
breast cancer 4T1 cells into the ﬂanks of both hind legs of mouse.
Mice were assigned to three groups: Group 1: control group with no
treatment; Group 2: carbon ion open ﬁeld radiation (CI-OFR group)
targeting the entire tumor; And Group 3: partial volume carbon ion

microporous radiation (CI-MPR group) targeting the hypoxia region.
And the tumors on the left hind legs of mice were irradiated with
single fraction of 20 Gy of CIRT in Groups 2 and 3.
Results: Mice treated with CI-MPR or CI-OFR showed that signiﬁcant
growth delay on both the irradiated and unirradiated of tumor as
compared with the control groups. Tumor regression of left tumor
irradiated with CI-OFR was more prominent as compared with the
tumor treated with CI-MPR; however, the regression of the unirradiated
tumor in both CI-MPR and CI-OFR group was similar.
Conclusions: Biological-guided CIRT using the newly developed microporous technique targeting tumor hypoxia region could induce robust
abscopal effects similar to CIRT covering the entire tumor (Figs. 1–3).
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FIGURE 3. The response after irradiation on EBT3 film and evaluation of tumor volume change of the irradiated and unirradiated tumors.
(A) The response and one vertex of irradiation could be noted in CI-OFR and CI-MPR group on the EBT3 film, respectively. (B) Tumor
volume change on left side (irradiated) during the observation. (C) Tumor volume change on right side (unirradiated) during observation.
(D) Quantitative analysis of irradiated tumor (left side) volume change on day 15. (E) Quantitative analysis of unirradiated tumor (right
side) volume change on day 15. Each bar represents the standard error, and P <0.05, 0.01, 0.001, 0.0001 are indicated by *, **, ***, ****.

(OA29) The Genomic and Transcriptomic Landscape of Radiation-induced Lymphomas in p53 Deﬁcient Mouse Models
Yun Li, MD PhD1, Erik Fredlund, PhD2, Kyle Halliwill, PhD3, Cassandra Adams, PhD3, Kuang-Yu Jen, PhD4, Allan Balmain, PhD, FRS3;
1
University of California San Francisco, 2Karolinska Institute, 3UCSF,
4
UC Davis
Background: Large-scale sequencing studies have revolutionized our
understanding of cancer genomes, revealing a catalogue of somatically-acquired cancer-driving mutations that are the focus of cancer
therapeutics. However, the impact of inherited germline variants has
not been well-studied in radiation (RT) induced cancers. Deﬁciency
of the tumor-suppressor gene TP53 is known to play a central role in
radiation induced T-cell lymphomas. Previous studies have shown
that some driver mutations exclusively or preferentially occur on one
parental allele, indicating the strong effects of inherited polymorphisms in shaping tumor genomes.

Objectives: We hypothesize that p53-status will impact the biological
pathways that underlie the development of radiation-induced lymphomas. The goal of this study was to deﬁne the genome wide mutation
patterns in radiation induced lymphomas using a well characterized
mouse model of radiation-induced T cell lymphoma, as well as
to identify possible therapeutic opportunities for radiation induced
malignancies.
Methods: We exposed a well characterized genetically heterogeneous
mouse model of T cell lymphoma (129/SvImJ x M. spretus backcross)
that are either germline p53+/- or p53-/- to a single dose of 4 Gy total
body gamma RT. We performed both whole exome sequencing (WES)
and microarray expression analysis on a subset of 32 lymphomas.
Standard pipelines including BWA/PICARD/GATK/MuTect/PinDel/
CNVKit and R packages affy/limma were used. In silico analysis of
human cancer mutations were derived from COSMIC, TCGA, cBioPortal and published T-ALL sequencing studies.
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Results: All animals developed aggressive lymphomas <12 months
after RT. The p53-/- animals had shorter tumor latencies (107+/-36 d)
compared with p53+/- mice (222+/-57 d, P = 2.36x10-10, log-rank test),
and had 2-fold the point mutations compared with lymphomas from p53
+/- mice (8 vs 4 mutations; P = 0.03, Wilcoxon test). Recurrent
p53-dependent and/or strain-speciﬁc point and structural mutations
were identiﬁed at loci with known human homologs eg Notch1, Pten,
and Ikzf1. Point mutations in the E1 ubiquitin activating enzyme Uba1
were exclusively seen in lymphomas from p53-/- mice. These mutations
map to the ubiquitin-activating and E2 interacting domains of Uba1,
suggesting that the disruption of the ubiquitin pathway is a driver of
RT-induced lymphomas.
Conclusions: Our data demonstrate the profound inﬂuence of both
germline strain-speciﬁc polymorphisms and the timing of p53 loss on
the overall pathways to tumorigenesis, as well as on selection of speciﬁc
mutations in potential drug target genes, such as Uba1.

(OA30) Racial Differences in Treatments and Toxicity in
Non-Small Cell Lung Cancer Patients Treated with
Thoracic Radiation Therapy
Anna Laucis, MD, MPhil1, Kimberly Hochstedler, MS1, Matthew
Schipper, PhD2, Peter Paximadis, MD3, Thomas Boike, MD4, Derek
Bergsma, MD5, Benjamin Movsas, MD6, Munther Ajlouni, MD7,
Annette Kretzler, MD8, Daniel Spratt, MD1, Robert Dess, MD2,
Melissa Mietzel, MS2, Michael Dominello, DO9, Martha Matuszak,
PhD2, Reshma Jagsi, MD, DPhil2, James Hayman, MD, MBA2, Lori
Pierce, MD, FASCO, FASTRO1, Shruti Jolly, MD1; 1University of
Michigan Department of Radiation Oncology, 2University of Michigan,
3
Lakeland Radiation Oncology, 421st Century Oncology, 5Department
of Radiation Oncology at Mercy Health Saint Mary’s, 6Department of
Radiation Oncology, Henry Ford Cancer Institute, 7Henry Ford Cancer
Institute, HFHS, 8Department of Radiation Oncology at Henry Ford
Hospital, 9Wayne State University
Background: Racial disparities are of particular concern for lung
cancer patients given historical differences in surgery rates for African-American lung cancer patients that resulted in lower overall
survival and higher recurrence rates compared with rates in White
patients.
Objectives: The overall objective of this study was to examine racial
differences in thoracic radiation therapy (RT) treatments and toxicities
in a large cohort of patients from a multi-institutional consortium
database of non-small cell lung cancer (NSCLC) patients.
Methods: A large multi-institutional statewide prospectively collected patient-level database of locally advanced (stage II or III)
NSCLC patients who received thoracic RT from March 2012 to
November 2019 was analyzed to assess the associations between race
and treatment and toxicity variables. Race (White or African-American) was deﬁned by patient self-report or if not available then by the
electronic medical record system classiﬁcation. Race categories other
than White or African-American comprised a small minority of
patients and were excluded from this analysis. Patient-reported toxicity was determined by validated tools including the Functional
Assessment of Cancer Therapy–Lung (FACT-L) quality of life
instrument. Provider-reported toxicity was determined by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Uni-variable and multi-variable regression models were then ﬁtted to
assess relationships between primary outcomes by race and indicators
of high-quality treatment and secondary analysis of symptoms.
Spearman rank correlation coefﬁcients were calculated between
provider reported toxicity and similar patient reported outcomes for
each race category.
Results: A total of 1441 patients from 24 institutions with mean age of
68 years (range 38–94) were evaluated; 226 patients were AfricanAmerican, of whom 61% were treated at three facilities. Race was not
signiﬁcantly associated with RT treatment approach, use of concurrent
chemotherapy, or the dose to the planning target volume (PTV) or
organs at risk including the heart and lungs. However, there was
increased patient-reported general pain in African-American patients
(compared with White patients) at several time points including pre-RT
(22% (vs 15%), P = 0.02) and at the end of RT (30% (vs 17%),
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P = 0.001). African-American patients were signiﬁcantly less likely to
have provider-reported grade 2+ radiation pneumonitis (odds ratio (OR)
0.36, P = 0.03), despite similar levels of patient-reported respiratory
toxicities such as cough and shortness of breath and even after controlling for known patient and treatment-related factors. Correlation
coefﬁcients between provider- and patient-reported toxicities were
generally similar across race categories.
Conclusions: In this large multi-institutional observational study, we
reassuringly found no evidence of differences in radiation treatment or
chemotherapy approaches by race, in contrast to historical differences
by race in surgical care that led to worse survival and outcomes in
minority race patients. However, we did unexpectedly ﬁnd that AfricanAmerican race was associated with lower odds of provider-reported
grade 2+ radiation pneumonitis despite similar patient-reported toxicities of shortness of breath and cough. There are several possibilities
for this ﬁnding including that pneumonitis is a multifactorial diagnosis
that relies on clinical as well as radiologic information and clinical
information alone may be insufﬁcient. The Spearman correlation analysis also revealed stronger correlations between patient- and providerreported toxicities in White patients compared with African-American
patients, particularly for trouble swallowing/esophagitis. These ﬁndings
together for pneumonitis and esophagitis discouragingly suggest possible under-recognition of symptoms in black patients. Further investigation is now warranted to better understand how these ﬁndings
impact the care of racially diverse lung cancer patients.

(OA31) Tapping into the Power of Crowd Innovation to
Develop an Artiﬁcial Intelligence Tool for Pancreatic
Radiotherapy
Karl Bush, PhD, MCCPM1, Diego Toesca, MD1, Richel Baclay, MD1,
Daniel Chang, MD1; 1Stanford University
Background: Crowd innovation is the process of inviting a large,
worldwide community of highly proﬁcient software developers, generally
not working in the healthcare industry, to rapidly produce a large number
of high-quality, and often novel, algorithmic solutions to a posed problem.
Crowd innovation is most often implemented in a contest format, in which
the programmer contestants compete for cash prizes to produce the highest
scoring solution to the problem. This study offers a pivotal exploration into
the power and potential of crowd innovation for radiation oncology and
radiology software automation.
Objectives: In this work, we determine the efﬁcacy of using the nontraditional approach of crowd innovation, to rapidly develop a diverse set
of machine learning based algorithms for automatic pancreatic tumor
segmentation. The objective for the study was to probe the quality that
expert programmers from outside healthcare could achieve in automated
segmentation, and determine whether the approach could rival traditional
frameworks of graduate student/post-doctoral fellow algorithm development. The endpoint for the segmentation was for use in a pancreatic cancer
management solution, both in prediction of pancreatic tumor surgical
resectibility, and in target delineation for radiation therapy.
Methods: We conducted a 10-week, prize based, competition open to
Topcoder, Inc. community contestants (total prize money of
$30,000). Contestants were provided a training dataset containing
120 CT scans and contour data for pancreatic tumors and surrounding vessels (superior mesenteric artery, celiac axis/common
hepatic artery, and superior mesenteric vein/portal vein), and competed in building algorithms to auto-segment a validation dataset
containing 60 CT scans with no contours. An F-score metric was
used to rank the contestants’ algorithms using a separate, unrevealed
dataset of 62 patients. F-score calculations included both the tumor
and vessel contours, but with vessels weighted 7-times lower than
the tumor. Contestants were offered a $3,000 prize bonus for algorithms exceeding an F-score of 0.7 to encourage quality algorithms
beyond simply winning prize money.
Results: 167 contestants registered for the competition, across 34
countries, and submitted a total of 337 algorithms. The winning solution (average F-score = 0.72) implemented a 3D-UNet model in a 3D
semantic segmentation approach, which was found to be accurate in
tumor and vessel delineation. All other winning algorithms used 2D
model approaches. Top 5 algorithm performance was strongly
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FIGURE 1. 3D (left) and axial (right) views of an auto-segmented pancreatic tumor and surrounding vessels.

TABLE 1. Precision and Recall Scores for Tumor and Vessels for Top 5 Contestants’ Algorithms

FIGURE 2. Tumor contour F-scores (left) and vessel contour F-scores (right), ordered in increasing order, for the 62 patient scoring
dataset.

correlated by patient. In 82% of patient cases, all top 5 algorithms
succeeded in achieving an F-score > 0.6. The top 5 scoring solutions
provided useful auto- segmentation capabilities for pancreatic tumors
and surrounding vessels, and have been integrated into a model for
predicting pancreatic tumor resection success before surgery.
Conclusions: The use of crowd innovation for healthcare challenges
has seen limited use, but offers great potential for rapid development of
high quality segmentation algorithms with reasonable ﬁnancial commitments (Figs. 1, 2 and Table 1).

(OA32) Immune Cell Inﬁltrates in Low Grade Glioma and
Impact of Immunological Microenvironment Affecting
Tumor Biology and Oncologic Outcome
Anupam Rishi, MD1, Homan Mohammadi, MD2, Daniela Martir, MS3,
Eric Welsh, PhD4, Timothy Robinson, MD, PhD5, Daniel Oliver, MD2,

Steven Eschrich, PhD2, Javier Torres-Roca, MD1, Hsiang-Hsuan
Michael Yu, MD2, G. Daniel Grass, MD, PhD1, Kamran Ahmed, MD1;
1
Department of Radiation Oncology, H. Lee Mofﬁtt Cancer Center &
Research Institute, 2H. Lee Mofﬁtt Cancer Center & Research Institute,
3
Ponce Health Sciences University, 4Department of Biostatistics and
Bioinformatics, H. Lee Mofﬁtt Cancer Center & Research Institute, 5H.
Lee Mofﬁtt Cancer Center and Research Institute, Department of
Radiation Oncology
Background: Prediction of response to immune therapies relates to
the presence, distribution, and activation of immune cell inﬁltrates
(ICI). Little is known about the immune contexture of low-grade
glioma (LGG), and how ICI may predict the outcome. CIBERSORT
provides an estimate of ICI via a gene expression deconvolution
algorithm.
Objectives: In this novel study, we analyzed the presence of ICI, and
the neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR)
ratios with respect to outcomes in LGGs.
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FIGURE 1. The Kaplan–Meier curve shows the overall survival is
significantly higher with the presence of memory B-cells (10-year
OS 84.4% vs 38%, HR 3.9, 95% CI 1.1-13.6, P = 0.02; log-rank).

Methods: From an IRB-approved institutional tissue biorepository,
we identiﬁed patients treated between 2004–2012, with LGG who
underwent excision and had complete gene expression proﬁling.
Gene expression levels were assessed by Affymetrix Hu-RSTA
assays. For ICI, the presence and high expression dichotomized by
median were used to assess relationships with overall survival (OS)
and progression-free survival (PFS). For NLR, 2.4 was used based
on published data in primary GBM. Time-to-event analyses were
performed with Kaplan-Meier estimates and compared via log-rank
test. Associations of factors and outcomes were explored using Cox
regression.
Results: A total of 41 LGG patients were identiﬁed, with a median
age of 36.5 years (range, 18-65 y) and 43.9% (18 patients) females.
All patients were either grade 2 astrocytoma, 16 (39%) patients or
oligodendroglioma/oligo-astrocytoma, 25 (61%) patients. All
patients underwent surgery, with gross total excision (GTR) achieved in 19 (46.3%), and sub-total excision (STR) in 22 (53.7%)
patients. Ten (24.4%) patients received adjuvant radiation therapy.
The frontal lobe was the most common primary site in 27 (65.8%)
patients. Median OS and PFS from date of surgery were

FIGURE 2. The Kaplan–Meier curve shows the overall survival is
significantly higher with pre-surgery NLR < = 2.4 (10-year OS
30.4% vs 66.7%, P = 0.05; log-rank).
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FIGURE 3. The Kaplan–Meier curve shows the progression-free
survival is significantly worse with the presence of neutrophils
(10-year OS 7.5% vs 84.4%, HR 7.9, 95% CI 1.8–35.1; P = 0.002;
log-rank).

141 months (95% conﬁdence interval (CI) 94.2–187.8 mo) and
83 months (95% CI 47.4–118.6 mo), respectively. 5- and 10-year
OS was 64.2 and 35.1%, respectively. Among ICI, the presence of
memory B-cells signiﬁcantly improved OS (10-year OS 84.4% vs
38%, hazard ratio (HR) 3.9, 95% CI 1.1-13.6; P = 0.02). In addition, the presence of neutrophils adversely affected PFS (10-year
OS 7.5% vs 84.4%, HR 7.9, 95% CI 1.8–35.1; P = 0.002). No other
ICI subtypes affected OS or PFS signiﬁcantly. Patients with presurgery NLR > 2.4 had signiﬁcantly worse OS (10-year OS 30.4%
vs 66.7%, P = 0.05). PLR did not affect OS or PFS.
Conclusions: LGGs have a distinct immunological microenvironment and ICIs may play a pivotal role in tumor biology affecting
progression and survival. The knowledge of ICI and NLR may
serve as a unique risk-stratiﬁcation and guide clinical decisions
(Figs. 1–3).

(OA33) Response to Whole-Lung Low-Dose Radiation
Therapy (LD-RT) Predicts Freedom from Intubation in
Patients Receiving Dexamethasone And/or Remdesevir for
COVID-19-Related Pneumonia
Clayton Hess, MD MPH1, Tony Eng, MD1, Tahseen Nasti, PhD1,
Vishal Dhere, MD1, Troy Kleber, BS2, Jeffrey Switchenko, PhD, MS3,
Brent Weinberg, MD4, Nadine Rouphael, MD1, Sibo Tian, MD1,
Soumon Rudra, MD1, Luisa Taverna, (student)1, Alvaro Perez, (student)1, Raﬁ Ahmed, PhD1, Mohammad Khan, MD, PhD2; 1Emory
University, 2Department of Radiation Oncology, Winship Cancer
Institute of Emory University, 3Winship Cancer Institute at Emory
University, 4Emory University Hospital
Background: Low-dose radiation is a known focal anti-inﬂammatory
treatment for various benign conditions. Phase I/II clinical trials have
explored whole-lung low-dose radiotherapy (LD-RT) as a potential
treatment for patients with COVID-19-related pneumonia. Initial ﬁndings require reproduction. Concomitant LD-RT administration with
existing therapies requires safety evaluation.
Objectives: To explore the safety and efﬁcacy of LD-RT in patients
receiving concurrent dexamethasone and/or remdesevir. To get investigate the predictive value of 3-day lab value response of C-reactive
protein levels following LD-RT on 28-day intubation and recovery rates.
Methods: Patients with COVID-19-related pneumonia receiving dexamethasone and/or remdesevir were treated with 1.5 Gy whole-lung
LD-RT, followed for 28 days or until hospital discharge, and compared
with controls blindly matched by age, comorbidity, and disease
severity. Eligible patients were hospitalized, SARS-CoV-2 positive, had
radiographic consolidations, and required supplemental oxygen.
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Endpoints included safety, clinical recovery, intubation, radiographic
changes, and biomarker response.
Results: 40 total patients were available for analysis. 20 patients
receiving concurrent dexamethasone and/or remdesevir were treated
with whole-lung LD-RT between Jun 11 and Dec 7, 2020 and were
compared with 20 matched controls. Following LD-RT, freedom from
intubation improved from 68% in controls to 86% (P = 0.09). Predictive
inﬂammatory and cardiac markers rapidly fell following LD-RT,
including C-reactive protein (CRP) (P = 0.02) and creatine kinase (CK)
(P < 0.01), indicative of reduced cascading inﬂammation and cardiac
injury. Eighty percent of LD-RT patients experienced rapid decline in
CRP within 3 days and were classiﬁed as LD-RT responders. Intubation-free survival was 100% following LD-RT when the CRP
responded, vs 66% in matched controls (P = 0.01). Oxygenation
requirements were lower following LD-RT among CRP responders
compared with matched controls: 32% lower per individual (P = 0.03)
and 56% lower for the cohort (P = 0.06). No patient whose CRP
declined following LD-RT died or required intubation.
Conclusions: A cohort of patients with COVID-19-related pneumonia
treated with LD- RT demonstrated superior freedom from intubation
compared with matched controls, especially LD-RT responders
(P = 0.01). LD-RT appears safe to deliver with concurrent drugs. LDRT lowered CRP and CK biomarkers. CRP response predicted favorable outcome. Optimal timing for LD-RT after oxygen dependence but
before intubation may extinguish immunopathology before systemic
spread. Conﬁrmatory clinical trials are warranted. Clinical Trial Registration: NCT04366791.
FIGURE 1. CD8+ T cell and FoxP3+ T regulatory cell (Treg) counts
on pre and post treatment tumor biopsies.

(OA34) A Pilot Study to Assess the Combination of HighDose Conformal Radiation Therapy and Pembrolizumab in
Modulating Local and Systemic T-cell Responses in
Advanced Malignancies
Christopher Luminais, MD1, Alexander Mathew1, Kimberly A. Bullock, PhD1, Gina R. Petroni, PhD1, Richard J. Price, PhD1, Timothy N.J
Bullock, PhD1, James Larner, MD1; 1University of Virginia
Background: Although there has been tremendous interest in the use of
high-dose conformal radiation therapy (HDCRT) to enhance immunotherapy (IO), the optimal sequencing of IO and HDCRT is unknown
both in terms of local control and distant (abscopal) responses.
Objectives: To use repeated tissue biopsies to estimate the effect of
different sequencing orders of IO and HDCRT and to describe the
immunologic effects.
Methods: This was a Phase I, prospective, randomized trial. Twentyone patients with metastatic solid malignancies who were eligible for
HDCRT (24 Gy in 3 fractions) and pembrolizumab (200 mg) were
randomized to 3 arms: Arm A, concurrent HDCRT (day 1 start) and
pembrolizumab (days 1, 43, 64, and 85); Arm B, pembrolizumab ﬁrst
(days 1, 43, 64, and 85) followed by HDCRT (day 22 start); Arm C
HDCRT ﬁrst (day 1 start) followed by pembrolizumab (days 22, 43, 64,
and 85). Patients underwent biopsy of the treated lesion pre-treatment
and post-treatment on days 22 and 43. The primary endpoint was local
CD8+ T cell and FoxP3+ T regulatory cell (Treg) counts. Post hoc,
RNA sequencing of biopsy specimens was performed followed by
bioinformatics analyses, including differential gene expression, gene set
enrichment analysis, cell type deconvolution, and TCR analysis.
Results: Primary malignancies treated included: breast (6), colon (5),
salivary (2), sinus (1), esophagus (1), leiomyosarcoma (1), melanoma

(1), pancreatic (1), thyroid (1), larynx (1), and testicular (1). Repeated
measure modeling was used to assess the CD8+ T cell and Treg counts.
No pattern for CD8+ T cell and Treg counts was observed within or
between arms (Fig. 1). Transcripts associated with DNA damage,
including DDB2, were upregulated 3 weeks after HDCRT in nearly all
patients in all arms (Fig. 2A). Upregulation of immune regulatory
transcripts consistent with activation of an adaptive immune response,
such as IL17D, were only observed when pembrolizumab was administered concomitant with or before HDCRT (Fig. 2B). Gene sets
associated with T-cell activation were signiﬁcantly enriched after
pembrolizumab, with attenuation after HDCRT (Fig. 2C). Conversely,
leukocyte deconvolution revealed that HDCRT increased the proportion
of intratumoral M2 macrophage signatures, whereas pembrolizumab
decreased it (Fig. 2D).
Conclusions: Surprisingly, the timing of IO and HDRT did not result in
a consistent CD8+ T cell or Treg pattern within or between arms. This
could be a result of testing within a heterogeneous population with
advanced disease. RNA-sequencing revealed that while order of therapy
administration did not impact the ability of HDCRT to induce DNA
damage transcripts, it may inﬂuence pembrolizumab’s propensity to
activate anti-tumor immune mechanisms. Further, HDCRT acutely
induced M2 macrophage signatures regardless of treatment arm.
Together, these results underscore the importance of understanding the
immunological consequences of HDCRT and their inﬂuence on
immunotherapy.
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FIGURE 2. RNA sequencing results: A, DDB2 expression; B, IL17D expression; C, T-cell activation associated get set enrichment; D,
intratumoral M2 macrophage signatures.

(OA35) Should Immune System Sparing Dose Constraints
Be Integrated into the QUANTEC Guidelines?
Bhanu Prasad Venkatesulu, MD1, Prashanth Giridhar, MD2, Rituraj
Upadhyay, MD3, Amrish Sharma, PhD4, Hagar Elghazawy, MD5, Thiraviyam Elumalai, MD6, Supriya Mallick, MD7, Cheng Cheng-En Hsieh,
MD4; 1Loyola University Chicago, 2All India Institute of medical sciences,
3
The University of Texas MD Anderson Cancer Center, 4MD Anderson
Cancer Centre, 5Ain Shams University, 6Christie, 7National cancer institute
Background: Multiple reports have shown that radiation delivery for
tumors in close proximity to lymphoid organs such as bone marrow,
spleen or unintended radiation to circulating pool of lymphocytes traversing organs such as heart and lung is known to deplete the circulating lymphocyte populations. This radiation-related lymphopenia is
known to cause inferior tumor control outcomes which translate into
inferior overall survival outcomes in high-grade gliomas, head and neck
tumors, lung cancer, pancreatic cancer, hepatocellular carcinoma, and
Gynecological malignancies. Currently, there are no standardized dose
constraints that are available to limit the dose to the resident and circulating lymphocyte populations. This is much more pertinent in the
current immunotherapy era wherein ongoing clinical trials are trying to
optimally time and sequence radiation and immunotherapy combinations for potentially synergistic and or additive effects.
Objectives: Collate the radiation-related dosimetric parameters that
predict the incidence of severe lymphopenia in solid tumors
Methods: We did a systematic review of PubMed, Cochrane Central,
and Embase in accordance with the PRISMA statement and pooled the
dosimetric parameters that have been related to radiation-related lymphopenia and can be used to limit the incidence of lymphopenia.
Results: 633 abstracts were shortlisted for abstract screenings and 35
articles fulﬁlled the inclusion criteria. The CNS dose constraints that
were most pertinent to spare the circulating lymphocytes in the brain
were Whole Brain mean dose <31 Gy, Whole-brain Dmin <2 Gy
V10 < 68%, hypothalamus Dmax <56 Gy, and V25 < 56% were signiﬁcant predictors of no severe lymphopenia (SL). The thoracic dose
constraints were effective dose to immune cells (EDIC) (based on mean

lung and mean heart dose) the range of < 4.0, 4.0-6.5, 6.5-9.5,
and > 9.5 Gy translated into 2-year OS rates of 72, 52, 49, and 15% for
locally advanced non-small-cell lung cancer, Mean lung dose of
<12 Gy, lung V5 <45%, and mean heart dose of <5.2 Gy heart
V5 < 38%, mean thoracic dose <5 Gy, V20 of thoracic vertebra < 26%
were predictors of no SL. In Esophagus cancer mean body dose
exposure strong predictor for G4 nadir-Odds ratio 1.22 per Gray,
increase of 1 Gy in mean splenic dose (MSD) predicted a 2.9% decrease
in nadir absolute lymphocyte count (ALC), Heart V15 < 73%, T-spine
V5 < 72%, Body V10 < 18%, Lung V5 < 50%, and Aorta V5 < 93%
were strong predictors of no grade 4 lymphopenia, the 2year OS rates
were 66.7%, 42.7%, and 16.7% for EDIC <2 Gy, 2-4 Gy and > 4 Gy.
In gastric cancer mean splenic dose (MSD) ≥ 35 Gy poor prognostic
factor for OS and recurrence-free survival. In pancreatic cancer, dosimetric parameters of spleen such as V10(32.6 vs 16%); V15(23.2 vs
9.5%), and V20 (15.4 vs 4.6%), 1-Gy increase in MSD increased the
odds of grade 3 lymphopenia by 18.6%. In liver cancer, MSD, V5, V25,
and V30 of the spleen for the Min ALC were 227.72 cGy, 17.84, 0.98,
and 0.42%, respectively. In rectal cancer, Pelvic bone marrow (PBM)
volume receiving at least 30 Gy (V30) was signiﬁcantly associated with
lymphopenia. In Gynecological malignancies, bone marrow V10 > 85%
was associated with higher odds of developing lymphopenia, risk of SL
was associated with bone marrow V40 > 599cc.
Conclusions: This systematic review is a preliminary attempt to provide
dose constraints to spare the immune system during radiation delivery.
The aforementioned dose constraints require prospective validation in
clinical trials to better spare the immune system and augment the efﬁcacy of radiation.

(OA36) Primary Intraocular Lymphoma: Outcomes and
Toxicity After Radiation Therapy
Chelsea Pinnix, MD, PhD1, Ethan Damron, BS2, Jillian Gunther,
MD, PhD1, Penny Fang, MD1, Susan Wu, MD1, Bouthaina Dabaja,
MD1, Sattva Neelapu, MD1, Loretta Nastoupil, MD1, Sairah Ahmed,
MD1, Paolo Strati, MD1, Jason Westin, MD1, Luis Fayad, MD1,
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Raphael Steiner, MD1, Ranjit Nair, MD1, Dan Gombos, MD1, Nathan
Fowler, MD1; 1MD Anderson Cancer Center, 2McGovern Medical
School at UTHealth
Background: Primary intraocular lymphoma (PIOL) is an aggressive,
rare hematologic malignancy comprised of large B-cells primarily
involving the retina and vitreous. Radiation therapy (RT) is occasionally excluded over fears regarding toxicity.
Objectives: We sought to examine the outcomes and toxicity associated
with RT for PIOL patients (pts).
Methods: We reviewed the charts of 26 PIOL pts treated between 20032020 at our institution. We included pts without additional sites of CNS
involvement that received ocular RT as part of their treatment.
Results: The median age at diagnosis was 69.5 years (range: 48–90); 21
pts (81%) were female. The most common presenting symptoms ( > 1
possible) were blurred vision (n = 19, 75%), ﬂoaters (n = 15, 59%), and/
or vision loss (n = 12, 46%). Ophthalmologic examination revealed
suspicious vitreous cells (n = 23, 88%) and/or retinal/choroidal inﬁltrate
(n = 9, 35%). Eighteen pts (69%) had bilateral ocular involvement. In
all pts, gross disease was limited to the eyes. All pts underwent lumber
puncture (LP) to rule out CNS disease; 14 pts had LP ﬂow analysis
completed. In 3 pts (12%), CSF cytology revealed rare, atypical lymphoid cells, but follow-up MRI studies were unremarkable. Twenty-two
pts (85%) received a median of 5 (1–6) cycles of systemic chemotherapy before RT. Seventeen pts (65%) were treated with rituximab
(R), methotrexate (Mtx), procarbazine (P), and vincristine. Two pts
(8%) received single agent Mtx, 2 pts (8%) received Mtx and R, and 1
pt (4%) received Mtx and P. Before RT, 3 pts (12%) received intravitreal Mtx and 3 pts (12%) received intrathecal Mtx. Ten pts (38%) had
chemotherapy abbreviated due to toxicity. Nine pts (35%) received
consolidative cytarabine chemotherapy after RT and 6 pts (23%)
underwent autologous bone marrow transplant. All pts received ocular
RT, with 24 pts (92%) receiving treatment bilaterally, to a median dose
of 36 Gy in 20 fractions (range 28.5–39.6 Gy in 15-24 fractions). The
median follow up time was 41.8 months (95% CI 19.7–83) from start of
RT. Three pts (12%) relapsed in the eyes at a median of 4 months
(1–42) post-RT. Eleven pts (42%) developed relapsed lymphoma in the
brain at a median of 31 months (5–53) post-RT. The median progression free survival and overall survival was 24.1 (95% CI 4.9–36.3)
and 42.5 (95% CI 3.3–75.8) months from start of RT, respectively.
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Thirteen patients (50%) had cataracts removed before RT; 13 pts (50%)
developed post-RT cataracts. Twenty pts (77%) had dry eyes that
persisted > 3 months after RT. No pt developed optic neuropathy following RT. Five pts (19%) developed keratopathy. One pt (4%)
developed retinopathy post-RT, and 1 pt (4%) had preexisting diabetic
retinopathy worsened by RT. No patient developed blindness after
therapy.
Conclusions: In this single-center review of combined treatment modality
therapy for PIOL, severe visual complications were uncommon. Additional
therapies to prevent distant CNS relapses are warranted.

(OA37) Low-Dose Radiotherapy for Low Grade NonHodgkin Lymphoma of the Orbit
Christopher Wright, MD1, Jonathan Baron, BS1, Daniel Lee, BS1,
Maribel Carpenter1, Cesar Briceno, MD2, Elise Chong, MD3, Amit
Maity, MD PhD1, John Plastaras, MD PhD1, Ima Paydar, MD1;
1
Department of Radiation Oncology, University of Pennsylvania,
2
Department of Ophthalmology, University of Pennsylvania, 3Department of Medicine, Hematology/Oncology Division, University of
Pennsylvania
Background: Orbital low grade non-Hodgkin Lymphomas (LGNHLs)
are the most common tumor of the ocular adnexa. Marginal zone
lymphoma (MZL) followed by follicular lymphoma (FL) are the most
commonly represented histologies. Low-dose radiotherapy (LDRT),
previously deﬁned as 2 Gy x 2 fractions, for orbital LGNHLs has
resulted in response rates exceeding 90% (Fasola, et al IJROBP 2013).
Additional data, however, suggests lower doses are associated with
inferior response rates (Desai, et al Blood 2017). Radiotherapy (RT) is a
proven treatment modality for this entity, but no prior data exists
comparing response rates following LDRT to moderate-dose RT
(MDRT, RT dose > 4 Gy).
Objectives: Herein, we compare overall response rates (ORR) and
complete response (CR) rates for patients with orbital LGNHLs treated
with LDRT vs MDRT.
Methods: We retrospectively reviewed 38 consecutive courses of RT
across 36 patients treated for LGNHL of the orbit at a single institution.
Bilateral disease was present in 15 patients. Nine patients had advanced

FIGURE 1. Rates of complete response, partial response and stable disease following radiotherapy by low-dose radiotherapy and
moderate-dose radiotherapy groups.
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TABLE 1. Characteristics Associated with Complete Response
versus Partial or Worse Response to RT Using a Univariate Logistic
Regression Analysis
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Conclusions: RT for LGNHL of the orbit is an effective treatment
modality with ORR exceeding 90%. Due to the exquisite radiosensitivity of orbital LGNHL, LDRT produces similar response rates as
compared with more protracted RT courses. Present data suggests that
LDRT should be considered for patients with orbital LGNHL; however,
further studies with larger patient numbers are warranted to show signiﬁcant associations (Fig. 1 and Table 1).

(OA38) Rayos Contra Cancer Connects Volunteers and
Clinics to Impact Radiotherapy Together

stage disease or secondary orbital lymphoma following systemic dissemination. Represented indolent histologies included MZL (20
patients), FL (11 patients), and mantle cell lymphoma (MCL, 5
patients). ORR were recorded according to Deauville or RECIST criteria with a response characterized as a complete response (CR) or
partial response. Univariate Cox regression analysis was performed for
characteristics associated with the studied outcomes.
Results: LDRT was delivered for 14 courses and MDRT for 24 courses.
The median MDRT dose was 24 Gy (range 21-36 Gy in 1.5-2 Gy
fractions). Concurrent or sequential Rituximab was used in 8 patients.
Advanced stage (odds ratio (OR) 7, P = 0.021) and year of RT ≥ 2016
(OR 24, P = 0.008) were associated with increased use of LDRT. For
the LDRT group, ORR and CR were 100% and 50%, respectively,
compared with 87.5% and 58.3%, respectively, for the MDRT group.
No evaluated characteristics, including the use of LDRT, were signiﬁcantly associated with inferior ORR. Unilateral orbital involvement
was associated with inferior CR rates (OR 0.22, P = 0.042) compared
with bilateral orbital involvement.

Benjamin Li, MD, MBA1, David Martinez, MD2, Gustavo Sarria, MD3,
Fei Yang, BA4, Raymond Carter, BA5, Serguei Castaneda, MD6,
Oluwadamilola Oladeru, MD, MA7, Daniel Wakeﬁeld, MD, MPH8,
Soha Ahmed, MD, MBA9, Shada Wadi-Ramahi, PhD10, Maria Caicedo, MD11, Anuja Jhingran, MD12, Adam Shulman, MS13, Apolo
Salgado, MD14, Layth Mula-Hussain, MD15, Dante Roa, PhD16; 1Rayos
Contra Cancer, UCSF, 2Rayos Contra Cancer, Oncosalud AUNA,
3
Rayos Contra Cancer, University Medical Hospital Bonn, 4Rayos
Contra Cancer, Vanderbilt University Medical Center, 5Rayos Contra
Cancer, St. Jude Children’s Research Hospital, 6Rayos Contra Cancer,
Thomas Jefferson University, 7Rayos Contra Cancer, Massachusetts
General Hospital, 8Rayos Contra Cancer, University of Tennessee
Health Science Center; Harvard T.H. Chan School of Public Health,
9
Rayos Contra Cancer, Aswan University, 10University of Pittsburgh
Medical Center, 11Rayos Contra Cancer, Instituto Nacional de Cancerologia, 12MD Anderson Cancer Center, 13Rayos Contra Cancer,
Sarah Cannon Cancer Center, 14Rayos Contra Cancer, Instituto
Nacional del Cancer, 15Rayos Contra Cancer, The Ottawa Hospital
Cancer Centre, 16Rayos Contra Cancer, University of California Irvine
Background: Rayos Contra Cancer (RCC) is a 501(c)(3) non-proﬁt
organization whose mission is to create sustainable access to timely,
high-quality, and affordable radiation treatment for cancer in limitedresource settings globally. RCC has a clinic-centric approach and
focuses on education and training programs in areas where support is
otherwise scarce for radiation therapy.
Objectives: Demonstrate the potential of coordinated education and
training to reach and improve radiation oncology team conﬁdence,
knowledge, and competence in clinics globally.
Methods: From 2019 to 2021, RCC created, administered, and measured 9 longitudinal curriculum programs to clinics with functional
medical equipment but gaps in education and training. Each curriculum
focused on purely practical aspects of the clinic-wide transition to new
radiotherapy techniques. RCC used the Project ECHO (Extension for
Community Health Outcomes) telehealth model with professional peerto-peer support and synchronous group learning in underserved
communities via teleconferencing. Each curriculum consisted of live
1-hour sessions given 1-2 times per week over 3-4 months. Programs
used multi-institutional collaboration, involved medical professional,
trainee, and student volunteers, and incorporated cloud-based

FIGURE 1. Number of clinics trained from 2019–2021, by region.
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TABLE 1. Training Program Sessions, Participants, and Patient Impact

technology. We measured participation, costs, and educational outcomes and gathered facility operation details to estimate patient impact.
Results: 43 countries, 77 clinics, and 1,060 clinicians participated in 9
training cohorts. Clinicians included 398 (37.5%) radiation oncologists
and residents, 240 (22.6%) medical physicists and physics trainees, 210
(19.8%) radiation therapists, 77 (7.3%) other, and 141 (13.3%) not
recorded. A total 165 sessions were delivered by 9 education teams
comprised of 82 radiation oncology professionals, 28 residents or physics
graduate students, 35 medical or pre-medical students, and 76 on-site
clinic coordinators. Educators included 37 (43.5%) medical physicists, 30
(35.3%) radiation oncologists, 15 (17.6%) radiation therapists, 3 (3.5%)
dosimetrists. Notably, 28 (37.8%) of 74 US-based educators were originally from outside the US. RCC’s 3-year expenses totaled $43,273. The
USD market value of all programs combined was $3,176,000, and RCC
charged $0. Paired measurements of pre- vs. post-curriculum clinician
conﬁdence, knowledge, and competence signiﬁcantly improved across
multiple practical domains. Based on treatment facility data, the estimated
clinical beneﬁt to date is 75,017 patient lives impacted per year.
Conclusions: Based on 3 years of experience, each volunteer educator
has the potential to impact approximately 1,000 patient lives per year
through participation in RCC education and training. Participating
clinics in RCC programs showed improved conﬁdence, knowledge, and
competence. With low-cost coordination at the volunteer student
through resident level, we show a vehicle to improve radiotherapy
globally (Fig. 1 and Table 1).

(OA39) 18F-Fluciclovine PET/CT to Distinguish Radiation
Necrosis from Tumor Progression in Brain Metastases
Treated with Stereotactic Radiosurgery: A Prospective Pilot
Study
Timothy Smile, MD1, Martin Tom, MD2, Frank DiFilippo, PhD1,
Stephen Jones, MD, PhD1, John Suh, MD3, Erin Murphy, MD1, Jennifer Yu, MD, PhD1, Alireza Mohammadi, MD1, Gene Barnett, MD,

MBA1, Steve Huang, MD1, Guiyun Wu, MD1, Nancy Obuchowski,
PhD1, Manmeet Ahluwalia, MD1, David Peereboom, MD1, Glen Stevens, DO, PhD1, Robin Davis1, Megan Firman1, Samuel Chao, MD1;
1
Cleveland Clinic, 2Miami Cancer Institute, Baptist Health South
Florida, 3Department of Radiation Oncology, Taussig Cancer Institute,
Cleveland Clinic
Background: 18F-Fluciclovine PET/CT is a widely available FDAapproved amino acid radiotracer for evaluation of suspected prostate
cancer recurrence.
Objectives: To determine if 18F-ﬂuciclovine PET/CT has utility in
distinguishing tumor progression (TP) from radiation necrosis (RN)
among patients with brain metastases having undergone prior stereotactic radiosurgery (SRS).
Methods: The primary objective is to estimate the accuracy of 18Fﬂuciclovine PET/CT in distinguishing RN from TP. We enrolled adult
subjects with brain metastases who underwent prior SRS and presented
with a follow up MRI brain (with DSC MR perfusion) which was
equivocal for RN versus TP. Based on equivocal MRI before PET,
subjects were divided into pre-PET subgroups of equivocal with suspicion for TP or RN, or truly equivocal, by the study neuroradiologist.
Within 30 days of equivocal MRI brain, subjects underwent 18Fﬂuciclovine PET/CT on a Siemens Biograph mCT scanner following a
10 mCi bolus dose immediately before PET. PET data were collected in
list mode for 25 mins post-injection and were reconstructed as a static
image of data 10-25 mins post-injection, and as a dynamic series of four
5-min frames between 5-25 mins post-injection. Quantitative metrics for
each lesion were documented including SUV max, SUV mean, SUV
peak, and normal brain SUV mean. Lesion to normal brain ratios were
calculated. The reference standard was clinical follow up with MRI
brain (with DSC MR perfusion) every 2-4 months until multidisciplinary consensus (or tissue conﬁrmation) for diagnosis of RN
versus TP.
Results: From 7/2019-9/2020, 14 of 16 planned subjects enrolled and
underwent 18F-ﬂuciclovine PET/CT for evaluation of 19 brain lesions.
Primary histology was NSCLC in 6, breast in 4, melanoma in 3, and
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TABLE 1. NSCLC: non-small cell lung carcinoma, RN: radionecrosis, TP: tumor progression, E: equivocal, Dx: diagnosis, SUV:
standardized uptake value

endometrial in 1. Among all 19 imaged lesions, ranges of quantitative
metrics were: SUV max, 2.18-12.1; SUV mean, 1.16-7.37; SUV peak,
1.06-4.45; normal brain SUV mean, 0.19-0.44; SUV max/normal ratio,
7.5-45.4; SUV mean/normal ratio, 4.2-26.3; and SUV peak/normal
ratio, 3.9-26.4. Follow up was completed for 10 patients as described in
the Table. No adverse events have been reported.
Conclusions: In this population, 18F-ﬂuciclovine PET/CT produces a
wide range of lesion quantitative metric values and low uptake in the
normal brain. Ongoing follow up is required, however, preliminary
results are promising and suggest 18F-ﬂuciclovine PET/CT may be able
to accurately distinguish RN from TP. Final results of this pilot study
are expected within a year. Phase II and III studies are under development (Table 1).

(OA40) Multi-institutional Validation of Recursive Partitioning Analysis for Overall Survival in Patients Undergoing Spine Radiosurgery for Spine Metastasis
Jonathan Hanan, BA1, Samuel Chao, MD2, Arjun Sahgal, MD3, Wei
Wei, MS2, Mikki Campbell, MHE3, Chandana Reddy, MS4, Lilyana
Angelov, MD5, John Suh, MD6, Anthony Magnelli, MS6, Salim Balik,
PhD6, Ping Xia, PhD6, Kailin Yang, MD, PhD6, Alireza Mohammadi,
MD2, Ehsan Balagamwala, MD6; 1Case Western Reserve University
School of Medicine, 2Cleveland Clinic, 3Department of Radiation
Oncology, Sunnybrook Odette Cancer Centre, University of Toronto,
4
Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, 5Department of Neurosurgery, Cleveland
Clinic, 6Department of Radiation Oncology, Taussig Cancer Institute,
Cleveland Clinic
Background: The recently developed recursive partitioning analysis
(RPA) classiﬁcation system for overall survival (OS) in patients
undergoing spine stereotactic radiosurgery (sSRS) yielded three distinct
prognostic groups for patients with spine metastasis. We sought to
externally validate this RPA with a larger patient cohort using a multiinstitutional dataset.
Objectives: Validate the recursive partitioning analysis (RPA) for spine
stereotactic radiosurgery (sSRS).
Methods: 444 patients were utilized to develop the recently published
sSRS RPA predictive of OS in patients with spine metastases. The RPA
identiﬁed three prognostic classes: RPA Class 1 was deﬁned as KPS > 70
and controlled systemic disease (n = 142); RPA Class 2 was deﬁned as
KPS > 70 with uncontrolled systemic disease or KPS ≤ 70, age ≥ 54 and
absence of visceral metastases (n = 207); RPA Class 3 was deﬁned as KPS
≤ 70 and age <54 years or KPS ≤ 70, age ≥ 54 years, and presence of
visceral metastases (n = 95). Data from a large tertiary care center was
utilized to validate this RPA. A total of 221 patients (467 spinal segments)

were in the validation cohort and divided based on their RPA classes.
Kaplan-Meier method was used to estimate OS and log-rank test was used
to compare OS between RPA classes.
Results: In the validation cohort (221 patients), the median OS was
19.9 months and the median follow-up was 36 months (range, 0.170.8 mo). The majority (85%) of patients received 24 Gy (range, 20-35 Gy)
in 2 fx (range, 2-10). Forty-three (19.5%) patients were in RPA Class 1,
165 (74.7%) patients in RPA Class 2 and 13 (5.9%) patients in RPA Class
3. The median OS in the validation cohort based on RPA Class was
54 months for Class 1, 15.8 months for Class 2 and 6.8 months for Class 3.
Patients in RPA Class 1 had a signiﬁcantly better OS compared with those
in Class 2 and Class 3 of the validation cohort (P < 0.01). The difference in
OS between RPA Class 2 and Class 3 was not statistically signiﬁcant due
to small number of patients in RPA Class 3.
Conclusions: The external dataset validated the spine sSRS RPA for
RPA Classes 1 and 2. RPA Class 3 was not validated successfully,
which was likely due to small patient numbers. Based on our validation,
upfront spine SRS is strongly supported for patients in RPA Class 1.
Additionally, either upfront spine SRS or conventional radiotherapy is
supported for RPA Class 2 patients. Patients in RPA Class 3 would
beneﬁt most from upfront conventional radiotherapy. Given successful
validation, this RPA will be utilized as enrollment criteria for an
upcoming investigator-initiated trial.

(OA41) Concurrent versus Sequential Stereotactic Radiosurgery and Immune Checkpoint Inhibition in Brain
Metastases: An International Cooperative Group Study
Eric Lehrer, MD, MS1, Jason Gurewitz, BA2, Timothy Malouff, MD3,
Kenneth Bernstein, MS2, Douglas Kondziolka, MD2, Brianna Jones,
MD1, Phillip Bonney, MD4, Samir Patel, MD5, Joshua Palmer, MD6,
Kareem Fakhoury, MD7, Chad G. Rusthoven, MD7, David Mathieu,
MD8, Christopher Deibert, MD9, Piero Picozzi, MD10, Cheng-chia Lee,
MD, PhD11, Sonam Sharma, MD1, Ajay Niranjan, MD12, L. Dade
Lunsford, MD12, Jason Sheehan, MD, PhD13, Manmeet Ahluwalia,
MD, MBA14, Daniel Triﬁletti, MD15; 1Icahn School of Medicine at
Mount Sinai, 2NYU Langone Medical Center, 3Mayo Clinic, 4University
of Southern California, 5University of Alberta, 6The Ohio State University Wexner Medical Center, 7University of Colorado School of
Medicine, 8Université de Sherbrooke, Centre de recherche du CHUS,
9
Emory University, 10IRCCS Humanitas Research Hospital, 11Taipei
Veteran General Hospital, 12University of Pittsburgh, 13University of
Virginia, 14Miami Cancer Institute, 15Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA
Background: Multiple single institution retrospective analyses have
suggested that concurrent administration (within 4 wk) of stereotactic
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radiosurgery (SRS) and immune checkpoint inhibitors (ICI) is associated with improved overall survival (OS) when compared with
sequential administration (more than 4 wk) in patients with brain
metastases (BrM). However, there are limited data analyzing the risk of
developing radiation necrosis (RN) and OS by timing of therapy.
Objectives: To evaluate the risk of development of RN and OS in
patients with BrM treated with SRS/ICI.
Methods: The International Radiosurgery Research Foundation
approved the analysis. Logistic and Cox regression models were used to
identify covariates associated with the development of RN and OS. The
Kaplan-Meier method and log-rank test were used to compare OS at 1and 2-years post SRS. Patients with < 3-months of follow up were
excluded.
Results: There were 546 patients (223 melanoma/287 NSCLC/36 RCC)
across 10 institutions with 2,880 BrM. Median follow-up was
15.5 months, median age was 66 years (interquartile range [IQR]: 5672 y). Median Karnofsky Performance Status (KPS) was 90. Median
margin dose was 20 Gy (IQR: 18-20 Gy) in 1 fraction. The mean total
BrM volume was 3.59cc, and mean V12 Gy was 8.33cc. Active
extracranial disease was present in 78.0% at time of SRS. There were 65
patients (11.9%) who experienced RN (46.2% Grade 1, 40.0% Grade 2;
12.3% Grade 3; 1.5% Grade 4). On multivariate analysis, the number of
SRS courses (Odds Ratio [OR]: 2.59, 95% conﬁdence interval [CI]:
1.72-4.00; P < 0.001), total volume of treated BrM (OR: 1.09; 95% CI:
1.03-1.15; P < 0.001), melanoma histology (OR: 2.79; 95% CI: 1.395.68; P = 0.004), RCC histology (OR: 3.96; 95% CI: 1.23-11.44;
P = 0.01), receipt of previous intracranial radiation therapy (RT) before
SRS (OR: 8.88; 95% CI: 2.96-26.34; P < 0.001) were associated with
the development of RN. When compared with anti-PD-1 monotherapy,
anti-CTLA-4+anti-PD-L1 therapy (OR: 0.22, 95% CI: 0.07-0.57;
P = 0.004) was associated with a lower likelihood of developing RN.
Concurrent over sequential therapy (P = 0.26) and V12 (P = 0.49) were
not signiﬁcant. On multivariate analysis, female sex (Hazard Ratio
[HR]: 0.62; 95% CI: 0.48-0.82; P < 0.001) and KPS (HR: 0.97; 95%
CI: 0.96-0.99; P < 0.001) were prognostic for OS. Concurrent versus
sequential therapy (P = 0.55), melanoma histology (P = 0.20), and RCC
histology (P = 0.21) were not signiﬁcant. The OS at 1-year was 74.1%
vs. 76.4% and at 2-years was 56.3% vs. 53.8% for the concurrent and
sequential groups, respectively (P = 0.69).
Conclusions: The risk of RN remains low at approximately 12% in
patients treated with ICI/SRS, and 6.5% of patients develop
symptomatic RN. This risk is signiﬁcantly increased when patients
undergo multiple SRS courses, have received prior cranial RT, and
harbor more radioresistant tumor histologies (melanoma and RCC).
Concurrent immunotherapy does not appear to increase this risk.

(OA42) Proton
Chordomas

Radiation

Therapy

for

Pediatric

Myrsini Ioakeim-Ioannidou1, Daniel Kim, MD MBA1, Andrzej Niemierko, PhD1, Paul Caruso, MD1, David ebb, MD1, Yen-lin chen, MD1,
Thomas DeLaney, MD1, Shannon MacDonald, MD1; 1Massachusetts
General Hospital
Background: Chordomas are rare primary bone tumors that arise from
ectopic remnants of the embryonic notochord with an overall incidence
of 0.08 per 100,000 in general population. Pediatric chordomas are very
rare and comprise 5% of all chordoma cases. The most common
location of pediatric chordomas is the base of the skull (BOS) followed
by the mobile spine and the sacrum. Treatment for chordomas generally
involves high-dose proton radiation therapy (PRT) with or without
surgical resection.
Objectives: We report outcomes for pediatric patients with BOS and
spinal chordomas treated with PRT.
Methods: Between 1981 and 2019, 236 pediatric patients with BOS
(n = 194) or spinal (n-42) chordomas were treated with PRT or combined proton/photon approach (comboRT) at a single institution. The
primary endpoints were overall survival (OS) and progression free
survival (PFS). Cox proportional hazards regression and Kaplan Meier
estimates were used for survival analyses.
Results: A total of 133 female and 103 male patients were identiﬁed.
Median age at diagnosis was 10.9 years (range, 0.8-21 y) and 13.1 years
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FIGURE 1. Kaplan-Meier survival curves for overall survival for
skull base pediatric chordomas.
(range, 3.6-21 y) in the BOS and spinal cohort, respectively. The
majority of the patients (n = 154) were diagnosed with conventional
chordoma, 57 with a chondroid subtype, 13 with atypical/cellular, and
12 with poorly-differentiated chordoma. All patients underwent surgical
resection (range, 1-8). 54 patients underwent gross total resection, 171
patients underwent STR while 11 patients had biopsy only. 23 patients
received pre-RT chemotherapy. 62 patients developed progressive
disease before the delivery of RT. Median total dose was 76 Gy (RBE)
(range, 39.7-83.3 Gy) delivered in 1.2 - 2.2 Gy (RBE) fractions (1.2 Gy
for BID). The median maximum dose to the brainstem was 65.7 Gy
(RBE) (range, 40.8 - 80). The median maximum dose to the spinal cord
was 63 Gy (RBE) (range, 30.6-68.5 Gy). At a median follow-up of
8.7 years (range, 0.6–35.6) from the date of diagnosis 68 patients
recurred (42 local, 18 distant and 8 iatrogenic). The 5- and 10-year OS
rates for BOS chordomas were 83% and 77%, respectively. The 5- and
10-year OS rates for spinal chordomas were 77% and 66%, respectively. The 5- and 10-year PFS rates in the BOS cohort were 75% and
71%, respectively. The 5- and 10-year PFS rates in the spinal cohort
were 66% and 62%, respectively. RT was well tolerated, with most
acute side effects limited to moderate erythema, otitis media and cervical dysphagia. Late toxicities included 5 cases of radiation myelitis, 4
cases of brainstem injury, 4 cases of temporal lobe injury and single
case each of moyamoya disease, Lhermitte’s syndrome, and esophageal
stricture. 3 patients developed secondary radiation related malignancies.
Conclusions: This is the largest cohort of pediatric chordomas in the
literature to date. High dose PRT following surgical resection is an
effective treatment with a high rate of disease control and minimal late
toxicity (Figs. 1 and 2).

FIGURE 2. Kaplan-Meier survival curves for progression-free survival for skull base pediatric chordomas.
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(OA43) Risk Factors for the Development of Leptomeningeal Disease and Outcomes Following Stereotactic
Radiation for Patients with Breast Cancer Brain
Metastases
Matthew Mills, MD1, Chetna Thawani, BS2, Nicholas Figura, MD1,
Daniel Oliver, MD3, Timothy Robinson, MD, PhD1, Hsiang-Hsuan
Michael Yu, MD3, Peter Forsyth, MD3, Kamran Ahmed, MD4; 1H. Lee
Mofﬁtt Cancer Center and Research Institute, Department of Radiation
Oncology, 2USF Morsani College of Medicine, 3H. Lee Mofﬁtt Cancer
Center & Research Institute, 4Department of Radiation Oncology, H.
Lee Mofﬁtt Cancer Center & Research Institute
Background: As the prognosis for patients with breast cancer brain
metastases (BCBM) improves due to signiﬁcant improvements in systemic therapy, the number of patients at risk for leptomeningeal disease
(LMD) has increased. While local therapies such as surgical resection
and stereotactic radiation (SRT) are known risk factors for LMD, the
identiﬁcation of patients with BCBM most at risk for LMD remains
unclear.
Objectives: To identify the risk factors for the development of LMD in
patients with BCBM after SRT.
Methods: This is a retrospective review of 181 patients who underwent
SRT to 664 BCBM from 2004 to 2019. The Kaplan-Meier method was
used to calculate time to LMD from SRT and overall survival (OS) from
the diagnosis of LMD, with log-rank testing to identify signiﬁcant correlations with patient and treatment characteristics. Univariate analysis
(UVA) was completed with the Cox proportional hazards model.
Results: Median follow up from SRT was 11.4 months. Of the 181
patients, 60 (33%) had HR+/HER2- subtype, 30 (17%) had HR-/HER2
+ subtype, 47 (26%) had HR+/HER2+ subtype, and 44 (24%) had HR-/
HER2- subtype. The median interval of initial breast cancer diagnosis to
brain metastasis disease was 52 months (range: 0-321). Of the 664
BCBMs, 534 (80%) received single fraction stereotactic radiosurgery
(SRS) with a median dose of 21 Gy (range 12-24 Gy), and 130 (20%)
received fractionated stereotactic radiation therapy (FSRT), with a
median dose of 25 Gy (range: 12.5-35 Gy) delivered in 3 to 5 fractions.
There were 68 cases (10%) of SRT to a postoperative cavity. Of the 181
patients, 24 (13%) developed LMD at a median of 18 months (1-57)
from BCBM diagnosis and a median of 6.6 months (0.6-29) from SRT.
Twelve and 24-month rates of LMD were 14% and 21%, respectively.
Patients who were diagnosed with BCBM ≤ 52 months after original
breast cancer (BC) diagnosis had a signiﬁcantly greater risk of LMD
(12 mo LMD 21% vs 7%, P = 0.026). There was a trend toward signiﬁcance for patients with extracranial systemic metastasis for greater
risk of LMD (12 mo LMD 26.8% vs 10.9%, P = 0.055) After diagnosis
of LMD, 6 and 12-month rates of OS were 35% ad 18%, respectively.
An interval between SRT and LMD diagnosis ≤ 6 months was the only
identiﬁed variable prognostic for inferior OS (6-month OS 0% vs 47%,
P < 0.001).
Conclusions: The risk of LMD for patients with BCBM after SRT
remains relatively low, though patients with a short interval from BC
diagnosis to BCBM diagnosis are at high risk of LMD. While the
prognosis for patients with LMD is dismal, OS is particularly poor for
those who develop LMD soon after SRT.

Abstracts

Objectives: We sought to characterize the impact of peri-operative
radiation therapy (RT) in sarcomas with TP53 alterations. Our objectives were type of ﬁrst relapse (local versus metastatic) and DFS
according to peri-operative RT administration and TP53 status.
Methods: MOSCATO and ProﬁLER trials were precision oncology
trials in advanced pan-histology tumors. Genomic molecular proﬁling
was done by targeted next-generation sequencing and comparative
genomic hybridization array. This is an ad hoc analysis of sarcoma
patients included in these trials. Molecular data from patients was
associated to their clinical data in localized standard-of-care treatment
using the national prospective French Sarcoma Group database.
Homozygous deletions and mutations of TP53 were retained as signiﬁcant alterations. For comparison of categorical variables, Fisher’s
exact test was used. For comparison of DFS, univariate Cox models
were used.
Results: A total of 155 sarcomas, including 123 soft-tissue sarcomas
(STS), were initially localized and surgically resected, amongst which
46 leiomyosarcomas (30%), 14 undifferentiated pleomorphic sarcomas
(9%) and 15 liposarcomas (10%). STS were grade 1, 2 and 3 in 19%,
34% and 47% of patients, respectively. TP53 status was determined on
primary tumor and metastasis in 77 cases each (50%, 1 not available).
Peri-operative RT was administered in 61 patients (39%). TP53 alterations were found in 40 sarcomas, including 35 STS, and were treated
with peri-operative RT in 18 cases, including 16 STS patients. Irrespective of RT, ﬁrst recurrence was metastatic in 37 and local in 3 of the
TP53 altered tumors, whereas it was metastatic in 81 and local in 31
cases of TP53 wild-type (WT) sarcomas (P = 0.01; Table 1). In STS
subgroup, there was only one local relapse and 34 metastatic relapses in
the TP53 altered tumors (P = 0.01). There were 13% (N = 8/61) local
recurrences in patients receiving RT versus 28% (N = 26/94) without
RT (P = 0.027). In TP53 altered sarcomas, there was one (6%, N = 1/
18) and two (9%, N = 2/22) local relapses with or without RT,
respectively (P = 1; Table 1). In TP53 WT sarcomas, there was 16%
(N = 7/36) and 33% (N = 24/72) of local relapses, with or without RT
(P = 0.04). In TP53 altered STS, the only local recurrence was in a
patient without peri-operative RT. In TP53 altered sarcomas, median
DFS with or without peri-operative radiotherapy was 10 and 14 months
(P = 0.5) and DFS rate at 12 months was 72% (95%CI = 54-96) and
41% (95%CI = 25-68) with or without RT, respectively. In TP53 WT
tumors, median DFS with or without peri-operative RT was 17 months
in both groups (Fig. 1).
Conclusions: In our retrospective cohort, TP53 alterations are associated with metastatic relapse, which warrants further validation. We are
recording the pathological response to radiotherapy, in sarcomas who
underwent pre-operative radiation therapy, which will be available for
presentation at ARS.

(OA44) Impact of Peri-operative Radiotherapy on Localized Sarcomas with TP53 Alterations: Retrospective Pooled
Analysis of Two Precision Medicine Trials
Elise Nassif1, Edouard Auclin2, Rastilav Bahleda3, Charles Honore3, Olivier
Mir3, Sarah Dumont3, Benoite Mery4, Khalil Hodroj4, Mehdi Brahmi4,
Olivier Tredan4, Isabelle Ray-Coquard4, Jean-Yves Blay4, Christophe
Massard3, Axel Le Cesne3, Armelle Dufresne4, Antonin Levy3, Cecile Le
Pechoux3, Ritsuko Komaki5; 1MD Anderson Cancer Center, 2APHP,
3
Gustave Roussy, 4Leon Berard, 5Baylor College of Medicine
Background: Sarcomas are rare diseases with a dismal prognosis. We
have previously reported an unfavorable prognostic impact of TP53
mutations on disease-free survival (DFS) in sarcomas and an increased
objective response rate to chemotherapy.

FIGURE 1. Disease-free survival according to TP53 status and
peri-operative radiotherapy administration. XRT = Radiotherapy;
WT = Wild-Type.
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TABLE 1. Type of Relapse According to TP53 Alterations, Treatment Modalities and Major Clinic-Pathological Characteristics at Diagnosis

(OA-01JIT) Prognostic Value of Baseline Metabolic Tumor
Volume in Intermediate-Risk Hodgkin Lymphoma After
Chemo-radiation Therapy: FDG PET Parameter Analysis
in a Subgroup from COG AHOD0031
Sarah Milgrom, MD1, Jihyun Kim, MD2, Alin Chirindel, MD3, Jongho
Kim, MD PhD3, Qinglin Pei, PhD4, Lu Chen, PhD5, Allen Buxton,
MS6, Sandy Kessel, BA6, Jeffrey Leal, BA3, Kathleen McCarten, MD7,
Bradford Hoppe, MD8, Suzanne Wolden, MD9, Cindy Schwartz, MD10,
Debra Friedman, MD11, Kara Kelly, MD12, Steve Cho, MD13; 1University of Colorado, 2University of Wisconsin School of Medicine and
Public Health, 3Johns Hopkins University, 44. Children’s Oncology
Group, Statistics and Data Center, Department of Biostatistics, University of Florida, 5University of Florida, 6Children’s Oncology Group,
Statistics and Data Center, 7IROC, 8Mayo Clinic Florida, 9Memorial
Sloan Kettering Cancer Center, 10Medical College of Wisconsin,
11
Vanderbilt University, 1212. Pediatric Oncology, Roswell Park
Comprehensive Cancer Center, 13Department of Radiology, University
of Wisconsin School of Medicine and Public Health
Background: Positron emission tomography (PET)-based measures of
baseline total-body tumor burden may improve risk stratiﬁcation in
pediatric and adolescent patients with intermediate-risk Hodgkin
lymphoma (HL).
Objectives: To assess for an association of metabolic tumor volume
(MTV) and total lesion glycolysis (TLG) with event-free survival (EFS)
To deﬁne which thresholds, used to deﬁne the MTV and TLG, are the
most prognostic.

Methods: Evaluable patients were identiﬁed from a cohort treated
homogeneously with the same combined modality regimen on the
multi-center, prospective Children’s Oncology Group AHOD0031
study. Eligible patients had high-quality baseline PET scans. MTV and
TLG were each measured based on 15 thresholds for every patient.
Univariate and multivariable Cox regression and Kaplan-Meier survival
analyses assessed for an association of MTV and TLG with EFS.
Results: From the AHOD0031 cohort (n = 1,712), 86 patients were identiﬁed who i) were treated with 4 cycles of ABVE-PC chemotherapy followed by involved ﬁeld radiotherapy and ii) had a baseline PET scan that
was amenable to quantitative analysis. Based on univariate Cox regression
analysis, 6 PET-derived parameters were signiﬁcantly associated with EFS.
For each of these, Kaplan-Meier analyses and the log-rank test were used to
compare patients with highest tumor burden (i.e. highest 15%) to the
remainder of the cohort. EFS was signiﬁcantly associated with all 6 PET
parameters (all P < 0.029). In a multivariable model controlling for
important covariates including disease bulk and response to chemotherapy,
MTV2BP (MTV deﬁned by the threshold of 2 * blood pool SUVmean)
was signiﬁcantly associated with EFS (P = 0.012).
Conclusions: Multiple baseline PET-derived volumetric parameters
were associated with EFS. MTV2BP was highly associated with EFS
when controlling for disease bulk and response to chemotherapy. These
two factors, bulky disease and early response to chemotherapy, are used
in current trials to guide risk-adapted treatment. Thus, baseline PET
measures of metabolic tumor burden may provide additional prognostic
information and improve risk stratiﬁcation for individualized treatment
regimens in intermediate-risk HL.
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(P001) Human-Induced Pluripotent Stem Cell Derived
Cerebral Organoids as a Model of Normal Brain Tissue
Response to Proton Radiation
Lawrence Bronk, PhD1, Julianna Bronk, MD, PhD2, Sanjay Singh,
PhD1, Xiaochun Wang, PhD1, Dadi Jiang, PhD1, Fada Guan, PhD1,
Albert Koong, MD, PhD1, Radhe Mohan, PhD1, Frederick Lang, MD1,
David Grosshans, MD, PhD3; 1MD Anderson Cancer Center, 2University of Texas MD Anderson Cancer Center, 3The University of Texas
MD Anderson Cancer Center
Background: Treatment-related sequelae following cranial irradiation
have life changing impacts for patients and their caregivers. Characterization of the basic response of human brain tissue to irradiation is
challenging due to a lack of representative preclinical models. However,
due to advances in stem cell biology, neuroscience, and tissue engineering, the direct study of human brain tissue in vitro is becoming possible.
Objectives: Cerebral organoids (COs), a novel human brain tissue
model system, have previously been applied to study neurological
disease and disorders including Zika and COVID-19 virus exposure and
autism spectrum disorder. However, COs have not been translated into
the ﬁeld of neuro-oncology to study of the sequalae of oncologic
treatment effects. We aim to establish a CO model to study the radioresponse of normal human brain tissue.
Methods: COs were grown using human induced pluripotent stem cells
and a modiﬁed Lancaster protocol (1,2), irradiated using protons to 0, 2,
5, and 9 Gy and prepared for immunostaining at 2-days post-irradiation.
To examine the effect of irradiation on the neural stem cell (NSC)
population, sections were stained for SOX2 and Ki-67 expression
denoting NSCs and proliferation respectively. Slides were imaged and
scored using the CellProﬁler software package. LDH release was
quantiﬁed over time as a marker of cell damage.
Results: The percentage of proliferating NSCs 2-days post-irradiation
was found to be reduced for proton irradiated COs (23.7 ± 5.2%
(P = 0.14), 17.8 ± 6.5% (P = 0.02), and 20.9 ± 2.1% (P = 0.05) at 2, 5,
and 9 Gy-RBE respectively) compared with control (33.0 ± 5.5%). At
2-days post irradiation to 2 Gy, increased apoptotic markers, cleaved
caspase-3 and cleaved PARP, were found. LDH release increased when
assayed at timepoints of 2, 4, and 6-days post proton irradiation to 9 Gy
and decreased towards baseline on day 9 and 11.
Conclusions: The loss of proliferating NSCs, upregulation of apoptosis,
and time dependent acute LDH release demonstrate the early effects of
proton radiation in a model of human brain tissue. Our initial results
indicate COs will be a valuable model to study the effects of radiation
therapy and immediate next steps will focus on deﬁning the predominant mechanisms of and therapeutic interventions to mitigate proton
radiation mediated brain tissue damage.

(P002) Measuring and Molecularly Deﬁning Intra-Tumoral
Hypoxia in High-Risk Sarcoma
David Shultz, MD, PhD1, Jennifer Dorsey, BS2, Patrick Veit-Haibach,
MD.2, Rebecca Gladdy, MD, PhD2, Harley Chan, PhD2, Jay Wunder,
MD.2; 1Princess Margaret Cancer Centre, 2University of Toronto
Background: Tumor hypoxia is associated with poor outcomes in soft
tissue sarcoma (STS) through mechanisms that are not fully understood.
We are currently conducting a clinical trial of high-risk STS in which
we are measuring hypoxia with FAZA-PET/MRI and pimonidazole
(PIMO) uptake detected through immunohistochemistry (IHC).
Objectives: To investigate hypoxia-speciﬁc epigenetic proﬁles, we plan
to isolate PIMO+ and PIMO- tumor cells from surgically resected
tumors and then assess DNA methylation in these populations using an
array-based approach. To generate preliminary data and establish the
techniques required to evaluate clinical samples, we prepared methylated
DNA from two primary cell lines (ST148 and ST548) generated from
patients with high-risk STS (undifferentiated pleomorphic sarcoma).
Methods: Cells were grown in a hypoxic or normoxic chamber for
72 hours. Bisulﬁte converted DNA was prepared and analyzed using an
850K methylation site array. All computational analyses were performed
in R. We used DMRforPairs to compare median methylation values in a
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pairwise fashion. Regions with median differences in M values (dM) >
0.5 in at least one pairwise comparison were considered relevant.
Results: In ST148 and ST548, 93, and 27 relevant regions were identiﬁed, respectively. Within each cell line, several of the identiﬁed regions
were within putative regulatory elements of the same gene. For example,
in STS148, 5 of 93 identiﬁed regions were within or adjacent to
SH3YL1, which has previously been identiﬁed as a hypoxia-repressed
gene. Several of the same hypoxia associated genes were identiﬁed in
both cell lines (e.g. SLC6A13, DIP2C, KDM5A, and CBWD1).
Conclusions: Our initial results demonstrate proof of principle that
hypoxia-regulated gene expression in high risk STS is likely associated
with changes in DNA methylation. This approach offers a method for
identifying potential mechanisms by tumor hypoxia contributes to
treatment failure. We are currently seeking to replicate this analysis
ex vivo tumor samples.

(P003) Biological Effects of Pre-treatment Low Dose Radiation on Peri-tumoral and Tumoral Tissues Involved with
Squamous Cell Skin Cancer
James Welsh, MS, MD1, Jaime Barumen, MD2, Richard Blankenbecler,
PhD3, Colin Donahoe3, Linda Ritchie3, Valeria Barrón-Palma, PhD4,
Eligia Juárez-Torres, PhD4, Frank Melendez, MD5, Bhanu Venkatesulu,
MD6; 1Hines VA, 2General Hospital of Mexico, 3BioGenome Therapeutics, 4Hospital General de México, 5Universidad Nacional
Autónoma de México, 6Loyola University/Hines VA
Background: Low dose radiation (LDR) may have paradoxically
beneﬁcial effects via an adaptive response. This adaptive response can
mitigate against the potential adverse effects of high-dose radiation
therapy and chemotherapy. In a human clinical trial of radiation therapy
for skin cancer plus pre-treatment low dose irradiation, we aimed to
identify molecular characteristics of the adaptive response in terms of
microRNA expression proﬁles.
Objectives: A human clinical trial (n = 8) was conducted to determine
the biological effects of integrating low dose radiation (LDR, 0.1 Gy)
into standard radiotherapy (2 Gy fractions) over the ﬁrst two weeks of
radiation treatment for epidermoid skin cancers with the speciﬁc aim of
determining adaptive responses. In this study we aimed to: 1. identify
the molecular details (in miRNAs) behind the adaptive response and 2.
To integrate the LDR adaptive response into clinical practice.
Methods: RNA was obtained from skin biopsies and processed for genetic
expression using Affymetrix Human gene chips Clarion-D (138K genes).
The aim was to determine how low dose radiation modiﬁes genetic expression in both healthy and tumor tissue. To determine this, a human clinical trial
(n = 8) was conducted to ascertain the biological effects of integrating 0.1 Gy
of LDR into standard radiotherapy (2 Gy fractions) over the ﬁrst two weeks
of radiotherapy for squamous cell skin cancers. Biopsy samples were collected and total RNA preparation (100 ng), labeled cRNA synthesis,
hybridization, scanning, and image analysis were performed. Changes in
biological response were measured using Affymetrix microarrays. Pathway
analysis was performed using the Affymetrix Transcriptome Analysis Console software and the Wikipaths database.
Results: The differences in gene expression in healthy tissue due to
LDR exposure were low (325 genes, mostly downregulated). The 20
most important biological processes that were affected include Senescence and Autophagy in Cancer, and Genotoxicity Pathway (both
downregulated). The differences in gene expression in malignant tissue
following LDR exposure were signiﬁcantly more pronounced (5,651
genes, mostly upregulated). The 20 most important biological processes
affected are shown in Figures 5 and 6 and Tables 4-6, and include
Allograft rejection pathway in skin cancer (upregulated).
Conclusions: Low doses of radiation (0.1 Gy) have a narrow effect on
gene expression when administered to healthy peritumoral tissues.
Downregulated genes predominate, and DNA repair mechanisms are
stimulated by the ﬁrst low dose to this healthy tissue. In contrast, a pronounced effect on gene expression was induced by LDR delivered to
malignant tissue. Upregulated genes predominate and are linked to antitumor immune response, especially Allograft rejection. This antitumor
immune rejection response is more noticeable after the ﬁrst low-dose
session than after the second week, possibly due to immune cell depletion
induced by the intervening high dose fractions. Also, after the second
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administration of LDR, inﬂammatory and oxidative stress processes and
tumor growth predominate, the latter perhaps as a tumor reaction to
overcome radiotherapy-induced damage via accelerated re-population.
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TABLE 1. Radiation Characteristics

(P004) Pattern and Timing of Recurrence in Node-positive
Breast Cancer Patients After Trimodality Therapy:
Opportunity for Improved Oligometastases Detection and
Salvage Local Therapy
Rojine Ariani, MS1, Lindsay Hwang, MD2, Jason Ye, MD1; 1Keck
School of Medicine of USC, 2University of Southern California
Background: Patients with node-positive breast cancer (BC) experience high rates of metastatic recurrence in distant sites even after
completion of trimodality therapy with surgery, systemic therapy and
radiation (RT). There is growing evidence that early detection and
treatment of oligometastatic disease ( ≤ 5 lesions) with aggressive local
therapies such as stereotactic body radiotherapy (SBRT) may improve
survival, but national guidelines have yet to offer any recommendation
for routine screening imaging for distant metastatic disease in breast
cancer patients without clinical signs or symptoms.
Objectives: A single-institution retrospective review of high-risk BC
patients treated with curative-intent trimodality therapy was performed to
describe rates, patterns, and extent of recurrence as well as imaging
modalities used in initial detection, to identify effective surveillance imaging
strategies for prompt detection of asymptomatic oligometastases that may
beneﬁt from SBRT before progression to diffuse metastatic disease.
Methods: Ninety-four node-positive BC patients treated at a safety-net
hospital between 2008-2019 were identiﬁed through the institution
cancer registry, of which 21 developed recurrence as reported in the
institution electronic medical records. These patients were divided into
subgroups of oligometastatic disease (10 patients) or diffusely metastatic disease (11 patients).
Results: The median recurrence-free survival (RFS) following RT in
the oligometastatic and diffusely metastatic subgroups was 18 months
and 36 months, respectively. Adjuvant chemotherapy was signiﬁcantly
associated with improved RFS and high-grade disease trended towards
an association with improved RFS on univariable analysis, but only
adjuvant chemotherapy maintained signiﬁcance on multivariable analysis. Following RT, the median overall survival (OS) for the oligometastatic subgroup was not reached. The median OS for the diffusely
metastatic cohort was 57 months. Four oligometastatic patients progressed to diffusely metastatic disease in a median of 17 months, with a
median survival of 57 months following progression. All patients who
recurred had distant metastatic disease on initial detection, most commonly in bone (14 patients). Recurrences were most frequently ﬁrst
detected by CT body imaging (11 patients).
Conclusions: Recurrent disease, limited or diffuse, was detected in 22%
of node-positive breast cancer patients within a median time of
≤ 36 months following RT. Patients with limited oligometastatic disease
had overall improved survival compared with those with diffusely
metastatic disease. All recurrences involved distant sites and were most
commonly detected by CT imaging. This study highlights the need for
improved surveillance imaging strategies in high-risk node-positive
breast cancer patients to allow for the timely detection of asymptomatic
oligometastatic disease while still amenable to aggressive local salvage
therapy before diffuse progression.

(P006) Proton Therapy for the Treatment of Men with
Breast Cancer
Julie Bradley, MD1, Jayden Curry, BS2, Raymond Mailhot Vega, MD,
MPH2, Xiaoying Liang, PhD2, Nancy Mendenhall, MD2; 1University of
Florida Department of Radiation Oncology, 2University of Florida
Background: While breast cancer treatment for men involves multimodality therapy including radiotherapy (RT), few men have received
proton therapy (PT) for breast cancer. One case report exists in the literature (1), yet an NCDB review of male breast cancer found 13/4070
men were treated with PT between 2004 and 2014 (2). Men have a higher
baseline risk of cardiac toxicity and there is an established correlation
between heart dose and cardiac toxicity, supporting the use of PT in men.

Objectives: To provide a descriptive analysis of PT in men with breast
cancer.
Methods: Men who received PT for localized breast cancer between
2012 and 2020 were identiﬁed from a prospective database. Toxicities
were prospectively recorded using CTCAE v4.0.
Results: Three patients were identiﬁed: 1 Black and 2 white. All had
ER+ PR+ Her2neu- disease and received adjuvant endocrine therapy.
None had positive genetic testing. All patients received PT to the left
chest wall and comprehensive regional lymphatics. Acute toxicity
consisted of 1 patient with grade 2 dermatitis and fatigue; no grade 3+
toxicity. Table 1 provides PT details. Patient A was 75 years old at
diagnosis with diabetes, hypertension, prior myocardial infarction with
cardiac stents, and atrial ﬁbrillation with a pacemaker. After work-up
for a palpable retroareolar mass, he underwent mastectomy and sentinel
lymph node biopsy (SLNB), with grade 2 invasive ductal carcinoma
(IDC), positive lymphovascular space invasion (LVSI), pT2 N1a(sn).
At 3.8 years after PT, there was no evidence of disease, with the only
toxicity of grade 1 telangiectasia. With comorbidities of DVT and
hypertension, Patient B was 60 years old when diagnosed with bilateral
retroareolar breast cancer. He underwent bilateral mastectomies and
SLNB with left grade 1 IDC, pT2 N1mi(sn) and right pTis N0(sn). At
13 months of follow-up, he had no evidence of disease and no toxicity.
Patient C was a healthy 80-year-old with clinical T2 N1 M0 disease.
After 4 months of neoadjuvant tamoxifen, he underwent left modiﬁed
radical mastectomy, with grade 2 IDC, LVSI positive, with a 0.1-cm
posterior margin. He had 18/20 nodes positive, ypT1cN3a. Grade 2
lymphedema developed postoperatively, before PT. He received 6
cycles of adjuvant paclitaxel and cyclophosphamide. Anastrozole was
started after completion of PT. Two months later, a subcarinal node that
was mildly enlarged at diagnosis but biopsy-negative increased in size
and FDG avidity. Systemic therapy changed to palbociclib and letrozole. He remained under radiographic surveillance with no in-ﬁeld
recurrence or other distant disease progression 6 months after PT.
Conclusions: In a small case series for a rare diagnosis, PT to the chest
wall and regional lymphatics including internal mammary nodes
resulted in low cardiac exposure, high local-regional disease control,
and minimal toxicity. PT should be considered for treatment of men
with breast cancer to achieve cardiac sparing.
References:
1. Giap BQ, Giap F, Einck JP, et al. A case study: proton therapy for
male breast cancer with previous irradiation. Int J Part Ther. 2016;
2:579–583.
2. Yadav S, Karam D, Bin Riaz I, et al. Male breast cancer in the United
States: treatment patterns and prognostic factors in the 21st century.
Cancer. 2020;126:26–36.

(P007) Radiation Treatment for Breast Cancer in Women 40
Years Old and Younger: Demographics, Outcomes, and Toxicity
Julie Bradley, MD1, Jayden Curry, BS2, Christopher Morris, MS2,
Nancy Mendenhall, MD2; 1University of Florida Department of Radiation Oncology, 2University of Florida
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Background: Women diagnosed with breast cancer at a young age face
unique challenges, including early menopause, reproductive and sexual
health issues, and altered physical appearance and functional status (1).
In addition, young age is a known adverse prognostic factor for breast
cancer (2).
Objectives: This analysis evaluates a cohort of women age ≤ 40 treated
with radiotherapy (RT) for breast cancer at a single institution.
Methods: From a prospective database, patients with breast cancer
treated at the University of Florida with radiotherapy between October
2010 and July 2019 were identiﬁed. Disease control was assessed using
the Kaplan-Meier product limit method. The log-rank test assessed
statistical signiﬁcance between strata of prognostic factors. Toxicity was
recorded using CTCAE v4.0.
Results: Thirty-seven women were identiﬁed, 65% with left-sided
breast cancer, and 2 diagnosed during pregnancy. Two patients were
treated for a local-regional recurrence, having failed after initial
management without RT. Median age was 36 years (range, 23–40).
Median follow-up was 3.8 years (range, 1.2–10.1). Thirty percent of
patients were Black and 54% white. Cardiac risk factors included
49% with hypertension and 8% with diabetes. Median BMI was 30.3
(range, 15.4–52.3). Genetic testing was positive for a pathological
mutation in 8% and for a variance of unknown signiﬁcance in 19%.
Most patients had stage I or II disease (76%). One patient had oligometastatic stage IV disease treated with curative intent. Moreover,
78% had invasive, 59% high-grade, and 22% triple-negative disease. Over half of the patients had breast-conserving surgery (54%).
Of those with mastectomy, 56% had reconstruction. Furthermore,
59% received chemotherapy and 65% endocrine therapy; 41%
underwent neoadjuvant systemic therapy. Median radiation dose
55.4 Gy (range, 50-70). The 3-year local-regional control, progression-free survival, and overall survival were 88%, 86%, and
94% respectively. On UVA, no variables were associated with localregional control. Progression-free survival was higher for patients
with N0 vs N+ disease (91% vs 73%, P = 0.04). Inferior overall
survival was associated with the presence of lymphovascular invasion and triple-negative disease (P = 0.04 and P = 0.03). There was a
trend for worse progression-free and overall survival for black
women (P = 0.07 and 0.08). Grade 1 lymphedema was the most
common toxicity (35%). Four patients developed pulmonary
embolism after RT, 2 had progressive heart failure, and 1 developed
fat necrosis requiring surgery. Three patients had pregnancies after
treatment for breast cancer, 1 of which resulted in an incomplete
abortion complicated by hypovolemic shock.
Conclusions: Despite the young age of women in this cohort, overall
disease control was high. However, early recurrences developed in a
subset of patients and were associated with node-positive disease,
lymphovascular invasion, and a trend towards Black race. The rate of
pulmonary embolism was higher than expected and further examination
of toxicity will provide a better understanding of potential exacerbating
factors and preventative measures.
References:
1. Black KZ, Eng E, Schaal JC, et al. The other side of through: young
breast cancer survivors’ spectrum of sexual and reproductive health
needs. Q Health Res. 2020;30:2019–2032.
2. Love RR, Duc NB, Dinh NV, et al. Young age as an adverse
prognostic factor in premenopausal women with operable breast cancer.
Clin Breast Cancer. 2002;2:294–298.

(P008) Clinical and Toxicity Outcomes in Re-Irradiation for
Recurrent Breast Cancer
Kelsey Corrigan, MD, MPH1, Samantha Buszek, MD1, Karen Hoffman,
MD, MPH1, Simona Shaitelman, MD, MEd2, George Perkins, MD,
MBA3, Benjamin Smith, MD4, Eric Strom, MD1, Welela Tereffe, MD1,
Wendy Woodward, MD PhD4, Michael Stauder, MD1; 1MD Anderson
Cancer Center, 2Department of Radiation Oncology, The University of
Texas MD Anderson Cancer Center, 3smoulder@mdanderson.org,
4
University of Texas MD Anderson Cancer Center
Background: Locoregional recurrence (LRR) of breast cancer in
patients with prior radiotherapy (RT) to the breast or chest wall is a
therapeutic dilemma. Typically, patients receive systemic therapy
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and surgery for treatment of their recurrence, but the role of reirradiation (re-RT) is debated. Up to half of patients who receive reRT experience acute toxicities, with many also having signiﬁcant
long-term toxicities. Limited data exists examining the clinical and
toxicity outcomes in breast cancer patients with LRR who
require re-RT.
Objectives: We investigated the clinical efﬁcacy and toxicity outcomes
of women with breast cancer requiring re-irradiation for LRR.
Methods: We identiﬁed breast cancer patients with LRR who were
treated with re-RT between 2014 and 2020 at our institution. Demographic and clinical variables were extracted from the medical record.
Toxicity and treatment-related factors were compared between patients
using χ2 testing. Overall survival (OS) was evaluated using the KaplanMeier method.
Results: 54 breast cancer patients with LRR were analyzed. Median
[interquartile range (IQR)] age was 58 [49-65] years. A majority were
ER-positive (63%), Her2-negative (85%), and high grade (57%). The
most common site of recurrence was the breast (48%), followed by:
chest wall (37%), soft tissue/bone (7%), skin (6%), regional lymph
nodes (LN) (4%). 43 (80%) patients had resection of their recurrence.
50 (93%) patients received 2D (electron)/3D RT and 4 (7%) patients
received advanced radiation techniques ([ARTTs]: IMRT, VMAT).
The median [IQR] total re-RT dose and fractionation was 60 [50-62]
Gy and 2 [1.9-2] Gy/fraction. 36 (67%) patients received a radiation
boost. 20 (37%) patients experienced acute grade 2+ toxicities. The
most common acute toxicity was dermatitis (37 patients, 69%). Other
toxicities included hyperpigmentation (26 patients, 48%) and breast
pain (15 patients, 28%). Patients receiving a total re-RT dose ≥ 50 Gy
were more likely to experience any toxicity (81% vs. 36%, P < 0.01).
Presence of any acute toxicity was not associated with use of 2D/3D
RT versus ARTTs (72% vs. 75%, P = 0.89). Patients with LN recurrence had worse 5-year OS (50%) compared with the other sites of
recurrence (chest wall, 78%; breast, 94%; skin, 100%; soft tissue/bone,
100%). There was no difference in median OS in patients receiving
surgery (74 vs. 79 mo, P = 0.34), radiation boost (79 vs. 76 mo,
P = 0.27), or ARTTs (89 vs. 79 mo, P = 0.90) for treatment of their
recurrence.
Conclusions: Re-RT is efﬁcacious for control of LRR in breast cancer,
however more data are needed to determine the safety of using higher
total re-RT doses. Toxicity outcomes were similar between patients
receiving 2D/3D RT and ARTTs. Additional follow-up and analysis are
necessary to evaluate long-term survival outcomes and toxicities in
these patients.

(P009) Magnetic Resonance Guided Accelerated Partial
Breast Irradiation - Single Institution Experience Using
ViewRay Technology
Jadranka Dragovic, MD1, Kate Aldridge, RTT, CMD2, Anthony
Doemer3; 1Henry Ford Health System, 2Henry Ford Hospital, 3Henry
Ford Cancer Institute
Background: In the recent years PBI has emerged as an alternative to
WBI. This results in less normal tissue irradiated, less morbidity and
late complications, greater patient convenience. The comparative efﬁcacy and toxicity proﬁles of PBI compared with WBI have shown
similar ipsilateral breast tumor recurrence rates and reduced acute
toxicities. With the advent of dedicated magnetic resonance-guided
radiation therapy systems such as the MR-Linac there is potential for
further improvement in the delivery of PBI and increased safety. We
present our experience of MR-guided PBI in early-stage breast cancer
(08/2017 -01/2021) and compare to patients treated with brachytherapy
(1/2010 - 8/2015).
Objectives: 1) Assess the efﬁcacy and toxicity of adjuvant PBI using
MR-GRT in early-stage breast cancer. 2) Compare to outcomes of HDR
brachytherapy patients 3) Determine situations where online adaptive
RT may be beneﬁcial.
Methods: Fifty patients treated with PBI (MR-GRT) and 29 treated
with HDR brachytherapy (Contoura) were evaluated. Criteria for PBI
included: unifocal tumors.
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Results: Acute reactions were minimal with skin reactions mild to none
and limited to the lumpectomy site (RTOG score 0-1). Late effects
were localized mild skin hyper-pigmentation. One patient had a rib
fracture. There are no recurrences to date, with a median follow up of
12 months. None of the patients qualiﬁed for online adaptive planning,
but end-inhale breath hold was utilized for left-sided tumors for cardiac
sparing. In the brachytherapy group one had a local recurrence (at 3 y)
and 12/29 had signiﬁcant persistent seroma/thickening/retraction at the
treated site.
Conclusions: PBI using MR-guided radiation therapy is a feasible, well
tolerated regimen for early-stage breast cancer with a favorable acute
and late toxicity proﬁle and excellent cosmetic result. The follow-up is
presently too short for recurrence evaluation, but so far no relapses were
seen at a median follow up of 12 months. When compared with brachytherapy the acute and late morbidity are signiﬁcantly lower and the
cosmetic result superior.

(P010) Predictors of Radiation Dermatitis and Esophagitis
in Early Stage Breast Cancer Patients Receiving Adjuvant
Whole Breast Radiation Therapy
Stephen Dzul, MD PhD1, Seongho Kim, PhD2, Hyejeong Jang, BS2,
Michael Dominello, DO1, James Ninia, MS1; 1Wayne State University,
2
Karmanos Cancer Institute
Background: Breast conserving surgery followed by adjuvant whole
breast radiation therapy is standard of care in the management of early
stage breast cancer. Radiation dermatitis is one of the most common
toxicities associated with whole breast radiation therapy and is frequently treated with topical ointments and NSAIDS.
Objectives: This study investigates clinical factors associated with
increased incidence of Grade 2+ radiation dermatitis in patients
undergoing adjuvant whole breast radiation.
Methods: An institutional database was developed to include all
patients with a history of breast cancer or DCIS undergoing adjuvant
whole breast radiotherapy at a single institution from 2013-2019.
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Records were reviewed to identify patient’s age, BMI, radiation
dose and fractionation, prone vs supine position, inclusion of boost,
and inclusion of regional nodal irradiation. Radiation treatment
plans were reviewed to identify breast size, and volume of breast
receiving > 105% and > 107% prescription dose (V105%, V107%).
Medical records were reviewed to identify which patients experienced at least patchy moist desquamation (silvadene prescription
was used a surrogate for this toxicity) during or immediately following their course of radiotherapy. Univariable and multivariable
logistic regression analyses were performed to identify correlations
between patient factors associated with incidence of dermatitis and
esophagitis.
Results: 370 patients were included in the ﬁnal analysis. 43% of
patients were obese and 15% were morbidly obese. 42% of patients
received hypofractionated radiation treatment. 35% of patients were
treated with an additional supraclavicular ﬁeld (SCF) to include
regional lymph nodes. 22% of patients were treated in prone position.
Grade 2+ dermatitis was diagnosed in 39% of patients. On univariable
analysis, obese and morbidly obese patients were more likely to
develop dermatitis (Obese: OR 1.65, P = .032, Morbidly Obese: OR
4.28, P <0.001). On multivariable analysis, larger breast volume (OR
TABLE 1. Logistic Regression Analyses of Patient Features
Associating With Incidence of Dermatitis
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2.75, P < .001) was associated with increased incidence of dermatitis
while prone position (OR 0.42, P = .013) and hypofractionated radiotherapy was associated with decreased incidence of dermatitis (OR
0.50, P = .027). V107% and presence of a SCF had a positive correlation and age had a negative correlation with dermatitis on univariable
analysis but these correlations were not present on multivariable
analysis. Addition of a boost to the lumpectomy cavity did not affect
the rate of dermatitis.
Conclusions: Radiation dermatitis is a common toxicity observed in
patients undergoing adjuvant breast radiation therapy. Large breast
volume was associated with a higher rate of dermatitis while prone
position and hypofractionated radiation reduced rates of dermatitis.
Addition of lumpectomy cavity boost did not increase the incidence of
dermatitis. Hypofractionated, prone radiotherapy with or without boost
likely decreases the risk of grade 2+ dermatitis, particularly for women
with large breast volumes (Table 1).

(P011) Impact of Surgery Type and Radiation Fractionation on Outcomes in Node-Negative Metaplastic Breast
Cancer
Yufei Liu, MD PhD1, Puneet Singh, MD1, Stacy Moulder, MD1,
Wendy Woodward, MD PhD1, Simona Shaitelman, MD, MEd2, George
Perkins, MD, MBA3, Anthony Lucci, MD1, Lavinia Middleton, MD1,
Benjamin Smith, MD1, Melissa Mitchell, MD PhD1; 1University of
Texas MD Anderson Cancer Center, 2Department of Radiation
Oncology, The University of Texas MD Anderson Cancer Center,
3
smoulder@mdanderson.org
Background: Metaplastic breast cancer is a rare aggressive subtype
with poor outcomes and early recurrences. As practice patterns shift
toward hypofractionation in early stage breast cancer patients worldwide, we sought to assess local therapy use in node negative metaplastic
breast cancer in a single institution and associated oncologic outcomes.
Objectives: 1. Assess the clinical outcomes of patients with metaplastic
breast treated with surgery with or without adjuvant radiation at our
institution. 2. Assess whether metaplastic breast cancer can be effectively treated with hypofractionation.
Methods: After IRB approval, we retrospectively reviewed the charts of
metaplastic patients treated between January 2014 and January 2020 at
our institution, a timeframe with increased utilization of hypofractionation. Patients with non-inﬂammatory, non-metastatic breast cancer
with known radiation status were included in the analysis. All patients
were node negative clinically and pathologically. Data were collected
on chemotherapy use, radiation use, surgery type, tumor subtype, tumor
stage, recurrences and deaths. Kaplan-Meier estimates of 2 year
recurrence and survival were performed in SPSS 24.
Results: A total of 50 metaplastic patients were identiﬁed who met the
inclusion criteria, with a median follow-up time of 26 months from
diagnosis. Median age was 58, range 24-84. Seventy-two percent of
patients were White. Seventy-six percent of tumors were triple negative,
18% hormone positive, and 6% Her2 positive. Most patients received
chemotherapy, 82%, with 51% of these receiving it neoadjuvantly.
Table 1 shows actuarial 2 year local recurrence, any recurrence and

TABLE 1. Outcomes of Metaplastic Breast Cancer Patients
Treated With Lumpectomy or Mastectomy With or Without
Radiation
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overall survival by local therapy subtype. To date, all local recurrences
captured had developed within 20 months of diagnosis; median time to
local recurrence was 11 months. The minimum follow-up was
16 months in patients treated with lumpectomy and hypofractionation.
Clinical stage was T1 20%, T2 62%, T3 12% and T4b 6%. All T4b
patients received mastectomy and radiation. Patients selected for mastectomy alone were more likely to be early stage cT1/2 (100%), compared with patients receiving mastectomy and radiation cT1/2 (45%).
Staging for lumpectomy patients receiving hypofractionation were cT1
33%, cT2 67%, as compared with lumpectomy with conventional
fractionation cT1 18%, cT2 76%, cT3 6%. All hypofractionation
patients were hormone negative, one was Her2 positive.
Conclusions: While limited by low numbers, this analysis suggests that
hypofractionation should be further studied in early stage metaplastic
breast cancer. Continued review of outcomes with larger patient numbers is needed. Patients with higher stage disease have poorer outcome,
despite aggressive local therapy with mastectomy and radiation.

(P012) Prospective Pilot Study of Radiation Dermatitis
Among Patients with Breast Cancer Evaluated Using Deep
Machine Learning
Sung Jun Ma, MD1, Shawn Matott, PhD1, Robert DeLeon, PhD1,
Simon Fung-Kee-Fung, MD1, Saif Aljabab, MD1; 1Roswell Park
Comprehensive Cancer Center
Background: Patients and clinical studies often rely on experienced
radiation oncologists to evaluate the severity of radiation dermatitis
(RD). However, available grading tools are heterogeneous and subjective. In recent years, deep machine learning (DML) algorithms have
emerged in diagnosing various skin disorders.
Objectives: In this prospective feasibility pilot study, we explore the
ability of DML to detect RD in breast patients and correctly describe the
skin ﬁndings and grading using the Common Terminology Criteria for
Adverse Events (CTCAE v5.0).
Methods: Our institutional review board approved this study. Videos of
bilateral breasts were obtained weekly during radiation and up to onemonth post-treatment. Video recordings were split into frames and
binned by a radiation oncologist. Two separate convolutional neural
network models were developed. One model classiﬁed frames by skin
ﬁndings and the other by CTCAE grade 0 to 4. Skin ﬁndings included:
normal skin, irradiated healing skin, faint erythema/hyperpigmentation,
brisk erythema/hyperpigmentation, dry desquamation, moist desquamation, moist desquamation with bleeding, skin ulceration, and skin
necrosis. Images were divided into 80% training set and 20%
validation set.
Results: A total of 12 women were enrolled (8 White and 4 African
American) between June 2020 and October 2020. A total of 4,530
images were collected and binned into normal skin (n = 2,624), irradiated healing skin (n = 317), faint erythema/hyperpigmentation (n = 867)
and brisk erythema/hyperpigmentation (n = 577). Desquamation classes
were aggregated (n = 145) due to their small sample size for this initial
analysis. No skin ulceration or necrosis was observed. For our ﬁrst
model to classify skin ﬁndings, overall accuracy for the model was
84%. The model distinguished normal skin from any grade of radiation
dermatitis or post-radiation skin with an accuracy of 95%. However,
given small sample sizes of images with radiation dermatitis, the
model’s accuracy ranged from 57% to 74% for differentiating among
recently irradiated skin, faint or brisk erythema or hyperpigmentation,
and desquamation. For our second model to grade using CTCAE v5.0,
images were binned into grade 0 (n = 1,844), grade 1 (n = 801), and
grade 2 (n = 301). Grade 3 images were excluded for analysis given its
limited sample size. No grade 4 or 5 toxicities were observed. Overall
accuracy was 82%. The model identiﬁed grade 0, 1, and 2 correctly
with the accuracy of 87%, 74%, and 74%, respectively. The model was
more accurate on White patients with an overall accuracy of 85%,
compared with that of 75% on African American patients.
Conclusions: Our prospective pilot study demonstrates that using both
of our DML models to identify radiation dermatitis is feasible. We are
now planning to accelerate data collection to increase all classes’ sample
sizes to further internally and externally validate our model.
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(P013) Five Day Accelerated Partial Breast Irradiation
(APBI) Using Stereotactic Body Radiation Therapy (SBRT)
in Stage 0-II Breast Cancer: A Report of 186 Patients with
up to 3 Year Follow-up
Rufus Mark, MD1, Valerie Gorman, MD1, Steven McCullough, PhD1;
1
Baylor Scott & White Medical Center
Background: Randomized trials in selected early stage breast cancer
patients with up to 10 year follow-up have proven that Accelerated
Partial Breast Irradiation (APBI) given via High Dose Rate (HDR)
implant bid in 5 days is equivalent to whole breast External Radiation
Therapy (XRT) given qd in 5-6 weeks in regard to breast tumor local
recurrence (LR) [1-2]. However, complications with APBI implant in
a Medicare database review have been signiﬁcant, with 3.95% of
women requiring Mastectomy, 16.2% developing infections, and
another 16.3% experiencing non-infection complications including
rib fractures, fat necrosis, and breast pain [3]. Recently APBI using
non-invasive Intensity Modulated Radiation Therapy (IMRT) or
Stereotactic Body Radiation Therapy (SBRT) given qd in 5 fractions
has been shown in another randomized trial with 10 year follow-up to
be equivalent to qd XRT in 6 weeks, with respect to LR [4]. IMRT/
SBRT was superior in regard to acute effects, late effects, and
cosmesis.
Objectives: In the randomized clinical trial of APBI IMRT/SBRT, the
Clinical Target Volume (CTV) was deﬁned by the injection of individual ﬁducial markers bordering the surgical cavity. At our institution,
we have used the Biozorb ﬁducial system to localize the CTV for
SBRT. We sought to conﬁrm the APBI SBRT/IMRT results with a
simpler ﬁducial system.
Methods: Between 2017 and 2020, 186 patients have undergone
SBRT targeted to a Biozorb deﬁned CTV with the walls of the surgical cavity sewn to the Biozorb device. Eligible patients were older
than age 40, had tumor sizes < 3 cm, negative surgical margins, and
negative sentinel node dissections. SBRT dose was 30 Gy given in 5
fractions. Dose Constraints were as follows: V-30 Gy < 105%,
Ipsilateral Breast V-15 Gy < 50%, Ipsilateral Lung V-10 Gy < 20%,
Contralateral Lung V-5 Gy < 10%, Heart V-3 Gy < 20%, Contralateral Breast Dmax < 2 Gy and Skin Dmax < 27 Gy. The Planning
Target Volume (PTV) ranged from 27 to 355 cc with a median of 80
cc. PTV = CTV + 1-2 cm.
Results: Follow-up ranged from 1-36 months with a median of
18 months. LR has been 0% (0/186). There have been no biozorb
related infections, reactions, or rejections. There have been no cases of
radiation induced seromas, skin reactions, or soft tissue necrosis. Four
patients, 2.2% (4/186) developed pain around the Biozorb site. Three
cases were resolved within 2 days on a 2 week course of steroids. One
patient required 3 courses, with the last being 1 month. Cosmetic results
as rated by the Surgeon, Radiation Oncologist, and Nurse, were rated
excellent in 98.9% (184/186) of cases.
Conclusions: Non-invasive APBI with SBRT given qd over 5 days
targeted to Biozorb has resulted in LR, complications, and cosmetic
results which compare favorably to invasive APBI given bid with HDR
implant. At last follow-up, there have been no LR, skin reactions, or
complications. Cosmesis has been excellent in 98.9% of patients.

(P014) Predictors of Metastatic Breast Cancer Presentation
in a Vulnerable Patient Population
Mary McGunigal, MD1, Rhea Bhatt, BS2, Nima Aghdam, MD3;
1
Georgetown University Hospital, 2Georgetown University, 3Beth
Israel Deaconess Medical Center
Background: Socially disadvantaged populations in the United States
experience worse outcomes compared with the general population when
diagnosed with breast cancer. One potentially vulnerable population
includes patients under age 65 that qualify for Medicare due to debilitation. This group includes patients who have received social security
disability insurance for at least 2 years and those who have been
diagnosed with end-stage renal disease or amyotrophic lateral sclerosis;
current literature suggests this population experiences worse oncologic
outcomes.
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Objectives: Our study goal was to utilize the National Cancer Database
(NCDB) and perform analyses to determine what factors among
patients under the age of 65 who qualify for Medicare predict for a
higher likelihood of presenting with stage IV breast cancer.
Methods: The NCDB was queried for breast cancer patients diagnosed
from 2004-2014 who were below the age of 65 and qualiﬁed for
Medicare. Patients were excluded if they presented with noninvasive
disease or if their AJCC stage was unknown. Patients were excluded if
any social determinants (race, income quartiles, Charlson-Deyo
comorbidity score, travel distance) or hospital factors (facility type,
facility location) were unknown. Pearson χ2 test was used to identify
associations between categorical variables and stage. Univariate analysis of sociodemographic factors was performed. Statistically signiﬁcant factors were included in a multinomial logistic regression model
to determine independent covariates associated with stage IV
presentation.
Results: 56,964 patients met study criteria. Based on P values (P <
0.05) and strength of odds ratios, the following variables were included
in the ﬁnal model: race, income, comorbidity score, travel distance,
facility type, and facility location. All covariates except facility location
and distance were signiﬁcant predictors of metastatic disease presentation. Race was a signiﬁcant predictor, with white patients less
likely to have stage IV presentation (OR 0.73, P < 0.001) compared
with black patients. Individuals earning <$38,000 annually were signiﬁcantly more likely to present at stage IV (OR 1.15, P < 0.001).
Patients who traveled shorter distances to treatment facility had nonsigniﬁcantly higher odds of presenting at stage IV (OR 1.37, P = 0.608).
Higher comorbidity score was a signiﬁcant predictor of Stage IV disease at presentation.
Conclusions: Multiple sociodemographic factors were powerful predictors of a stage IV breast cancer presentation in this select population
of patients under 65 years old who qualify for Medicare due to debilitation. A deeper understanding of these factors can help identify
patients at high risk of a metastatic cancer presentation to provide
screening and preventative services at an earlier stage in this vulnerable
population.

(P015) Ductal Carcinoma in Situ (DCIS) of the Breast:
Impact of Age, Grade, and Receptor Status on Survival
Mary Nittala, DrPH1, Satyaseelan Packianathan, MD, PhD2, Gary
Shultz, DO3, Eswar Mundra, MD3, William Woods, MSN. NPC3,
Maria Smith, MSN, NPC3, Barbara Craft, MD3, Srinivasan Vijayakumar, MD, MPH3; 1The University of Mississippi Medical Center,
2
Univerity of Mississippi Medical Center, 3University of Mississippi
Medical Center
Background: Ductal carcinoma in situ (DCIS) women who underwent
surgery (lumpectomy/mastectomy) are at risk for recurrence within the
breast; adjuvant radiotherapy (RT) often reduces the risk for recurrence.
We decided to investigate the factors that improves the overall survival
(OS) and loco-regional control (LRC) in DCIS women patients at an
academic medical center to help tailor treatment decisions.
Objectives: The objective of this study was to evaluate LRC and OS
rates of DCIS women patients treated with surgery ± RT and hormonal
modulation.
Methods: This is a retrospective analysis of 44 DCIS patients treated
between 2007 and 2017 at an academic state institution. All of them
underwent lumpectomy and/or mastectomy (surgery) followed by
adjuvant irradiation to a median total dose of 50 Gy (range 40.5–
50.4 Gy). For all 44 DCIS patients, LRC and OS were estimated using
the Kaplan-Meier method. The signiﬁcance of survival variables were
analyzed using the Cox univariate and multivariate proportional hazards
model. A P-value of less than 0.05 was considered statistically signiﬁcant. The SPSS 24.0 software was used for data analysis.
Results: The baseline characteristics of all 44 DCIS patients were
documented over a median follow-up of 70 months (range 5–147 mo).
Patients were stratiﬁed into three age groups (< 50 y (3) vs. 50- 70 y
(31) vs. > 70 y (10); median age of 64 y; range 46–80 y). Overall,
34.1% of DCIS diagnoses were low grade, 29.5% intermediate grade,
and 36.4% were high grade. Older women were more likely to develop
low grade DCIS than the younger women. Following surgery, 50% of
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TABLE 1. Baseline Characteristics of DCIS Patients
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TABLE 2. Univariable & Multivariable Cox Regression for Overall Survival
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patients had negative tumor margins; ER was positive in 88.6% and PR
positive in 79.5%. Ninety percent of patients had a lumpectomy and
40.9% used Tamoxifen. The ﬁve-year rates for LRC, and OS were 0 vs.
69 vs. 50% (P = 0.030) and 33.7 vs. 70.8 vs. 60% (P = 0.041),
respectively. On Cox multivariate analysis, younger age [ < 50 y]
(P = 0.023), African-American ethnicity (P = 0.011), and ER positivity
(P = 0.007) were associated with a statistically improved signiﬁcant OS.
Conclusions: Outcomes in patients diagnosed with DCIS of the breast
appears dependent upon age, ethnicity, and ER receptor status; this
information may potentially help tailor treatment decisions in these
patients (Tables 1, 2 and Fig. 1).

(P016) Dosimetric and Acute Toxicity Analysis with
Hypofractionated Regional Nodal Irradiation for Breast
Cancer

FIGURE 1. Overall survival and loco regional control of DCIS
patients categorized by age group.

Adam Richman, MD1, Michael Schad, BS1, Emilia Diego, MD2,
Priscilla McAuliffe, MD, PhD2, Ronald Johnson, MD2, Jennifer Steiman, MD2, Donald Keenan, MD, PhD2, Joanna Lee, MD2, John Vargo,
MD3, Sushil Beriwal, MD, MBA, FABS, FASTRO1; 1Department of
Radiation Oncology, UPMC Hillman Cancer Center, 2Department of
Breast Surgical Oncology, UPMC Hillman Cancer Center, 3Department of Radiation Oncology, Hillman Cancer Center, University of
Pittsburgh Medical Center
Background: Hypofractionated regional nodal irradiation (RNI) breast
radiotherapy has been shown to be effective and safe in clinical trials.
However, there is limited dosimetric analysis available with this regimen to see which factors predict for pneumonitis. The ongoing RTCHARM study limits the percentage of ipsilateral of lung volume that
receives ≥ 18 Gy (V18) to 35-40% [1].
Objectives: To evaluate the rates of acute pneumonitis in women
treated with hypofractionated RNI at our institution and to identify
dosimetric factors predictive for pneumonitis.
Methods: We performed a retrospective review of all breast cancer
patients treated with hypofractionated RNI deﬁned as the undissected
axilla and supraclavicular region +/- intramammary nodes following
either lumpectomy or mastectomy at our institution from 9/2018 to 8/
2020. The primary endpoints were acute and chronic symptomatic
pneumonitis. Secondary endpoints included acute and chronic skin
toxicity. The Kaplan–Meier method was used to estimate event-time
probabilities for the primary endpoints. Predictors of symptomatic
pneumonitis were analyzed using log rank tests between groups.
P-values <0.05 were considered signiﬁcant.
Results: 126 patients qualiﬁed with a median follow up of
11.1 months (interquartile range [IQR] 8.17–18.23). Median age
was 72 years (IQR 66–78) and 88.9% of patients had node-positive
disease. Overall, 56.3% of patients received whole breast RT and
43.7% of patients received chest wall RT. 100 patients (79%)
received 40.05 Gy in 15 fractions and 23 patients (18%) received
42.56 Gy in 16 fractions. Surgical bed boost was given to 92.1% of
patients. The median ipsilateral lung maximum dose (Dmax) was
41.57 Gy (IQR 40.61–42.61) and mean dose (Dmean) was 9.78 Gy
(IQR 8.39–11.48). Ipsilateral lung V5 was 40.73% (IQR
35.17–46.30), V10 was 27.40% (IQR 22.59–32.35), and V20 was
20.63% (IQR 16.72–25.74). Contralateral lung median Dmax and
Dmean were 2.79 Gy (IQR 1.68–5.24) and 0.20 Gy (IQR
0.16–0.25), respectively. Mean heart Dmax was 13.71 Gy (standard
deviation [SD] 0.93), mean Dmean was 4.23 Gy (SD 2.97), and
median V20 was 0.00% (IQR 0.00–0.00). For acute radiation dermatitis, the rate of grade 2 toxicity was 30.4% for lumpectomy and
42.6% for mastectomy and the rate of grade 3 toxicity was 7.2% for
lumpectomy and 1.9% for mastectomy. There was no grade 4+ acute
radiation dermatitis. Acute grade 2 pneumonitis was seen in one
patient (0.8%) and no patients developed acute grade 3+ or chronic
grade 2+ pneumonitis. Of the patients that underwent a post-radiation therapy chest CT (n = 38, 30.4%), 68.4% had radiographic
evidence of grade 1 pneumonitis.
Conclusions: The overall incidence of acute symptomatic pneumonitis
in patients treated with hypofractionated RNI is very low. V20 < 26%
appears to be safe to limit symptomatic pneumonitis. No clinical or
dosimetric factors were predictive for symptomatic pneumonitis.
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(P017) Comparison of Skin Toxicity and Outcomes for
Three and Four Week Hypofractionated Whole Breast
Irradiation Regimens
Juliana Runnels, MD1, Juliana Runnels, MD1, Alexander Rose, BS1,
Ben Liem, MD2, David Lee, MD, PhD2, Thomas Schroeder, MD2;
1
University of New Mexico School of Medicine, 2Section of Radiation
Oncology, Division of Hematology-Oncology, Department of Internal
Medicine, and University of New Mexico Comprehensive Cancer
Center, University of New Mexico School of Medicine
Background: Multiple randomized trials have shown that whole breast
radiation therapy delivered in fewer, larger fractions is safe and effective. This recent evidence supports hypofractionation, but the optimal
dose-fractionation schedule remains controversial. At our institution,
physicians use either a 4-week course (42.56 Gy/16Fx, 10 Gy/4Fx
sequential boost) or a 3-week course (48 Gy/40 Gy/15Fx, concomitant
boost). Half our physicians perceived an increase in acute skin toxicity
with the 3-week regimen. The other half did not. Patients are referred to
the next available physician, similar to a randomization. A retrospective
review of these patients may provide a comparison with fewer selection
biases inherent in retrospective studies.
Objectives: Acute skin toxicity is a common symptomatic side effects
of breast irradiation. We sought to compare the incidence of acute skin
toxicity in patients treated with 3 versus 4 weeks of radiation therapy for
breast cancer.
Methods: An IRB-approved retrospective review identiﬁed 342
patients treated with hypofractionated radiation therapy from 2013 to
2020. 195 treated with the 4-week regimen and 147 with a 3-week
regimen. Primary endpoint was acute skin toxicity assessed by: CTCAE
v4.0 physician-scored toxicity during weekly visits, use of topical silver
sulfadiazine, and patient recollection of skin toxicity (assessed by telephone survey done as part of the study). Secondary endpoints were
patient-reported cosmesis by BCTOS, overall survival, and local
recurrence-free survival. Log-rank tests were used to compare grade ≥
2 skin toxicity between arms. Fischer’s exact test were used for comparing toxicities between the two groups and two-sided P values were
reported.
Results: Median follow-up was 26 months (3-93 mo). Overall grade ≥
2 CTCAE weekly assessed acute skin toxicity was 30% (33% 3-week
vs. 27% 4-week; P = NS). Topical silver sulfadiazine use was 39%
3-week vs. 35% 4-week, P = .NS. Recollection of acute skin toxicity on
telephone survey was 77% 3-week vs. 69% 4-week, P = .008. 206
(60%) responded to the telephone survey at time of data collection. This
also noted the 3-week course was more likely to report peak skin
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toxicity after completion of RT (38% vs 18%, P = .005). BMI > 30 was
more common in the 4-week group than the 3-week group (48% vs
29%, P = 0.007). BCTOS showed no difference between the groups in
cosmesis, function, pain (1.55 vs. 1.63, 1.24 vs. 1.21, 1.51 vs. 1.42,
P = NS). There was no difference in overall or local recurrence free
survival (97.9% vs 95.9%, 98.9% vs 97.4%, P = NS). 3% (10 of 342)
patients had died, 1% (3) from breast cancer, 1% (3) from non-breast
second cancer, and 1% (4) due to other causes.
Conclusions: In this comparison of two popular hypofractionation
regimens, we observed comparable physician-reported acute skin toxicity, cosmesis, and disease control outcomes. Limitations to this study
include the possibility of measurement bias and selection bias. The
3-week group reported more peak skin toxicity after completion of
treatment, this could be associated with under-reporting of skin CTCAE
weekly assessment on the 3-week regimen. A higher number of patients
with greater BMI was present in the 4-week regimen. Both could skew
results in favor of the 3-week regimen. Across treatment arms, there
was a higher incidence of silver sulfadiazine prescribed than physicianrecorded acute toxicity. Though the treatments compared in this analysis varied by a short time interval, hypofractionation could make
treatment more convenient and accessible for many patients. Additional
comparative analyses that incorporate patient-reported outcome measures are encouraged to determine the most safe and effective treatment
for individuals.

(P018) Wrong Number: The Inappropriate Use of an Age
Cutoff Heuristic to Allocate Adjuvant Therapy for Highrisk, Early-stage Breast Cancer Patients Following Breast
Conserving Surgery
Wesley Talcott, MD, MBA1, Daylian Cain, PhD, MBA2, Daniel Yang,
MD1, Sarah Mougalian, MD1, Suzanne Evans, MD MPH3; 1Yale
School of Medicine, 2Yale School of Management, 3Yale New Haven
Health/Smilow Cancer Center
Background: Patient age is a continuous variable that should be
incorporated into oncologic decision making. However, providers under
time pressure have been shown to process age by dividing patients into
“older” vs “younger” categorical subgroups. Use of this cognitive
shortcut (“age cutoff heuristic”) simpliﬁes incorporation of patient age
into treatment decisions but may lead to inappropriate treatment allocation around the age cutoff used for dichotomization.
Objectives: We hypothesized the existence of an age cutoff heuristic
leading to non-evidence-based adjuvant treatment allocation among

FIGURE 1. Likelihood of a CALGB/PRIME ineligible patient being recommended adjuvant breast-directed radiation therapy following
breast conserving surgery demonstrating early stage breast cancer with high-risk features, by age at diagnosis. Likelihood of being
recommended adjuvant radiation therapy declines sharply for patients aged 69 versus age 70.
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FIGURE 2. Forest plot of odds ratios for being recommended adjuvant radiation therapy. Each point represents a multivariable regression
including the subset of patients with the corresponding age at diagnosis as well as the patients aged 1 year younger at diagnosis. The OR
and 99% CI representing the association between each year-over-year age increase and likelihood of radiation recommendation are
plotted. In this MVA age 70 at diagnosis was independently associated with significantly reduced odds of being recommended adjuvant
radiation versus age 69 at diagnosis. No other year-over-year age increase was independently associated with likelihood of being
recommended radiation.

high-risk, early-stage breast cancer patients based on a patient’s age
being ≥ 70, and characterized recommendation of adjuvant therapy in
this population.
Methods: We used the National Cancer Data Base to identify women
aged 50-80 years with pT1-2 node-negative breast carcinoma diagnosed
2004-2017, who underwent lumpectomy. Among these, we identiﬁed
162,111 patients with CALGB 9343/PRIME II-ineligible features other
than age (estrogen receptor negative, endocrine therapy not planned,
ﬁnal margins positive, or size > 3 cm)(cohort 1), and 394,946 hormone
receptor positive (HR+) patients with tumors > 5mm (cohort 2). Multivariable logistic regressions (MVA) with odds ratios (OR) and 99%
conﬁdence intervals (CI) were performed for “year-over-year” age
pairings, from patients aged 50 and 51 up to patients aged 79 and 80 at
diagnosis. Age at diagnosis, along with 21 additional disease and
patient factors potentially associated with treatment decisions, were
included in these MVA. Age was treated as a categorical variable in
these MVA to determine if any single year-over-year age difference was
independently associated with a difference in likelihood of adjuvant
therapy recommendation.
Results: Overall, 87.3% of patients with CALGB 9343/PRIME II
ineligible breast cancer were recommended adjuvant radiation therapy
(n = 140,513) and 92.3% of HR+ patients with tumor size > 5 mm were
recommended adjuvant endocrine therapy (n = 364,048). Among cohort
1, rate of adjuvant radiation recommendation decreased sharply at age
70, from 90-92% between the ages of 50 to 69, declining to 81% for
those aged 70 (Fig. 1). Regressions for each year-over-year age pair
showed year-over-year age difference was only an independent predictor adjuvant radiation recommendation at age 70 vs 69 (OR 0.47, CI
0.40-0.55, P < 0.001) (Fig. 2). For cohort 2, rates of endocrine therapy
recommendation showed a smaller absolute decline at age 70, but yearover-year age difference was again only a predictor of endocrine therapy recommendation at age 70 vs 69 (OR 0.86, CI 0.76-0.97,
P = 0.001).
Conclusions: We observed a sharp and unique step-off in adjuvant
therapy recommendation between ages 69 and 70. This suggests use of
an age cut off heuristic to process patient age in this population as a
categorical, binary variable. This is a previously undescribed

phenomenon in high-risk, early-stage breast cancer, and a practice with
concerning implications for evidence-based care allocation.

(P019) Patient Reported Outcomes Version of the Common
Terminology Criteria for Adverse Events and CTCAE in
Breast Cancer Patients Receiving Radiation Therapy:
Single-center Prospective Registry Experience
Cameron Thorpe, MD1, Todd DeWees, PhD1, Michael Golafshar, MS1,
Ronik Bhangoo, MD1, Tamara Vern-Gross, DO1, Lisa McGee, MD1,
William Wong, MD2, Michele Halyard, MD1, Sameer Keole, MD2,
Carlos Vargas, MD2; 1Mayo Clinic, 2Mayo Clinic Arizona
Background: Adverse events during cancer treatment are recorded by
providers using the US National Cancer Institute’s (NCI) Common
Terminology Criteria for Adverse Events (CTCAE). However,
symptomatic adverse events are often underreported by physicians and
do not fully represent the full scope of the impact that cancer treatment
has on patients
Objectives: We sought to investigate the relationship between PROCTCAE and CTCAE for breast cancer (BC) patients undergoing radiation therapy (RT) from a prospective registry for a large, singleinstitution.
Methods: From a prospectively maintained registry, all patients treated
with RT for BC with curative intent from November, 2015 to June,
2019 at our institution were eligible for this analysis. To be included
patients were required to have at least one PRO-CTCAE survey. PROCTCAE questionnaires were administered at baseline, end-of-treatment,
3, 6, 12 months, then annually. Correlation between CTCAE and PROCTCAE was measured using Pearson’s correlation coefﬁcient (r) and
univariate Logistic regression was utilized to measure the clinical
magnitude of that correlation.
Results: Three-hundred and thiry-one (331) patients were included for
analysis. Patient and tumor characteristics included: 82% ER(+), 77%
PR(+), 10% HER2(+), and 66% ECOG 0. Treatment characteristics
included: median dose 40.05 Gy (range, 40–50.4 Gy), 75% underwent
lumpectomy, 39% received chemotherapy, 85% treated with photon,
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15% treated with proton beam therapy, and 40% received a boost
(median 10 Gy, range 5.4–14 Gy). “Moderate” or worse PRO-CTCAE
correlated with CTCAE grade ≥ 2 (r = 0.35, P < 0.0001). ‘Severe’ or
worse PRO-CTCAE correlated with CTCAE grade ≥ 3 (r = 0.19,
P < 0.001). Furthermore, ‘Moderate’ or worse PRO-CTCAE was predictive of developing CTCAE grade ≥ 3 (OR = 3.25, 95% CI [0.9511.2], P = 0.06).
Conclusions: PRO-CTCAE and CTCAE offer complimentary information and both should be reported in cancer trials. In this cohort of breast
cancer patients, ‘Moderate’ or worse PRO-CTCAE predicted for development of CTCAE grade ≥ 3. Patients who report ‘Moderate’ or worse
PRO-CTCAE should be monitored closely for development of toxicities.
Future studies in breast cancer should report on both PRO-CTCAE and
CTCAE to better understand how patients tolerate treatment.

(P020) Patterns of Care and Utilization of Radiation for
Women with High Grade Ductal Carcinoma in Situ: A
National Cancer Database Analysis
Irini Youssef, MD1, Benjamin Silver, MD1, Jared Pasetsky, MD1,
Fleure Gallant, MD2, David Schreiber, MD1; 1SUNY Downstate Health
Sciences University, 2Maimonides Cancer Center
Background: Ductal carcinoma in situ (DCIS) currently comprises
25% of newly diagnosed breast cancers, and this rate continues to rise
with improvements in screening. While prospective studies have demonstrated a reasonably low risk of recurrence in “good-risk” patients
with lumpectomy without radiation, ECOG 5194 showed the risk of
developing ipsilateral breast events in patients with high-nuclear grade
DCIS, who received lumpectomy alone, increased without plateau.
Objectives: The purpose of this study was to retrospectively review the
National Cancer Database (NCDB) to assess patterns of care in patients
with high-grade DCIS treated with lumpectomy with or without
radiation.
Methods: The National Cancer Database (NCDB) was queried to
identify women treated with lumpectomy for high grade DCIS of the
breast from 2004-2016. Data regarding age, tumor size, endocrine
therapy use, ER receptor status, margin status, race, insurance type and
distance from the treatment center were collected. Radiation fractionation was collected and categorized as hypofractionation, standard
fractionation, and other, if the fraction size could not be clearly ascertained. Clinical and patient-related factors were compared between
patients who received radiation and no radiation. Frequency distributions between categorical variables were compared using the χ2
test. Multivariable logistic regression was used to identify co-variables
associated with the use of radiation.
Results: A total of 16,100 patients met the eligibility criteria. Of those,
10, 378 (65%) received adjuvant radiation. On multivariable regression,
patients who received radiation were more likely to be ER- (OR 1.68,
95% CI 1.54-1.83, P < 0.001), and have tumor size of 1cm or larger
(OR 1.23, 95% CI 1.13-1.33, P < 0.001). Those less likely to receive
radiation included great-circle distance of > 20 miles (OR 0.80, 95% CI
0.71-0.91, p0.005), distance > 30 miles (OR 0.54, 95% CI 0.48-0.60,
P < 0.001), and age > 65 years (OR 0.68, 95% CI 0.60-0.78,
P < 0.005). There were no differences in radiation utilization based on
the year of diagnosis. Fractionation technique was categorized as
standard or hypofractionated in 64.3% of patients. Of those, the use of
hypofractionation increased from 1% in 2004 to 9.2% by 2010 and to
51.7% by 2016.
Conclusions: There appears to be an underutilization of radiation
therapy for women with high grade DCIS, particularly those who live
> 20 miles from a treatment facility. Prospective evaluation of ultrahypofractionated regimens and/or intra-operative regimens in DCIS
patients is warranted and may improve utilization of adjuvant RT.

(P021) Clinical Factors Associated with Local Control or
Radiation Necrosis for Patients Undergoing Single Fraction
SRS
Gregory Alexander, MD1, Jill Remick, MD2, Emily Kowalski, MD1,
Kai Sun, MS3, Stewart Becker, Physicist1, Naru Lamichhane, PhD1,
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Howard Eisenberg, MD1, Graeme Woodworth, MD1, William Regine,
MD1, Mark Mishra, MD1; 1University of Maryland, 2Emory, 3University of Maryland School of Medicine Department of Epidemiology
and Public Health
Background: Single-fraction stereotactic radiosurgery (SF-SRS) for the
treatment of brain metastases can be delivered with either a GammaKnife platform (GK-SRS) or with a frameless linear accelerator (LASRS). These techniques vary based on patterns of prescribing, patient
setup and radiation delivery but the effect of these differences on
clinical outcomes is unknown.
Objectives: We seek to examine clinical factors associated with radiation necrosis and local failure in patients undergoing single fraction
SRS in patients with metastatic brain cancer.
Methods: Patients treated for metastatic brain cancer treated with SFSRS from 2014-2020 were retrospectively reviewed and clinical outcomes were recorded on a per lesion basis. Covariates between groups
were compared using a χ2 analysis for dichotomous variables and t-test
for continuous variables. Median follow up was calculated using the
reverse Kaplan Meier (KM) method. Primary endpoints of local control
(LC) and symptomatic radiation necrosis (RN) were estimated using the
KM method with salvage WBRT used as a censoring event. Outcome
estimates were compared using the log-rank test. Multivariate analysis
(MVA) and Cox proportional hazards modeling were used for statistical
analyses. Propensity score (PS) adjustments were used to reduce the
effects confounding variables. Further subset analyses of lesions treated
with GK-SRS and LA-SRS were performed.
Results: Overall, 119 patients with 287 lesions were included for
analysis which included 57 patients (127 lesions) treated with LA-SRS
compared with 62 patients (160 lesions) treated with GK-SRS. In terms
of lesion size, there was no statistically signiﬁcant differences in percentage of lesions > 2 cm treated with GK-SRS vs LA-SRS (14.17% vs
8.75%; P = 0.147). For the entire cohort the median follow-up was
11 months (15.2 mo GK-SRS vs 7.9 mo LA-SRS) with median OS
15.9 months (16.2 mo GK-SRS vs 12.3 mo LA-SRS). On both multivariate and univariate analysis, there was no statistically signiﬁcant
differences between GK-SRS and LA-SRS for local failure or in risk of
radiation necrosis analysis (multivariate adjusted P-value = 0.44).
Tumor size ( > 2 cm vs ≤ 2 cm) was predictive of both risk of radiation
necrosis and local failure. Subset analysis of lesions treated with LASRS did not ﬁnd the addition of PTV margin or timing of MRI used for
treatment planning to be associated with clinical outcomes. Subset
analysis of lesions treated with GK-SRS found that the ﬁrst quartile of
dose rate was associated with increased risk of radiation necrosis,
(P = 0.0001), but lesion characteristics were imbalanced between
groups.
Conclusions: In our retrospective cohort, we found no statistically
signiﬁcant differences in the incidence of symptomatic radiation
necrosis or local control in patients treated with GK-SRS when compared with LA-SRS. Other clinical variables may be important and
require consideration. Further study with well-matched prospective
cohorts is required to validate these results.

(P022) Stereotactic Radiosurgery in Patients with Trigeminal Neuralgia and Diabetes Mellitus: A Retrospective
Review
Jack Allen, Undergraduate Student1, Nathan Munson, MD1, Michael
Ray, MD, PhD1, Shaneli Fernando, MD1; 1ThedaCare Regional Cancer
Center, Appleton, Wisconsin
Background: Trigeminal Neuralgia (TN) is a neurological disorder
characterized by intense unilateral pain in the face following a stimulus.
TN treatments predominantly consists of stereotactic radiosurgery
(SRS), microvascular decompression, or percutaneous rhizotomy. Type
2 diabetes (T2D) is a disease that affects many patients with TN, and
may have an impact on TN treatment.
Objectives: The objective of the current retrospective review is to
examine variances in treatment outcomes using SRS for TN in patients
with T2D and in the absence of T2D.
Methods: Clinical data from 34 consecutive TN patients (2007-2013)
was collected following treatment with SRS in our department. Patients
were allocated to T2D (n = 13) and T2D absent groups (DA) (n = 21).
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Diabetic status was deﬁned as hemoglobin A1C (HbA1C) > 6.5% or
fasting blood glucose levels (FBGL) > 130 mg/dL. HbA1c results were
available for 11 patients within the T2D group. The remaining two T2D
patients had FBGL > 130 mg/dL in three consecutive visits. The
patient age was DA = 65.0 ± 16.3 and T2D = 70.5 ± 14.3. The DA group
consisted of 14 females and 7 males, while the T2D group consisted of
9 females and 4 males. Before SRS, pain levels were determined using
the Barrow Neurological Institute (BNI) Pain Intensity Score. Treatment
outcomes were measured using the BNI score one-week post operation
and one year following SRS. The differential in BNI score following the
operation was then analyzed using a two sample t test for difference
in mean.
Results: Before SRS the DA group had a BNI score of 4.80 ± 0.4, the
T2D group had a BNI score of 4.84 ± 0.37. One week following
treatment the scores were DA = 1.92 ± 1.26 and T2D = 2.10 ± 1.51. One
year after SRS the results were DA = 2.41 ± 1.51 and T2D = 1.58 ±
1.40. Comparison of the starting BNI score and the BNI score at the
one-week post SRS visit of the DA group to the T2D group did not
yield a signiﬁcant difference in BNI score (P = 0.9066). Comparison of
the DA group BNI score before SRS and BNI score one-year post
operation to the T2D group yields a signiﬁcant mean difference
(P = 0.0121). The DA group experienced a 1.417 greater BNI pain
reduction (95% CI: 2.499, 0.3347) as compared with the T2D BNI
score at the 1-year mark.
Conclusions: This exploratory study suggests a relationship between
decreased treatment efﬁcacy of SRS one year following the operation
and T2D in TN patients. Further studies are needed to examine a
possible decrease in treatment efﬁcacy for T2D patients with TN for
treatments such as microvascular decompression or percutaneous
rhizotomy.

(P023) Radiotherapy for Management of Brain Metastases
from Thyroid Cancer: A National Cancer Database Study
Erik Blomain, MD1, Michael Binkley, MD1, Duc Giao, Visiting Student1, Thomas Churilla, MD2, Scott Soltys, MD1, Erqi Pollom, MD1;
1
Stanford University, 2Northeast Radiation Oncology Center, Geisinger
Commonwealth School of Medicine
Background: Brain metastasis is a rare presentation of thyroid cancer
and there is a paucity of data regarding management. Although stereotactic radiosurgery (SRS) is a standard of care for patients across
many histologies, the current NCCN guidelines do not support a universal role for this modality in thyroid cancer. Alternatives to SRS
include whole brain radiotherapy (WBRT) and best supportive care;
however, current practice patterns regarding the relative use of these
modalities remains largely undeﬁned.
Objectives: In that context, the present study queried the National
Cancer Database to look at practice patterns and outcomes in patients
with brain metastases from thyroid cancer with a goal of informing
management.
Methods: The Participant User File (PUF) for Thyroid Cancer was
obtained from the NCDB in accordance with all institutional and
organizational regulations. The data was formatted using SAS and
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FIGURE 2. Cumulative incidence of death: anaplastic versus differentiated thyroid cancer.

analyzed in R studio and Graphpad Prism. The PUF was screened by
patients who presented with brain metastases and/or who received
brain-directed radiotherapy. Kaplan–Meier analysis was performed for
overall survival, as was multivariable regression analysis. Descriptive
statistics were collected regarding patient demographics and treatment
information.
Results: Overall, we identiﬁed a cohort of 289 patients. Median age
was 63 years old (range 19-90 years old) and 56.1% were female.
68.5% of patients were white, 13.8% were black and 11.1% were latino
(several other races were represented <5%). 16.6% received SRS,
55.0% received other brain-directed radiotherapy, and 28.4% received
no brain-directed RT. Histologic breakdown was as follows: Papillary
45.7%, Anaplastic 15.2%, Other 10.7%, Medullary 10.0%, Follicular
9.7% and Unknown 8.7%. In terms of practice patterns, there appeared
to be a trend towards decreasing use of non-SRS brain radiotherapy,
although this is potentially confounded by missing data from recentlytreated patients. Median follow up was 213.2 weeks, and median overall
survival was 40.9 weeks. On multivariable analysis, treatment modality
(SRS versus other brain RT versus no brain RT) was not signiﬁcant in
terms of OS (hazard ratio 1.09, P = 0.55); however, anaplastic histology
was signiﬁcantly associated with worse overall survival (hazard ratio
3.5, P = 0.00000005), and anaplastic patients’ median overall survival
was 8.4 weeks.
Conclusions: Brain metastases from thyroid cancer portend a poor
prognosis (< 1 year median in our study), particularly for patients with
anaplastic histology. The decision to treat with radiotherapy and the
type of radiotherapy utilized did not appear to affect overall survival,
consistent with other retrospective and prospective data in brain metastases from other histologies. Of note, our case number was rather
limited, potentially due to the relatively rare nature of this metastatic
presentation. Despite this limitation, the present study represents to our
knowledge the largest dataset to date of thyroid cancer brain metastases
treated with radiotherapy. Within the limitations inherent to NCDB
studies, our data suggest clinical equipoise in the management of these
patients (Figs. 1 and 2).

(P024) Intracranial Response to Combination BRAF and
MEK Inhibitor Therapy in Patients with Metastatic
Melanoma

FIGURE 1. Overall Survival.

Caressa Hui, MD1, Yufan (Fred) Wu, MD1, Kevin Liu, BS2, Navjot
Sandhu, BS1, Erik Blomain, MD1, Michael Binkley, MD1, Melanie
Gephart, MD, MAS1, Steven Chang, MD1, Gordon Li, MD1, Sunil
Reddy, MD1, Iris Gibbs, MD1, Scott Soltys, MD1, Erqi Pollom, MD1;
1
Stanford University, 2Carnegie Mellon University
Background: Combination BRAF+MEK inhibitor therapy is now
widely used in the treatment of metastatic melanoma. However, data for
intracranial response to these drugs are limited.
Objectives: We aimed to evaluate the intracranial efﬁcacy of BRAF
+MEK inhibitors in patients with BRAF-mutant melanoma with brain
metastases and to determine patterns of failure of these new agents to
inform optimal integration of local intracranial therapy.
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Methods: We identiﬁed patients with BRAF-mutant melanoma with
metastasis to the brain with at least one untreated brain metastasis (BM)
at the time of initiation of BRAF+MEK inhibitors at our institution from
2006 to 2020. We obtained per-patient and per-lesion data on demographics, treatment, and outcomes. Cumulative incidence of local (LF),
distant intracranial (DF) and extracranial failure (EF) were calculated
with competing risk analysis with death as a competing risk, and censored at the last brain MRI follow up. LF was calculated on a per-lesion
basis while DF and EF were calculated on a per-patient basis. DF was
deﬁned as any new intracranial lesions. Overall survival (OS) was
analyzed using Kaplan-Meier. Logistic regression was used to identify
predictors for LF.
Results: We identiﬁed 10 patients with 63 untreated BM. Median age
was 50.5 years old. Median sum of the diameters of the 5 largest
untreated BM per patient was 20 mm (interquartile range 15-39 mm)
and median diameter for all measurable lesions was 4 mm. Median
follow up time was 9.0 months (range 1.4 mo-46.2 mo). Median OS
was 13.6 months. The 1-year cumulative incidence of LF, EF and DF
were 17.1%, 71.4%, and 88.6%, respectively. Median time to LF, DF,
and EF from start of BRAF+MEK inhibitors was 9.0 months,
4.7 months and 7.0 months, respectively. Larger size of the BM was
associated with LF (odds ratio 1.13 per 1 mm increase in diameter, 95%
conﬁdence interval 1.019 to 1.308, P < 0.02). 6 patients (60%) experienced signiﬁcant toxicities with BRAF+MEK inhibitors, with 1
patient switching to another BRAF plus MEK inhibitor, 4 patients
requiring treatment breaks or decreased dose, and 1 patient stopping
therapy. 2 (20%) patients eventually received stereotactic radiosurgery,
and 2 (20%) received whole-brain radiotherapy for intracranial
progression.
Conclusions: Although patients with BRAF-mutant melanoma with
BM had fair LC on BRAF+MEK inhibitors, the competing risk of
death, distant intracranial and extracranial progression were high.
Patients with larger BM may beneﬁt from local therapy.

(P025) Treatment Fractionation and Lymphopenia in
Patients Receiving Radiation for Glioblastoma: Could
Hypofractionation Reduce Toxicity?
Sean Koerner, MD, MS1, Joshua Rodríguez-López, MD2, Zaid
Siddiqui, MD1, John Flickinger, MD, FACR1; 1UPMC Hillman Cancer
Center, 2Department of Radiation Oncology, UPMC Hillman Cancer
Center, University of Pittsburgh School of Medicine
Background: Prognosis in patients with glioblastoma (GBM) is
impacted by their ability to receive temozolomide (TMZ), both concurrently with radiation therapy (RT) and in the adjuvant setting.
Lymphopenia is a common side effect of TMZ therapy, and post-RT
lymphopenia may inhibit adjuvant TMZ treatment and therefore
decrease survival.
Objectives: We sought to assess the impact of RT fractionation on
lymphopenia.
Methods: We identiﬁed patients treated with external beam radiation
therapy (EBRT) for GBM from at our institution from 2012 through
2017. Treatment data, including fractions delivered, total dose, radiation
technique, site of primary tumor, and age at diagnosis, was extracted
from our treatment electronic medical record (EMR). Laboratory data
from our hospital EMR was retrospectively assessed, and individual
patient lymphopenia during treatment and in the month following
radiation therapy was recorded by the Common Terminology Criteria
for Adverse Events (CTCAE), version 5.0, and collated with treatment
data. We deﬁned grade 2 lymphopenia (WBC <0.8) as sufﬁcient to
impact TMZ administration, and hypofractionated treatment as ≤ 15
fractions. Wilcoxon signed-rank test was performed to assess for a
correlation between number of fractions delivered and development of
lymphopenia.
Results: 472 patients with RT treatment data were assessed for qualifying laboratory data, and 340 patients had sufﬁcient laboratory data
for assessment of lymphopenia according to our criteria. Median age
was 65, and 57.9% of patients received a conventionally fractionated
course, with 42.1% receiving hypofractionated treatment and the
majority (91.3%) receiving concurrent TMZ. Patients who did not
receive concurrent TMZ were either medically ineligible before RT
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initiation or declined chemotherapy. A total of 7 patients developed
grade ≥ 2 lymphopenia, an incidence of 2.03%; four, two, and one were
categorized as grade 2, 3, and 4, respectively. All patients who developed RT-associated lymphopenia were in the conventionally fractionated cohort, and the correlation between fractions received and
increased CTCAE lymphopenia grade was signiﬁcant (P < 0.001).
Conclusions: Increased fractionation of RT is correlated with increased
incidence and CTCAE grade of lymphopenia. Hypofractionation may
reduce the likelihood of developing lymphopenia and impact patient
prognosis through capacity to receive adjuvant temozolomide therapy.

(P026) Deﬁnitive Radiation Therapy for Chordoma: A
Systematic Review
Nicholas Gravbrot1, Riley McDougall1, Baldassarre Stea, MD PhD2;
1
University of Arizona College of Medicine - Tucson, 2Banner/University of Arizona/Dept. Radiation Oncology
Background: Chordomas are rare, slow-growing malignancies arising
from remnants of the primitive notochord. En bloc resection is not often
achieved due to local invasion, and systemic adjuvant treatments are of
limited beneﬁt. High rates of local recurrence and poor long-term
prognoses are common after primary surgery alone. Traditionally, the
role of radiotherapy (RT) is postoperatively after partial resection, but
deﬁnitive high-dose RT has recently been explored as an alternative.
Objectives: To review the literature on deﬁnitive RT in chordoma
treatment.
Methods: Following the Preferred Reporting items for Systematic
Reviews and Meta-Analyses guidelines, a systematic review was conducted. Four databases were queried: PubMed, ScienceDirect, Embase,
and Cochrane. Studies included original research articles in peerreviewed journals with patients undergoing deﬁnitive RT for biopsyproven chordoma. Case reports, conference papers/abstracts, protocols,
and book chapters were excluded.
Results: Twenty studies were included for analysis. Follow-up durations ranged from 1-5 years. Many series reported pooled data, combining chondrosarcoma and other pathologies, adjuvant or salvage RT,
and combination or multiple monotherapies (e.g. proton or carbon ion
or photon); as such, abstraction by pathology, disease state, or modality
was not possible. 543 patients were included: 363 sacral, 117 skull base,
23 mobile spine, and 40 location undisclosed. Carbon ion monotherapy
in 196 patients (all sacral), proton in 65 (48 sacral, 10 skull, 2 spine, 5
undisclosed), and photon in 14 (7 skull, 2 spine, 5 undisclosed). The
rest of patients (n = 268) either received combination therapy (proton/
carbon, photon/proton) with cumulative doses reported in Gy adjusted
for RBE of protons and carbon ions or were part of series with pooled
monotherapy results. Most patients received 60-78.3 Gy. The mean
5-year local control (LC), overall survival (OS), progression-free survival (PFS) were 78.9% (range 46.0-89.0%), 78.9% (44.0-100.0%), and
90.9% (80-100%), respectively. For studies with shorter follow-up,
3-year LC, OS, and PFS were 82.5% (53.0-92.0%), 88.9% (67.096.0%), and 79% (72.0-89.6%), respectively. Results were similar
regardless of location or RT modality. Most studies used CTCAE to
note toxicities. Early grade 3-4 toxicities were seen in 42 patients and
delayed grade 3-4 toxicities in 48; no grade 5 toxicities were reported.
Toxicities included acute dermatitis (4.6%), acute neuropathies (1.3%),
chronic radiation dermatitis (6.1%), and chronic neuropathies (1.7%).
Conclusions: Although en bloc gross total resection has been advocated
as the standard of care for chordomas, this is rarely possible and
commonly fraught with complications. Deﬁnitive treatment of biopsyproven chordomas with high-dose, charged particle RT appears to be
reasonably effective, offering comparable tumor control rates to those
of upfront surgical debulking with acceptable toxicity.

(P027) American Radium Society Appropriate Use Criteria
for the Management of Brain Metastases in EGFR-mutated
Non-Small Cell Lung Cancer
Seema Nagpal, MD1, Veronica Chiang, MD2, Michael Milano, MD,
PhD3, Scott Soltys, MD1, Manmeet Ahluwalia, MD, MBA4, Samuel
Chao, MD5, Amit Garg, MD6, Melanie Gephart, MD, MAS1, Lia
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Halasz, MD7, Siavash Jabbari, MD8, Jonathan Knisely, MD9, Simon
Lo, MB, ChB, FACR, FASTRO7, Joshua Palmer, MD10, Arjun Sahgal,
MD11, Martin Tom, MD12, Tony Wang, MD13, Eric Chang, MD14;
1
Stanford University, 2Yale University, 3University of Rochester,
4
Miami Cancer Institute, 5Cleveland Clinic, 6MD Anderson Cancer
Center, 7University of Washington, 8Laurel Amtower Neuro-Oncology
Center and Cancer Institute at Sharp Healthcare, 9Weill Cornell
Medicine, 10The Ohio State University Wexner Medical Center,
11
Department of Radiation Oncology, Sunnybrook Odette Cancer
Centre, University of Toronto, 12Miami Cancer Institute, Baptist Health
South Florida, 13Columbia University, 14University of Southern California Keck School of Medicine
Background: Epidermal growth factor receptor (EGFR) mutated nonsmall cell lung cancer (NSCLC) can be treated with a number of small
molecule tyrosine kinase inhibitors (TKIs) that have central nervous
system (CNS) penetration. How the evolving role of TKIs in the
treatment of NSCLC impacts decision making for stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) for brain
metastases (BrMs) is of particular interest.
Objectives: The ARS Appropriate Use Criteria group for brain
malignancies sought to review the literature on EGFR-targeted systemic
therapy for the treatment of BrMs.
Methods: The panel developed 3 key questions (KQs) to help guide the
literature search and selection of studies: A) Can radiation therapy (SRS
or WBRT) be deferred in patients receiving a potentially CNS-active
TKI? B) If radiation therapy is recommended (SRS or WBRT), should
it be given together with TKI or in sequence? C) At time of CNS
progression on TKI, should RT be deferred if another CNS-penetrating
TKI is available? The search results were screened by article type and
relevance to the key questions. Selected articles were then assigned an
evidence grade by 2 reviewers according to the Evidence Table
Development guidelines of the ACR-ARS.
Results: The initial search yielded 738 articles, from which 40 articles
were selected. The expert panel developed 8 model cases, with up to 5
sub-variants each, addressing the KQs and relevant clinical questions
that were not easily addressed by articles in the literature search. The
panel elected to design a case variant for leptomeningeal disease as well
as a case using hypothetical future therapies with varying CNS penetration, degree and duration of response. Management options ranged
from deferring any form of radiation therapy through multiple lines of
therapy to using SRS or WBRT in combination with TKIs in the
upfront setting. The panel will vote on the appropriateness using a
9-point scale, with 1-3, 4-6 and 7-9 corresponding to not appropriate,
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may be appropriate, and usually appropriate (respectively). Agreement
vs. disagreement of panelist will be determined by the number of outliers. We will present these results.
Conclusions: The development of multiple brain-penetrant drugs for
the treatment of metastatic cancers has given patients and physicians an
increasing number of treatment options for brain metastases, including
the deferral of WBRT or SRS. We did not identify deﬁnitive studies
dictating the sequence of therapy for CNS-penetrant drugs and radiation. Until such studies are designed and completed, the ARS-AUC
committee hopes these cases will help guide clinicians through
increasingly complex decision making.

(P028) An Analysis of Facebook Groups for Patients with
CNS Tumors
Ryan O’Keefe, BA1, Molly Murphy, Student2, Annabelle Huffman,
Student2, Andrea Matienzo Carrillo, Student2, Lauren St. John, Student2, William Hornyak, Student2, Christine Hill-Kayser, MD1; 1University of Pennsylvania, 2College of the Holy Cross
Background: The utilization of social media is a common method for
cancer patients and caregivers to share stories, provide support, and
disseminate information. Numerous studies have raised concerns about
the quality of information shared amongst cancer-focused social media
groups and have called for providers to serve as moderators (GageBouchard E et al J. Cancer Educ 2018; Petukhova T, et al Dermato
Online J. 2020). Other work investigated the content and quality of
social media posts related to glioblastoma on YouTube, Facebook,
Twitter, and Instagram. (Bird C, et al Cureus 2020; ReFaey K, et al J
Clin Neuro 2018). YouTube is the largest source of information and
tends to focus on surgery and patient experiences, whereas Facebook is
most used for patient-to-patient support. To date, there has not been a
thorough evaluation of Facebook groups available for common CNS
tumors beyond glioblastoma.
Objectives: This study investigated the presence of Facebook groups
related to common central nervous system (CNS) tumors on Facebook
to better understand available resources for patients, their intended
purposes, and potential opportunities for provider involvement.
Methods: On August 9, 2020, the terms “glioblastoma” (GBM),
“astrocytoma” (ACM), “meningioma” (MGM), and “oligodendroglioma” (ODM) were searched on facebook.com under the
“Groups” tab. All groups from the search were manually pulled and
coded. Groups were included for ﬁnal analysis if they were in English,
related to the tumor-type, had > 2 posts per week, and membership

TABLE 1. CNS Tumor Facebook Group Selection, Features, and Purpose
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> 10 people. Data points of interest were extracted from each page’s
“About” tab between August 10-22, 2020.
Results: 292 Facebook groups were found using the search terms, 70
met inclusion criteria (Table 1). GBM-related groups were most common and MGM-related groups had the largest average membership size
with the most average annual posts (Table 1). 41 (58.6%) were private
groups, and 22 (31.4%) had rules regarding posting content. Most
groups were created for the purpose of sharing support and stories or to
describe an individual’s journey with their disease (Table 1). Astrocytoma-related groups were predominantly created to describe an individual’s journey, with 9 of 11 being pediatric patients. Groups created
to share general information about the disease, to discuss research or
clinical trials, or to fundraise were less common.
Conclusions: MGM-related groups on FB had the most activity, possibly due to its high prevalence amongst CNS tumors and longer life
expectancy. Most groups identiﬁed were not currently active. In line
with previous work, groups focused on individual journeys and support
were most common. There were few public groups focused on sharing
general information or discussing research, potentially limiting the
opportunities for providers to contribute. Future work should explore
the content of discussion in such groups, and the desire for, and effects
of, physician involvement.

(P029) Outcomes of Adults Treated with Brain Hypofractionated Stereotactic Radiosurgery in an Established
CNS Multidisciplinary Clinic for Radiation Oncology and
Neurosurgery
Wencesley Paez, MD1, Samantha Bowen, BA2, Rohi Gheewala, BS3,
Brandon Lucke-Wold, MD, PhD4, Jeremy Ciporen, MD2, Timur Mitin,
MD, PhD1; 1Department of Radiation Medicine, Oregon Health &
Science University, 2Department of Neurological Surgery, Oregon
Health & Science University, 3School of Medicine, Oregon Health &
Science University, 4Department of Neurosurgery, University of
Florida
Background: Our multidisciplinary central nervous system (CNS)
clinic provides synchronous consultation and follow-up visits with a
neurosurgeon and a radiation oncologist at a community hospital center.
Hypofractionated stereotactic radiosurgery (hfSRS) is commonly used
for management of primary and secondary malignant disease in the
brain. A signiﬁcant challenge in the follow-up of patients treated with
hfSRS to brain lesions is to distinguish pseudoprogression (PP) from
tumor recurrence (TR) for which treatment and prognosis are different.
Objectives: To determine the rate of tumor control (TC), pseudoprogression (PP) and tumor recurrence (TR) among adult patients with brain
primary and secondary malignant disease treated at a multidisciplinary
CNS community hospital center clinic with hfSRS.
Methods: We conducted an IRB-approved retrospective review of
treatment outcomes for consecutive patients treated with hfSRS for
brain tumors between June 2017 and December 2019. Post-treatment
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imaging and/or histology when available were reviewed for assessment
of treatment response.
Results: Forty-six brain lesions in 18 consecutive patients were treated
with hfSRS over a period of 30 months. The rate of tumor control with
no evidence of progression or pseudoprogression was 67% (31 out of
46 lesions). Among the remaining 15 lesions, TR was determined in
eight lesions for an overall rate of TR of 17% (8 out of 46 lesions). Six
lesions (13%) were determined to represent PP. Table 1 summarizes
management and outcomes among patients with progressing lesions
after hfSRS.
Conclusions: Adult patients with brain primary and secondary malignant disease evaluated and treated in our multidisciplinary CNS clinic
have a high rate of disease control in line with previously published
results from large academic institutions and multi-institutional clinical
trials. The integrated evaluation and management of radiographic progression after hfSRS allows for a nuanced multidisciplinary interpretation of radiographic and clinical ﬁndings. Thereby, reducing
unnecessary clinical visits, tests, procedures and leading to improved
clinical care through prompt systemic, surgical and radiation treatment
modalities that minimizes re-treatment of PP and avoids undertreatment
of TR.

(P030) American Radium Society's Appropriate Use Criteria on Postoperative Management of Lower Grade
Gliomas
Martin Tom, MD1, Michael Milano, MD, PhD2, Scott Soltys, MD3,
Arjun Sahgal, MD4, Jonathan Knisely, MD5, Veronica Chiang, MD6,
Seema Nagpal, MD3, Simon Lo, MB, ChB, FACR, FASTRO7, Samuel
Chao, MD8, Siavash Jabbari, MD9, Tony Wang, MD10, Joshua Palmer,
MD11, Melanie Gephart, MD, MAS3, Amit Garg, MD12, Manmeet
Ahluwalia, MD, MBA13, Lia Halasz, MD7, Eric Chang, MD14; 1Miami
Cancer Institute, Baptist Health South Florida, 2University of Rochester, 3Stanford University, 4Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, 5Weill Cornell
Medicine, 6Yale University, 7University of Washington, 8Cleveland
Clinic, 9Laurel Amtower Neuro-Oncology Center and Cancer Institute
at Sharp Healthcare, 10Columbia University, 11The Ohio State University Wexner Medical Center, 12MD Anderson Cancer Center,
13
Miami Cancer Institute, 14University of Southern California Keck
School of Medicine
Background: “Lower grade gliomas” refer to WHO grade 2 and 3
gliomas. Their optimal postoperative management remains controversial, especially in light of contemporary prognostic and predictive
molecular characteristics which were not available during the design of
earlier clinical trials.
Objectives: The American Radium Society (ARS) Appropriate Use
Criteria Brain Malignancy Committee sought to develop consensus
guidelines for the postoperative management of lower grade gliomas.
Methods: The committee developed 4 key questions regarding: 1)
Timing of postoperative therapy (i.e. adjuvant vs. salvage approaches);

TABLE 1. Management and Outcomes Among Patients (n = 8) With Clinical Evidence of Progression After Brain hfSRS

Brain lesions (n = 15) with radiographic evidence of progression after brain hfSRS. *Avastin (A), Steroids (S), Redo-craniotomy (C), Re-irradiation (R).
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2) Monotherapy vs. combined modality therapy (i.e. postoperative
radiotherapy [RT] vs. chemotherapy vs. chemoradiotherapy); 3) Type
of chemotherapy used in conjunction with radiotherapy (i.e. procarbazine, lomustine, and vincristine [PCV] vs. temozolomide [TMZ]); and
4) Radiotherapy dose. The panel systematically reviewed the literature
according to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines, and voted accordingly on the appropriateness of various management options for representative case variants.
Results: The search identiﬁed 6,244 studies, of which 38 were included
after screening and in-depth review. The committee designed 6 case
variants, each consisting of 1-2 subvariants, with emphasis on patient
age, patient performance, patient symptomatology, tumor size, tumor
location, tumor grade, tumor molecular classiﬁcation, and extent of
resection. Management options included initial observation, adjuvant
monotherapy (RT, PCV, or TMZ), adjuvant combined modality therapy
(RT with PCV or RT with various combinations of TMZ), various RT
doses, and proton therapy. After two rounds of voting, disagreement
remained for some treatment options within the case variants. The
committee recommended a third round of voting for these scenarios.
Conclusions: Multiple postoperative management options are available for
lower grade gliomas, which are heavily inﬂuenced by molecular classiﬁcation and other clinical characteristics. Until recently completed and
ongoing clinical trials using updated molecular classiﬁcation are published,
the ARS Brain Malignancy Committee endeavors for this Appropriate Use
Criteria document to aid decision making for clinicians. Final voting is
underway and will be followed shortly by the consensus guideline.

(P031) Patterns of Care and Treatment Disparities in the
Management of Benign Central Nervous System Meningioma
Felicia Lew, DVM1, Christopher Weil, MD2, Calvin Rock, MD2, Ryan
Kraus, MD2, Donald Cannon, MD2, Randy Jensen, MD PhD2, Lindsay
Burt, MD2; 1Elson S Floyd College of Medicine, 2University of Utah
Huntsman Cancer Institute
Background: Observation/active surveillance, surgery and radiotherapy (RT) are all standard of care treatment options in the management of benign central nervous system (CNS) meningioma.
Objectives: In this analysis, we sought to describe the patterns of care
in the management of benign CNS meningioma and identify temporal
and sociodemographic trends in the utilization of surgery and radiotherapy, including the use of stereotactic radiosurgery (SRS) compared
with external beam radiotherapy (EBRT).
Methods: We queried the National Cancer Database (NCDB) to identify
all patients with benign meningioma of the CNS diagnosed from 2004 to
2017. Clinical characteristics, demographic information and treatment
approaches were analyzed using standard T and χ2 tests. Predictors of
receipt of any treatment and radiotherapy technique were identiﬁed with
univariable and multivariable logistic regression modeling.
Results: We identiﬁed 252,258 patients diagnosed with benign CNS
meningioma between 2004 and 2017, of which 133,008 (53%) received
no treatment and 119,250 (47%) received either surgery, RT or both. Of
the patients who received treatment, 98,611 (83%) had surgery only,
14,556 (12%) received RT and 6,077 (5%) had surgery and RT. Of the
patients who received RT, 61% received single- or multi-fraction SRS
and 39% received fractioned EBRT. On multivariable analysis, patients
were more likely to be observed if they were diagnosed from 2009-2012
(Odds ratio [OR] 0.66, 95% Conﬁdence Interval 0.65-0.68) and 20132017 (OR 0.57, 0.55-0.58), had no insurance (OR 0.60, 0.57-0.63),
Medicaid (OR 0.71, 0.68-0.74), Medicare (OR 0.50, 0.48-0.51), or a
Charlson co-morbidity score of 3+ (0.75, 0.71-0.79). Those more likely
to receive treatment were Asian (OR 1.2, 1.1-1.3) or Hispanic-White
ethnicity (1.1, 1.03-1.1), from the geographic West (OR 1.2, 1.2-1.3), or
treated at an academic/research institution (OR 3.4, 3.24-3.56). Black
patients were more likely to receive RT than Whites (OR 1.2, 1.1-1.2)
and less likely to receive surgery (OR 0.96, 0.93-0.98). Blacks and
Hispanic-Whites were more likely to receive EBRT than SRS compared
with Non-Hispanic Whites (OR 1.3, 1.2-1.4, and OR 1.5, 1.3-1.7,
respectively). Black patients were also less likely to receive both surgery and RT compared with Whites (OR 0.71, 0.68-0.73), while
patients treated at academic/research institutions compared with community hospitals were more likely to receive both (OR 5.8, 4.9-6.4).
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Conclusions: Active surveillance as a treatment strategy for CNS
meningiomas has been increasing over the past decade, however there
are noticeable disparities in which patients receive treatment. At risk
populations, including the uninsured and minorities, are less likely to
receive treatment and less likely to receive less toxic treatments like
SRS. Further evaluation is warranted to address the underlying cause of
the inequities.

(P032) Impact of Prior Y90 Dosimetry on Toxicity and
Outcomes Following Stereotactic Body Radiation Therapy
for Hepatocellular Carcinoma
Shauna Campbell, DO1, Aditya Juloori, MD2, Timothy Smile, MD1,
Danielle LaHurd, PhD1, Naichang Yu, PhD1, Neil Woody, MD1, Kevin
Stephans, MD1; 1Cleveland Clinic, 2University of Chicago
Background: Stereotactic body radiation therapy (SBRT) is the only
non-invasive local therapy for the treatment of hepatocellular carcinoma
(HCC) and is often utilized following transarterial embolization. There
is a paucity of data reporting safety and outcomes of patients (pts)
receiving SBRT after yttrium-90 (Y90).
Objectives: We sought to evaluate the impact of Y90 and SBRT
composite plan dosimetry on toxicity and outcomes of HCC pts.
Methods: An IRB-approved registry of 260 liver SBRT pts was used.
Pts included in analysis received Y90 before SBRT and had post-Y90
PET imaging (measuring Bremsstrahlung component of Y90). Volume
of ablated liver was estimated using the sharp edge of PET gradient and
the SBRT volume receiving at least 30 Gy (V30). Characteristics
between groups were compared using χ2 and independent t-test. Clinical, imaging, and laboratory follow up are reported.
Results: Twenty eights pts with median follow up of 14 m (4.6-49.6)
were included. Pts received 1 (N = 15), 2 (N = 10), or 3 (N = 3) prior
Y90 treatments, to a median volume of 286 cm3 (21-1512) a median 4.4
m (1.1-82.9) before SBRT. SBRT dose ranged from 24-50 Gy in 3-5
fractions with a median PTV of 117 cm3 (26-857). Y90 and V30
overlap ranged from 0-577 cm3 with a median of 80 cm3. Treatment
intent was deﬁnitive in 23 pts, to downstage within transplant criteria in
4 pts, and as a bridge to transplant in 1 pt. Baseline Child-Pugh (CP)
score was A, B, and C in 23, 3, 2 pts, respectively. At a median 9 m
(1.5-46.4) after SBRT local control was 93%. Liver, nodal, and distant
failure had an incidence of 11%, 3.6%, and 11%, respectively. Change
in CP score was analyzed at 1-2 m and 3 m post SBRT. Twenty six
patients had at least 1 calculable time point. Change in CP class from A
to B was seen in 6 pts (26%), of which two recovered back to CP A by 3
m. The 3 CP B pts did not change class, and the 2 CP C pts received
successful liver transplants 2-3 m after SBRT downstaging. Factors
associated with an increase in CP score within 3 m of SBRT include
SBRT mean liver dose (P = 0.001), SBRT V30 (P = 0.049), and
<1200 cm3 of un-ablated liver (P = 0.003). Volume of liver treated by
Y90 and time between Y90 and SBRT was not associated with an
increase in CP score within 3 m of SBRT. Non-hematologic toxicity
include 2 acute biliary stricture (grade 2&3), 1 late biliary stricture
(grade 2), 1 late chest wall pain (grade 1), and 1 late grade 2 radiographic myonecrosis. One CP A pt died 4 weeks after SBRT of cardiopulmonary comorbidities.
Conclusions: Time between Y90 and SBRT, volume of liver exposed
to prior Y90, and overlap between V30 and Y90 volumes do not appear
to adversely impact CP score within 3 m of SBRT. Dosimetric properties including mean liver dose, V30, and un-ablated liver volume
<1200 cm3 are associated with an increase in CP score within 3 m of
SBRT. Pts with HCC previously treated with Y90 appear to tolerate
SBRT well with no clinically signiﬁcant change in CP score, minimal
toxicity, and excellent local control.

(P033) Causes of Death Among Unresectable Non-metastatic Pancreas Cancer Patients Receiving MR-guided
SABR
Michael Chuong, MD1, Roberto Herrera, BS1, Matthew Hall, MD,
MBA1, Rupesh Kotecha, MD1, Antonio Ucar, MD2, Fernando De
Zarraga, MD1, Santiago Aparo, MD1, Sarah Joseph, MD1, Kathryn
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Mittauer, PhD1, Alonso Gutierrez, PhD, MBA1, Diane Alvarez, MSc1,
Tino Romaguera, DSc1, James McCullough, DMP1, Horacio Asbun,
MD1, Ramon Jimenez, MD1, Raj Narayanan, MD1, John Bryant, MD3,
Minesh Mehta, MD FASTRO4, Adeel Kaiser, MD1; 1Miami Cancer
Institute, 2Miami Cancer Institue, 3Mofﬁtt Cancer Center, 4Department
of Radiation Oncology, Baptist Health South Florida
Background: Nearly all patients with pancreas cancer (PCa) eventually
die from progressive disease. It has been shown in autopsy studies that
while distant metastases (DM) are a common cause of death from PCa,
locoregional (LR) progression may be directly responsible for up to
one-third of PCa-related deaths. Magnetic resonance image (MRI)guided stereotactic ablative body radiation therapy (SABR) is a novel
treatment strategy that may improve long-term locoregional control
(LRC) and survival (OS) through signiﬁcant dose intensiﬁcation.
Objectives: The objective of this study was to describe causes of death
in PCa in patients treated with MRI-guided SABR.
Methods: 50 patients with initially non-metastatic adenocarcinoma of
the pancreas treated at a single institution on a 0.35T-MR Linac from
2018-2020 were evaluated. Patients had locally-advanced (82%), borderline resectable (8%), or medically inoperable disease (10%).
Induction chemotherapy (CT) was routine (94%), usually FOLFIRINOX (58%) or gemcitabine/nab-paclitaxel (26%). Median prescribed
dose was 50 Gy (range 40-50) in 5 fractions; median biologically
effective dose (BED10) was 100 Gy10. Elective nodal irradiation (ENI)
started in early 2019, including a margin around the celiac axis and
SMA. Post-SABR therapy included Whipple procedure (14%), irreversible electroporation (10%), and/or CT (52%).
Results: Median follow-up was 18 months (range 7-39 mo) from
diagnosis. 24 (48%) patients developed DM; the liver (50%), peritoneum (41.7%), and lung (29.2%) were the most common sites. 27
patients (54%) were dead at time of analysis. Median LRC, DM free
survival, and OS were 32, 23, and 21 months, respectively. Causes of
death were hepatic failure from DM (14.8%), peritoneal carcinomatosis
causing bowel obstruction/large volume ascites (14.8%), unknown
(11.1%), abdominal vasculature insufﬁciency/bleeding not from LRF
(11.1%), cholangitis possibly from LRF (7.4%), cachexia/malnutrition
(7.4%), head trauma from fall (7.4%), respiratory failure from DM
(3.7%), ischemic colitis from LRF (3.7%), GI bleed from LRF (3.7%),
intra-abdominal abscess not from LRF (3.7%), pneumonia without DM
(3.7%), sepsis (3.7%), and brain metastasis (3.7%).
Conclusions: This is the ﬁrst comprehensive analysis of causes of death
in PCa patients receiving MR-guided SABR. Despite routine induction
CT, the predominant cause of death was from progressive liver/peritoneal metastases. Our data suggest that ablative radiation dose may
reduce the probability of death potentially from LRF (14.8%) and
thereby increase long-term OS compared with historical outcomes using
chemotherapy alone or non-ablative doses. Nearly all who died from
LRF were treated within the ﬁrst 6 months of starting our MR-guided
SABR program and did not receive ENI; further investigation is needed
to better understand whether this or other treatment factors inﬂuence the
probability of death from LRF and OS.

(P034) Intraoperative Radiation After Pelvic Short Course
Radiotherapy for Patients with Locally Advanced Rectal
Adenocarcinoma with Involved or Threatened Circumferential Resection Margin
Emma Holliday, MD1, Zooha Kahn, BS2, Michael Rooney, MD3,
Prajnan Das, MD MS MPH4, George Chang, MD3, Oliver Peacock,
MD3, Gabriel Sawakuchi, PhD3, Ethan Ludmir, MD1, Eugene Koay,
MD PhD4, Grace Smith, MD MPH1, Cullen Taniguchi, MD PhD4,
Bruce Minsky, MD1, Albert Koong, MD, PhD1; 1MD Anderson Cancer
Center, 2University of Texas Rio Grade Valley School of Medicine,
3
University of Texas MD Anderson Cancer Center, 4MD Anderson
Background: Recent trials have shown short course radiotherapy
(SCRT) delivered as a component of total neoadjuvant therapy can
improve disease-free and overall survival for patients with high risk
locally advanced rectal cancer (LARC). However, patients with tumors
that involve or threaten the circumferential resection margin (CRM) still
have a high risk of local recurrence. Intraoperative radiotherapy (IORT)
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enables delivery of additional radiation to the margin of concern at the
time of surgery and may help to mitigate local recurrent risk.
Objectives: Our objectives were to evaluate outcomes for patients with
LARC who received IORT after SCRT-based neoadjuvant therapy and
analyzed radiation toxicity, operative complications and disease control.
Methods: Patients with LARC who were treated with preoperative
SCRT and IORT were identiﬁed. All patients had a preoperative
magnetic resonance imaging exam showing a threatened (< 2 mm) or
involved CRM. SCRT consistent of 25 Gray in ﬁve fractions and was
delivered as part of a multimodality preoperative regimen. IORT dose
ranged from 10-15 Gy and was delivered with high dose rate (HDR)
brachytherapy. Patient charts were reviewed and information regarding
demographics, tumor staging, treatment details, radiation toxicities,
post-operative complications and oncologic outcomes were recorded.
Results: A total of 10 patients with LARC were identiﬁed who received
SCRT-based neoadjuvant treatment and IORT. Seven patients had
involved CRM (< 1 mm), and three had threatened CRM (1-2 mm).
Four patients received SCRT followed by consolidative chemotherapy
and six received SCRT sandwiched between induction and consolidative chemotherapy. Five patients experienced G2+ toxicity during
the time-period spanning the start of SCRT to six weeks after SCRT
completion. Five patients underwent low anterior resection, one
underwent abdominoperineal resection and four underwent pelvic
exenteration. No patient had a pathologic complete response, but two
patients had minimal residual disease with a tumor regression grade of 1
and <10% viable tumor. Six patients had negative surgical margins
( > 2 mm); one patient had a close margin of 2 mm, and three patients
had involved radial margins (R1). The median [IQR] length of hospitalization after surgery was 11 [7-14] days, three patients required
readmission and two patients required reoperation due to complications
including anastamotic leak and abscess. With a median follow up of
19.5 months, no patient developed a pelvic recurrence. Six patients
developed distant recurrences; three were in the lung, two were in the
liver and one was in the peritoneum. One patient died with distant
recurrence 18 months after treatment.
Conclusions: The use of IORT after SCRT-based neoadjuvant therapy
is safe and feasible. In our series of 10 high risk patients, none developed pelvic recurrences. Further data are needed to determine whether
the addition of intraoperative radiation improves local recurrence rates
over preoperative radiation alone.

(P035) Predictive Accuracy of Digital Rectal Exam Following Chemoradiation in Rectal Cancer
Moataz El-Ghamry, MD1, Garrett Jensen, MD2, Tyson Amundsen,
MD1; 1Baylor Scott and White, 2Baylor Scott & White
Background: Watch and wait (W&W) after complete or major
response to neoadjuvant chemoradiotherapy (CRT) has been proposed
as an alternative to radical resection in early stage rectal cancer. The
utility of assessing response by magnetic resonance imaging (MRI) is
an area of controversy. The accuracy of digital rectal examination
(DRE) in predicting pathologic response has seldom been investigated.
Objectives: We conducted a retrospective analysis to assess the predictive accuracy of MRI and DRE following neoadjuvant CRT with
regard to pathologic complete response (CR).
Methods: From 2015-2020, 28 patients were retrospectively identiﬁed
that met our studies inclusion criteria. Each was treated with neoadjuvant CRT followed by surgery for rectal cancer. Each had a palpable lesion assessed by DRE before and after CRT, followed by surgery, was performed by a senior radiation oncologist.
Results: Clinical T stage of patients was T2, 3 and 4 in 11, 79 and 11%,
respectively. Clinical N stage of patients was N0, 1, and 2 in 36, 50, and
7%, respectively. Surgical procedure performed was low anterior resection,
abdominal perineal resection, or transanal excision in 10 (35%), 12 (43%),
and 6 (21%), respectively. Pathology demonstrated a CR in 8 (29%)
patients. Median RT dose was 5400 cGy (range 4140-5400 cGy). Correlation between DRE and pathological response was signiﬁcant
(P = 0.0019). In 11 (39%) patients with a CR on DRE, pathology showed
CR in 7 (64%) patients, and a partial response with <1 cm of residual tumor
in 2 (18%) patients. Correlation between MRI and pathological response
was not signiﬁcant (P = 0.2805). In 5 (19%) patients with a CR on MRI,
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pathology showed CR in 3 (60%) patients. Of 4 patients with a CR on both
MRI and DRE, 3 (75%) had a pathological CR.
Conclusions: A DRE performed by an experienced physician before
and after CRT has higher accuracy than MRI in detecting CR. DRE, in
addition to MRI, may help better identify patients with rectal cancer
who are candidates for a W&W approach.

(P036) Magnetic Resonance-guided Adaptive Radiation
Therapy for Treatment of Locally-recurrent Pancreatic
Adenocarcinoma
Kylie Kang, MD1, John Lattin, BS2, Joshua Schiff, MD3, Olga Green,
PhD3, Alex Price, MS3, Deshan Yang, PhD3, William Hawkins, MD3,
Ryan Fields, MD3, Pamela Samson, MD, MPHS1, Shahed Badiyan,
MD3, Lauren Henke, MD, MSCI4, Hyun Kim, MD3; 1Department of
Radiation Oncology, Washington University School of Medicine in St.
Louis, 2St. Louis University School of Medicine, 3Washington University School of Medicine, 4henke.lauren@wustl.edu
Background: There are limited treatment options for locally recurrent
pancreatic adenocarcinoma, especially after prior resection or radiation
therapy. The use of magnetic resonance (MR)-guided adaptive radiation
therapy (MRgART) has been reported for the treatment of inoperable
pancreatic adenocarcinoma, but there is a paucity of data on its application in locally recurrent cases.
Objectives: We aim to report on our institutional experience with
MRgART for treatment of locally-recurrent pancreatic adenocarcinoma.
Methods: Eighteen patients with locally recurrent pancreatic adenocarcinoma were treated at our institution between 2015-2019 with
MRgART. Demographic and treatment-related characteristics were
collected from the institutional electronic medical record and treatment
planning system. Kaplan-Meier with log-rank analysis was conducted,
with statistical signiﬁcance deﬁned as P < .05.
Results: Median time from diagnosis to ﬁrst local failure (LF) was
17.8 months (range: 6.4 - 56.6 mo). Six patients had deﬁnitive fractionated
chemoradiation before their local recurrence to a median dose of 52.2 Gy
(range: 45 - 55 Gy). Salvage MRgART was delivered to a median of
50 Gy (BED10 = 100 Gy; range: 50 - 67.5 Gy) for radiation-naïve patients
and a median of 32.5 Gy (BED10 = 53.6 Gy; range: 25 - 50 Gy) for those
who had received prior radiation; two patients did not receive salvage
MRgART at ﬁrst LF (had salvage chemotherapy alone) but underwent
MRgART at subsequent progression. Aside from one salvage regimen of
67.5 Gy over 15 fractions, all patients received salvage MRgART over
ﬁve fractions. Median planning target volume (PTV) was 132.6 cc (range:
16.2 - 292.3 cc). The most common organs at risk requiring adaptation
were small bowel and stomach, with 67% of cases requiring adaptation for
every fraction. Median overall survival from time of diagnosis was
34.7 months; median survival after salvage MRgART was 8.7 months.
One- and three-year local control rates were both 66%, and one- and threeyear overall survival rates were 78% and 18%, respectively. There was no
association between local control post-MRgART or overall survival and
PTV, BED10, or receipt of salvage chemotherapy.
Conclusions: Locally recurrent pancreatic adenocarcinoma can be
treated with MRgART with acceptable local control rates, even in cases
of prior deﬁnitive chemoradiation. MRgART was utilized for every
fraction in the majority of cases and allowed for plan adjustments to
meet luminal OAR constraints.

(P037) Stereotactic MRI-guided Adaptive Radiation Therapy for Non-metastatic Pancreatic Cancer; Outcomes and
Toxicity Analysis for Patients Treated in an Underserved
Urban Center
Celina Kirsch, PAC1, Eric Schaff, MD2, Parag Parikh, MD2, Benjamin
Movsas, MD3, Farzan Siddiqui, MD, PhD, CPE3, David Kwon, MD2,
Pin Li, PhD2, Gazala Khan, MD2, Rupen Shah, MD2; 1Henry Ford
Cancer Institute, 2Henry Ford Health System, 3Department of Radiation Oncology, Henry Ford Cancer Institute
Background: Stereotactic MRI-guided Adaptive Radiation Therapy
(SMART) is an emerging technology for treatment of pancreatic cancer
patients. Initial results show favorable survival and toxicity. However,
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data is still sparse overall, and especially in underserved patient populations. The purpose of this study is to review SMART outcomes at
our underserved urban academic cancer.
Objectives: Stereotactic MRI-guided Adaptive Radiation Therapy
(SMART) is an emerging technology for treatment of pancreatic cancer
patients. Initial results show favorable survival and toxicity. However,
data is still sparse overall, and especially in underserved patient populations. The purpose of this study is to review SMART outcomes at
our underserved urban academic cancer.
Methods: In this IRB approved retrospective chart review we reviewed
98 patients with non-metastatic pancreatic cancer, who completed
SMART between November 2018-January 2021. All 98 patients were
treated with 50 Gy in 5 daily fractions with adaptive technique as deemed
appropriate by treating radiation oncologist. The primary endpoints were
overall survival (OS), progression free survival (PFS), and both acute and
late grade 3+ GI toxicity. OS, PFS, locoregional control and distant
control were estimated by Kaplan-Meier method and compared using logrank test. The effect of clinical features on OS was assessed using univariate and multivariate Cox proportional hazard models. OS and PFS
were calculated from completion of radiation. Grade 3+ GI toxicity
probably or deﬁnitively related to radiation was recorded. All incidences
of GI bleeding, regardless of attribution, were also recorded.
Results: Median follow up was 20.9 months from time of diagnosis and
14 months from radiation. 21 (21%) patients were borderline resectable,
42 (43%) locally advanced, 22 (22%) medically inoperable and 13
(13%) resectable. Neoadjuvant chemotherapy was given to 86 (88%)
patients with a median of 3.5 months of chemotherapy (range 1-12),
leaving 11 (12%) patients who did not have systemic chemotherapy.
Median overall survival from radiation for the whole group was
15.7 months, and 1-year OS was 58%. There was a statistically signiﬁcant worsening of overall survival from diagnosis between ECOG 2+
and ECOG 0/1 patients (HR 1.94, 1.05-3.57). 27 (27%) patients went on
to have surgical resection with 23 (82%) having R0 resection, and 3
(11%) have an R1 resection. Improved OS was seen in patients with
surgical resection (HR 0.06, 0.02-0.23). Acute grade 3+ GI toxicity from
radiation was seen in 4 (4%) patients and late toxicity from radiation was
seen in 6 (6%) patients. GI bleeding was seen in 16(16%) patients, 10
(62%) of which were on anticoagulation at the time of GI bleed and 5
(19%) of which had surgery. Portal vein complications occurred with 7
(7%) having portal vein thrombosis and 6 (6%) portal vein stenosis.
Conclusions: SMART showed durable responses in pancreatic cancer
patients with an acceptable toxicity proﬁle. Attention needs to be paid to
the moderate incident of GI bleeding, however further work is necessary
to determine if bleeding was due to radiation, surgery, or disease progression. Surgical resection as well as performance status of ECOG 0-1
were associated with improved overall survival. Further follow up will
be necessary to determine further durability of treatment response and
long-term survival in these patients.

(P038) Outcomes of MR-guided Stereotactic Body Radiotherapy (SBRT) or yttrium-90 Transarterial Radioembolization for Hepatocellular Carcinoma Treated at an
Urban Liver Transplant Center
Evan Liang, MD1, Garret Greer, MD1, Charlotte Burmeister, MS1, Peter
Massa, MD1, Jadranka Dragovic, MD1, Parag Parikh, MD1; 1Henry
Ford Health System
Background: There are overlapping indications for both stereotactic body
radiotherapy (SBRT) and yttrium-90 (Y90) trans-arterial radioembolization as
locoregional treatments for hepatocellular cancer, though most centers preferentially use one modality over the other. MR-guided radiation allows both
effective on-table localization and integrated motion management as compared with many traditional linear accelerators, allowing SBRT to be done
more easily. Y90 radioembolization has been a well-established modality to
deliver highly conformal dose due to the localization of the microspheres to
the vascular supply of a tumor. We looked at patient characteristics and
treatment outcomes for patients receiving MR-guided SBRT or Y90 at an
urban transplant center.
Objectives: To compare patient characteristics and treatment outcomes
of MR-guided SBRT with Y90 transarterial radioembolization in a liver
transplant center.
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Methods: This retrospective single-institution study analyzed patients
with HCC treated with SBRT or Y90 from August 2017 to September
2020. To select a patient population eligible for either treatment
modality, any Y90 procedures for lesions > 10 cm or for treatment
volumes > 1000 cc were omitted from the cohort. A total of 239
patients were included in the analysis, receiving a total of 98 courses of
SBRT and 187 courses of Y90 treatment. Local control (LC), freedom
from liver progression (FFLP), and overall survival (OS) rates were
measured from treatment completion date to death date or last followup. All outcomes were censored at time of loss to follow-up; LC and
FFLP were censored at time of liver transplant if applicable. Cox
regression models were used for survival, with signiﬁcant factors on the
univariate analysis further analyzed with a multivariate model.
Results: Median time to follow-up was 11 months (0-44 mo). The
mean size of lesions treated with SBRT were smaller than those
treated with Y90 (2.7 cm vs 4.3 cm, P < 0.01). The groups of patients
differed in liver disease characteristics, with SBRT patients having
fewer Child-Pugh A disease (62% vs 80%, P < 0.01), more having
received locoregional treatments to the liver in the past (81% v 35%,
P < 0.01), and more disease in previously treated liver (57% vs 25%,
P < 0.01). Dose of radiation for SBRT was 45-50 Gy administered in
5 fractions; dose of Y90 radiation to tumor was prescribed to a
median of 235.2 Gy (range 55.8-512.3 Gy). There was a higher rate of
one year LC in the SBRT cohort (77% vs 57%, P < 0.01), while
median FFLP (9 mo vs 8 mo, P = NS) and median OS were not
signiﬁcantly different (24 mo vs 21 mo, P = NS). Multivariate analysis revealed size of largest lesion (P < 0.01) was correlated with
decreased local control; a 1 cm increase in tumor size was associated
with a 25% increased risk of local failure. Subsequent transplant
(P < 0.01) was the remaining signiﬁcant factor. Treatment modality
did not remain an independent predictor of LC. Predictors of OS in
multivariate analysis included age (P = 0.01), prior liver treatments
(HR 2.86, P < 0.01), size of largest lesion (P < 0.01), Child-Pugh
stage (P < 0.01), portal vein thrombosis (HR 1.6, P = 0.04), and
subsequent liver transplant (HR 0.08, P < 0.01).
Conclusions: These ﬁndings support the effectiveness of both MRguided SBRT and Y90 transarterial radioembolization in locoregional
management of HCC at a single institution despite clear differences in
the patient cohorts. Though survival outcomes were comparable, local
control differences favored the cohort treated by SBRT, in large part
due to differences in tumor size. This data supports further investigation
in a randomized study between SBRT and Y90.

(P039) Induction Chemotherapy for Locally Advanced
Esophageal Cancer: Can Additional PET/CT Parameters
Inﬂuence Patient Selection?
Jordan McDonald, BS1, Rutika Mehta, MD, MPH2, Anupam Rishi,
MD3, Austin Sim, MD, JD3, Kutjim Latiﬁ, PhD3, Jessica Frakes, MD3,
Jose Pimiento, MD4, Jacques Fontaine, MD4, Sarah Hoffe, MD3; 1USF
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Health Morsani College of Medicine, 2Department of Medical Oncology, H. Lee Mofﬁtt Cancer Center & Research Institute, 3Department of
Radiation Oncology, H. Lee Mofﬁtt Cancer Center & Research Institute, 4Department of Surgical Oncology, H. Lee Mofﬁtt Cancer Center
and Research Institute
Background: In the concurrent chemoradiation (CRT) setting, maximum standard uptake value (SUVmax) on PET/CT has been less
prognostically predictive than other metabolic parameters. The CALGB
80803 trial evaluated SUVmax response as a surrogate marker to guide
treatment decisions in the induction chemotherapy (IC) setting. As the
SUVmax only measures the most metabolically active voxels of tumor,
it overlooks volumetric change.
Objectives: To determine if integrating metabolic tumor volume
(MTV) and Total Lesion Glycolysis (TLG) into post-IC assessment
better predict treatment response before concurrent chemoradiation
(CRT).
Methods: We identiﬁed sequential clinical stage III and IV (by virtue of
non-regional adenopathy) EC patients treated with Folinic acid, Fluorouracil, and Oxaliplatin (FOLFOX) IC with pre and post IC PET/CT
performed at our institution before CRT to 50.4 Gy. SUVmax was
evaluated on these scans to assess response. As per the CALBG trial,
those with SUVmax decline of ≥ 35% in the primary tumor were
classiﬁed as responders while those <35% were non-responders.
Analysis of initial and post IC scans manually imported into Mirada
software was performed to identify additional metabolic parameters at
different thresholds including the TLG and MTV.
Results: Between 2017 and 2019, we identiﬁed 15 patients, 11 males
(73.3%) and 4 females (26.7%), treated with induction FOLFOX
(median age 67 and median initial stage III). The majority of tumors
were adenocarcinomas (80%, n = 12) and in the distal esophagus/
gastroesophageal junction (73.3%, n = 11). Responders showed the
greatest difference in TLG compared with MTV at all thresholds
(21.7% difference in median TLG reduction at variable, 18.8% at 2.5,
and 24.5% at 4.0, compared with 27% difference in median MTV
reduction at variable, 22.9% at 2.5, and 24.7% at 4.0) , with all those
initial TLG > 260 exhibiting response. The median reduction in
SUVmax was 42.0% (Range: -7.1-92.5%, Interquartile Range: 28.273.2%). With a median follow up of 2.5 years (range 1.97-3.96 y) 10
(66.7%) patients remain alive at this time with a crude median survival of 2.42 (range 1.97-3.96) years, while 5 (33.3%) patients are
deceased with a crude median survival of 1.60 (range 0.59-2.45)
years from diagnosis. 8 (53.3%) patients have remained free of progression, recurrence, or metastasis and one (6.7%) patient experienced recurrence but was successfully treated. Survivors had a
median TLG reduction of 98.3% at variable threshold, 90.1% at 2.5,
and 96.6% at 4.0.
Conclusions: TLG parameters may be used for additional prognostic value in the locally advanced EC setting to determine extent
of tumor response to IC. Further prospective study of additional
metabolic parameters on pre and post IC imaging is warranted
(Figs. 1 and 2).

FIGURE 1. Larger change in median pre and post IC TLG values among responders vs. non-responders at all thresholds.
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FIGURE 2. Percent reduction in TLG is increased in responders vs.
non-responders at all thresholds.

(P040) Validation of the Neoadjuvant Rectal Cancer (NAR)
Scores for Prognostication Following Total Neoadjuvant
Therapy (TNT) for Locally Advanced Rectal Cancer
April Metzger, MD1, Stephen Abel, DO1, Alexander Kirichenko, MD,
PhD1, James McCormick, DO1, Dulabh Monga, MD1, Rodney Wegner,
MD1; 1Allegheny Health Network
Background: The neoadjuvant rectal cancer (NAR) score is a prognostic tool for locally advanced rectal cancer treated with total neoadjuvant therapy (Valentini V, et. al. J Clin Oncol 2011). It has been
previously validated as an endpoint that predicts survival more accurately than pathologic complete response (pCR) (Raissouni S, et. al. J
Clin Oncol 2014) and is the primary endpoint of the ongoing NRGGI002 Phase II trial. The score uses the variables of clinical tumor
stage, pathologic tumor stage, and pathologic nodal stage which are
commonly available, furthering its utility in the clinical setting.
Objectives: Using the National Cancer Database (NCDB) we aimed to
validate the NAR score’s ability to predict survival in a large hospital
based dataset.
Methods: We queried the NCDB from 2004-2014 to identify all stage
II and III rectal cancer patients that received total neoadjuvant therapy
(TNT) followed by surgical resection. Selection for patients receiving
TNT included receipt of preoperative multi-agent chemotherapy and
radiation. Patients were excluded if they had non-adenocarcinoma
histology, unknown clinical or pathologic staging, less than 6 months
of follow up, and positive margins. Overall survival (OS) was calculated using Kaplan-Meier curves evaluating NAR score and pCR
separately. A multivariable Cox proportional hazards model was used
to identify factors associated with survival. Multivariate regression
was used to evaluate characteristics associated with a favorable (< 15)
NAR score.
Results: Our ﬁnal patient cohort yielded 209 patients for analysis with
a median age of 62. The median follow up time was 43.8 months
(Range: 7.1–135.3 mo). Factors associated with worse survival
included age > 62 years old (P = 0.046), lower income (P = 0.03),
and unfavorable ( ≥ 15) NAR score (P = 0.04). Comorbid score, CEA
level, race, lymphovascular invasion, perineural invasion, and
insurance status did not predict for survival. On multivariate regression, tumors with perineural invasion and a higher comorbidity score
( > 1) were less likely to have a favorable NAR response (P = 0.0093
and P = 0.0117). Of note, pCR was not associated with improved
survival (P = 0.0949).
Conclusions: This NCDB analysis further validates the utility of the
NAR score as a prognostic tool in patients receiving TNT for locally
advanced rectal cancer. Tumors with perineural invasion and patients
with a higher comorbidity score had worse NAR scores.

(P041) The Implications of Treatment Delays in Adjuvant
Therapy for Resected Cholangiocarcinoma Patients
Matthew Parsons, MD1, Shane Lloyd, MD2, Skyler Johnson, MD3,
Courtney Scaife, MD1, Robin Kim, MD2, Rebecca Kim, MD MPH2,
Heloisa Soares, MD PhD2, Ignacio Garrido-Laguna, MD PhD2, Randa
Tao, MD3; 1University of Utah Huntsman Cancer Institute, 2University
of Utah, Huntsman Cancer Institute, 3Huntsman Cancer Institute at the
University of Utah
Background: The role of timing of adjuvant therapy in the setting of
CCA has not yet been studied. The BILCAP study initially required
patients to start adjuvant therapy within 8 weeks of surgery, however
the protocol was later adjusted to allow initiation within 12 weeks and
later extended again to 16 weeks. The SWOG trial required enrollment

FIGURE 1. Fifteen-year overall survival for patients who were
treated before and after various time points. Data are shown for
patients treated before and after 59 days (the median).
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TABLE 1. Predictors of Initiation of Adjuvant Therapy Within the
First Half of Patients ( ≤ 59 d) Assessed by Multivariable Analysis

within 8 weeks. However, the impact of these time points has not been
formally analyzed. With the emergence of COVID-19 delaying therapy
for a number of oncology patients, we set out to evaluate factors
associated with delays in the initiation of adjuvant therapy for CCA as
well as the impact of these delays on survival outcomes.
Objectives: To understand factors associated with timing of adjuvant therapy
for cholangiocarcinoma and the impact of delays on overall survival (OS).
Methods: Data from the National Cancer Database (NCDB) for patients
with non-metastatic bile duct cancer from 2004 to 2015 were analyzed.
Patients were included only if they underwent surgery and adjuvant
chemotherapy and/or radiotherapy (RT). Patients who underwent neoadjuvant therapy or palliative treatments were excluded. Pearson’s χ2d
test and multivariate logistic regression analyses were used to assess the
distribution of demographic, clinical, and treatment factors. After propensity-score matching with inverse probability of treatment weighting,
OS was compared between patients initiating therapy past various time
points using Kaplan Meier analyses and doubly-robust estimation with
multivariate Cox proportional hazards modeling.
Results: In total, 7,733 of 17,363 (45%) patients underwent adjuvant
treatment. The median time to initiation of adjuvant therapy was 59 days
(interquartile range 45-78 d). Age over 65, black and Hispanic race, and
treatment with RT alone were among the factors associated with later
initiation of adjuvant treatment (Table 1). Patients with larger tumors and
high grade disease were more likely to initiate treatment early. After propensity score weighting, there was an OS decrement to initiation of
treatment beyond the median of 59 days after surgery (Fig. 1).
Conclusions: We identiﬁed patient and disease characteristics that are
related to the timing of adjuvant therapy in patients with biliary cancers.
Troublingly, there are racial disparities associated with the timely initiation
of adjuvant therapy. There was an OS decrement associated with delays
beyond the median time point of 59 days. This ﬁnding may be especially
relevant given the treatment delays seen as a result of COVID-19.

(P042) Surgery After Neoadjuvant Stereotactic MRI
Guided Adaptive Radiation in Pancreatic Cancer: Multiinstitutional Toxicity and Survival Outcomes
Eric Schaff, MD1, Celina Kirsch, PAC1, Parag Parikh, MD1, Michael
Chuong, MD2, Roberto Herrera, BS2, Horacio Asbun, MD2, Ramon
Jimenez, MD2, Farzan Siddiqui, MD, PhD, CPE3, Gazala Khan, MD1,
Santiago Aparo, MD2, Fernando De Zarraga, MD2, Antonio Ucar,
MD4, Rupen Shah, MD1, Pin Li, PhD1, Benjamin Movsas, MD3, David
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Kwon, MD1; 1Henry Ford Health System, 2Miami Cancer Institute,
Department of Radiation Oncology, Henry Ford Cancer Institute,
4
Miami Cancer Institue
Background: Favorable toxicity and survival outcomes after dose
escalated stereotactic MR guided adaptive radiation therapy (SMART)
have been recently published for locally advanced (LA) and borderline
resectable (BR) pancreatic cancer. Perioperative morbidity and mortality are not well understood after ablative radiation therapy, which
may temper enthusiasm for offering surgery.
Objectives: The purpose of this study was to investigate survival and
toxicity in resected pancreas cancer patients after neoadjuvant
ablative SMART.
Methods: In this IRB approved analysis, we retrospectively reviewed
33 consecutive patients with resectable, BR, and LA pancreatic cancer
based on NCCN 2.2021 staging criteria who were treated at 2 institutions from 2017-2020 with neoadjuvant SMART 50 Gy in 5 fractions
on a 0.35T MR Linac and later underwent deﬁnitive surgical resection.
Overall survival (OS) and locoregional control (LRC) were evaluated
by Kaplan-Meier method.
Results: Median follow up was 22.4 months from diagnosis and
17.8 months from last day of RT. Most had BR (55%), otherwise
initially resectable (33%) or LA (12%) pancreatic cancer. Median
duration of induction chemotherapy was 3.5 (SD 1.6) months with most
common regimens being FOLFIRINOX (74%), gemcitabine/abraxane
(24%) and FOLFOX (3%). Performance status was ECOG 0, 1, 2 in 16
(48.5%), 12 (36.4%), and 5 (15.2%), respectively. Whipple was performed in 27 (82%) of patients, distal pancreatectomy in 4 (12%), and
total pancreatectomy in 2 (6%). The median duration from SMART
completion to surgery was 6.9 weeks (4.7-44.1). R0 resections were
achieved in 28 (84.8%) of patients with the rest being R1, all in BR
patients. Vascular resection/reconstruction was performed of the portal
vein (PV) in 8 (24.2%) patients, SMV in 4 (12%), SMA in 1 (3%), and
common hepatic artery in 2 (6%). Vascular resection/reconstruction was
performed in all LA patients. Median OS, 1-year OS, and 2-year OS
from diagnosis were 29.6 months, 93.8%, 81.5%, respectively. Median
OS from RT was not yet reached; 1-year OS was 90.9%. LRC at 1 and
2 years was 97% and 93%, respectively. Radiation related acute and late
grade 3+ gastrointestinal toxicity was seen in 2 (6%) and 2 (6%)
patients. Post-op mortality at 30 and 90 days was seen 2 (6%) and 3
(9%) of patients with 1 death from GI bleed attributed to surgery and 1
death from hepatic ischemia related to PV resection.
Conclusions: To the best of our knowledge, this is the ﬁrst report
suggesting that surgery for pancreas cancer after dose escalated
5-fraction SMART is feasible. Further clariﬁcation is needed with
respect to ideal patient selection and timing for surgery, the safety of
arterial versus venous resection/reconstruction, and histopathologic
response after delivery of ablative versus non-ablative radiation dose.
3

(P043) Executive Summary of the American Radium SocietyTM (ARS) Appropriate Use Criteria (AUC) for LocoRegional Gastric Adenocarcinoma: Systematic Review and
Guidelines
Leila Tchelebi, MD1, Rachit Kumar, MD2, Navesh Sharma, DO, PhD3,
Christopher Anker, MD4, Joseph Herman, MD5, Karyn Goodman,
MD6, William Jones, MD7, Nelson Yee, MD3, Madappa Kundranda,
MD, PhD2, Timothy Kennedy, MD, MBA8, Percy Lee, MD9, Suzanne
Russo, MD10, William Small, MD, FACRO, FACR, FASTRO11,
Warren Suh, MD12, Salma Jabbour, MD8; 1PennState Health, 2Banner
MD Anderson Cancer Center, 3Penn State Health, 4University of
Vermont, 5Northwell Health, 6Icahn School of Medicine Mount Sinai,
7
University of Texas Health Science Center at San Antonio, 8Rutgers
Cancer Institute of New Jersey, Robert Wood Johnson Medical School,
Rutgers University, 9University of Texas MD Anderson Cancer Center,
10
Case Western Reserve University School of Medicine and University
Hospitals, 11Loyola University Chicago, Stritch School of Medicine,
Cardinal Bernardin Cancer Center, 12University of California at Los
Angeles, Ridley-Tree Cancer Center
Background: Gastric cancer is a leading cause of cancer mortality
worldwide. Most patients present with locally advanced or advanced
disease for which multi-modal therapy is often indicated.
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Objectives: To systematically evaluate data regarding the use of neoadjuvant, peri-operative, surgical and adjuvant treatment options in
patients with operable or inoperable gastric cancer and to develop
Appropriate Use Criteria (AUC) recommended by a panel of gastrointestinal oncology experts convened by the American Radium Society
(ARS). In particular, the role for radiation therapy in the management of
these patients was speciﬁcally addressed.
Methods: Preferred Reporting Items for Systematic reviews and MetaAnalyses (PRISMA) methodology was used to develop an extensive
analysis of peer-reviewed phase 2/2R/3 trials as well as meta-analyses
found within the Ovid Medline database between 2010 to 2020. These
studies were used to inform the expert panel, which then rated the
appropriateness of various treatments in 5 broadly representative clinical scenarios through a well-established consensus methodology
(modiﬁed Delphi).
Results: For patients with medically operable locally advanced gastric
cancer, the strongest recommendation was for peri-operative chemotherapy based on high quality data. Acceptable alternatives included
surgery followed by either chemotherapy or concurrent chemoradiotherapy (CRT). For patients with upfront resection of stage I-III
gastric cancer (no neoadjuvant therapy), the group strongly recommended adjuvant therapy with either chemotherapy alone or CRT,
based on high quality data. For patients with locally advanced disease
who received pre-operative chemotherapy without tumor regression, the
group strongly recommended postoperative chemotherapy or postoperative CRT. Finally, for medically inoperable gastric cancer patients,
there was moderate consensus recommending deﬁnitive concurrent
CRT. In cases when the group endorsed radiation therapy, the suggested
radiation doses and target volumes varied based on the clinical scenario.
The most agreed upon dose/fractionation schedule was 45-46 Gray in
25-26 fractions for adjuvant radiation and 50-50.4 Gray in 25-28
fractions for deﬁnitive radiation.
Conclusions: Patients with gastric cancer are at high risk of both
locoregional and distant relapse (49%) after surgery alone. The addition
of chemotherapy and/or radiation, either in the neoadjuvant, adjuvant,
or perioperative setting, result in improved survival rates for patients.
For inoperable patients, deﬁnitive CRT is a reasonable treatment option,
though largely palliative. Radiation planning for gastric cancer requires
multiple detailed considerations including primary tumor location
within the stomach and the location of draining, regional lymph nodes.

(P044) Sarcopenia and Abdominal Fat Distribution Are
Prognostic for Overall Survival in Patients with Unresectable Pancreatic Cancer Undergoing Stereotactic Body
Radiotherapy
Yufan (Fred) Wu, MD1, Chika Nwachukwu, MD, PhD2, Diego Toesca,
MD1, Yufei Liu, MD PhD3, Amanda Koong1, Rie von Eyben, MS1,
Albert Koong, MD, PhD4, Daniel Chang, MD1; 1Stanford University,
2
UT Southwestern Medical Center, 3University of Texas MD Anderson
Cancer Center, 4MD Anderson
Background: Various measures of body composition have been shown
to have predictive value on clinical outcomes in cancer. Sarcopenia and
abdominal fat distribution (speciﬁcally the amount of visceral fat relative to subcutaneous fat) are two such measures which can be easily
assessed via computed tomography (CT) scan and have been shown to
be negatively correlated with survival outcomes in gastrointestinal
malignancies.
Objectives: The purpose of this study is to evaluate the prognostic
value of sarcopenia as well as the distribution between visceral fat and
subcutaneous fat on overall survival (OS) in patients with unresectable
pancreatic cancer (PC) undergoing stereotactic body radiotherapy
(SBRT).
Methods: A retrospective analysis was conducted of all patients treated
with deﬁnitive SBRT for unresectable PC between 2001 and 2015 at
our institution. Data from pretreatment abdominal CT scans, patient/
tumor characteristics, and outcomes were collected. Sarcopenia was
quantiﬁed by measuring the total psoas area and total muscle area at a
single axial CT slice at the mid-third lumbar vertebral body. Abdominal
fat distribution was assessed at the same CT slice using visceral fat area
(VFA) and subcutaneous fat area (SFA). These CT structures were
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TABLE 1. Patient and Treatment Characteristics

automatically generated using predeﬁned ranges of Hounsﬁeld units.
Sarcopenia and increased fat distribution were deﬁned based on previously published thresholds. OS was estimated via the Kaplan-Meier
method.
Results: A total of 196 patients were identiﬁed, with a median followup of 12.9 months (patient characteristics in Table 1). 75% of patients
were sarcopenic, and this group was signiﬁcantly older than non-sarcopenic patients. 43% of patients had elevated VFA, and this was
associated with female sex. Sarcopenia on its own did not correlate with
OS, but in patients with body mass index ≥ 25, sarcopenic patients had
worse median OS than non-sarcopenic patients (13 vs. 17 mo,
P = 0.01). This was similarly true in the subgroup of male patients (11
vs. 24 mo, P = 0.03), but not in females. Regarding fat distribution,
patients with a VFA:SFA ratio > 1.2 had signiﬁcantly worse median
OS than those with a VFA:SFA ratio < 1.2 (10 vs. 14 mo, P = 0.003).
This association held true in the male subgroup (10 vs. 13 mo,
P = 0.006), but interestingly, a VFA:SFA ratio > 1.2 was associated
with better median OS in females (15 vs. 14 mo, P = 0.047). Multivariable analysis revealed that low serum albumin and not receiving
chemotherapy were independent predictors of worse OS.
Conclusions: This is the largest study to date that investigates the
relationship between measures of body composition with survival
outcomes in unresectable PC patients undergoing SBRT. Sarcopenia
was found to be correlated with worse OS in overweight/obese patients
as well as in males. A high VFA:SFA ratio was also associated with
inferior OS. Both prognostic factors are assessable via CT scan which
can help to guide management in the future without requiring invasive
procedures.
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(P045) PSA: Declining Utilization of Brachytherapy for the
Treatment of Prostate Cancer
Lauren Andring, MD1, Todd A Pezzi, MD, MBA2, Chad Tang, MD1,
Gary Walker, MD3; 1UT MD Anderson Cancer Center, 2MD Anderson
Cancer Center, 3Banner Health
Background: Despite a growing body of literature demonstrating
expanding indications for the use of brachytherapy, multiple prior
studies have shown that over time rates of brachytherapy utilization
have been decreasing.
Objectives: To analyze rates of brachytherapy use for prostate cancer
over time and evaluate patient characteristics, demographics and factors
predictive for its utilization.
Methods: Data was retrospectively analyzed from the National Cancer
Database (NCDB) for patients with localized prostate cancer treated
between 2010 and 2015. Patients were included if they had biopsy
conﬁrmed localized adenocarcinoma of the prostate, were treated with
radiation as deﬁnitive local therapy, and were at least 18 years old.
Utilization rates of external beam radiation (EBRT), brachytherapy
(BT) and combination (EBRT + BT) were evaluated over time. Univariable (UVA) and backwards elimination multivariable (MVA)
analysis were performed to determine characteristics predictive for
brachytherapy use.
Results: We analyzed 178,837 patients with localized adenocarcinoma
of the prostate treated between 2010 and 2015 with radiation therapy.
During the period from 2010-2015, the use of EBRT increased from
67% to 78%, BT (both monotherapy and combination with EBRT)
decreased from 33% to 22%, BT monotherapy decreased from 25% to
16% and EBRT + BT decreased from 8% to 6%. Age > 70, government
funded insurance or lack of insurance, intermediate or high-risk disease
and treatment at an academic center were associated with signiﬁcantly
lower utilization of brachytherapy (all P < 0.001), while higher median
county income was associated with increased use (P = 0.02). On MVA
patient age, insurance provider, treatment facility, and NCCN risk
category were independent predictors for brachytherapy utilization
(Table 1). Notably, on both UVA and MVA brachytherapy practice
decreased with increasing year of diagnosis (OR 0.881, 95% CI 0.8530.910, P < 0.001).
Conclusions: Rates of brachytherapy utilization for the treatment of
prostate cancer continue to decrease over time. Treatment at an academic center was associated with reduced likelihood of brachytherapy
use. This has signiﬁcant implications for the training of future radiation
oncology residents/fellows and direct consequences for both our
patients and healthcare expenditure.
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(P046) Does the Addition of Brachytherapy And/or
Androgen Deprivation Therapy to External Beam Radiotherapy Correlate with Improved Survival in Men with
Unfavorable Intermediate-risk Prostate Cancer?
Neal Andruska, MD PhD1, Temitope Agabalogun, BS1, Benjamin
Fischer-Valuck, MD2, Randall Brenneman, MD PhD1, Yi Huang, MS1,
Hiram Gay, MD1, Jeff Michalski, MD, MBA1, Ruben Carmona, MD
MStat3, Brian Baumann, MD1; 1Department of Radiation Oncology,
Washington University School of Medicine in St. Louis, 2Department of
Radiation Oncology, Emory University School of Medicine, 3Department of Radiation Oncology, University of Miami School of Medicine
Background: External beam radiotherapy (EBRT) ± brachytherapy
boost (BT) ± androgen deprivation therapy (ADT) is currently recommended for men with unfavorable intermediate-risk prostate cancer
(UIR-PCa). However, the ideal radiotherapy regimen for UIR-PCa is
not well-deﬁned since clinical trials have rarely addressed treatment
decisions in this cohort, with most trials grouping UIR patients with
either favorable intermediate-risk or high-risk disease. Three clinical
trials have shown that adding BT to EBRT improves biochemical
progression-free survival but did not report differences in metastaticfree survival, cancer-speciﬁc survival, or overall survival. Given that
higher-risk patients were included and likely derived the most beneﬁt
from intensifying treatment, it remains unclear whether men with UIRPCa derived the same beneﬁt from a BT boost.
Objectives: The addition of BT to EBRT+ADT in UIR-PCa has a
radiobiologic advantage, permitting further dose escalation beyond
doses that can be delivered routinely with EBRT. We therefore
hypothesized that EBRT+BT ± ADT would be associated with
improved overall survival (OS) relative to EBRT ± ADT in men with
UIR-PCa.
Methods: 32,246 men diagnosed between 2004-2015 with UIR-PCa
treated with EBRT ± ADT ( ≥ 72 Gy in 1.8-2.0 Gy per fraction) or
EBRT+BT (40-50.4 Gy EBRT, followed by HDR-BT or LDR-BT)
were identiﬁed in the National Cancer Database (NCDB). Patients with
a Charlson-Deyo comorbidity index (CDCI) score > 1, who received
systemic therapy other than ADT, or missing key information were
excluded. Inverse propensity of treatment-weighted (IPTW) multivariable analysis (MVA) using Cox regression modeling was used to
compare OS hazard ratios. Covariables included age, race, ethnicity,
year of diagnosis, CDCI score, insurance status, educational and socioeconomic metrics, treatment at an academic center, PSA as diagnosis,
Gleason score, clinical T-stage, and receipt of ADT.
Results: Patients were stratiﬁed into four treatment groups: (i) EBRT
(n = 13,265), (ii) EBRT+ADT (n = 13,123), (iii) EBRT+BT (n = 3,440),
(iv) EBRT+ADT+BT (n = 2,418). Propensity-weighted MVA showed
the following. EBRT+ADT correlated with improved OS relative to

TABLE 1. Multivariable Logistic Regression Model for
Brachytherapy Treatment

FIGURE 1. Propensity weighted Kaplan-Meier curve stratified by
EBRT+ADT versus EBRT+BT without ADT. P value represent
P-log rank.
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EBRT alone (Hazard Ratio (HR): 0.92, [95% Conﬁdence Interval: 0.870.98], P = .005). Compared with EBRT+ADT, EBRT+BT (HR: 0.77
[0.69-0.85], P = 3x10-7) and EBRT+BT+ADT (HR: 0.75 [0.67-0.83],
P = 6x10-8) were both associated with improved OS. Relative to EBRT
+BT, EBRT+BT+ADT was not associated with improved OS (HR:
0.99 [0.87-1.11], P = .82). 10-year OS for the EBRT+ADT versus
EBRT+BT without ADT was 55% and 70%, respectively (P < 0.0001)
(Fig. 1).
Conclusions: The addition of brachytherapy to EBRT correlated with
reduced mortality in men with UIR-PCa. While ADT+EBRT was
associated with better OS relative to EBRT, EBRT+BT+ADT resulted
in comparable survival to EBRT+BT, suggesting that omitting ADT
with EBRT+BT may be an option for men who want to avoid ADT.

(P047) A Prospective Study of MR-guided Focal Salvage
HDR Brachytherapy for Radiorecurrent Prostate Cancer:
Updated Results of 30 Patients
Hans Chung, MD1, Mark Corkum, MD1, Andrew Loblaw, MD1, ChiaLin Tseng, MD1, Ananth Ravi, PhD1, Melanie Davidson, PhD1, Matt
Wronski, MD1, Masoom Haider, MD2, Gerard Morton, MD1; 1Sunnybrook Odette Cancer Centre, 2University of Toronto
Background: Salvage therapies for localized radiorecurrent prostate
cancer often carry signiﬁcant short- and long-term morbidity. Focal
salvage high dose rate (HDR) brachytherapy is an appealing treatment
technique which delivers an ablative dose of radiotherapy to the portion
of the prostate containing recurrent disease; however, limited prospective data is available.
Objectives: We sought to explore the toxicities, health related quality of
life and efﬁcacy of focal salvage HDR brachytherapy after previous
deﬁnitive radiotherapy.
Methods: Patients with locally recurrent prostate cancer after previous
external beam radiotherapy (EBRT) and/or brachytherapy were enrolled
on a prospective clinical trial. Patients received MRI-guided, ultrasound-based focal HDR brachytherapy delivered over two fractions of
13.5 Gy delivered 1-2 weeks apart. Adjuvant androgen deprivation
therapy (ADT) was not used. Toxicity was measured using CTCAE v4.
Posttreatment response was evaluated using MRI 1-2 years after salvage. Biochemical failure was deﬁned as PSA nadir + 2 ng/mL.
Results: Thirty patients were treated between November 2012 and
September 2019. Median follow-up was 35 months (range: 13–92 mo).
Fifteen patients were initially treated with EBRT, 3 with low dose rate
(LDR) brachytherapy monotherapy, 1 with EBRT and LDR brachytherapy boost, 2 with EBRT and HDR brachytherapy boost, and 9 with
HDR brachytherapy as monotherapy (all 19 Gy in a single fraction).
Median clinical target volume (CTV) at time of salvage was 5.22 mL
(range: 2.18–15.71 mL), corresponding to a median of 20.0% of the
prostate volume (range: 8.8–39.2%). Median PSA at salvage was 4.46
ng/mL (range: 0.99–11.63 ng/mL). The median CTV V100 was 96.5%
(range: 90.5–99.5%), and median CTV D90 was 15.1 Gy per fraction
(range: 13.6–18.1 Gy). Seventeen patients experienced subsequent
biochemical failure, and 9 have received ADT and/or further local
salvage. No patients have died from prostate cancer. Median time to
biochemical failure was 41.5 months, and median time to ADT/salvage
therapy was 70.6 months. The three-year biochemical failure-free event
rate was 61.8% (95% CI 44.0–86.6%), and three-year ADT/salvage
therapy-free event rate was 86.0% (95% CI 74.1–99.8%). No acute
grade ≥ 3 GU/GI toxicity was observed. One late grade 3 GU toxicity
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event occurred, cystitis at 42 months post treatment, which did not
persist on follow-up. No late grade ≥ 3 GI toxicity was seen. Of the 28
patients who had a post-treatment MRI, 26 had evidence of a local
treatment response.
Conclusions: In our updated results, we found focal salvage HDR
brachytherapy is well tolerated with a favorable side effect proﬁle and
3-year biochemical control rates in line with other salvage therapies for
radiorecurrent prostate cancer. While early MRI response at the treated
site is common, this does not preclude subsequent biochemical failure.

(P048) Comparative in Silico Analysis of Intensity Modulated Scanning Beam Proton Therapy (IMPT) and Volumetric Modulated Arc Photon Radiotherapy (VMAT) for
the Post-Operative Treatment of Prostate Cancer
Ian Cruickshank, BS RT(T)1, Hao Chen, PhD2, Aditya Halthore, MD2,
Heng Li, PhD3, Curtiland Deville, MD2; 1Howard University College of
Medicine, 2Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins Hospital, 3Johns Hopkins University
Background: Limited data exists regarding the dosimetric techniques
and potential advantages of modern scanning beam proton therapy
relative to conventional photon therapy modalities for prostate cancer
patients in the post-operative setting.
Objectives: Our purpose was to evaluate the dosimetric differences in
IMPT versus IMRT for the post-operative treatment of prostate cancer.
Methods: The 3DCT data of 7 consecutive, post-prostatectomy patients
treated at our institution with adjuvant or salvage IMPT in 2020 were
used to generate VMAT and IMPT plans using 3 different beam
arrangements: 2-ﬁeld (opposed laterals), 3-ﬁeld (opposed laterals inferiorly matched to posterior beam superiorly), and 4-ﬁeld (opposed laterals inferiorly matched superiorly to 2 posterior oblique beams). Prescription was 50 Gy in 2 Gy fractions delivered to elective pelvic nodal
regions (i.e., whole pelvis) and 20 Gy in 2 Gy fractions delivered to the
prostate bed for a total dose of 70 Gy in 35 fractions. PT doses are
reported in Gy (RBE) = 1.1 Gy. Dose goals for target and relevant
organs at risk (OAR), as well as dose-volume histogram parameters
were assessed. The paired 2-sided Wilcoxon signed-rank test was used
to compare the 4-ﬁeld IMPT versus VMAT plans, with P < 0.05 indicating statistical signiﬁcance.
Results: CTV coverage met pre-speciﬁed dose goals for all plans with
99% of CTVs receiving ≥ 100% of the prescription doses. The 2-, 3-,
and 4-ﬁeld IMPT plans showed similar doses to the bladder and bladder
minus CTV (bladderless-CTV), while the 4-ﬁeld IMPT plan showed the
lowest mean and low to intermediate doses to the bowel cavity and
rectum. For example, mean bowel cavity V15 and V45 for the 2-, 3-,
and 4-ﬁeld IMPT plans were respectively 549.2 ± 282.6 cc and
110.7 ± 39.8 cc, 303.0 ± 102.0 cc and 92.7 ± 32.6 cc, and 263.4 ± 97.3 cc
and 90.6 ± 40.6 cc. Mean rectum V50 and V60 for the 2-, 3-, and 4-ﬁeld
IMPT plans were 26.8 ± 8.9% and 18.7 ± 7.4%, 28.9 ± 10.5% and
19.5 ± 8.0%, 24.3 ± 4.8% and 16.7 ± 4.1% respectively. When comparing the 4-ﬁeld IMPT and VMAT plans, the rectal, bowel, and bladder
parameters in Table 1 differed signiﬁcantly.
Conclusions: The 4-ﬁeld IMPT beam arrangement showed the greatest
reductions in dose to the bowel cavity and rectum compared with
VMAT and the 2- and 3-ﬁeld IMPT arrangements. These data can
inform the future clinical management and delivery of proton therapy
for prostate cancer in the post-prostatectomy setting (Fig. 1).
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FIGURE 1. Dose volume histogram comparison of 2-, 3-, and 4-field IMPT and IMRT for the clinical target volumes and organs at risk
including bladder, bladder minus CTV (bladderless-CTV), and bowel cavity.
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TABLE 1. Comparison of VMAT IMRT and 4-field IMPT Target
Coverage and OAR Constraints

FIGURE 1. Proportional change of hemoglobin over time by
treatment group. For patients with normal hemoglobin ( > 13.2)
before treatment, the graph displays the proportion of patients
that developed mild to severe anemia at three distinct posttreatment time bins.

Results: 3285 men were included in the analysis. Treatment regimens
among these patients consisted of 239 treated with brachytherapy alone,
88 treated with EBRT, 206 treated with EBRT/brachytherapy, and 2752
treated with surgical resection. Up to 6 months following treatment,
41% of men treated with EBRT developed mild anemia, compared with
22, 6, and 50% for EBRT/brachytherapy, brachytherapy alone, and
surgery, respectively. An additional 6% of men treated with surgery
developed moderate/severe anemia in this time frame. Between 6 and
12 months following treatment, 40% of patients treated with EBRT had
mild anemia, compared with 0% for both EBRT/brachytherapy and
brachytherapy alone and 12% for surgical patients. Between 12 and
24 months, 33% of patients treated with EBRT had anemia, compared
with 9, 5, and 7% for EBRT/brachytherapy, brachytherapy, and surgery,
respectively. When considering ADT use, patients treated with EBRT/
ADT had more episodes of anemia than trimodality therapy at all time
points (50 vs. 21% at 0-6 months, 56 vs. 0% at 6–12 months, and 33 vs.
13% at 12–24 mo).
Conclusions: EBRT was associated with more and longer duration
anemia compared with either brachytherapy or combined brachytherapy
and EBRT, suggesting brachytherapy boost reduces the risk of anemia.
Anemia is a common occurrence after surgery in the perioperative
period, but then is unlikely to persist. Further studies are required to
determine if there is a dosimetric correlation for these observations
(Fig. 1 and Table 1).

(P049) Comparing the Impact of External Beam Radiotherapy, Brachytherapy, and Surgery on the Development
of Anemia and Subsequent Temporal Recovery in Patients
Treated for Localized Prostate Cancer
Jordan Fenlon, MD1, Krystal Straessler, PhD1, Jonathan Tward, MD,
PhD1; 1Huntsman Cancer Institute at the University of Utah
Background: Studies that explore pelvic radiotherapy’s effect on anemia predate intensity-modulated radiation therapy and have not tracked
the temporal recovery of Hemoglobin (Hgb) levels.
Objectives: The present study explores the impact of external beam
radiotherapy (EBRT), brachytherapy, and surgical treatments on Hgb
levels and subsequent temporal recovery.
Methods: Patients diagnosed with localized prostate cancer after the
year 2008 who had normal pretreatment Hgb levels ( > = 13.2 g/dL)
were identiﬁed in a prospectively maintained institutional outcomes
database. Patients were stratiﬁed by treatment modality (brachytherapy,
external beam radiation [EBRT], combined brachytherapy and EBRT,
or surgery. The proportion of patients who became mildly (Hgb 10–
13.2 g/dL) or moderately/severely (Hgb <10 g/dL) anemic was evaluated at time bins of 0-6 months, 6-12 months, and 12 - 24 months. For
patients with multiple Hgb levels in a time bin, the average value was
used. Patients were censored at the initiation of any additional cancer
therapies.

TABLE 1. Number of Patients With Evaluable Hemoglobin by
Treatment Group

For patients with normal pre-treatment hemoglobin ( > 13.2), the number of
patients with evaluable hemoglobin by treatment group in each distinct posttreatment time bin is displayed.
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(P050) Androgen Deprivation Therapy and Radiotherapy
Practice Patterns for Unfavorable Intermediate Risk Prostate Cancer
Shaakir Hasan, D.O.1, Stanislav Lazarev, MD2, Madhur Garg, MD3,
Keyur Mehta, MD3, Robert Press, MD1, Arpit Chhabra, MD1, J Isabelle
Choi, MD1, Charles Simone, MD, FACRO1, Daniel Gorovets, MD4;
1
New York Proton Center, 2Mount Sinai, 3Monteﬁore, 4Memorial Sloan
Kettering Cancer Center
Background: Per National Comprehensive Cancer Network (NCCN)
guidelines, the nonsurgical treatment algorithm for unfavorable intermediate risk (UIR) prostate cancer (PC) includes external beam radiotherapy (EBRT) with short-course androgen deprivation therapy (ADT),
or EBRT with brachytherapy (BT) with or without ADT. The current
practice patterns and patient selection criteria in this setting are unclear.
Objectives: Using the National Cancer Database (NCDB), radiation
treatment patterns for UIR PC were evaluated.
Methods: Clinical and demographic characteristics associated with
each treatment were assessed via multivariable binomial regression
analysis, expressed as odds ratios (OR) with 95% conﬁdence intervals.
Results: There were 68,283 eligible men with a median age of 70 years
treated with radiotherapy between the years 2004-2015 and who met the
NCCN criteria for UIR PC. The most common treatment was EBRT +
ADT (38.0%), then EBRT alone (32.2%), BT alone (9.7%), EBRT +
BT (8.4%), EBRT + BT + ADT (7.1%), and BT + ADT (4.7%). ADT
utilization decreased over time, from 58% in 2004 to 49% in 2015, as
did BT utilization, from 39% in 2004 to 22% in 2015 (P <0.001).
Patients were classiﬁed as UIR because of Gleason 4+3 disease
(60.5%), Gleason 3+4 with PSA between 10-20 (18.5%), clinical T2b
or T2c (17.5%), or 50% or more cores positive (3.5%). On multivariable
analysis, Gleason 4+3 (HR = 1.45, 1.39-1.50), high volume disease
(OR = 1.53, 1.59-1.72), stage T2b/T2c (OR = 1.66, 1.59-1.72), PSA
between 10-20 (OR = 1.86,1.79-1.93), older age (OR = 1.004, 1.0011.006), treatment at a non-academic center (OR = 1.37, 1.28-1.44),
Black patients (OR = 1.11, 1.06-1.17), Hispanic patients (OR = 1.17,
1.09-1.28), lower income areas (OR-1.12, 1.05-1.19), rural areas
(OR = 1.18, 1.09-1.27), treatment before 2008 (OR = 1.41, 1.35-1.48),
and EBRT (vs BT or combination) (OR = 1.81, 1.75-1.88) were all
associated with increased ADT use. Gleason 4+3 (HR = 0.94,0.890.98), T2b/T2c (OR = 0.91,0.87-0.95), PSA between 10-20 (OR = 0.73,
0.70-0.76), older age (OR = 0.96, 0.957-0.963), Hispanic patients
(OR = 0.71, 0.64-0.78), Black patients (OR = 0.84, 0.79-0.88), nonrural areas (OR = 0.74, 0.68-0.81) treatments after 2007 (OR = 0.68,
0.65-0.71) were each independently associated with decreased BT utilization. Lower PSA (OR = 1.28), Gleason 3+4 (OR = 1.17), and
treatment at academic centers (OR = 1.92) were independent predictors
of hypofractionation (all P < .05) The two non-surgical NCCN-recommended treatments for UIR PC, EBRT+ADT and EBRT+BT, were
analyzed in a separate subset. Independent correlates of EBRT+BT
include Gleason 3+4 (OR = 1.28, 1.19-1.38), low volume disease
(OR = 1.32, 1.18-1.46), T1c/T2a (OR = 1.21, 1.12-1.31), PSA under 10

FIGURE 2. ADT use by year.

(OR = 2.22, 2.06-2.39), younger age (1.06, 1.055–1.065), non-Hispanic
(OR = 1.55, 1.30-1.85), and white patients (OR = 1.40, 1.27-1.53).
Conclusions: Only approximately half of UIR PC patients treated with
radiotherapy between 2004-2015 adhered to the current NCCN recommendations, with a trend away from ADT and BT in more recent
years. Older patients with more aggressive UIR criteria were more
likely to receive ADT and less likely to receive BT (Figs. 1 and 2).

(P051) Was There a Differential Delay in Urologic Oncology
Diagnoses Due to the COVID 19 Pandemic?
Kevin Healey, Medical Student 1st year1, Mitchell Finkelstein, High
School Student2, Miriam Williams, CAO1, Steven Finkelstein, MD,
DABR, FACRO2; 1AUI, 2FCA / US Oncology Network
Background: In community urology, a delay in performing routine
screening evaluation and treatment procedures secondary to the
COVID-19 pandemic delayed the number of urological oncology
patient seeking care according to data from Medicare and United States
insurers. Thus, it is unclear if this delay inﬂuenced urologic oncology
and non-oncology equally.
Objectives: Our hypothesis is that there may be a differential delay in
urologic oncology diagnoses due to the COVID 19 Pandemic.
Methods: This is a retrospective review of prospectively collected data;
new patients referred to a large multispecialty community urology
organization before COVID 19 (quarter 2 April-June 2019) were
compared with during COVID 19 (quarter 2 April-June 2020). Data was
obtained using electronic medical records for completeness. Urology
disease data were recorded and compared.
Results: As compared with previous year quarter 2, there was an overall
decrease in new patient referrals to a large multispecialty urology
organization. With respect to urologic oncology and urologic nononcology, there was a signiﬁcant decrease in new patient visits. With
respect to urologic oncology, prostate, bladder, and testicular were
signiﬁcantly affected; diagnostic procedures related to workup were
decreased accordingly. Lastly, referrals to radiation oncology for
prostate, bladder, and testicular were impacted negatively with a differential delay by disease subsite.
Conclusions: The data suggest a differential delay in urologic oncology
diagnoses due to the COVID 19 pandemic in some large community
urology organizations. Data over time will assess these changes
across 2021.

(P052) Radiotherapy Does Not Increase the Frequency of
Revision of Perineal Urethrostomy in Penile Cancer: A
20-year International Multicenter Experience

FIGURE 1. Type of treatment partitioned by risk factor.

Peter Johnstone, MD, FACR, FASTRO1, Hielke-Martijn de Vries, na2,
Juan Chipollini, Assistant Professor3, Franklin Boyd4, Fernando
Korkes, MD, PhD5, Maarten Albersen6, Eduard Roussel, Department of
Urology6, James Jiang, MD7, Viraj Master, MD PhD FACS8, Oscar
Brouwer, Netherlands Cancer Institute2, Philippe Spiess, MD, MS,
FACS1; 1Mofﬁtt Cancer Center, 2Netherlands cancer institute, 3The
University of Arizona, 4University of South Florida Morsani College of
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Medicine, 5ABC Medical School, 6University Hospitals Leuven, 7Emory
University School of Medicine, 8Emory University
Background: Perineal urethrostomy (PU) is the deﬁnitive form of
urinary diversion in patients with locally advanced or anatomically
unfavorable penile cancer (PeCa) requiring total penectomy. Prior
studies would suggest PU failure rates in up to 30% of cases, although
this has been infrequently reported in patients with cancer.
Objectives: Because of lack of clinical evidence, radiotherapy (RT) is
seldom recommended for pN1/pN2 PeCa lesions but may be used for
extra-nodal (pN3) disease. We previously described a large, multiinstitutional experience of PU for PeCa with respect to complications,
and now describe the role of perioperative RT in the process.
Methods: In our cohort, 299 patients from seven international centers in
Belgium, Brazil, China, Netherlands, UK and the United States
underwent PU for urinary diversion for PeCa between 2000 and 2019.
Median patient age was 67 years and median follow-up was 24 months.
Demographic and clinicopathologic characteristics were reviewed. Six
patients received pre-operative RT; ﬁve of them with chemotherapy. 43
received RT post-operatively, 28 (65%) with chemotherapy.
Results: 75 patients (25%) developed a 30-day post-operative complication with a single postoperative death. Wound infection (49%) and
dehiscence (19%) were most common. Over 65% (n = 50) of complications were minor (Clavien–Dindo Grade I and II). Only adjuvant
chemoradiation was signiﬁcantly associated with post-operative complication (OR: 2.39, 95%CI 1.09-5.24). Urethral stenosis occurred in
12% (n = 36) of cases. Almost 80% occurred in the ﬁrst year (median
5.7 m; IQR 3.1-12 m). Twenty-seven patients underwent surgical
revision and 9 were treated conservatively. Pre-operative or adjuvant
therapy was not signiﬁcantly related to subsequent PU stenosis.
Conclusions: When RT is delivered for PeCa it is usually to the prepubic fat, groin and lateral pelvis, and not to the course of the PU.
Given the large number of patients and diverse circumstances and eras
involved, it appears that post-operative RT may be delivered without
signiﬁcant increase in the risk of stenosis and surgical revision. We
acknowledge limitations of this retrospective study and its implicit
selection bias. However, our follow-up is sufﬁcient for perioperative
complications and early stenosis rates contributing to revision.

(P053) Outcomes of Axumin PET/CT-detected Prostate
Cancer Nodal Recurrences: A Single Institution Experience
Andrew Keller, MD1, Ankur Patel, MD1, Leonard Appleman, MD,
PhD1, David Friedland, MD1, Roby Thomas, MD1, Adam Olson, MD2;
1
UPMC Hillman Cancer Center, 2Department of Radiation Oncology,
UPMC Hillman Cancer Center, University of Pittsburgh School of
Medicine
Background: Nodal recurrence from prostate cancer is an emerging
disease state that represents a therapeutic dilemma for oncologists. The
advent of advanced PET imaging modalities offers greater sensitivity to
detect oligometastatic disease in this patient cohort and renders radiation therapy, such as stereotactic body radiation therapy (SBRT) or
Intensity Modulated Radiation Therapy (IMRT), an attractive alternative to androgen deprivation therapy alone.
Objectives: Whether addition of local therapy confers long-term biochemical control is uncertain. We evaluated outcomes of prostate cancer
patients with recurrent nodal disease detected by Axumin PET/CT.
Methods: A retrospective analysis of 23 patients with prostate adenocarcinoma nodal recurrences detected by Axumin PET/CT scan treated
with SBRT, EBRT, or ADT alone from 2017-2018 was performed.
Median patient age was 67 (range 49-83). Initial deﬁnitive treatment
consisted of radical prostatectomy for 14 patients and RT +/- ADT for 9
patients. Median PSA at time of Axumin PET/CT scan was 5.5 ng/mL
(range 0.7-39.0 ng/mL). 11 patients underwent SBRT, 6 patients
underwent IMRT with simultaneous or sequential boost to gross nodal
disease, and 8 patients underwent ADT alone. 7 of 17 patients treated
with RT received ADT at time of RT. SBRT was to a total dose of 3550 Gy in 5 fractions. IMRT was to a dose of 45-72 Gy in 25-40 fractions targeting pelvic nodes plus/minus prostatic fossa or PA nodal
region, with boost to gross disease. Local control of treated disease
following RT, biochemical control, ADT-free interval, freedom from
new sites of disease, and overall survival, were calculated from date of
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Axumin utilizing the Kaplan-Meier estimator. Biochemical control was
deﬁned as the time until sustained PSA rise > 0.2 ng/mL above PSA at
time of Axumin PET/CT scan. Log-rank test was utilized for univariate
analysis.
Results: Median follow-up was 27 months. Median overall survival
was not reached, with all patients surviving until last follow-up. Median
biochemical control was 32.0 mos (95% CI 20.7-43.3 mos). For patients
not receiving ADT at time of RT, median ADT-free interval was 16.0
mos (95% CI 4.0-28.0 mos). Follow-up imaging was available in 18
patients. Of patients receiving RT, 2-year local control of treated disease
was 100%. Median freedom from new sites of disease was 27 mos
(95% CI 16.7-37.3 mos), with 7 patients developing additional sites of
disease, including 5 cases of additional nodal-only failure. Of the 18
patients with follow-up imaging, 10 (56%) had no evidence of radiographic progression. There were no cases of grade 3+ toxicity following
RT. On univariate analysis, Gleason score, time from initial deﬁnitive
management to Axumin PET/CT, and addition of RT were not statistically signiﬁcant predictors of biochemical control or freedom from
additional sites of disease.
Conclusions: RT in the form of SBRT or IMRT are well-tolerated,
effective local treatment for patients with recurrent nodal disease secondary to prostate cancer. Prognostic factors associated with long-term
biochemical control remain unclear and require a larger sample size to
detect.

(P054) Improvements in Rectal Dosimetry Using Rectal
Hydrogel Spacer in Patients with Prostate Cancer Undergoing HDR Brachytherapy
Charles Lee1, Iavor Veltchev1, Mengying Deng1, Rebecca Shulman,
MD1, Teh Lin1, Robert Price1, Mark Hallman1, Eric Horwitz1, Jessica
Wong1; 1Fox Chase Cancer Center
Background: High-dose-rate brachytherapy (HDR-BT) is highly
effective in the deﬁnitive and salvage treatment of prostate cancer.
Acute grade 2+ rectal toxicity may occur from 5% of prostate cancer
patients treated with HDR-BT monotherapy to over 20% of patients in
the salvage or re-irradiation setting. Recently, polyethylene glycolbased rectal hydrogel spacers (RHS) have been increasingly used to
create separation between the rectum and prostate. Studies investigating
its use in the external beam radiotherapy (EBRT) setting demonstrate
improved dosimetry and reduced rectal mucosal injury. However,
sparse data exist investigating its use with HDR-BT. This is the ﬁrst
study investigating the dosimetric effect of RHS placement on patients
undergoing HDR-BT by utilizing a novel replanning technique.
Objectives: Rectal V75% (rV75) is directly correlated with acute rectal
toxicity. We aim to demonstrate improvement in rV75 in patients with
RHS undergoing HDR-BT by comparing plans in the same patients.
Secondary objective is to quantify changes in prostate (target volume)
coverage in plans with and without RHS.

FIGURE 1. Correlation of change in rectal V75% and RHS
volume.

S64 | www.amjclinicaloncology.com
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Copyright r 2021 Wolters Kluwer Health, Inc. All rights reserved.

American Journal of Clinical Oncology



Volume 44, Number 10, October 2021

Methods: A prospective institutional database was queried for patients
undergoing HDR-BT with RHS in place from January 2020–November
2020 for either deﬁnitive, adjuvant, or salvage treatment of prostate
cancer. A novel replanning technique was used, negating the RHS
volume and using the negated contours as a surrogate for the rectum.
New plans were generated for each patient using this technique, with
the goal of at least 95% prostate coverage. Wilcoxon signed rank tests
and Spearman correlation were used to assess dosimetric differences
between original treatment plans and regenerated plans for correlations
between separation and volume.
Results: Twenty-one HDR-BT procedures were performed in 12
patients. Five had HDR-BT monotherapy (2700 cGy in 2 fractions), 4
patients received salvage HDR-BT (2400 cGy in 2 fractions), and 3
patients received HDR-BT boost (1500 cGy in 1 fraction following
EBRT 4600 cGy in 23 fractions). Median RHS volume was 7.44 cm3
(IQR: 4.59-9.56 cm3). Rectal dosimetric parameters were signiﬁcantly
worse in regenerated plans compared with original plans. However, all
21 regenerated plans were clinically acceptable based on institutional
criteria. In the original treatment plans, rV75 was 0.0 cm3 in all cases;
in regenerated plans, median rectum V75% (rV75*) was 0.74cm3 (IQR:
0.62-0.87 cm3), P < 0.001. Spearman correlation of the difference
between rV75* vs rV75 (ΔrV75) was found to be signiﬁcantly correlated with RHS volume (rho = 0.52, P = 0.016, Fig. 1), prostate volume
(rho = 0.51, P = 0.018), and radiation dose (rho = 0.46, P = 0.035).
Median prostate V100% in original cases was 98.56% (IQR: 98.0699.08) and was 96.07% in replanned cases (IQR:95.06-97.30),
P < 0.001. There were no signiﬁcant differences between median
prostate V150% and V200%.
Conclusions: RHS signiﬁcantly reduces rectum V75% in patients
undergoing HDR-BT. Larger RHS volumes inserted appear correlated
with larger magnitude of rectum V75% reduction. RHS should be
considered for all patients, especially those undergoing combination or
salvage treatment, to limit rectal toxicity. Reduction in prostate V100%
in replanned cases likely underestimates actual attainable prostate
V100% in patients undergoing HDR-BT without RHS.

(P055) Dose Differentiated HDR Prostate Brachytherapy –
a Feasibility Assessment of MRI Guided Dose Escalation to
Dominant Intraprostatic Lesions
Christopher Luminais, MD1, David Cousins, MD1, Hamidezra Nourzadeh, PhD1, Eric Aliotta, PhD1, Bruce Libby, PhD1, Timothy Showalter, MD1; 1University of Virginia
Background: Prostate brachytherapy is routinely performed with
TRUS or CT based planning. Neither modality can delineate dominant
intraprostatic lesions (DILs). Prostate MRIs performed during workup
can identify high risk DILs. DILs are known to be a high risk locations
for local recurrence and there is clinic interest in dose escalating DILs.
MRI registration at the time of brachytherapy allows DIL delineation
and dose escalation.
Objectives: This retrospective study assesses the maximum achievable
dose escalation to DILs while respecting OAR objectives.
Methods: Our institution offers combination HDR prostate brachytherapy (15 Gy in 1 fx) + pelvic EBRT (45 Gy in 25 fx) to patients with
unfavorable intermediate or high risk prostate cancer. We identiﬁed 24
patients treated with combination therapy from 2013–2016 who had an
available pre-treatment prostate MRI with 1-3 visualized DILs. Each
patient’s MRI was rigidly co-registered to the intra-procedure TRUS
and used to contour any visible DILs. DIL contours were transferred to
the TRUS based planning system. Original TRUS based prostate and
OAR volumes were not altered. Original treatment plans were

TABLE 1. Original Plan and MRI Reoptimized Dosimetry
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experimentally re-optimized to dose escalate the DILs. Dosimetric
indices from the original and the reoptimized plans were compared
using a two-tailed paired T-test. Each reoptimized plan was deemed
acceptable if it achieved all of the following criteria: prostate D90 >
100%, prostate V100 > 90%, urethra D10 < 118%, rectum V80 <
0.5 cc, bladder D1cc < 75%, or if it did not exceed OAR doses of the
original plan.
Results: All reoptimized plans met the acceptability criteria. Achieved
dosimetry is reported in Table 1. Mean DIL D90 was signiﬁcantly
increased from 134% on the original plans to 154% on the re-optimized
plans. Mean urethra D10 and mean bladder D1cc were signiﬁcantly
reduced from 123% to 117% and 72% to 65%, respectively. Mean
rectum V80 did not change signiﬁcantly. Prostate D90 and V100 were
reduced from 106% to 102% and 93% to 91%, respectively. Decreased
prostate coverage was considered acceptable as D90 > 100% and V100
> 90% were achieved. We estimate that image registration and DIL
dose escalation would increase procedure time by 15 minutes using
standard treatment planning software.
Conclusions: Using MRI for delineation of DILs, we were able to
reoptimize HDR brachytherapy plans to dose escalate DILs to a mean
D90 of > 150% while maintaining favorable prostate coverage and
OAR doses. Based on this ﬁnding, we estimate that a goal DIL D90
dose of > 150% (or 22.5 Gy) is an aggressive but achievable goal while
meeting OAR dose constraints. We will use this analysis to inform an
upcoming prospective clinical trial of MRI guided prostate HDR brachytherapy at our center.

(P056) Early Toxicity Outcomes for Initial Implementation
of Cs-131 Seeds for Low-dose-rate Prostate Brachytherapy
David Marshall, MD, MS1, Shauna McVorran, MD2, Bradley DePaoli,
MD2, Bethany Broekhoven, MS2, Elizabeth Hilliard, MS3, Hong Li,
PhD2; 1Department of Radiation Oncology, Medical University of
South Carolina / Hollings Cancer Center, 2Medical University of South
Carolina, 3SUNY Upstate Medical University
Background: Low dose rate (LDR) prostate brachytherapy is an
attractive deﬁnitive treatment option for localized prostate cancer with
equivalent oncologic outcomes compared with external beam radiation
therapy (EBRT) and radical prostatectomy (RP) with the beneﬁt of
being a convenient outpatient minimally invasive procedure. As the
utility of LDR brachytherapy has been established, the focus has shifted
to improving the side effect proﬁle while maintaining oncologic outcomes. Most data in this sphere were gathered using I-125 and Pd-103
seeds, but since Cs-131 was introduced in 2004, several institutions
have adopted its use with the hypothesis that its shorter half-life and
slightly higher average energy would produce dosimetric advantages
that may improve outcomes and decrease duration or severity of side
effects.
Objectives: To report acute toxicity outcomes with the ﬁrst 50 patients
treated with Cs-131 LDR brachytherapy at our institution, compared
with our experience with I-125 and Pd-103.
Methods: An IRB-approved retrospective chart review was performed
on the ﬁrst 50 patients treated with Cs-131 LDR brachytherapy for
localized prostate cancer at our institution. Patients receiving either a
full or partial implant were included; these patients were treated to doses
of 100 Gy and 80 Gy prostate minimal peripheral dose, respectively.
Patients receiving partial implants generally received 45 Gy external
beam radiotherapy starting 6-8 weeks after implant. These data were
compared with cohorts of the last 50 patients treated with I-125 brachytherapy and the last 50 patients treated with Pd-103 brachytherapy to
standard doses. Data regarding AUA prostate symptom score, Sexual
Health Index for Men (SHIM), and RTOG GI toxicity score were
assessed pretreatment and at 1-month and 7-month time points. Demographic and clinical data were also collected. Descriptive statistics
were used to summarize variables. A linear mixed model was used to
compare means and to identify variables as prognostic for acute toxicity
(P ≤ 0.05).
Results: The mean AUA score at 1-month post-treatment was signiﬁcantly higher for patients treated with Cs-131 (P < 0.001) but
declined rapidly and was equivalent to the scores seen with I-125 and
Pd-103 at 7 months. A similar trend was seen with the mean RTOG GI
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toxicity score. The mean SHIM score at 1-month post-treatment was
signiﬁcantly lower (P < 0.001) with Cs-131, but this also improved by
7 months to be equivalent to those seen with I-125 and Pd-103,
respectively. On multivariate analysis, the type of isotope used did not
predict the AUA, SHIM, or RTOG toxicity score grade or the need for a
catheter post brachytherapy.
Conclusions: In patients treated in our initial experience with Cs-131
LDR prostate brachytherapy, acute GU, GI, and sexual side effects
peaked higher but decreased faster compared with patients treated with
I-125 or Pd-103 isotopes. The isotope used did not predict for AUA,
SHIM, or RTOG toxicity score or the need for a catheter post
brachytherapy.

(P057) Disparities in Radiation Therapy Access for Prostate
Cancer in the United States
Shearwood McClelland III, MD1, Ulysses Gardner, MBA, RTT2,
Curtiland Deville, MD3; 1Department of Radiation Oncology, Indiana
University School of Medicine, 2Wright State University Boonshoft
School of Medicine, 3Department of Radiation Oncology and Molecular
Radiation Sciences, The Johns Hopkins Hospital
Background: Major advances in the role of radiation oncology for
treating prostate cancer increases the importance of equity in access to
radiation therapy (RT). In 2016, the ﬁrst comprehensive investigation
examining the pervasiveness of health disparities in RT access found
that the most prominently studied organ site was prostate.
Objectives: As disparities research has continued to dramatically
increase, we sought to assess the evolution of RT access disparities in
prostate cancer since that initial investigation.
Methods: A comprehensive literature search was undertaken in June
2020 using the PubMed database (www.pubmed.gov) and the query
[prostate AND (radiation OR proton) AND (disparities OR “socioeconomic status” OR “health services research” OR inequity OR race
[Title])] from 2017-2020. Studies were excluded which were not based
in the United States, did not examine health inequities, did not examine
RT, or did not examine prostate cancer.
Results: Forty-four of 184 studies found met inclusion criteria. Health
disparities were most prominently reported by race (35 studies) followed by insurance status (12 studies), age (6 studies), socioeconomic
status (8 studies), geographic location (9 studies), and practice characteristics (6 studies).
Conclusions: Health disparities in access to radiation therapy for prostate
cancer remain substantial despite signiﬁcant advancements in radiation
oncology. Access to radiation therapy for prostate cancer is most likely
multifactorial; several considerations must be included when assessing
systems to decrease existing inequalities. High-level evidence research
focusing on reducing disparities is needed and highly anticipated to
improve health and survival outcomes for all patients with prostate cancer.

(P058) Association of Second-Generation Antiandrogens
with Depression in Prostate Cancer
Kevin Nead, MD, MPhil1, Malgorzata Nowakowska, BS2, Xiudong
Lei, PhD1, Mackenzie Wehner, MD, MPhil1, Paul Corn, MD1, Sharon
Giordano, MD1; 1MD Anderson Cancer Center, 2Baylor College of
Medicine
Background: Previous studies have shown a consistent link between
hormone therapy (HT) to treat prostate cancer, such as androgen deprivation therapy (ADT), and depression risk (Dinh KT, et al JCO 2016;
Nead KT, et al Urol Oncol 2017). However, the association between
second-generation antiandrogens (AAs) and depression is unknown.
Objectives: To test the hypothesis that second-generation AAs carry an
increased risk of depression, including compared with traditional
forms of HT.
Methods: This retrospective cohort study analyzed Surveillance,
Epidemiology, and End Results (SEER)-Medicare and Texas Cancer
Registry (TCR)-Medicare data from 2011-2015, with a follow-up period
of 2 years after diagnosis. Data were analyzed from February to May
2021. Of 210,804 patients diagnosed with prostate cancer in 2011-2015,
we identiﬁed 30,069 patients with primary prostate cancer diagnosed at
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age > 66 years without a second cancer in 12 months. We included
patients with continuous Medicare Parts A, B, and D coverage. We
excluded individuals who received any form of HT before prostate cancer
diagnosis and those previously diagnosed with depression. The following
treatment groups were compared: (1) no HT group, (2) traditional HT
group (HT without second-generation AA exposure), and (3) secondgeneration AA group. We implemented time-varying exposure multivariable Cox proportional hazards models to determine the association of
ADT use with depression using the inverse probability treatment weighted
(IPTW) method.
Results: Of 30,069 patients, 17,710 (59%) received no HT, 11,311
(38%) received traditional-HT only, and 1,048 (3%) received a secondgeneration AA. The cumulative incidence of depression at 2 years was
highest among second-generation AA users; 13.7% versus 7.2% and
4.8% in the traditional-HT only and no-HT groups, respectively;
P < 0.001. Multivariable Cox proportional hazards analysis showed that
the second-generation AA group had an increased risk of depression
compared with the no-HT group (HR = 2.16, 95%CI 1.81-2.59;
P < 0.001) and the traditional-HT group (HR = 2.26, 95%CI 1.88-2.73;
P < 0.001), including with stratiﬁcation by localized (HR = 2.73, 95%
CI 2.19-3.42; P < 0.001) and regional/distant disease (HR = 2.56, 95%
CI 1.81-3.61; P < 0.001).
Conclusions: Patients with prostate cancer who received a secondgeneration AA had a large and clinically signiﬁcant absolute increased
risk of depression compared with patients who received traditional HT
alone or no HT.

(P059) Short-Term ADT and Dose-Escalated IMRT in
Patients with Intermediate-Risk Prostate Cancer: Beneﬁt or
Caution?
Arthur Hung, MD1, Carl Post, MD1, Jenna Kahn, MD1, Claire Turina,
BS1, Tomasz Beer, MD, FACP1; 1Oregon Health & Sciences
University
Background: In the era of dose-escalated prostate radiation therapy
(RT), the use of androgen deprivation therapy (ADT) is undeﬁned for
intermediate-risk prostate cancer (IR). Randomized data demonstrates
an improvement in biochemical control without an associated
improvement in overall survival. Yet there is also growing concern of
the risk of ADT to be detrimental to quality of life and increase cardiac
events.
Objectives: This single-institution retrospective analysis aimed to
evaluate outcomes of IR prostate cancer patients treated with RT with or
without concurrent/adjuvant short-term ADT.
Methods: Data was collected from 559 consecutive patients treated
with dose-escalated IMRT with daily IGRT for newly diagnosed
prostate cancer from December 2002–March 2016. IMRT prescription
was 78 Gy / 39 fractions or 70 Gy / 28 fractions. Biochemical recurrence-free survival (BCRFS), distant metastasis-free survival (DMFS),
prostate cancer-speciﬁc survival (PCSS), and overall survival (OS) were
calculated using Kaplan-Meier methodology. We focused our results on
the patients with favorable (FIR) or unfavorable intermediate-risk (UIR)
prostate cancer.
TABLE 2. Clinical Characteristics of the IR Population
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TABLE 1. Second Pelvic Cancers following Radiotherapy for
Localized Prostate Cancer: Systematic Reviews/Meta-analysis,
SEER Data and Randomized Clinical Trials

Second cancers after radiotherapy: Systematic Reviews and SEER Data.

FIGURE 1. A, BCRFS for IR patients treated with and without ADT.
B, OS for IR patients treated with and without ADT.
Results: With a median follow-up of 93 months, 260 patients had IR, of
which 69.6% (N = 181) had UIR disease, 78.8% (N = 205) were treated
with moderately hypofractionated RT to 70 Gy in 28 fractions, and
36.2% (N = 94) received ADT, 89 UIR and 5 FIR, with median ADT
duration of 6 months (range, 3-30; 90% received 6 mo). 7-yr BCRFS
was 94.1% vs. 86.2%, P = 0.067, for ADT and no ADT respectively,
and no difference in DMFS or PCSS was observed. ADT was associated with signiﬁcantly worse 7-yr OS (80.0% vs. 91.3%, P = 0.010).
When stratiﬁed by age, patients <70 years who received ADT had even
worse 7-yr OS (93.4% vs. 77.3%, P = 0.002), whereas those ≥ 70 years
had similar OS (P = 0.918). Analysis of the UIR cohort alone, showed
similar results; 7-yr BCRFS and 7-yr OS in patients who received ADT
versus no ADT were 93.7% vs. 85.9% (P = 0.093), and 79.0% vs.
90.6% (P = 0.019), respectively.
Conclusions: In our 15-year experience treating IR prostate cancer with
dose-escalated IMRT with daily IGRT, short-term concurrent ADT was
associated with a statistically signiﬁcant worse OS as well as non-statistically signiﬁcant improvement in BCRFS. Additional studies are needed
to determine if ADT is beneﬁcial or detrimental for patients with IR
prostate cancer treated with dose-escalated radiation (Table 2 and Fig. 1).

(P060) Second Pelvic Cancers (SPCs) Following Radiotherapy for Localized Prostate Cancer: Analysis of Systematic Reviews/Meta-analysis (S/M), SEER Data and
Randomized Clinical Trials (RTCs)
Mack Roach, MD1, Stella Ling, MD1, Yun Li, MD, PhD1, ANN
LAZAR, PHD2; 1UCSF, 2UCSF Helen Diller Family Comprehensive
Cancer Center

Background: Radiation Oncologist are frequently confronted with
questions concerning the risk of SPCs (rectal, colon and or bladder)
following the use of deﬁnitive external beam radiotherapy (EBRT) in
men with localized prostate cancer. Several systematic reviews/metaanalyses (S/M), retrospective studies, and data from a limited number of
randomized trials have attempted to shed light on this question. Of note,
data from Johns Hopkin’s revealed that men undergoing a radical
prostatectomy (RP) had a standardized mortality ratio (SMR) = 0.43
(95% CI:0.29-0.57) for subsequent cancers of the colon, rectum, anus
and 0.47 (95% CI:0.22-0.73) for subsequent bladder cancer (BC),
compared with men in the general population (GP) (Eiﬂer et al, J of
Urol, 2012). This observation suggests that studies using post radical
prostatectomy (RP) patients as a control for estimating the risk of SPCs
after RT may be associated with substantial bias.
Objectives: To determine whether: (1) the literature is in agreement
with the estimated risk of SPCs; (2) whether the S/M published to date
are likely to be biased by using a RP control group: (3) whether the
evidence from RT vs No RT from RCTs supports the magnitude of the
risk of SPCs.
Methods: A review of S/M and selected retrospective studies was
performed using the search terms “second cancers”, “systematic
reviews” and “radiotherapy treatment” and “prostate Cancer”, for the
years 2001-2021. In addition, relevant papers identiﬁed in the S/Ms, and
papers identiﬁed through the search (n = 225) were screened by two
authors (MR, SL). Twenty-four papers were identiﬁed and selected for
this analysis, with the most common reason for exclusion being case
reports, review articles, modeling dosimetric only analysis, another
cancer site or “other”. Six of these papers were characterized as S/M
and 15 used Surveillance Epidemiology End Results (SEER) data. Two
RCTs involving systemic therapy +/- RT (n = 2) were reviewed for data
concerning the risk of SPCs.
Results: Table 1 summarizes the results of the six S/M reported
(2014–2018). The standardized incidence rates (SIR), odds ratio (OR),
and RR > 1 ranging from 1.33 to 1.79 with the vast majority of studies
using post RP patients as the control group. The SEER based studies
selected for this analysis, generally resulted in similar estimates of the
risk of SPCs. Neither the S/M nor SEER based analyses acknowledged
the RP vs RT selection biases, although some performed “propensity
matching” and some tested bias (e.g. Ottawa-Newcastle scale). No
statistically signiﬁcant increased risk of second cancers was found
involving the rectum or colon for either RCT but a 2% higher risk of
bladder cancer was noted beyond 10 years in Scandinavian Prostate
Cancer Groups-7 trial.
Conclusions: Based on the available data from S/Ms and populationbased studies there appears to be a relatively low but increased risk of
SPCs. Given the selection bias associated with the use of RP patients as
the major RT comparison group in most of these studies, the actual risk
of SPCs is likely to be substantially lower than the estimates reported.

(P061) Non-adaptive MR-guided Radiotherapy for Prostate
SBRT: Less Time, Equal Results
Maria Sandoval, MD1, Kujtim Latiﬁ, PhD1, G. Daniel Grass, MD,
PhD2, Javier Torres-Roca, MD2, Stephen Rosenberg, MD MS1, Kosj
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Yamoah, MD PhD1, Peter Johnstone, MD, FACR, FASTRO1; 1Mofﬁtt
Cancer Center, 2Department of Radiation Oncology, H. Lee Mofﬁtt
Cancer Center & Research Institute
Background: The use of stereotactic body radiation therapy (SBRT) is
widely utilized for treatment of localized prostate cancer. Magnetic
resonance guided radiotherapy (MRgRT) was introduced in 2014 and
has recently been implemented in SBRT for prostate cancer, as it
provides opportunity for smaller margins and adaptive daily planning.
Currently, both publications of MRgRT for prostate SBRT describe
European clinical experiences (Alongi, et al Rad Oncol 2020; Bruynzeel, et al Int J Radiat. Oncol. Biol. Phys 2019), which utilized adaptive
planning. However, adaptive planning adds signiﬁcantly to the time
required for daily treatment.
Objectives: Since prostate SBRT has demonstrated acceptable toxicity
for several years, we did not consider daily adaptation critical to the
process of prostate SBRT. After Institutional Review Board approval,
we analyzed and now report our experience using MRgRT without
adaptation.
Methods: Between September 25, 2019 and December 21, 2020, 36
consecutive patients were treated with MRgRT prostate SBRT at our
center. One patient had Gleason Grade Group (GG) 1, 23 patients had
GG 2 and 12 had GG 3 prostate cancer. Nine patients (25%) received
adjuvant leuprolide for a median of 4.5 months (range 4–6 m). Our
clinical pathway allows for a maximum prostate gland volume of 60cc;
median prostate volume of this cohort was 35.0 cc (range 17–58.4 cc).
Median pre-treatment PSA was 6.30 (range 2.55–16.77). Each patient
was treated with 36.25 Gy delivered in ﬁve fractions over 2 weeks with
urethral sparing to a maximal dose of 35 Gy. Target volumes included
the prostate gland and proximal seminal vesicles with a 3 mm margin.
Results: Median follow-up as of March 15, 2021 was 288 days (range
60 - 523). At a median of 33 days after completion of SBRT (range
19–102), all patients had ﬁrst follow-up data available. The median PSA
at ﬁrst visit was 2.75 (range 0.02–9.00) with a median AUA symptom
score of 10 (range 1–24). Second follow-up data are available for 31
(86%) patients at a median of 132 days after completion of SBRT
(range 77–267). At second follow-up, the median PSA was 1.83 (range
0.02–5.40) with a median AUA symptom score of 6 (range 1–33).
Twelve (33.3%) patients had third follow-up data with a median of
294 days (range 141–370) after SBRT. The median PSA was 1.14
(range 0.14–4.61) with an AUA score 8.5 (1–22) at the third follow-up.
The most common toxicity was grade 2 urethritis, managed in all cases
by tamsulosin. One patient developed grade 2 tenesmus relieved by
topical steroids.
Conclusions: By avoiding the extra time required for plan adaptation,
MRgRT without daily adaptation allows for successful prostate SBRT
with manageable toxicity. We continue to reserve our limited adaptive
treatment slots for preoperative pancreatic and ultra-central lung SBRT
patients, which require time intensive respiratory gating and adaptive
planning.

(P062) Early Results of Patient Reported Quality-of-life
After Moderately Hypofractionated Intensity Modulated
Proton Therapy Targeting the Prostate and the Regional
Pelvic Lymph Nodes for Prostate Cancer
William Wong, MD1, David Hillman, MS2, Carlos Vargas, MD1, Jean
Claude Rwigema, MD1, Thomas Daniels, MD3, Sameer Keole, MD1,
Bradley Stish, MD2, Thomas Pisansky, MD2, Richard Choo, MD2;
1
Mayo Clinic Arizona, 2Mayo Clinic Rochester, 3New Yok University
Background: High-risk prostate cancer (PCa) has an increased risk of
occult pelvic nodal metastasis and inclusion of pelvic lymph nodes
(PLN) in the clinical target volumes can be considered. Proton therapy
has a dosimetric advantage over photons by reducing the integral dose
to normal tissues in a large pelvic ﬁeld, potentially lowering treatment
toxicity and improving patient-reported quality-of-life (PRQOL).
Objectives: To report early changes in patient reported PRQOL using
the 26-item Expanded Prostate Index Composite (EPIC-26) questionnaire in a prospective study of moderately hypofractionated intensity modulated PT (H-IMPT) targeting the prostate, seminal vesicles
(SV) and PLN concurrently.
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Methods: 56 patients (pts) with high-risk or unfavorable intermediaterisk PCa were enrolled. H-IMPT consisted of 45 Gy (RBE 1.1) to PLN
and 67.5 Gy (RBE 1.1) to prostate and SV concurrently in 25 daily
fractions. All pts received androgen deprivation therapy. PRQOL was
assessed by the urinary incontinence (UI), urinary irritative/obstructive
symptoms (UO) and bowel function (BF) domains of EPIC-26. Mean
changes in domain scores were analyzed from baseline, at end of
H-IMPT and 3 months thereafter. A clinically meaningful change was
deﬁned as a score change > 50% of the baseline standard deviation.
Results: 55 pts completed the planned H-IMPT. Median follow-up was
25 months. 62% and 2% experienced acute CTCAE grade 1 and 2
gastrointestinal (GI) adverse events (AE), respectively. 65% and 35%
had acute CTCAE grade 1 and 2 genitourinary (GU) AE, respectively.
There was no acute grade ≥ 3 GI or GU AE. The mean scores of UO,
UI and BF at baseline were 84.6, 91.1 and 95.3, respectively. All three
scores declined at the end of H-IMPT (mean score change from baseline: -13.4, -2.74 and -13.7, respectively). The decline in UO and BF
scores were both statistically signiﬁcant and clinically meaningful,
while the decline in UI score was not clinically meaningful. At the end
of H-IMPT, clinically meaningful decline in UO, UI and BF scores
occurred in 54%, 25% and 73% of the pts, respectively. At 3 months
after H-IMPT, most acute GI and GU AE resolved, while all 3 PRQOL
scores improved compared with baseline (mean score change from
baseline: 0.64, -0.41 and -6.18, respectively). Fewer pts had clinically
meaningful decline in UO, UI and BF scores at 3 months (18%, 20%
and 43.9%, respectively) and there was no signiﬁcant reduction in the
mean UO and UI scores compared with baseline. Although mean BF
score improved at 3 months compared with the end of H-IMPT, it
remained lower than the baseline, and the reduction was clinically
meaningful.
Conclusions: This prospective study of H-IMPT targeting both PLN
and the prostate/SV showed a decline of UO, UI and BF domains of
PRQOL in the early post-treatment phase. UO and UI scores improved
at 3 months and were similar to the baseline. However, BF score
remained lower at 3 months and the decline was clinically meaningful.
Follow-up is continuing to assess the late changes in PRQOL.

(P063) Factors Affecting Perioperative Length of Stay for
Surgically Guided Interstitial Brachytherapy for Gynecologic Malignancies
James Cantrell1, Gabriel Vidal1, Pawan Acharya2, Patrick Newbury1,
Erich Schnell1, Sara Vesely2, Laura Holman3, Spencer Thompson1;
1
Department of Radiation Oncology/Stephenson Cancer Center/
OUHSC, 2Department of Biostatistics and Epidemiology/OUHSC,
3
Department of Gynecologic Oncology/Stephenson Cancer Center/
OUHSC
Background: Interstitial brachytherapy (IB) utilizes trans-perineal
placement of needle-catheters to deliver a conformal radiation dose, and
is used in the treatment of bulky tumors or sites of recurrence not wellcovered with traditional intracavitary devices. Historically, the application of IB was without the aid of direct visualization or image
guidance, and was associated with signiﬁcant complication rates. Currently, needle placement is performed under image guidance (ultrasound) or direct visualization (laparoscopy or laparotomy) to improve
safety and target coverage. Surgical guidance also allows for creation of
an omental shield providing protection to the organs at risk (OARs)
from radiation or mechanical injury from the needles.
Objectives: The goal of this study is to explore factors affecting perioperative length of stay (LOS) in patients treated with surgically-guided
IB (SGIB) for locally advanced primary or recurrent gynecological
cancer.
Methods: Patients undergoing SGIB between 2010-20 were identiﬁed,
and both Low Dose Rate (LDR) and High Dose Rate (HDR) cases were
included. We used the Kaplan-Meier method with log-rank test for
overall survival (OS) and χ2 test to assess the univariate association
between LOS and background characteristics. Survival duration was
deﬁned as the time from end of brachytherapy to death or last contact.
Results: A total of 38 patients were treated with SGIB. Mean follow up
time was 2.56 years (range 0.1-9.27 y). Patient, disease and treatment
characteristics are summarized in Table 1. In the HDR cohort, mean
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TABLE 1. Patient, Disease, and Treatment Characteristics

TABLE 1. (continued)

LOS for those receiving laparoscopy was 4.63 days versus 5.61 days for
laparotomy (P = 0.017). In the LDR cohort, mean LOS for those
receiving laparoscopy was 3 days versus 6.67 days for those receiving
laparotomy (P = 0.001). A cut-off was determined to account for
inherent differences in the radiation delivery times between LDR and
HDR, e.g., any LDR case with LOS greater than or equal to 5 or any
HDR case with a LOS greater than 6 days was considered longer than
expected. Univariate analysis was performed using brachytherapy type,
T-stage, age, performance status, pre-treatment patient reported QOL,
primary or recurrent disease, use of chemotherapy, number of needles
placed, and surgical approach to identify factors associated with a
longer than expected LOS. Only surgical approach was signiﬁcant for
longer than expected LOS, with 0% (0/11) of the laparoscopy group
versus 48% (12/27) of the laparotomy group in the “Longer than
Expected” category. OS was not statistically different between the
expected and longer than expected LOS groups (Fig. 1).
Conclusions: Surgical approach was the only signiﬁcant factor affecting LOS on univariate analysis. Unsurprisingly, laparoscopic approach
was associated with shorter LOS regardless of brachytherapy type
(LDR or HDR). LOS was not associated with a decrease in OS. Further
study is warranted to fully explore the potential role of laparoscopy
in SGIB.

FIGURE 1. Overall survival comparison grouped by LOS.
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(P064) Characteristics and Early Outcomes of the First 100
Patients with Cervical Cancer at the National Cancer
Center of Cambodia
Jacob Gardner1, Rath Beauta, MD2, Poly Bunpa, MD2, Mora Mel,
MD2, Vannyat Ath2, Sarameth Thou, MD2, Tracy Sherertz, MD3; 1Case
Western Reserve University School of Medicine, 2National Cancer
Center, Calmette Hospital, 3Kaiser Permanente Washington
Background: Cervical cancer is the most common cancer reported
among women in Cambodia, with an estimated 1500 new cases and 800
deaths annually. The history of cancer care in Cambodia is unfortunately dominated by the Khmer Rouge period from the mid-1970s until
the end of the 1990s, during which upwards of 25% of the population
was killed. Another casualty was the country’s healthcare infrastructure;
hospitals were abandoned, equipment was destroyed, and healthcare
professionals were persecuted. On January 15th, 2018, Cambodia
opened their ﬁrst dedicated cancer hospital - the National Cancer Center
(NCC) - at Calmette Hospital in Phnom Penh to provide modern
multidisciplinary cancer care to Cambodian citizens and advanced
oncology training for Cambodian health care professionals.
Objectives: We sought to gather descriptive statistics on the demographic, diagnostic, treatment, and outcome data of the ﬁrst 100 patients
with cervical cancer under care at the NCC.
Methods: The medical records of the ﬁrst 100 patients with cervical
cancer treated at the NCC were reviewed for demographic, diagnostic,
treatment, and outcome data. Data was drawn from archived paper
records and from electronic records on the ARIA Oncology Information
System. Descriptive statistics of each metric were calculated in Excel,
and included frequency, range, mean and median.
Results: Median age was 55 years. 40% of patients lived in Phnom
Penh. 23% of patients presented with stage I disease, 35% with stage II
disease, 20% with stage III disease, and 14% with stage IV disease.
42% of patients were treated with deﬁnitive surgery, 89% received
systemic chemotherapy, 96% received external beam radiation therapy,
and 73% received brachytherapy. Of the patients who received chemotherapy, 49.44% were treated concurrently with radiation therapy.
For those patients who received deﬁnitive-intent radiotherapy, the
median cumulative dose (EQD2) from external beam and brachytherapy
was as follows: HRCTV D90: 90.8 Gy, bladder maximum 2 cc:
77.45 Gy, and rectal maximum 2cc: 69.95 Gy. The median overall
treatment time was 148 days. The median follow-up period was
402 days. For the 25 patients for whom follow-up data has been collected, the frequency of acute toxicity - assessed at each patient’s last
follow-up - was as follows: 25 (100%) had Grade 1 bladder toxicity; 21
(84%) had Grade 1 rectal toxicity; & 4 (16%) had Grade 2 rectal toxicity. For the 14 patients with at least 1 year follow-up, 13 (93%) were
alive without recurrence at 12 months.
Conclusions: The opening of the NCC is a watershed moment for
improving access to cancer care in Cambodia. The data presented here
illustrate future challenges for care and hope for improving outcomes
for patients with cervical cancer in Cambodia. This early sample serves
as an initial step toward gaining a better understanding of the patient
population in Cambodia, and also highlights a need to continue outcomes-based review as the NCC broadens its scope and capacity to
provide care to its patients.

(P065) Human Papillomavirus Infection Among Cambodian Patients with Cervical Cancer
Jacob Gardner1, Rath Beauta, MD2, Michel Pluot, MD3, Sarameth
Thou, MD2, Aun Korn, MD3, Jae Jung, PhD4, Tracy Sherertz, MD5;
1
Case Western Reserve University School of Medicine, 2National
Cancer Center, Calmette Hospital, 3Calmette Hospital, 4Lerner
Research Institute, Cleveland Clinic Foundation, 5Kaiser Permanente
Washington
Background: Cervical cancer is the most common cancer reported
among women in Cambodia, with an estimated 1500 new cases and 800
deaths annually. Cervical cancer can be prevented by vaccination
against its primary causative agent: human papillomavirus (HPV).
Cambodia has yet to implement a nationwide HPV vaccination campaign, in large part because it remains unknown which subtypes of HPV
pose the greatest oncogenic threat to the Cambodian population. Dozens
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of oncogenic HPV subtypes have been identiﬁed around the world, and
the prevalence and distribution of these various subtypes can vary
drastically across geographic regions. It is therefore important to better
understand the prevalence of various oncogenic HPV subtypes among
Cambodian patients who develop cervical cancer so that the most
effective vaccination policy can be developed.
Objectives: 1). To determine which subtypes of HPV are represented in
a survey of 100 patients with biopsy-proven cervical cancer at Calmette
Hospital in Phnom Penh, Cambodia. 2). To help inform HPV vaccination policy in Cambodia.
Methods: HPV DNA is isolated from the cervical tumor biopsies of
100 patients from Calmette Hospital in Phnom Penh, Cambodia after
histological conﬁrmation of cervical squamous cell carcinoma or adenocarcinoma. Fifty samples comprise the “retrospective” cohort, collected from the archives of Calmette’s Pathology Department. Fifty
additional samples comprise the “prospective” cohort, collected from
new patients presenting to Calmette for evaluation and diagnosis of
cervical cancer. A microtome is used to section 10, 10μm-thick curls
from parafﬁn blocks containing each patient’s biopsy tissue. Commercially available kits are used to deparafﬁnize the tissue samples and
extract and isolate the HPV DNA. A polymerase chain reaction beadbased assay is used to amplify and genotype the viral DNA and identify
which subtypes are present in each tissue sample. For each HPV subtype detected, the prevalence among the study population is calculated.
Results: This study is still being carried out and has not produced any
results yet. We hypothesize that the HPV subtype prevalence distribution among patients with cervical cancer in Cambodia will be
similar to that of patients in Cambodia’s neighbor countries Thailand
and Vietnam, where such information is already known from prior
studies.
Conclusions: The results of this study will be submitted to Cambodia’s
Ministry of Health for consideration in the development of their HPV
vaccination policy.

(P066) Incorporation of Vaginal Brachytherapy to External
Beam Radiotherapy in Adjuvant Therapy for High-Risk
Early-Stage Cervical Cancer: A Comparative Study
Shahil Mehta, MD, MPH1, Boniface Yarabe, BA1, Omar Ragab, MD2,
David Nusbaum, MD3, Muneaki Shimada, MD4, Laurie Brunette, MD1,
Lynda Roman, MD1, Koji Matsuo, MD, PhD1; 1University of Southern
California, 2University of Southern California Keck School of Medicine, 3University of Chicago Medicine, 4Tohoku University, School of
Medicine
Background: For most patients with early stage T1-2 cervical cancer,
treatment options include surgical intervention with a hysterectomy or
concurrent chemotherapy and external beam radiotherapy (EBRT) followed by a vaginal brachytherapy (VBT) boost. Following hysterectomy there is a role for adjuvant radiation therapy in patients with
intermediate risk factors of lympho-vascular space invasion (LVSI),
stromal invasion, and large tumor size. Concurrent chemotherapy and
EBRT also beneﬁt patients with the high risk factors of positive pelvic
nodes, positive surgical margins and/or positive parametria. The role of
VBT boost for patients with high risk factors is unclear. The National
Comprehensive Cancer Network (NCCN) clinical practice guidelines
suggest that it may be most helpful for those with close or positive
margins, although the paucity of evidence is noted. Overall the literature
does not provide a clear answer as to whether adjuvant EBRT with VBT
boost provides additional beneﬁt to high risk early stage cervical cancer
patients. The objective of the current study was to examine trends,
characteristics, and outcomes of additional VBT after EBRT for highrisk early-stage cervical cancer in the United States.
Objectives: To examine trends, characteristics, and outcomes related to
addition of vaginal brachytherapy (VBT) to external beam radiotherapy
(EBRT) for adjuvant radiotherapy in high-risk early-stage cervical
cancer.
Methods: This comparative study is a retrospective observational
analysis of the National Cancer Institute’s Surveillance, Epidemiology,
and End Results (SEER) Program. Surgically-treated women with stage
T1-2 cervical cancer who had high-risk factors (nodal metastasis and/or
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parametrial invasion) and received adjuvant radiotherapy from 20002018 were examined. Propensity score inverse probability of treatment
weighting was used to assess the survival estimates for addition of
VBT use.
Results: Among 2,470 women with high-risk factors receiving EBRT, 760
(30.8%) had additional VBT. During the study period, there was an
increasing trend of VBT use from 27.4% to 36.1% (P < 0.001). In a multivariable analysis, year of diagnosis and high-risk tumor factors: parametrial involvement, large tumor size, and use of chemotherapy remained
independent characteristics associated with VBT use (all, P < 0.05). In
propensity score weighted models, VBT use with EBRT and EBRT alone
had comparable overall survival (OS) (5-year rates 73.8% versus 77.4%,
hazard ratio 1.07, 95% conﬁdence interval 0.92-1.25). Non-signiﬁcant
association was also observed in squamous vs non-squamous tumors,
young vs old age, low vs high lymph node ratio, chemotherapy use, and
simple or radical hysterectomy (all, P > 0.05). Lastly, the addition of VBT
was not associated with cervical cancer-speciﬁc survival (subdistribution
hazard ratio 1.15, 95% conﬁdence interval 0.94-1.41, P = 0.170).
Conclusions: Utilization of VBT with EBRT for adjuvant radiotherapy
in high-risk early stage cervical cancer is increasing in the United
States. Addition of VBT is associated with neither overall survival nor
cancer speciﬁc survival.

(P067) Clinical and FDG-PET Tumor Characteristics
Associated with Early Versus Late Distant Metastasis Following Curative Chemoradiation of Cervical Cancer
Suvidya Lakshmi Pachigolla, BSE1, Alexander Lin, MD/PhD2, Leslie
Massad, MD1, Premal Thaker, MD1, David Mutch, MD1, Matthew
Powel, MD1, Farrokh Dehdashti, MD1, Barry A SIEGEL SIEGEL,
MD3, Julie Schwarz, MD/PhD1, Stephanie Markovina, MD/PhD1, Perry
Grigsby, MD1; 1Washington University in St. Louis, 2Washington
University in Saint Louis, 3Washington University
Background: Distant failure is the predominant pattern of failure for
locally advanced cervical cancer treated with modern image-guided
radiation therapy (Tan et al IJROBP 2019). Distant recurrence can be
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apparent as early as 3 months after completion of therapy (Schwarz et al
IJROBP 2012), which may signal an aggressive tumor biology. Identiﬁcation of factors associated with early distant metastasis could help
select patients most likely to beneﬁt from adjuvant systemic therapy.
Objectives: To determine risk factors associated with early vs late distant recurrence in cervical cancer following deﬁnitive chemoradiation.
Methods: We included patients treated at an academic medical center with
FIGO Stage IB-IVA cervical cancer staged with FDG-PET who completed
curative chemoradiation therapy with brachytherapy, with a minimum of
3 months follow-up and restaging FDG-PET. Patients who subsequently
developed biopsy-proven distant metastasis were categorized to have earliest (3-6 mo), early (6-24 mo) or late ( > 24 mo) recurrence following
completion of therapy. Fisher’s exact test and Mann-Whitney U test were
computed for categorical and continuous variables, respectively. Logistic
regression was used to calculate odds ratios (ORs) with 95% conﬁdence
intervals (CI). Kaplan-Meier analysis demonstrated differences in the timing
of distant only vs concurrent distant + local failure.
Results: Of 574 patients treated with curative chemoradiation, 143
(25%) developed distant metastasis: 45 (31.5%) earliest, 65 (45.5%)
early, and 33 (23%) late. Among these three groups, there were no
signiﬁcant differences in age, race, FIGO 2009 stage, metabolic tumor
volume, SUVmax, treatment length, or baseline/end-of-treatment squamous cell carcinoma antigen (SCCA) levels. New areas of FDGuptake on 3-month post-treatment scan predicted the development of
distant metastasis within 6 months in 86% of cases and 100% of cases
by 2 years out from treatment. Compared with patients with late distant
metastasis, patients with earliest and early distant recurrences were
more likely to have PET-positive lymph nodes at diagnosis. Neither
pre-treatment nor end-of treatment variables were signiﬁcantly different
comparing the earliest vs early groups, so these patients were combined
for comparison with the late group. Patients with distant metastasis
within 2 years of radiation were more likely to have PET-positive
lymph nodes at diagnosis (OR: 3.0, 95% CI 1.4–6.9, P = 0.006). There
were 39 (27.3%) patients who also experienced local recurrence concurrently with their distant metastasis. Figure 1 shows that patients with
early distant metastasis were more likely to have concurrent local failure
than patients with late distant metastasis.

FIGURE 1. Kaplan-Meier curve showing time to recurrence stratified by distant alone recurrence vs. concurrent local and distant failure.
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TABLE 1. Patient, Tumor, and Treatment Characteristics

*Number of Cases Missing Data: Metabolic Tumor Volume–49; Cervix SUV Max–27; SCCA at Diagnosis–78; Delta SCCA–90; SCCA at RT Completion–90

S72 | www.amjclinicaloncology.com
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Copyright r 2021 Wolters Kluwer Health, Inc. All rights reserved.

American Journal of Clinical Oncology



Volume 44, Number 10, October 2021

Conclusions: Lymph node metastasis at time of diagnosis was the only
distinguishing risk factor for earliest/early vs. late distant metastasis.
The biological mechanisms that trigger late metastasis deserve further
exploration (Table 1).

(P068) Clinical and FDG-PET Tumor Characteristics
Associated with Early versus Late Distant Metastasis Following
Curative Chemoradiation of Cervical Cancer
Alexander Lin, MD, PhD1, Suvidya Lakshmi Pachigolla, BSE2, Leslie
Massad, MD2, Premal Thaker, MD2, David Mutch, MD2, Matthew
Powel, MD2, Farrokh Dehdashti, MD2, Barry A Siegel Siegel, MD3,
Julie Schwarz, MD, PhD2, Stephanie Markovina, MD, PhD2, Perry
Grigsby, MD2; 1Washington University in Saint Louis, 2Washington
University in St. Louis, 3Washington University
Background: Distant failure is the predominant pattern of failure for
locally advanced cervical cancer treated with modern image-guided
radiation therapy (Tan et al IJROBP 2019). Distant recurrence can be
apparent as early as 3 months after completion of therapy (Schwarz et al
IJROBP 2012), which may signal an aggressive tumor biology. Identiﬁcation of factors associated with early distant metastasis could help
select patients most likely to beneﬁt from adjuvant systemic therapy.
Objectives: To determine risk factors associated with early vs late
distant recurrence in cervical cancer following deﬁnitive chemoradiation.
Methods: We included patients treated at an academic medical center
with FIGO Stage IB-IVA cervical cancer staged with FDG-PET who
completed curative chemoradiation therapy with brachytherapy, with a
minimum of 3 months follow-up and restaging FDG-PET. Patients
who subsequently developed biopsy-proven distant metastasis were
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categorized to have earliest (3-6 mo), early (6-24 mo) or late ( > 24 mo)
recurrence following completion of therapy. Fisher’s exact test and
Mann-Whitney U test were computed for categorical and continuous
variables, respectively. Logistic regression was used to calculate odds
ratios (ORs) with 95% conﬁdence intervals (CI). Kaplan-Meier analysis
demonstrated differences in the timing of distant only vs concurrent
distant + local failure.
Results: Of 574 patients treated with curative chemoradiation, 143
(25%) developed distant metastasis: 45 (31.5%) earliest, 65 (45.5%)
early, and 33 (23%) late. Among these three groups, there were no
signiﬁcant differences in age, race, FIGO 2009 stage, metabolic tumor
volume, SUVmax, treatment length, or baseline/end-of-treatment squamous cell carcinoma antigen (SCCA) levels. New areas of FDGuptake on 3-month post-treatment scan predicted the development of
distant metastasis within 6 months in 86% of cases and 100% of cases
by 2 years out from treatment. Compared with patients with late distant
metastasis, patients with earliest and early distant recurrences were
more likely to have PET-positive lymph nodes at diagnosis. Neither
pre-treatment nor end-of treatment variables were signiﬁcantly different
comparing the earliest vs early groups, so these patients were combined
for comparison with the late group. Patients with distant metastasis
within 2 years of radiation were more likely to have PET-positive
lymph nodes at diagnosis (OR: 3.0, 95% CI 1.4–6.9, P = 0.006). There
were 39 (27.3%) patients who also experienced local recurrence concurrently with their distant metastasis. Figure 1 shows that patients with
early distant metastasis were more likely to have concurrent local failure
than patients with late distant metastasis.
Conclusions: Lymph node metastasis at time of diagnosis was the only
distinguishing risk factor for earliest/early vs. late distant metastasis.
The biological mechanisms that trigger late metastasis deserve further
exploration (Table 1).

FIGURE 1. Kaplan-Meier curve showing time to recurrence stratified by distant alone recurrence vs. concurrent local and distant failure.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

www.amjclinicaloncology.com

Copyright r 2021 Wolters Kluwer Health, Inc. All rights reserved.

| S73

Abstracts

American Journal of Clinical Oncology



Volume 44, Number 10, October 2021

TABLE 1. Patient, Tumor, and Treatment Characteristics

*Number of Cases Missing Data: Metabolic Tumor Volume–49; Cervix SUV Max–27; SCCA at Diagnosis–78; Delta SCCA–90; SCCA at RT Completion – 90.
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(P069) Clinical Outcomes and Dosimetric Data for Patients
with Gynecologic Malignancies: A Comparison Between a
Proton and Photon Matched Cohort
Ariel Pollock, MD1, Hunter Risher, MS2, Kai Sun, MS3, Ishan Oza4,
Kimberly Marter, CMD1, David Alicia, CMD1, Gautam Rao, MD5, Dana
Roque, MD5, Elizabeth Nichols, MD6, Pranshu Mohindra, MD, MBBS7;
1
Department of Radiation Oncology, University of Maryland Medical
Center, 2University of Maryland School of Medicine, 3University of
Maryland School of Medicine Department of Epidemiology and Public
Health, 4University of Maryland College Park, 5Division of Gynecologic
Oncology, University of Maryland School of Medicine, 6Department of
Radiation Oncology, University of School of Medicine, 7Department of
Radiation Oncology, University of Maryland School of Medicine
Background: Radiation (RT) for treatment of gynecologic (gyn)
malignancies confers a risk of gastrointestinal (GI), genitourinary (GU),
and hematologic (heme) toxicity. Proton therapy (PT) may confer
superior dosimetric sparing of bowel, bladder and marrow than volumetric arc therapy (VMAT), though supporting clinical data is lacking.
Objectives: In this IRB-approved retrospective matched-pair analysis,
we analyzed clinical outcomes and dosimetric differences between
intensity modulated proton therapy (IMPT) and VMAT when treating
gyn patients.
Methods: Patients with gyn malignancies treated with deﬁnitive or
adjuvant whole-pelvic ( ± para-aortic) IMPT and VMAT between
2014-2020 were analyzed. Patients with prior in-ﬁeld RT were
excluded. IMPT patients were matched 1:2 with a VMAT cohort (based
on receipt/timing of chemotherapy (ChT), RT ﬁeld, and receipt of
surgery). The Kaplan-Meier (KM) method was used to estimate overall
survival (OS). A conditional logistic regression was performed to
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compare incidence of grade 2+ and grade 3+ toxicity. A t-test analysis
was performed to compare mean dosimetric parameters.
Results: The cohort included 28 patients treated with IMPT and 51
treated with VMAT (total N = 79). Sites included uterus (n = 52), cervix
(n = 16), vagina (n = 3), vulva (n = 5) and ovary (n = 3). Median initial
dose for IMPT and VMAT was 50.4 and 45 Gy, respectively. Overall,
43% of patients received adjuvant RT, 75% received ChT of which
38% was concurrent. With a median follow up of 23 months, the 1-year
OS was 92% (95% CI 82-100%) and 88% (9% CI 80-96%) for IMPT
and VMAT cohort, respectively, P = 0.6. The differences in incidence
of any grade 2+ acute toxicity (n = 9, 32% vs n = 18, 35%), any grade 3+
acute toxicity (n = 2, 7% vs n = 10, 20%), any grade 2+ late toxicity (n = 6,
21% vs n = 10, 20%) and GI/GU grade 3+ late toxicity (n = 1, 4% vs n = 4,
8%) between IMPT and VMAT were not statistically signiﬁcant. All acute
grade 3+ toxicity in proton cohort were heme while acute grade 3+ photon
toxicities included heme, small bowel obstruction (SBO) and diarrhea. Late
GI/GU grade 3+ toxicity in proton cohort were RT enteritis in one patient
versus SBO (2 patients) and ﬁstula (2 patients) in VMAT cohort. Upon
dosimetric comparison, bone marrow V10 Gy (P < 0.001) and V20 Gy (P
< 0.001), small bowel V15 Gy (P < 0.001) and V45 Gy (P < 0.001) were
lower with IMPT but rectum V40 Gy was lower with VMAT (P = 0.03).
No signiﬁcant differences were seen in bone marrow V40 Gy and bladder
V40 Gy.
Conclusions: This initial clinical report of gyn cancer patients treated
with IMPT demonstrates excellent tolerance and efﬁcacy with possible
signal of acute (marrow) and late (GI/GU) toxicity reduction with
IMPT, corroborated by dosimetric superiority of IMPT in reducing
marrow and small bowel dose. This hypothesis generating data supports
need for an appropriately powered prospective trial to test utility of
IMPT (Fig. 1).

FIGURE 1. Acute and late grade 2+ and grade 3+ toxicity.
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TABLE 2. Cox Proportional Hazards Analysis of Factors that Affect
Survival

Leonid Reshko, MD1, Jeremy Gaskins, PhD2, Alyssa Farley, BS2,
Abbas Rattani, MD2, Grant McKenzie, MD2, Scott Silva, MD, PhD1;
1
Department of Radiation Oncology/University of Louisville, 2University
of Louisville
Background: Medically inoperable endometrioid adenocarcinoma of
the endometrium is a challenging clinical entity as deﬁnitive surgery
with risk-adaptive adjuvant therapy is the standard of care (AbuRustum, et al NCCN 2021 and Colombo, et al Int J of Gyn Cancer
2016). It is unknown whether deﬁnitive radiotherapy (RT) and/or hormone therapy (HT) provide the optimal oncologic outcomes due to the
absence of randomized data (Schwarz, et al Brachytherapy 2015;
Kupelian, et al IJROBP 1993; Podzielinski, et al Gynecologic Oncology
2012; Nikolopoulos, et al Obstet Gynecol Sci 2020, Macchia, et al
Oncology Letters 2016).
Objectives: The goal of this study is to evaluate the patterns of care and
efﬁcacy of RT and/or HT in the treatment of medically inoperable
endometrial adenocarcinoma.
Methods: We performed a query of the National Cancer Database
(NCDB) of patients with medically inoperable endometrioid adenocarcinoma of the endometrium diagnosed between 2004 and 2016.
Included in this analysis were patients in which deﬁnitive surgery was
not performed because it was contraindicated due to patient comorbidities. Additionally, patients were only included if they received
either RT, HT or both; did not receive chemotherapy; were neither stage
0 nor 4; were treated within 4 months of diagnosis and had a follow-up
time of at least 4 months. A Cox model was constructed to evaluate

TABLE 1. Multinomial Logistic Regression Model of Factors that Affect Hormone Therapy, Radiotherapy or Combination of Hormone
Therapy and Radiotherapy Utilization
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survival after controlling for confounding variables. A multinomial
logistic regression model was used to assess predictors of RT and/or
HT use.
Results: A total of 1,063 patients were included in this cohort. Patients
who received RT compared with HT were more likely to be older, be
diagnosed in earlier years, have government-issued insurance, be treated
at a lower-case volume center, have high-grade disease, have serious
medical comorbidities and live outside of metro areas as shown in
Table 1. Unadjusted 5-yr survival was 43.2% in patients receiving HT
compared with 37.3% in patients receiving RT. However, on multivariate analysis, patients who received HT had worse overall survival
compared with patients who received RT (adjusted hazard ratio (aHR)
1.25; 95% CI 1.02–1.54; P = 0.0322). Only 38 patients received both
RT and HT compared with 275 who received HT alone and 750 treated
with RT alone. There was borderline evidence that the combination of
RT and HT did worse than RT alone (aHR 1.48; 95% CI 1.00–2.19;
P = 0.0524). Other factors associated with worse survival were older
age, presence of serious medical comorbidities, government-issued
insurance, treatment at a lower-case volume center and high-grade
histology as shown in Table 2.
Conclusions: We identiﬁed factors associated with the receipt of RT
and/or HT in medically inoperable endometrial cancer patients. The
receipt of RT appears to correlate with superior survival than treatment
with HT alone when accounting for confounding variables. There was
an insufﬁcient number of patients treated with a combination of RT and
HT to draw a conclusion regarding the efﬁcacy of this regimen.

(P071) Robotically Assisted Intra-Operative Radiation
Therapy
Houman Vagheﬁ, MD, PhD1, Pamela Stone, MD1, James Wheeler,
MD, PhD1, John Lowden, DABR2, Samantha Korda, DABR2, Irina
Sparks, MD2, Grace Darnell, NP2; 1Goshen Cancer Center, 2Goshen
Center for Cancer Care
Background: Robotic surgery is one of the standards of care in the
surgical management of gynecologic malignancy. One of the goals of
an oncologic resection is to achieve negative margins. However, in
some instances an R0 resection is not achieved, which could lead to
increased local failure. Local control could be achieved by adjuvant
radiotherapy, commonly delivered with external beam radiotherapy.
Intra-operative Radiotherapy (IORT) is a technique where a single
intraoperative dose of radiation is delivered to the target. In robotic
resection IORT is usually not considered due to small port sites that can
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FIGURE 2. Intra-operative photo representing the IORT catheter,
introduced through the vagina, secured by the robotic arm, while
the bladder is tethered away out of the radiation field.

preclude the IORT applicator. However, transvaginal approach allows
adequate and safe physical space to deliver IORT.
Objectives: We describe the ﬁrst published report of robotic surgery
using a transvaginal approach to safely deliver balloon based IORT.
Methods: 75-year-old female with a nebulous past medical history
signiﬁcant for a gynecologic malignancy, treated with TAH/BSO in
1994 and radiation therapy. She presented with vaginal pain and
drainage. Physical exam showed a mass in the fornix, extending to the
vaginal cuff. Pelvic MRI revealed a 2.8 cm pelvic mass adjacent to the
vaginal cuff (Fig. 1). PET/CT showed no metastasis. She underwent a
robotically assisted radical upper vaginectomy, bilateral pelvic node
mapping and sampling, and bilateral pelvic node dissection. Intraoperatively, it became apparent that the resection of the tumor resulted
in the dissection to the left levator ani muscle over the rectum without
entry into the rectal mucosa. All margins were marked, and tissue was
sent for rapid frozen section and were noted to be positive for tumor.
Therefore, a decision was made to deliver IORT. The target adjacent to
the rectum was estimated to be superﬁcial and within the adequate range
of the 50KvP source. A 3-4 cm XOFT (TM) catheter was selected and
ﬁlled to 30mL. The IORT catheter was introduced with a transvaginal
approach after removal of the specimen. The catheter was docked
through the opened vaginectomy site and secured for IORT. The
bladder and the right ureter were tethered away from the radiation ﬁeld
by the robot. Trendelenburg position ensured that the bowel was moved
out of the radiation ﬁeld and 10 Gy was delivered (Fig. 2). The patient
had no apparent complications and was discharged in post-operative
day 1.
Results: Pathology showed G2, moderately differentiated invasive
squamous cell carcinoma with the tumor originating at the vaginal cuff
and extending deeply into the paravaginal tissue, positive for LVI and
PNI. The deep margin was positive, with 14 negative nodes. She was
staged to have a rpT2bN0 squamous cell carcinoma.
Conclusions: For select patients who have undergone prior radiation
therapy and whose imaging studies indicate a high risk for encountering
positive margins at the time of salvage surgery, IORT may be a feasible
treatment option using the XOFT balloon applicator even in conjunction with robotic surgery.

(P072) Vulvar Recurrence and Survival in Patients
Undergoing Adjuvant Radiation for High-Risk Vulvar
Cancer

FIGURE 1. MRI Axial T1 post-constrast image of the mass adjacent
to the vaginal cuff.

Alison Yoder, MD, MPH1, David Lakomy, BA2, Kelsey Corrigan, MD,
MPD1, Anuja Jhingran, MD1, Ann H. Klopp, MD, PhD3, Melissa
Joyner, MD, MBA4, Lauren Colbert, MD, MSCR1, Patricia Eifel, MD1,
Lilie Lin, MD1; 1MD Anderson Cancer Center, 2Dartmouth College
Geisel School of Medicine, 3The University of Texas MD Anderson
Cancer Center, 4M.D. Anderson Cancer Center
Background: Vulvar cancer is rare and primarily treated with surgical
resection. Adjuvant radiation therapy (RT) is recommended for patients
with close or positive margins or positive nodal disease.
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margins while 12 (48%) were treated for recurrence after prior deﬁnitive
surgery. In the 13 patients who required re-excision, 8 had negative
margins after re-excision. Margin status after re-excision was not
associated with VR (HR 1.48, P = 0.78). The risk of VR was not
increased if patients required re-excision compared with all other
patients (HR 0.64, P = 0.56). Patients were not at an increased risk of
VR if they were recurrent at time of presentation (HR 1.87, P = 0.29).
At last contact, 48 patients (70%) had no evidence of disease, 13 (19%)
had disease, and 8 (12%) had unknown disease status. Eight patients in
this cohort died of disease.
Conclusions: Re-excision to achieve negative margins or delivery of
additional boost dose to areas of close or positive margins appear to
be effective strategies to reduce the risk of VR. The presence of
lichen sclerosis is a strong predictor of vulvar relapse and may
warrant investigation as an indication for treatment intensiﬁcation
(Figs. 1 and 2).
FIGURE 1. Lichen sclerosis and vulvar recurrence. Kaplan-Meier
curve comparing vulvar recurrence in patients going through
adjuvant radiation for vulvar carcinoma with and without lichen
sclerosis, log-rank P = 0.005.
Objectives: We evaluated demographic, clinical, and treatment variables that might be associated with vulvar recurrence (VR) in patients
with vulvar cancer treated with postoperative RT with or without
chemotherapy.
Methods: After obtaining IRB approval, we retrospectively reviewed
the records of 69 vulvar cancer patients who were treated at our institution with vulvar resection followed by RT between 1999 and 2019.
The median total dose of RT to the vulva was 54 Gy (range 40-64) in 25
(20-33) fractions, with median RT duration of 39 days (27-53). RT
boost was given to the vulva in the majority of cases with close or
positive margins, median dose of 6 Gy (0-20). All time variables were
calculated from the start of RT. Variables associated with VR were
analyzed using cox proportional hazard model. The median follow-up
duration was 53 months.
Results: Most patients were White (n = 46/69, 67%) and the majority
(n = 60, 87%) had squamous cell carcinomas. Thirteen patients (18.6%)
had a history of lichen sclerosis (LS) diagnosed either before their
cancer diagnosis or at time of surgical resection. Most patients had only
one prior surgical resection before RT (n = 44, 64%), though 22 (32%)
had two prior resections and 3 (4%) underwent 3 total resections before
RT. Fourteen patients had VR after receiving adjuvant RT; median time
of 15 months. Patients with positive margins (HR 0.66, P = 0.50), nonsquamous histopathology (HR 0.51, P = 0.52), or who required > 1
surgery (HR 1.20, P = 0.73) were not at an increased risk of VR.
Patients with positive lymph nodes and those with LS were more likely
to have VR (HR 8.7, P = 0.04; HR 4.1, P = 0.01, respectively). Of the
14 patients with VR, 6 (43%) had LS. Patients with LS were more likely
to be older (mean age 71 vs 59, P = 0.1). Of the 25 patients who had
multiple prior resections, 13 (52%) had re-excisions for positive

FIGURE 2. Vulvar recurrence and re-excision. Kaplan-Meier curve
comparing vulvar recurrence in patients that required re-excision
for positive margins compared with those that did not receive reexcision, log-rank P = 0.056.

(P073) Two-year Patient-Reported Outcomes After Ipsilateral IMRT for T1-2 N2b Squamous Cell Carcinoma of
the Tonsils
Chike Abana, MD, PhD1, Adam Garden, MD1, Andrew Frankart, MD2,
Natalie Geier, MD3, Houda Bahig, MDCM, PhD4, Gary Gunn, MD1,
Abdallah S.R. Mohamed, MD1, Vinita Takiar, MD, PhD2, Jack Phan,
MD, PhD1; 1The University of Texas M.D. Anderson Cancer Center,
2
University of Cincinnati, 3The Christ Hospital, 4University of Montreal
Hospital Center
Background: Although unilateral neck irradiation is frequently
implemented in patients with well-lateralized stage T1-2 HPV+ tonsillar
squamous cell carcinoma (SCC) to minimize toxicity, its role in patients
with N2b (AJCC-7 staging) nodal disease remains controversial. We
have separately reported on contralateral nodal recurrence risk in
patients with N2b disease receiving unilateral neck radiation. The
patient reported outcomes (PRO) in these patients have not been previously reported.
Objectives: To evaluate the quality of life PRO proﬁle in patients with
AJCC 7th edition T1-2 N2b tonsillar squamous cell carcinoma treated
with unilateral neck radiation.
Methods: The PROs of 44 AJCC-7 T1-2 N2b tonsillar squamous cell
carcinoma (SCC) patients from two academic institutions treated with
deﬁnitive, ipsilateral intensity modulation radiation therapy (IMRT)
with or without systemic therapy were reviewed retrospectively. PROs
were completed using either the MD Anderson Symptom InventoryHead and Neck module (MDASI-HN) at the ﬁrst institution, or the
European Organization for Research and Treatment of Cancer Quality
of Life Questionnaire Head and Neck Module 35 (EORTC QLQH&N35) at the second institution. The primary endpoint was the head
and neck-related PROs at 2 years after completion of radiation.
Results: Twenty-eight of 30 and 4 of 14 patients from the ﬁrst and
second institutions, respectively, met the primary endpoint and were
further analyzed. Of these, 34.4% received radiation alone without
systemic therapy and 93.7% received ipsilateral-only neck IMRT. The
most common head and neck-related PRO was dry mouth at the ﬁrst
and second institutions (64.2% and 100%, respectively); the least
common was difﬁculty with voice or speech at the both institutions
(14% and 0%, respectively). There were also no reports of mouth pain
or soreness, trouble with teeth, opening mouth, or swallowing liquid/
pureed food at the second institution. The overall symptom severity for
all PRO categories in both modules were in the mild range, with the
highest mean score reported for dry mouth: 2.54 out of 10 on MDASIHN for the ﬁrst institution and 2.5 out of 4 on EORTC QLQ-H&N35
for the second institution. The rest of the mean scores for the ﬁrst
institution were < 1.5, while the remainder for the second institution
were ≤ 2. The locoregional control and overall survival after a median
follow-up of 4.5 years were each 100%.
Conclusions: We assessed the 2-year PROs for ipsilaterally radiated
tonsillar SCC from 2 institutions using either MDASI-HN or EORTC
QLQ-H&N35, and most reported mild symptom burden. These ﬁndings
suggest that ipsilateral-only IMRT is well tolerated in patients with
AJCC-7 N2b disease and can be safely employed as a de-escalation
strategy.
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(P074) Association Between Radiation Dose to Adjacent
Organs at Risk and Acute Patient Reported Outcome
During Radiation Treatment for Head and Neck Cancers

TABLE 1. Odds Ratio of Receiving Adjuvant Therapy After
Surgery for Several Variables

Mona Arbab, MD1, Yu-Hui Chen, PhD2, Roy Tishler, MD2, Jason
Glass2, Jo Ann Fugazzotto2, Joseph Killoran, PhD3, Rosh Sethi, MD2,
Eleni Rettig, MD3, Donald Annino, MD3, Laura Goguen, MD3, Ravindra Uppaluri, MD2, Carolyn Hsu2, Elaine Burke3, Glenn Hanna,
MD2, Jochen Lorch, MD2, Robert Haddad, MD2, Danielle Margalit,
MD2, Jonathan Schoenfeld, MD2; 1Indiana University, 2Dana Farber
Cancer Institute, 3Brigham and Women’s Hospital
Background: Anticipating patient-reported side effects during radiation
therapy (RT) based on RT dose to Organs At Risk (OARs) may promote focused patient-centered management during RT.
Objectives: We studied the association between dose to OARs and
patient reported outcomes (PRO) measured during head and neck RT.
Methods: We performed a retrospective evaluation of the association
between dose to OARs and PROs obtained weekly during treatment in
head and neck cancer patients receiving deﬁnitive or postoperative
radiation treatment with at least three prospectively-acquired PRO
surveys.
Results: Between 2015-2018, 169 patients had deﬁnitive (61%) or
postoperative (39%) intensity modulated radiation therapy (IMRT) for
Head & Neck (H&N) cancer and completed at least 3 PRO surveys
during RT. The majority of patients had oropharyngeal SCC (50%). We
identiﬁed associations between patient reports of: “Difﬁculty swallowing/chewing” and increased mean RT dose to the oral cavity, larynx
and pharyngeal constrictor muscles (PCM) (P = 0.0005, P = 0.02 and
P = 0.046 respectively); “choking/coughing” and larynx mean dose
(P = 0.003); “problems with mucus in mouth and throat” and oral
cavity, parotid and PCM mean dose (P< 0.001, 0.002, 0.04 respectively); “difﬁculty with voice/speech” and oral cavity, parotid and larynx mean dose (P = 0.03, 0.03 and 0.02); and “dry mouth” and oral
cavity and PCM mean dose (P = 0.0002, 0.02). There were no associations between PROs and T-classiﬁcation, smoking and whether RT
was delivered deﬁnitively or in the adjuvant setting.
Conclusions: Increased OAR dose to oral cavity, larynx, PCM and
parotids are associated with increased severity of patient-reported
symptoms including difﬁculty swallowing/chewing, choking/coughing,
problem with mucus in mouth and throat, difﬁculty with voice/speech
and dry mouth. Evaluating dose to OARs can assist in anticipating
patient-reported side effects of therapy and promote patient-speciﬁc
acute management.

Results: A majority of patients were managed with primary surgery
(2554/4678, 55%). Patients managed with surgery were younger (mean
age 61 vs 66 y old) with smaller primaries (T1: 51% v 31%,
P = < 0.0001). HPV status was known in 2910 patients, of which 63%
had HPV positive tumors. Surgery within 20 weeks of deﬁnitive radiation was rare (13/2124, 0.6%). By contrast 51% of surgical patients
received adjuvant therapy and nearly half (46%) of these patients
received adjuvant CRT (24% of all surgical patients). Factors associated
with increased likelihood of adjuvant therapy include treatment at a
community center (versus academic), tonsil subsite, T2 stage designation and N1 stage designation. The odds ratios of requiring adjuvant
therapy (vs no adjuvant therapy) for these variables are tabulated. For
adjuvant CRT speciﬁcally, the OR was increased signiﬁcantly for
clinical N1 disease (8.37, P = < 0.0001). In the group with known HPV
status, the OR for requiring adjuvant therapy was increased for HPV
positive tumors (1.39, P = 0.0076).
Conclusions: A majority of early stage oropharynx cancer patients who
undergo transoral surgery receive adjuvant therapy, while <1% of
similarly staged patients require adjuvant surgery following RT. More
advanced disease is associated with a higher odds ratio for adjuvant
therapy after surgery (Table 1).

(P075) Who Really Receives Single Modality Therapy?
Oropharynx Cancer
Nina Burbure, MD1, Mengying Deng1, Elizabeth Handorf, PhD1, John
Ridge, MD PhD1, Christopher Yao, MD1, Jessica Bauman, MD1,
Anshu Giri, MD1, Jeffrey Liu, MD1, Thomas Galloway, MD1; 1Fox
Chase Cancer Center
Background: Either radiation (RT) or transoral surgery + neck dissection promise the potential of single modality curative therapy for
appropriately selected oropharynx cancer patients. How many patients
are actually managed with single modality therapy is unknown.
Objectives: We queried the National Cancer Database (NCDB) to
determine what proportion of early stage oropharynx cancer patients
receive single modality therapy and to identify factors associated with
multi-modality therapy in this group of patients.
Methods: We identiﬁed 4678 patients treated curatively for early stage
(7th ed cT1-T2, cN0-N1) oropharyngeal squamous cell carcinoma
between 2010-2016. For those treated with primary surgery, the odds
ratio (OR) of requiring adjuvant therapy was determined using logistic
regression and adjusting for age, sex, race, comorbidity score, insurance
status, facility type, diagnosis year, disease subsite, clinical T and N
category and HPV status. Multinomial logistic regression was used to
determine the association between covariates and speciﬁc adjuvant
therapies (chemoradiation [CRT] or RT alone). For the primary RT
group, surgery within 20 weeks of RT completion was considered
multi-modality.

(P076) Prospective Evaluation of Oral Cavity Dosimetric
Parameters as Predictors of Quality of Life Outcomes in
Patients Undergoing Chemoradiation for Locally Advanced
Oropharyngeal Squamous Cell Carcinoma
Andrew Cook, MD1, Ankit Modh, MD2, Haythem Ali, MD3, Jawad
Sheqwara, MD3, Steven Chang, MD4, Tamer Ghanem, MD, PhD4,
Suhael Momin, MD4, Vivian Wu, MD4, Samantha Tam, MD, MPH4,
Xiaoxia Han, PhD5, Lamis Fakhoury, BA6, Benjamin Movsas, MD1,
Farzan Siddiqui, MD, PhD, CPE1; 1Department of Radiation Oncology,
Henry Ford Cancer Institute, 2Department of Radiation Oncology,
Carle Cancer Institute, 3Department of Hematology/Oncology, Henry
Ford Cancer Institute, 4Department of Otolaryngology, Henry Ford
Cancer Institute, 5Department of Public Health Sciences, Henry Ford
Cancer Institute, 6Henry Ford Cancer Institute
Background: Concurrent chemoradiation (chemoRT) for oropharyngeal squamous cell carcinoma (OPSCC) has improved survival;
however, this intensive treatment comes at the expense of increased
toxicity and worse quality of life (QOL). Data from a prospective
randomized trial was used to assess the impact of oral cavity (OC) dose
on QOL outcomes.
Objectives: Based off this prospective data, we would like to report on
the association between OC dose and quality of life outcomes.
Methods: All patients (n = 56) had AJCC 7th ed stage III-IV OPSCC
and underwent concurrent chemoRT. RT dose was 70 Gy in 35 fractions using a VMAT technique. To assess QOL, patients completed the
Patient-Reported Oral Mucositis Symptom (PROMS) scale at baseline,
weekly during treatment, and at 6-week follow-up (higher scores
indicate worse QOL). The OC was contoured using consensus guidelines (Brouwer, et al Radiother Oncol 2015). For dosimetric data, we
collected OC max and mean doses (Gy) and volume (%) receiving x Gy
(Vx) in 10 Gy increments. PROMS scores at week 7 (end of treatment)
and follow-up timepoints were used for analysis. In addition to the total
PROMS score, we analyzed question 1 individually (PROMS1-mouth
pain) and questions 4, 5, 6, and 9 combined (PROMS4569-difﬁculty
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eating and swallowing). PROMS scores were dichotomized at the
median to create two comparison groups, and dosimetric differences
were assessed using Wilcoxon-rank sum tests (P < 0.05 considered
signiﬁcant).
Results: At the week 7 endpoint, there were no differences noted in OC
doses when the total PROMS score was dichotomized at the median.
For PROMS1, there were signiﬁcant dosimetric differences noted in OC
mean dose (56.8 Gy vs 62.2 Gy, P = 0.04) and V50 (64.7% vs 81.5%,
P = 0.05) in the low and high score arms, respectively. Additionally,
differences in OC V40 (84.8% vs 92.7%, P = 0.08), V60 (48.6% vs
71.2%, P = 0.05), and V70 (28.4% vs 40.4%, P = 0.06) trended towards
signiﬁcance in the low and high score arms, respectively. For
PROMS4569, there were no signiﬁcant differences noted in the dosimetric parameters. At follow-up examining total PROMS score, there
was a signiﬁcant difference in OC V70 (25.6% vs 38.2%, P = 0.05) in
the low and high score arms, respectively. Additionally, OC V60
(47.8% vs 61.1%, P = 0.09) trended towards signiﬁcance in the low and
high score arms, respectively. For PROMS1 at follow-up, there were no
signiﬁcant differences noted in the dosimetric parameters. There were
also no signiﬁcant ﬁndings for PROMS4569 at follow-up; however, OC
V70 (27% vs 38.2%, P = 0.09) trended towards signiﬁcance in the low
and high score arms, respectively.
Conclusions: We found that patients who had worse QOL scores at the
end of treatment, especially related to mouth pain, had signiﬁcantly
higher OC mean and V50 dosimetric parameters. Additionally, higher
OC V60 and V70 parameters may predict for longer term detriment to
QOL. These variables should be optimized during treatment planning to
improve outcomes.
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FIGURE 2. Illustration of dose-weighted SUV computation.

Clifton Fuller, MD, PhD1, Hesham Elhalawani, MD, MSc2, Carlos
Cardenas, PhD1, Stefania Volpe, MD3, Souptik Barua, PhD3, Sonja
Stieb, MD3, Calvin Rock, MD3, Timothy Lin, MD3, Pei Yang, MD3,
Haijun Wu, MD3, Jhankruti Zaveri, BS3, Baher Elgohari, MD3, Lamiaa
Abdallah, MD3, Amit Jethanandani, MD3, Abdallah S.R. Mohamed,
MD4, Laurence E. Court, PhD1, Katherine Hutcheson, PhD3, Gary
Gunn, MD4, David Rosenthal, MD1, Steven Frank, MD1, Adam Garden, MD4, Arvind Rao, PhD5; 1MD Anderson Cancer Center, 2Brigham
and Women’s Hospital/Dana-Farber Cancer Institute, 3University of
Texas MD Anderson Cancer Center, 4The University of Texas M.D.
Anderson Cancer Center, 5University of Michigan
Background: Head and neck cancers radiotherapy (RT) is associated
with inevitable injury to parotid glands and subsequent xerostomia.

Objectives: We investigated the utility of SUV derived from 18FDGPET to develop metabolic imaging biomarkers (MIBs) of RT-related
parotid injury.
Methods: Data for oropharyngeal cancer (OPC) patients treated with
RT at our institution between 2005-2015 with available planning
computed tomography (CT), dose grid, pre- & ﬁrst post-RT 18FDGPET-CT scans, and physician-reported xerostomia assessment at
3-6 months post-RT (Xero 3-6 ms) per CTCAE, was retrieved, following an IRB approval. A CT-CT deformable image co-registration
followed by voxel-by-voxel resampling of pre & post-RT 18FDG
activity and dose grid were performed. Ipsilateral (Ipsi) and contralateral (contra) parotid glands were sub-segmented based on the
received dose in 5 Gy increments, i.e. 0-5 Gy, 5-10 Gy sub-volumes,
etc. Median and dose-weighted SUV were extracted from whole parotid
volumes and sub-volumes on pre- & post-RT PET scans, using in-house
code that runs on MATLAB. Wilcoxon signed-rank and Kruskal-Wallis
tests were used to test differences pre- and post-RT.
Results: 432 parotid glands, belonging to 108 OPC patients treated with
RT, were sub-segmented & analyzed. Xero 3-6 ms was reported as:
non-severe (78.7%) and severe (21.3%). SUV-median values were
signiﬁcantly reduced post-RT, irrespective of laterality (P = 0.02). A
similar pattern was observed in parotid sub-volumes, especially ipsi
parotid gland sub-volumes receiving doses 10-50 Gy (P < 0.05). KruskalWallis test showed a signiﬁcantly higher mean RT dose in the contra
parotid in the patients with more severe Xero 3-6 mo (P = 0.03). Multiple
logistic regression showed a combined clinical-dosimetric-metabolic
imaging model could predict the severity of Xero 3-6 mo; AUC = 0.78
(95%CI: 0.66-0.85; P < 0.0001).
Conclusions: We sought to quantify pre- and post-RT 18FDG-PET
metrics of parotid glands in patients with OPC. Temporal dynamics of
PET-derived metrics can potentially serve as MIBs of RT-related
xerostomia in concert with clinical and dosimetric variables (Figs. 1–3).

FIGURE 1. Parotid dose sub-volume generation.

FIGURE 3. Correlation between severity of post-radiotherapy
xerostomia and (A) Age; (B) Mean contralateral parotid gland dose
(Gy); (C) Post-radiotherapy contralateral parotid gland SUV-median;
and (D) Post-radiotherapy ipsilateral parotid gland SUV-median.

(P077) 18FDG Positron Emission Tomography Mining for
Metabolic Imaging Biomarkers of Radiation-induced
Xerostomia in Patients with Oropharyngeal Cancer
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(P078) Assessing Oral Intake Outcomes in Head and Neck
Cancer Patients Treated with Deﬁnitive Radiation with or
Without Chemotherapy
Ricardo Engel, BS1, Patrick Etta, BS1, Talha Gahzi, BS2, Amy Williams, PhD3, Samantha Tam, MD, MPH4, Suhael Momin, MD4, Steven
Chang, MD4, Tamer Ghanem, MD, PhD4, Diana Walker, MA5, Farzan
Siddiqui, MD, PhD, CPE6, Haythem Ali, MD7, Vivian Wu, MD4,
Jawad Sheqwara, MD7, Megan Carlson, MS8; 1Wayne State University
School of Medicine, 2Michigan State Univ College of Human Medicine,
3
Department of Otolaryngology-Head and Neck Surgery, Henry Ford
Hospital, 4Department of Otolaryngology, Henry Ford Cancer Institute, 5Speech Language Pathology and Otolaryngology, Henry Ford
Health System, 6Department of Radiation Oncology, Henry Ford
Cancer Institute, 7Department of Hematology/Oncology, Henry Ford
Cancer Institute, 8Speech-Language Pathology, Henry Ford Health
System
Background: Head and neck cancer treatment modalities can signiﬁcantly impact functional outcomes of patients, especially oral intake
(Brizel, et al N Engl J Med 1998; Kamal, et al Support Care Cancer
2019). Radiation therapy in particular has been associated with posttreatment xerostomia and dysphagia (Adelstein, et al J Clin Oncol 2003;
Hutcheson, et al Cancer 2013) which can affect quality of life and
impair weight gain, contributing to worse long-term outcomes (Payakachat, et al Head Neck, 2013). Early speech-language pathology
intervention has shown to be effective in improving these functional
outcomes in this population (Greco, et al Int J Radiat Oncol Biol
Phys 2018).
Objectives: The purpose of this study is to evaluate oral intake outcomes of patients undergoing deﬁnitive radiation therapy with or
without chemotherapy for head and neck squamous cell carcinoma.
Methods: A cohort of patients with stage III or IV squamous cell
carcinoma of the oropharynx, larynx, and hypopharynx treated with
deﬁnitive radiation therapy with or without chemotherapy were
extracted from system database. Patients with evidence of distant
metastases were excluded. Swallow function was assessed both pre- and
post-treatment (within four months of treatment initiation or conclusion)
with the Functional Oral Intake Scale (FOIS) (Crary et al, Arch Phys
Med Rehabil, 2005) as measured by a Speech-Language Pathologist
(SLP) involved in the patient’s care. Body mass index (BMI) was
evaluated within four months of treatment initiation and one year after
treatment completion. The use of enteral feeding at one-year posttreatment was also assessed. Data was analyzed with descriptive statistical methods, Wilcoxon sign rank tests, and χ2d tests.

TABLE 1. Description of Baseline Population

Abstracts

TABLE 2. Swallowing Outcomes and BMI

Results: The sample included 152 patients. Table 1 highlights patient
baseline characteristics, tumor location, and treatment. FOIS scores
decreased from pre-treatment to post-treatment, with 75% of patients
having a FOIS of 7 at pre-treatment compared with only 13.8% at the
post-treatment time point (Table 1). Median BMI also decreased from
pre-treatment to one-year post-treatment (Table 2). At one-year posttreatment, 23.7% patients (n = 33) required enteral feeding.
Conclusions: Deﬁnitive radiation therapy with or without chemotherapy in the treatment of head and neck cancer is associated with
impaired oral intake. Treatment is also associated with decreases in
BMI and longer use of enteral feeding, which may reﬂect sequelae of
impaired oral intake. These factors have a negative impact on quality of
life and can lead to long-term morbidity. Integrative treatment plans
would therefore beneﬁt from speech-language pathology interventions
throughout the treatment process.

(P079) Single Fraction Radiotherapy as Postoperative
Treatment (SF-PORT) for Resected, Stage I/II Merkel Cell
Carcinoma
Peter Goff, MD, PhD1, Stephanie Schaub, MD1, Kristina Lachance,
MS1, Emily Huynh1, Nikhil Harikrishnan1, Maclean Cook1, Yolanda
Tseng, MD1, Jay Liao, MD1, Smith Apisarnthanarax, MD1, Kent
Wallner, MD1, Paul Nghiem, MD, PhD1, Upendra Parvathaneni,
MBBS, FRANZCR1; 1University of Washington
Background: In the absence of randomized prospective data, the role of
postoperative radiotherapy (PORT) for localized Merkel cell carcinoma
(MCC) is controversial with varying practice patterns. Although a
majority of patients with resected stage I/II MCC without adverse
features may be cured with surgery alone, those with adverse features
including head and neck (HN) primary tumors have local recurrence
rates of 20% or more without PORT (Takagishi et al Adv Radiat Oncol,
2016). Extrapolating from our experience demonstrating high rates of
local control with single fraction radiotherapy (SFRT) for metastatic
MCC (Iyer et al Cancer Med, 2015), we hypothesized that SFRT (8 Gy)
may be effective as PORT to optimize local control for stage I/II MCC
with adverse risk features [e.g. HN disease, immunosuppression,
recurrent disease, non-oncologic resection, lymphovascular space
invasion (LVSI)], especially in patients for whom a conventional RT
course may not be feasible.
Objectives: Determine if single fraction radiotherapy (8 Gy) may be
effective as PORT to optimize local control for stage I/II Merkel cell
carcinoma with adverse risk features.
Methods: A single-institution, retrospective review of patients with
clinical or pathological stage I/II MCC receiving SFRT (8 Gy) as postoperative treatment (SF-PORT) was completed from a prospectivelyenrolled database.
Results: Thirty patients (median age 78 y) were identiﬁed who received
SFRT after wide local excision (n = 24; 80%), Mohs surgery (n = 1;
3%), shave or excisional biopsy only (n = 5; 17%) of the primary.
Patients had pathological stage I (n = 15; 50%), clinical stage I (n = 10:
33%), pathological stage II (n = 3; 10%) or clinical stage II (n = 2; 7%)
disease. All patients received SF-PORT (8 Gy) at a median of 43 days
(range: 14-203) following resection or biopsy. Five patients (4 with HN
disease) received SFRT to draining lymph nodes. The majority of
patients had HN tumors (77%), LVSI was present in 23%,17% were
immunosuppressed and 7% had locally recurrent disease (n = 2). At
median follow-up of 11.3 months (range: 3-45.7), no local or in-ﬁeld
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recurrences were observed. No local or distant recurrences, MCC speciﬁc deaths, or RT related toxicities grade > 1 (CTCAE v5.0) were
observed. There were two out-of-ﬁeld regional nodal recurrences in HN
patients who did not receive elective nodal RT.
Conclusions: Our early experience demonstrates a high rate of in-ﬁeld
local control in patients with stage I/II MCC with adverse features
managed with SF-PORT. This approach warrants further study.

(P080) Sex Differences in Health Related Quality of Life in
Head & Neck Cancer One Year After Treatment
Madeline Goosmann, MD1, Steven Chang, Attending1, Amy Williams,
PhD2, Samantha Tam, MD, MPH3; 1Henry Ford Hospital, 2Department
of Otolaryngology-Head and Neck Surgery, Henry Ford Hospital,
3
Department of Otolaryngology, Henry Ford Cancer Institute
Background: Head and neck cancer (HNC) makes up about 3% of all
cancers and is treated with systemic therapy, radiation, surgery, or a
combination of these. HNC treatment can be associated with decreased
patient reported health related quality of life (HR-QoL), which can lead
to depression.1 The majority of studies found that females reported
worse patient reported HR-QoL than males,2-7 however, there were a
few that did not have a signiﬁcant difference in overall patient reported
QoL.8-9 With the discovery of patient oriented outcomes (PROs) in
clinical practice affecting patient satisfaction, provider-patient relationship, and overall patient mortality,10 it is vital to include PROs in
the creation of treatment plans.
Objectives: The objectives of this project are to highlight the differences in HR-QoL between men and women. Ultimately, using these
PROs clinically will help to improve patient care, augment patientprovider trust, and optimize treatment plans. Using PROs and recognizing where unconscious biases of providers come into play is pinnacle, and this project aims to highlight how men and women’s experiences are different in the treatment of HNC.
Methods: Participants were given the FACT-H&N instrument one year
after treatment for head and neck cancer at a single tertiary academic
center to assess different aspects of Hr-QoL. Sex differences were
analyzed between the groups. A Wilcoxon Rank Sum test was performed to assess associations with sex and survey responses, as well as
to assess associations with total laryngectomy and survey responses.
Results: There were 100 participants from a single academic center of
which 73% were men and 27% women. Several of the questions had
signiﬁcant differences between men and women: “I feel ill
(P = 0.0299),” “I am satisﬁed with my family communication about my
illness P = 0.0075),” “I am satisﬁed with my sex life (P = 0.0496),”
“My voice has its usual quality and strength (P = 0.0057),” “I can
swallow naturally and easily (P = 0.0437),” and “I can eat solid foods
(P = 0.0248).” There were no signiﬁcant differences between men and
women with laryngectomies.
Conclusions: Overall, men felt more ill, were less satisﬁed with their
sex lives, were less likely to feel a normal strength and quality of voice,
felt decreased ability to swallow normally, and felt they could not eat
solid foods; women were less satisﬁed with communication about their
disease to their families. For those who had undergone laryngectomy,
there were no signiﬁcant differences between men and women. Different aspects of quality of life for men and women are affected by head
and neck cancer. Monitoring PROs are becoming increasingly standard
of care for patients, and providers need to be equipped understand how
to interpret data accordingly and understand the inherent biases.

FIGURE 1. Kaplan-Meier plot of overall survival based on institutional rate of trimodality therapy (surgery followed by adjuvant
chemoradiation).

following surgical resection. Underutilization of adjuvant radiotherapy
(aRT) or chemoradiotherapy (aCRT) may indicate inappropriate
pathologic risk stratiﬁcation and treatment selection, which may
adversely impact survival (OS) at an institutional level.
Objectives: Examine institution-level patterns of surgery, aRT, and
aCRT for esOPC in the United States and their associations with OS.
Methods: Cases of cT1-2 N0-1 M0 oropharynx squamous cell carcinoma who received upfront surgery from 2004-2015 were identiﬁed
from the NCDB. Cases treated at the same institution were grouped for
institution-level analysis. Survival distributions were estimated with
Kaplan-Meier and log-rank tests. Clustering effects by institution were

(P081) More TORS, More Problems? Institution-level
Patterns of Care for Early Stage Oropharynx Cancers in
the US
James Janopaul-Naylor, MD1, Yuan Liu, MS, PhD2, William Stokes,
MD1; 1Winship Cancer Institute at Emory University, 2Rollins School of
Public Health at Emory University
Background: Increasing use of TORS in early-stage oropharyngeal
cancer (esOPC) has stimulated debate over the role of radiotherapy,
both as deﬁnitive non-surgical treatment and as adjuvant therapy

FIGURE 2. Kaplan-Meier plot of overall survival based on institutional rate of adjuvant radiation (surgery followed by adjuvant
radiotherapy).
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calculated with optimal cut search using bias-adjusted log-rank tests.
Cox proportional hazards models were built with backward selection.
Results: 19,508 patients treated within 2,290 institution-years received
upfront surgery. Institution-level median rate of aRT was 9.0% (IQR
0-25%), and median rate of aCRT was 3.4% (IQR 0.0-20.0%), despite
median rate of positive margins of 25.0% (IQR 0.0-50.0%). From 20042007 to 2012-2015, median rate of upfront surgery increased from 42% to
50% (P < 0.01), the median rate of aRT increased from 6% to 9%
(P = 0.11), and the median rate of aCRT increased from 0% to 8%
(P < 0.01). On UVA, OS was longer for patients treated at institutions with
higher case volume, higher rates of upfront surgery, higher rates of aRT,
and higher rates of aCRT (all P ≤ 0.04). Applying optimal cut points, ﬁveyear OS was lower for patients at institutions with <11.9% of patients
receiving aRT (65.0% vs 69.1%; P < 0.01) and with <10.4% of patients
receiving aCRT (65.5% vs 69.4%; P < 0.01). On MVA there were signiﬁcant associations for race, comorbidities, income, lymph node size,
lymphovascular invasion, and HPV status with OS, but non-signiﬁcant
associations for lower institutional use of aRT (HR 1.05; 95%CI 1.00-1.11,
P = 0.06) or aCRT (HR 1.02; 95%CI 0.96-1.08, P = 0.55).
Conclusions: Low institutional rates of aRT and aCRT for esOPC do
not appear to be independently associated with OS. However, institution-level utilization of both upfront surgery and aCRT are increasing in
tandem, suggesting that patients previously considered poor or borderline surgical candidates are increasingly being offered surgery.
Moreover, institutions offering surgery exhibit a troubling mismatch
between reported risk factors and adjuvant therapy: one-quarter report
positive margins in ≥ 50% of cases, but three-quarters provide aCRT in
≤ 20% of cases. These ﬁndings underscore the importance of multidisciplinary care in optimal selection of upfront and adjuvant therapy in
esOPC (Figs. 1 and 2).

(P082) Improved Local Control in p16 Negative Oropharyngeal Cancers with Hypermethylated MGMT
Garrett Jensen, MD1, Gabriel Axelrud, MD2, David Fink, DO3,
Arundhati Rao, MD4, Kendall Hammonds, MPH4, Kimberly Walker,
MSHA4, Marcus Volz, BS4, Gowan Alan, MD4, Niloyjyoti Deb, MD4,
Sameer Jhavar, MD4; 1Baylor Scott & White, 2Covenant Health, 3Incyte
Diagnostics, 4Baylor Scott and White
Background: Patients with oropharyngeal cancers that are p16 negative
(p16-) have worse outcomes than those who are p16 positive (p16+)
and there is an unmet need for prognostic markers in this population.
O6-Methylguanine (O6-MG)-DNA-methyltransferase (MGMT) gene
methylation has been associated with response to chemoradiotherapy
(CRT) in glioblastoma.
Objectives: We sought to ﬁnd if MGMT promoter methylation was
associated with outcomes of locally advanced oropharyngeal and oral
cavity squamous cell carcinoma (OOSCC) in patients treated with
deﬁnitive concurrent CRT.
Methods: Patients were identiﬁed with primary OOSCC, known p16
status, retrievable pre-treatment biopsies, and at least 6 months of follow-up who received deﬁnitive concurrent CRT from 2004 to 2015.
Biopsies were tested for MGMT hypermethylation (MGMT+) using a
Qiagen pyrosequencing kit (Catalog number 970061). Outcomes were
subsequently recorded and analyzed.
Results: Fifty-eight patients were included with a median follow up of
78 (range 6-196) months. Fourteen patients (24.1%) had oral cavity
cancer and 44 (75.9%) had oropharyngeal cancer. A signiﬁcant difference was found for local recurrence free survival (LRFS) by combined
MGMT and p16 status (P = 0.0004). Frequency of LR in MGMT+/p16
+, MGMT+/p16-, MGMT-/p16+, and MGMT-p16- patients was 14.3,
14.3, 13.0, and 69.2%, respectively (P = 0.0019). A signiﬁcant difference was not found for distant recurrence free survival (P = 0.6165) or
overall survival (P = 0.1615). LRFS remained signiﬁcant on analysis
restricted to oropharyngeal cancer patients (P-value = 0.0038).
Conclusions: Patients who are p16- and MGMT+ with oropharyngeal
and oral cavity squamous cell carcinoma have signiﬁcantly better LC
with deﬁnitive CRT than those who are p16- and MGMT-. Prospective
studies are needed to verify these ﬁndings (Fig. 1).

FIGURE 1. Local recurrence free survival by MGMT and p16
status of a) patient cohort, b) oropharyngeal cancer, and c) oral
cavity cancer.

(P083) Analysis of Oral Microbial Flora in Patients
Undergoing Chemoradiation for Head and Neck Cancer
Raﬁ Kabarriti, MD1, Shalom Kalnicki, MD1, Chandan Guha, MD,
PhD1, Madhur Garg, MD2; 1Monteﬁore Medical Center, 2Monteﬁore
Background: Patients undergoing chemoradiation for head and neck
cancer experience treatment related side effects including mucositis and
xerostomia which can signiﬁcantly alter oral microbiome and provoke
microbial dysbiosis, further compounding and contributing to the
complex pathogenesis of the treatment related side-effects. In this study,
we prospectively evaluated the oral microbiome in patient undergoing
chemoradiotherapy for head and neck cancer.
Objectives: In this study, we prospectively evaluated the oral microbiome in patient undergoing chemoradiotherapy for head and neck
cancer.
Methods: Patients undergoing deﬁnitive or postoperative radiation
therapy with concurrent chemotherapy were prospectively enrolled in
an investigator initiated clinical trial assessing the supportive care
during chemoradiation for head and neck cancers. As part of the
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correlative portion of the study, oral swabs were collected and sent for
bacterial culture.
Results: There were a total of 60 oral swabs from ﬁfteen patients with a
median of 5 swabs per patient. 19 of these were collected during chemoradiotherapy and remaining 41 were collected following completion
of radiotherapy (up to 15 months post-treatment). Of the 19 swabs
during chemoradiotherapy, 89.4% (17) showed normal or mixed oral
ﬂora and 10.5% (2) were abnormal with one showing staphylococcus
aureus and another with candida albicans. Of the 41 swabs post-chemoradiotherapy, 58.5% (24) swabs showed normal or mixed oral ﬂora
and 41.5% (17) swabs were abnormal with 10 showing many staphylococcus aureus, 4 showing candida albicans, 1 showing many yeast
not candida albicans, 1 showing Beta Streptococcus group F and 1
showing Beta Streptococcus group C.
Conclusions: Patients with head and neck cancer undergoing chemoradiotherapy had an increase in abnormal oral microbial swabs postchemoradiotherapy with the most common microbial isolates including
staphylococcus aureus and candida albicans. Strategies to modulate the
oral microbial community for the treatment of chemoradiotherapy
treatment related side-effects are ongoing.

(P084) Intensity Modulated Proton Therapy Better Spares
Non-Adjacent Organs and Reduces the Risk of Secondary
Malignant Neoplasms in the Treatment of Sinonasal
Cancers
Luke Lewis, MD1, Paul Kreinbrink, MD1, Yongbin Zhang, MS1,
Madeline Doberstein, MS, RT(T)1, Max Richardson, MS, CMD,
RT(T)1, Morgan Westerﬁeld, MS, CMD, RT(T)1, Kevin Redmond,
MD1, Vinita Takiar, MD, PhD1; 1University of Cincinnati
Background: Sinonasal cancers (SC) are a rare and heterogeneous
group of malignancies arising from the nasal cavity, with a male predominance, a diversity of histologic sub-types and largely locally
advanced presentation (Youlden D, et al Cancer Epidemiol 2013).
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Surgery is the mainstay of treatment for SC but is often insufﬁcient to
achieve widely clear margins and satisfactory local control, thus adjuvant radiotherapy is frequently employed to improve outcomes. (Robins
K, et al Head Neck 2011). Despite the challenges posed by adjacent
anatomy and post-operative target delineation, advances in radiation
technology now allow for optimal SC treatment while reducing treatment morbidity.
Objectives: The potential dosimetric indications for treating SC with
intensity modulated proton therapy (IMPT) versus volumetric modulated arc therapy (VMAT) are unclear. This study compares dosimetric
parameters and risk of secondary malignant neoplasms (SMNs) using
IMPT and VMAT plans for the treatment of SC.
Methods: After IRB-approval, 10 patients previously treated with
IMPT for cancers of the ethmoid, sphenoid, maxillary, or cavernous
sinuses were identiﬁed. VMAT plans were generated for comparison.
Volume coverage and dose to organs at risk (OAR) were recorded and
compared using paired t-tests. Cases were divided into three groups
based on primary tumor location (ethmoid sinus, sphenoid sinus and
other) to evaluate for differences between proton and photon distribution by disease subsite. Organ equivalent dose (OED) of tissues
outside of the treatment volume was used to deﬁne the excess absolute
and relative risk of SMNs.
Results: In all cases, both VMAT and IMPT provide acceptable target
volume coverage and are able to meet OAR constraints. IMPT is
superior for brain V10 (P < 0.001), V30 (P = 0.012), and mean
(P < 0.001), brainstem maximum point dose (P = 0.027), ipsilateral
cochlea V30 (P = 0.003), contralateral cochlea mean (P < 0.001),
contralateral lacrimal gland mean (P = 0.007), contralateral parotid
mean (P = 0.029), spinal cord D0.01 (P = 0.015) and body outside of
the CTV V10 (P < 0.001), V20 (P < 0.001), and V30 (P = 0.009).
VMAT is superior for ipsilateral eye mean (P = 0.004), ipsilateral lens
mean (P < 0.001), CTV V100 (P = 0.003) and maximum dose
(P = 0.013). Ethmoid sinus tumors (n = 4) beneﬁt more from IMPT
dosimetry while tumors of the sphenoid sinus (n = 2) or other sites
(maxillary, cavernous sinus or multiple sinuses, n = 4) did not favor one

FIGURE 1. Parameters by anatomic location. Photons (solid), protons (dashed). Brain mean (A) and body minus CTV V10 (B) are
representative dosimetric parameters that favor IMPT due to decreased dose to distant organs and total dose respectively. Ipsilateral eye
mean (C) and maximum hot spot (D) are representative dosimetric parameters favoring VMAT for adjacent organ dose and target
coverage homogeneity respectively.
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FIGURE 2. Representative comparative plans. IMPT plans are shown on the left and VMAT plans are shown on the right of each panel.
Panel A demonstrates low dose spread with VMAT with a sphenoid tumor. Panel B demonstrates hotspots and heterogenous dose
distribution with IMPT with a tumor involving multiple sinuses. Panel C demonstrates the sharper dose falloff of VMAT around the eyes
with an ethmoid tumor. Panel D demonstrates more effective sparing of contralateral structures with IMPT with a maxillary sinus tumor.

modality over the other. The relative risk of SMNs with VMAT compared with IMPT was 3.35 (95% CI, 1.92-5.89).
Conclusions: For the treatment of SC, IMPT spares OARs that are not
immediately adjacent to the treatment volume and reduces the risk of
SMNs when compared with VMAT. However, VMAT spares OARs
abutting the target volume better than IMPT and has more homogeneous target coverage (Figs. 1 and 2). These differences suggest sinonasal tumors located superiorly, such as those of the ethmoid sinus,
beneﬁt most from IMPT while neither modality is superior for tumors in
other locations.

(P085) Recurrence of Primary Mucosal Head and Neck
Squamous Cell Carcinoma in Solid Organ Transplant
Recipients
Evan Liang, MD1, Marissa Gilbert, BS1, Farzan Siddiqui, MD, PhD,
CPE2; 1Henry Ford Health System, 2Department of Radiation Oncology, Henry Ford Cancer Institute
Background: Patients that undergo a solid organ transplant have been
shown to have a higher risk of developing cancer and even subsequent
recurrences due to the immunosuppressants required to prevent rejection. Most established literature has been in the setting of cutaneous
malignancies. In this study, we examine patients diagnosed with primary mucosal head and neck squamous cell carcinomas (HNSCC)
diagnosed post-transplant to analyze their disease characteristics and
clinical outcomes.
Objectives: To retrospectively characterize patients with primary
mucosal HNSCC with history of prior solid organ transplant to deﬁne
patient and tumor factors as well as analyze their long-term outcomes.
Methods: IRB approval was obtained for a retrospective evaluation
utilizing our institutional head and neck cancer database. The analysis
included patients who had previously undergone a solid organ

transplant and subsequently were diagnosed with a primary mucosal
HNSCC. These included patients diagnosed from March 2006 to March
2021. The onset of recurrence was analyzed to identify long-term health
implications for this patient cohort. Kaplan-Meier analyses were performed to calculate overall and disease-free survival.
Results: Out of 1,221 patients in our database, 24 patients met the
inclusion criteria. Three patients were excluded due to lack of treatment
or follow-up information, creating a sample of 21 patients. Of these, 13
(61.9%) received a liver, 4 (19%) received a kidney, 1 (4.8%) received a
lung, and 3 (14.3%) received two transplants. After receiving the
transplant, the median time to a HNSCC diagnosis was 6.4 years (range
of 0.5 y to 18.5 y). The primary tumors included 8 (36.3%) oropharyngeal, 8 (36.3%) oral cavity, 5 (22.7%) laryngeal, and 1 (4.5%)
hypopharyngeal lesion for a total of 22 lesions, with one patient having
concurrent primaries of the oral cavity and oropharynx. The cohort
included 1 (4.7%) stage 0, 7 (33.3%) stage I, 3 (14.3%) stage II, 3
(14.3%) stage III, and 7 (33.3%) stage IV; no patients had distant
metastasis at time of diagnosis. Of the patients, 7 (33.3%) were treated
with surgery alone, 6 (28.6%) received post-operative radiation/chemoradiation, 6 (28.6%) were treated with deﬁnitive chemoradiation, and
2 (9.5%) received deﬁnitive radiation. Median overall survival was
31 months. After treatment, 6 (28.6%) patients experienced a recurrence. Disease-free survival was 72.1% at 12 months. All patients who
had a recurrence also died within the follow-up period. The median time
of death after recurrence for all six patients was 11.5 months (range of
1 month to 22 mo).
Conclusions: Solid organ transplant patients are at a higher risk of
developing many different cancers. Treatment of primary mucosal
HNSCC is frequently done with curative intent and can be associated
with signiﬁcant morbidity. A better understanding of how solid organ
transplant history modiﬁes the disease course can help properly guide
treatment decisions. In particular, this series highlights a high rate of
mortality among patients who experience a disease recurrence. Further
research is needed to better understand the risks associated with
recurrence in solid organ transplant patients.
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(P086) Development of a Novel Accelerator System and
New Targeted Drugs for BNCT
Tioga Martin, PhD1, Kataro Matsumoto, PhD2, Fuyuhiko Tamanoi,
PhD2, Michael Torgov, PhD3, Linnette Capo, MS1, Maki Ikeura, BA4,
Chunying Zhang, MS1, Maria Malinao1, James Welsh, MD5, Kendall
Morrison, PhD1; 1TAE Life Sciences, 2Institute for Integrated CellMaterial Sciences, Institute for Advanced Study, Kyoto University,
3
Company, 4TAE life sciecnes, 5Department of Radiation Oncology;
Loyola University Stritch School of Medicine and Edward Hines Jr VA
Medical Center
Background: Boron neutron capture therapy (BNCT) is a binary
radiation modality: following infusion with a 10B-containing compound that targets cancer cells, the tumor is irradiated with a low-energy
neutron beam that triggers ﬁssion of the 10B isotope. The ﬁssion
releases nuclear fragments that cause dsDNA breaks resulting in
apoptotic cell death. BNCT development has been hindered by a
number of practical hurdles, especially the need for a nuclear reactor as
a source of neutrons and the reliance on poorly soluble boronophenylalanine (BPA) for 10B delivery. We are developing a new
neutron source and drugs to overcome these hurdles.
Objectives: For successful BNCT at least 20 μg of 10B needs to be
delivered per gram of tumor and the minimal tumor:healthy cell boron
ratio 3:1. BPA has several inefﬁciencies including solubility and
inadequate boron delivery. We aim to overcome these by developing
new boron-carrying entities including unnatural amino acids, small
peptides and boron enriched nanoparticles.
Methods: Boronated amino acids are designed based on known LAT-1
substrates and synthesized by adding boronic acid and puriﬁed using
preparative HPLC. The aqueous solutions are formulated to achieve
high concentrations. Nanoparticles are based on periodic mesoporous
organosilica that can be complexed with BPA. All boronated amino
acids and BPMOs are tested for their uptake using FaDu and other cell
lines representing the cancer indication currently treatable by BNCT.
Intracellular boron concentration is measured by ICP OES.
Results: We developed a compact 2.5 MeV tandem accelerator neutron
source operating at 10mA with a lithium target generating neutrons in
the epithermal spectrum ideal for BNCT. We are testing novel boronated artiﬁcial amino acids possessing good solubility, and with cellular
uptake and retention, and easier formulation than BPA. TDP-747, an
amino acid analogue that is taken up by the large neutral amino acid
transporter (LAT-1), which is upregulated in many cancers. In vivo,
TDP-747 has shown encouraging boron delivery. In addition, we have
generated boronated biodegradable periodic mesoporous organosilica
nanoparticles (BPMO) that carry boron through attachment of BPA.
They are approximately 200 nm in size and are able to carry large
amounts of BPA and target tumors by the EPR (enhancer permeability
and retention) effect. We have shown in the CAM tumor model that
they are effective for BNCT using neutrons from the KUR1 reactor in
Kyoto, Japan.
Conclusions: A compact tandem accelerator suitable for BNCT in
hospital settings has been developed along with novel boron drugs with
improved tumor selectivity and 10B loads. BNCT is experiencing now
a revival due to the introduction of accelerator-based neutron sources
and it was approved in April 2020 for the treatment of recurrent head
and neck cancer. We are readying our accelerator system for regulatory
submission in the US and in Europe, with a target date of 2022 and a
goal to start clinical trials in in the next 2 to 3 years.

(P087) Utilizing the Genomic Proﬁle to Characterize Radiosensitivity and Progression in Non-melanoma Skin
Cancers
Russell Palm, MD1, Daniela Martir, MS2, G. Daniel Grass, MD, PhD3,
Steven Eschrich, PhD4, Eric Welsh, PhD5, Javier Torres-Roca, MD3,
Evan Wuthrick, MD3, Kamran Ahmed, MD3; 1Mofﬁtt Cancer Center,
2
Ponce Health Sciences University, 3Department of Radiation Oncology, H. Lee Mofﬁtt Cancer Center & Research Institute, 4H. Lee Mofﬁtt
Cancer Center & Research Institute, 5Department of Biostatistics and
Bioinformatics, H. Lee Mofﬁtt Cancer Center & Research Institute
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Background: Radiotherapy is employed in both the adjuvant and
deﬁnitive settings in the management of basal and squamous cell
skin cancers. The radiosensitivity index (RSI) is an extensively
validated signature of radiosensitivity. Higher RSI values (scale 0-1)
are associated with greater radioresistance. The CIBERSORT
algorithm is a computational method that infers the presence of
tumor inﬁltrating leukocytes (TILs). Previous studies have shown
the presence of TILs have varying signiﬁcance amongst cancer
histologies.
Objectives: In this study, we characterized RSI and correlated the
presence of TILs assessed through the CIBERSORT algorithm with
clinical outcomes in basal and squamous cell skin cancers from our
institution’s tissue biorepository.
Methods: A retrospective collection of clinical data for patients treated
at our institution with transcriptionally proﬁled tissue samples was
performed. A previously deﬁned cut point for RSI (greater than or equal
to 0.375) was used to deﬁne greater radioresistance. A total of 11 basal
cell and 16 squamous cell skin cancer samples were identiﬁed from our
institutional biorepository and stored between the dates of August 2006
through August 2010. All samples were surgically excised. Cox proportional hazard analyses were conducted to assess the presence of 22
individual TILs and risk of progression. Time-to-event analysis was
conducted with the Kaplan-Meier (KM) method with differences
assessed via log-rank.
Results: Median follow-up of samples following tissue collection was
12.7 months (range: 0.4-142.7 mo). Median patient age was 61 (3378 y). The 12-month KM rates of time to progression were 80% and
60% for basal and squamous cell samples, respectively P = 0.12. There
were no signiﬁcant differences between the RSI of basal cell (median
0.47, range: 0.28-0.86) and squamous cell samples (median 0.42, range:
0.26-0.54), P = 0.2. The majority of basal and squamous cell samples
were radioresistant, 73% and 69%, respectively. Signiﬁcant differences
were noted in the TIL proﬁles between samples noted to undergo
progression and those that did not. Elevated expression of neutrophils
(HR: 4.3; 95% CI 1.8-28.1; P = 0.03) and decreased resting mast cells
(HR 2.9; 95% CI 0.8-10.9; P = 0.09) trended towards predicting progression. No other variables were found to be signiﬁcant for
progression.
Conclusions: The majority of basal and squamous cell samples were
radioresistant in our analysis. Signiﬁcant differences were noted in the
presence of TILs between samples noted to undergo progression and
those that did not. These results may help inform clinical decision
making to identify tumors warranting treatment escalation.

(P088) Evaluating the Use of Primary Radiotherapy in
Metastatic Head and Neck Cancers: A Retrospective
Review
Riley McDougall1, Nicholas Gravbrot1, Charles Hsu, MD, PhD2, Jared
Robbins, MD3; 1University of Arizona College of Medicine - Tucson,
2
University of Arizona Cancer Center, 3University of Arizona
Background: Squamous cell carcinoma of the Head and Neck
(SCCHN) presents with distant metastases in ∼10% of cases. In this
scenario, systemic therapy is the standard of care, but some patients
receive local radiation therapy (RT). Understanding the prognosis and
outcomes for these patients is important to guide management and
determine the beneﬁt of primary site RT in this population.
Objectives: To review treatment practices and evaluate the role of
primary site RT in SCCHN with de novo distant metastatic.
Methods: Utilizing the National Cancer Database, a retrospective
analysis was conducted using data from 2010 to 2015. Only patients
with SCCHN and de novo distant metastatic disease were included. All
treatment modalities were evaluated to determine treatment patterns.
Univariate and multivariate analyses were performed for overall
survival (OS). Case-controlled matching was used to compare chemotherapy (CHT) vs chemoradiation (CRT) with deﬁnitive intent. Comparisons were made with and without a landmark analysis before
matching. Once matched, frequencies were analyzed. The 1-year OS,
3-year OS, and median OS were reported.
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Results: 4667 patients were included: 33.3% oral cavity, 27.4% oropharynx, 11.2% nasopharynx, 24.2% larynx, and 3.8% had a sinus
primary tumor. Osseous metastases alone were seen in 20.8% of
patients, lung in 49.0%, liver in 7.50%, brain in 1.5% and multi-organ
in 21.2% of patients. Primary-site RT alone was delivered to 444
patients, metastatic-site RT +/- CHT to 304, CHT alone to 1116, concurrent CRT (cCRT) to 679, sequential CRT (sCRT) to 536, surgical
intervention +/- other modalities (SURG) to 530 (adjuvantly 303 with
CHT and 248 with RT), and 1058 received no treatment. CRT patients
had relatively more advanced disease and nodal involvement when
compared with CHT. On multivariate analysis age, race, insurance
status, Charlson-Deyo score, primary location, T4 status, metastatic
location, and treatment modalities were signiﬁcant. Median OS began
from the start of therapeutic intervention: primary RT alone was
4.12 months, metastatic site RT +/- CHT was 5.65 months, CHT alone
was 8.57 months, cCRT was 9 months, sCRT was 14.34 months,
SURG was 10.5 months, and no treatment was 2.27 months. 2211
received RT, with 1410 receiving deﬁnitive intent (dRT) and 801
receiving palliative RT (pRT) (465 to primary, 336 to metastatic site):
16.2% receiving RT died in 30 days of receiving treatment (10.9% dRT,
25.5% pRT). In the matched cohort analysis, CHT vs CRT with and
without a landmark analysis noted 44.2% vs 58.5% and 43.0% vs
54.7% OS at 1-year, 9.0% vs 20.8% and 9.7% vs 19.4% OS at 3-years,
and a median OS of 11.14 vs 15.17 and 10.29 vs 14.58 months
(P < 0.001) respectively.
Conclusions: Deﬁnitive primary-site RT added to CHT may improve
overall survival in select patients with SCCHN with de novo distant
metastases. Further study in prospective and randomized trials is
warranted.

(P090) Evaluating Quality of Life and Functional Outcomes
in Salvage Surgery for Head and Neck Cancer
John Riley, DO1, Amy Williams, PhD2, Keisha Best, MS3, Nitika
Tripathi, BS3, Steven Chang, MD4, Tamer Ghanem, MD, PhD4, Suhael
Momin, MD4, Farzan Siddiqui, MD, PhD, CPE5, Vivian Wu, MD4,
Samantha Tam, MD, MPH4; 1Henry Ford Macomb Hospital,
2
Department of Otolaryngology-Head and Neck Surgery, Henry Ford
Hospital, 3School of Medicine, Wayne State University, 4Department of
Otolaryngology, Henry Ford Cancer Institute, 5Department of Radiation Oncology, Henry Ford Cancer Institute
Background: Unique challenges surround treatment for residual or recurrent
head and neck squamous cell carcinoma (HNSCC). Of the limited treatment
options for residual or recurrent HNSCC, salvage surgery is often the best
option. However, salvage surgery can result in signiﬁcant morbidity, affecting
both quality of life (QoL) and functional outcomes. Few studies have
examined QoL outcomes following salvage surgery in the setting of HNSCC.
Objectives: To analyze head and neck related quality of life and
functional outcomes in patients with head and neck cancer who
underwent salvage surgery.
Methods: In this IRB approved study, FACT-HN Version 4 was
administered pre-operatively and 6 months post-operatively to patients
undergoing salvage surgery for HNSCC between November 4, 2014
and April 27, 2020. Retrospective cohort analysis was performed on
this population with major outcome being postoperative QoL score.
Functional outcomes included postoperative tracheostomy and feeding
tube status. QoL outcomes were compared with paired t-tests. Univariate logistic regression was used to determine characteristics associated with presence of permanent tracheostomy and feeding tube,
deﬁned as presence greater than 30 days.
Results: Overall, 25 patients undergoing salvage surgery for HNSCC
were included in this analysis. Primary tumor sites were larynx/hypopharynx (44.0%), oral cavity (24.0%), oropharynx (20.0%), salivary
(4.0%), skin (4.0%), and unknown primary (4.0%). Salvage surgeries
consisted of total laryngectomy (36.0%), deﬁnitive neck dissection
(24.0%), mandibulectomy (16.0%), parotidectomy (8.0%), with total
laryngectomy/total glossectomy, radical tonsillectomy, TORS base of
tongue excision, and transoral laser laryngeal excision all comprising 4%
of cases. Total QoL scores were not signiﬁcantly different preoperatively
to postoperatively (mean 108.7, 95% CI = 97.7 to 119.7 vs. 103.8, 95%
CI: 93.1 to 114.5; P = 0.436, with maximum total score of 148). Patients
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with lower preoperative Emotional Well-Being (EWB) subscores demonstrated signiﬁcantly worse EWB subscores postoperatively (postoperative mean: 17.0, 95% CI: 14.5 to 19.4 vs. 21.7, 95% CI: 20.0 to
23.4; P = 0.002). Of patients who underwent tracheostomy tube placement, 53.8% (N = 7/13) remained tracheostomy dependent long-term
( > 30 d). Of patients who underwent feeding tube placement, 81.0%
(N = 17/21) remained feeding tube dependent long-term ( > 30 d). Tracheostomy and feeding tubes remained in place with median durations of
3.02 months (range 0.16 to 20.55) and 10.13 months (range 0 to 24.89),
respectively. All patients with T3/4 disease undergoing salvage surgery
required long-term feeding tube (N = 6).
Conclusions: This study provides important information about quality
of life and functional outcomes for patients undergoing salvage surgery
for HNSCC. There is a high rate of long-term tracheostomy and feeding
tube dependence following salvage surgery. While no difference was
found in head and neck related quality of life total score and sub-scores
at 6 months postoperatively, general emotional well-being preoperatively was most associated with general emotional well-being
postoperatively. This information should be taken into consideration when counseling and managing patients with residual or
recurrent HNSCC.

(P091) A Two-decade, Single-institution Experience of
Superﬁcial Radiation for Squamous Cell and Basal Cell
Carcinoma of the Skin in Select Patients
Sumi Sinha, MD1, Priyanka Ghosh, MD2, William Silveira, MD, PhD3,
Jason Chan, MD4, Sue Yom, MD, PhD, MAS5; 1University of California San Francisco, Department of Radiation Oncology, 2Weill
Cornell Medical College, 3Clovis Community Medical Center, 4University of California San Francisco, 5University of California, San
Francisco
Background: Skin cancer remains the most common form of cancer in
the United States. Non-melanoma skin cancers (NMSC) including
squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) are
largely considered curable disease with primary surgical resection.
However, surgery may not be recommended in patients with cancers in
cosmetically sensitive areas or who are of advanced age or with signiﬁcant co-morbidities. Radiotherapy is also recommended for patients
with positive margins after surgery, recurrent disease, or who prefer a
non-surgical approach. Superﬁcial radiotherapy has historically demonstrated excellent outcomes but its use has declined in recent years.
Objectives: The study aims to assess appropriate candidacy, therapy,
and outcomes of patients with SCC or BCC of the skin undergoing
treatment with superﬁcial radiotherapy.
Methods: A single-institution cancer registry was used to identify patients
who received superﬁcial radiation for SCC or BCC from 10/2003–8/2020
and records were retrospectively reviewed. Toxicity was assessed using
CTCAE version 5.0. Local control (LC) and overall survival (OS) were
estimated using Kaplan-Meier curves with 95% conﬁdence intervals (CI).
All statistical analysis was performed in STATA (version 14.2).
Results: Sixty-six patients were identiﬁed, 18 with SCC and 48 with
BCC. The median age was 78.6 years (interquartile range, IQR, 67.8–
88.4 y) and 43% were female. A history of melanoma was uncommon
(9%) though history of other NMSC was common (62%). Patients were
predominantly referred for lesions of the face (72%) or for multiple
lesions (15%) with the remaining having lesions in the head and neck
(12%). All treatments were given at 100 KV. The median number of
treated lesions was 1 (IQR 1-1) though up to 7 lesions were treated in a
single patient. Median lesion size was 15 mm (IQR 8-25 mm). Referral
was most often for surgical contraindications (32%) compared with
medical contraindications (21%), patient preference (23%), or positive
margins (18%). The most common treatment regimen was 51 Gy in 17
fractions (44%, biologically equivalent dose, BED = 66.3 Gy) followed
by 40 Gy in 10 fractions (11%, BED = 56 Gy). Treatment was tolerated
well with no grade 4 or higher toxicity though 3 patients (5%) experienced grade 3 toxicity. At a median follow-up of 1.9 years, overall
outcomes were excellent with 1 year LC 94.2% (95% CI 83.4-98.1%)
and 2 year local control 85.2% (95% CI 69.0-93.3%). One year OS was
94.1% (95% CI 82.8-98.1%) with no additional deaths at 2 years.
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Conclusions: Superﬁcial radiotherapy is an excellent treatment option
for patients who have contraindications to surgical management or who
prefer a non-surgical approach. These patients are more likely to be of
advanced age and/or have lesions on the face. Superﬁcial radiotherapy
should be considered as a major primary treatment for SCC and BCC of
the skin.

(P092) Utility of Chemotherapy in Intensity Modulated and
Proton Beam Reirradiation Therapy of Recurrent Head
and Neck Squamous Cell Malignancies
Moaaz Soliman, MD1, Chidinma Anakwenze, MD1, Courtney Pollard,
MD, Phd1, Mark Edson, MD2, Amy Moreno, MD1, Jack Phan, MD,
PhD3; 1MD Anderson Cancer Center, 2Kaiser, 3The University of Texas
M.D. Anderson Cancer Center
Background: More conformal radiation techniques have led to
increased interest in reirradiation of head and neck cancer (HNC). The
beneﬁt of the addition of chemotherapy in the setting of reirradiation of
recurrent HNC is currently unknown. We evaluated our 16-year institutional experience using intensity modulated radiation therapy (IMRT)
and proton beam therapy (PBT) for reirradiation of recurrent HNC
focusing on chemotherapy related outcomes.
Objectives: We aim to review the effects of using systemic therapy on
survival outcomes, including induction chemotherapy (ICT) and/or
concurrent chemotherapy (CC), in the setting of IMRT or PBT reirradiation in patients with recurrent HNC.
Methods: We retrospectively reviewed the records of consecutively
treated patients between 1999–2016 with deﬁnitive IMRT or PBT
reirradiation for recurrent HNC at one site to deﬁnitive doses. Only
patients with Squamous Cell Carcinoma (SCC) histology and treated
with curative intent were included in the analysis.
Results: Median follow-up for 209 eligible patients was 25.1 months
(range 1-167). Patients with a complete response to induction systemic
therapy demonstrated improved 2-year overall survival (OS) when
compared with those patients that had either a partial response, no
response, or progressive disease to induction chemotherapy (76% vs.
49%, Ρ = 0.026). There was no difference between partial responders
and non-responders to induction chemotherapy with regards to OS. In
addition, treatment with concurrent cisplatin doublet therapy demonstrated improved 2-year locoregional control (LRC) when compared
with treatment with concurrent single agent carboplatin (Ρ = 0.030) or
no concurrent chemotherapy (Ρ = 0.023) and trended towards
improvement when compared with treatment with concurrent single
agent cisplatin (Ρ = 0.064). Single agent platinum regimens did not
improve LRC when compared with no concurrent chemo during HNC
reirradiation.
Conclusions: Response to induction chemotherapy can be predictive of
outcome in the setting of reirradiation of recurrent head and neck
malignancies. Concurrent chemotherapy with particular platinum doublet regimens may improve LRC in the reirradiation setting.

(P093) Clinical Outcomes of Gamma Knife Boost for Head
and Neck Cancers with Skull Base Extension
Alan Sosa, MD1, Catherine Wang, PhD2, Theresa Nguyen, BS2, Jay
Reddy, MD2, Amy Moreno, MD2, Adam Garden, MD3, David
Rosenthal, MD2, Steven Frank, MD2, Clifton Fuller, MD, PhD2, Shalin
Shah, MD2, William Morrison, MD2, Gary Gunn, MD3, Shirley Su,
MBBS, FRACS2, Jack Phan, MD, PhD3; 1MD Anderson, 2MD
Anderson Cancer Center, 3The University of Texas M.D. Anderson
Cancer Center
Background: Many Head and Neck Cancers (HNC) have a predilection
for perineural spread which can track proximally and lead to skull base
involvement. In cases of skull base involvement, including gross/
residual disease after surgery, it can be challenging to deliver tumoricidal radiotherapy dose without exceeding nearby critical structure
constraints. The use of Gamma Knife stereotactic radiosurgery as a
boost (GK-boost) to the overall radiotherapy (RT) plan may further
improve sparing of these critical structures while escalating dose to
disease in the skull base.
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Objectives: We report the clinical outcomes of patients receiving a GKboost to the skull base as a component of their overall RT plan.
Methods: Patients with HNC and gross/residual skull base disease after
surgery treated with conventionally fractionated radiation therapy
(IMRT/IMPT) plus a GK-boost were retrospectively reviewed. Six
patients had squamous cell carcinomas, one patient had an adenoid
cystic carcinoma, and another patient had an initially unclassiﬁed epithelioid malignancy most consistent with melanoma. Treatment toxicity, survival, and local control were evaluated.
Results: Of the patients evaluated, 5 received adjuvant radiotherapy
within a mean of 7 weeks after surgery and 3 were treated with
deﬁnitive radiotherapy. The median dose for IMRT was 66 Gy in 3035 Fx. The median GK-boost dose was 8-12 Gy in a single fraction.
The boost was delivered to the trigeminal nerve tract in 6 patients
and the facial nerve tract in two patients. Median follow-up was
38 months. There were no local failures within the boost ﬁeld but
there was one local (and distant) failure in one patient with melanoma. Another patient developed a regional recurrence and expired.
The regional recurrence occurred 11.2 months after completing
treatment in the left orbit outside the prescribed PTV, which received
30 Gy or less. There were no grade 3 or higher acute toxicities
associated with GK-boost but there were three patients that developed asymptomatic temporal lobe radionecrosis. The median onset
of radionecrosis was at 12.8 months (range 9.3-33.9 mo) with a peak
in radiographic necrosis after a mean of 11.9 months followed by a
gradual improvement in two patients.
Conclusions: Gamma Knife boost to the skull base is well tolerated
and provides a durable local control beneﬁt. An ongoing dosimetric
comparative study will assess the extent of normal tissue dose
sparing. A larger prospective study is needed to validate these
clinical ﬁndings.

(P094) Association of Gene Alterations and Patterns of
Failure in HNSCC
Whitney Sumner, MD1, Xenia Ray, PhD2, Leisa Sutton, MAS2, Daniel
Rebibo, BS2, Parag Sanghvi, MD2, Vitali Moiseenko, PhD2, Ida Deichaite, PhD2; 1University of California, San Diego, 2Moores Cancer
Center, University of California, San Diego
Background: Head and neck squamous cell carcinoma (HNSCC)
represents a profoundly heterogeneous collection of malignancies with
rapidly evolving treatment paradigms. Next-generation sequencing has
been increasingly utilized in patients with recurrent or metastatic disease, which generates tremendous potential to understand associations
of genetic alterations with treatment outcomes in this population following radiation therapy (RT). The augmentation and validation of
these associations is critical to the development of radiogenomic databases with a goal of personalized, risk-adapted therapeutic regimens.
Objectives: This study presents the ﬁndings of an initial evaluation of
next-generation sequencing data in patients with HNSCC to identify
associations with treatment outcomes.
Methods: Next-generation sequencing data was collected from HNSCC
patients who received RT for primary or locally recurrent HNSCC. The
twelve most commonly altered genes were included for analysis as
genes of interest (GOI). Relevant patient characteristics and outcome
data including local recurrence (LR) and distant metastasis (DM) were
collected including site of metastatic disease. Associations with LR and
DM were assessed for each of the GOI.
Results: A total of 35 patients met inclusion criteria. On bivariate
analysis, LR was signiﬁcantly associated with alterations in TP53
(r = 0.44, P = 0.009), CDK2NA (r = 0.49, P = 0.003), CASP8 (r = 0.35,
P = 0.04) and NFE2L2 (r = 0.35, P = 0.04). Analysis of DM revealed
that BRCA2 was associated with a higher likelihood of DM (r = 0.44,
P = 0.01). Of patients who experienced DM, BRCA2 alterations were
found in nearly 40% compared with 0% without DM. Only two patients
experienced brain metastases, however these patients each harbored
alterations in four GOIs with BRCA2, NOTCH1 and PIK3CA alterations found in both patients.
Conclusions: Assessment of gene alterations in HNSCC represents a
promising area of exploration as we seek to predict treatment response
to RT and understand the populations at greatest risk for LR or DM.
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Here, we present next-generation sequencing in a cohort of HNSCC
patients demonstrating associations of gene alterations with both LR
and DM. Swift expansion of analyses in this domain are critical for both
prognostication and treatment optimization in this complex population.
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TABLE 2. Number and Types of Studies Identified in the
Literature Search

(P095) Re-irradiation of Recurrent or Second Primary
Head and Neck Cancer After Prior Radiation: Initial
Findings of an American Radium SocietyTM (ARS)
Appropriate Use Criteria Systematic Review
Matthew Ward, MD1, Shlomo Koyfman, MD2, Richard Bakst, MD3,
Danielle Margalit, MD4, Beth Beadle, MD5, Jonathan Beitler, MD,
MBA6, Steven Chang, MD7, Allen Chen, MD8, Jay Cooper, MD9,
Thomas Galloway, MD10, John Ridge, MD, PhD11, Jared Robbins,
MD12, Minh-Tam Truong, MBBS13, C. Jillian Tsai, MD, PhD, MS14,
Sue Yom, MD, PhD, MAS15, Farzan Siddiqui, MD, PhD, CPE16;
1
Levine Cancer Institute, Atrium Health, 2Cleveland Clinic, 3Mount
Sinai, 4Dana Farber Cancer Institute, 5Stanford, 6Knox County Health
Clinic, 7Department of Otolaryngology, Henry Ford Cancer Institute,
8
UC Irvine, 9Retired, 10Fox chase cancer center, 11Fox Chase, 12The
University of Arizona College of Medicine - Tucson, 13Boston University, 14Memorial Sloan Kettering Cancer Center, 15University of
California, San Francisco, 16Department of Radiation Oncology, Henry
Ford Cancer Institute
Background: In 2011, the Appropriateness Criteria for Retreatment of
Recurrent Head and Neck Cancer After Prior Deﬁnitive Radiation were
published. The American Radium Society (ARS) Appropriate Use Criteria (AUC) committee performed an updated literature review in 2021.
Objectives: Update the literature review to prepare for the upcoming
AUC.
Methods: The ARS convened a multidisciplinary expert panel
composed of radiation, medical and surgical oncologists. A search of
the medical literature was conducted using subject-speciﬁc keywords
in PubMed, Embase and Scopus databases. Five key questions were
approved by the committee. Screening identiﬁed articles containing
original data published from January 2000-December 2020 in the
English language. Articles were removed if they focused on salvage
therapies other than re-irradiation or were not otherwise relevant to
one of the key questions. The ﬁnal data tables contained the details
of all systematic reviews, meta-analyses, and prospective randomized trials and the highest level of evidence available for each key
question.
Results: The key questions are listed in Table 1. From the initial
search, 686 citations were identiﬁed, of which 231 were duplicates.
An additional 8 citations were identiﬁed through other sources. Of
the resulting 463 abstracts, 189 were excluded because they were
review manuscripts (N = 66) or because the primary subject focused
on the initial course of therapy (N = 43), were in non-English language (N = 23), or were published before 2000 (N = 23). In total, 274
manuscripts informed the panel discussion, of which 9 were systematic reviews/meta-analyses, 5 were prospective randomized trials,
28 were single-arm prospective studies, 15 were multi-institution
retrospective studies, 188 were single-institution retrospective studies and 29 were original manuscripts of other types (models, case
reports, etc.). Table 2 presents the 30 studies identiﬁed by type, with
those included in the detailed data table shaded (a single study may
be included in multiple cells).

TABLE 1. Key Questions

Conclusions: The AUC head and neck committee completed a literature
search intended to update the original reirradiation publication in 2011.
This updated literature review will inform the forthcoming updated AUC.

(P096) Expanding Our Understanding of Adherence: The
Role of Health Literacy and Cognitive Function in Adherence and Outcomes in Head and Neck Cancer
Amy Williams, PhD1, Maria Olex, PsyD2, Mary Kate Miller, PsyD3,
Marissa Gilbert, BS4, Farzan Siddiqui, MD, PhD, CPE5; 1Department
of Otolaryngology-Head and Neck Surgery, Henry Ford Hospital,
2
Medical College of Wisconsin, 3UMass Memorial Medical Center,
4
Henry Ford Health System, 5Department of Radiation Oncology,
Henry Ford Cancer Institute
Background: Health literacy is the degree to which a person has the
capacity to obtain, process, and understand basic information and
services needed to make decisions about their health care. Poor
health literacy has been associated with difﬁculties managing medications, assessing and evaluating health information, completing
medical and ﬁnancial forms, and comparing nutritional information
of foods. As such, health literacy is closely related to adherence to
medical treatment. Cognitive function contributes to one’s health
literacy, though also independently contributes to adherence.
Patients with head and neck cancers require complex, often multimodal care, and both health literacy and cognitive function have
been found to be lower than the general population. However no
study has examined the interaction between cognitive function and
health literacy within treatment for head and neck cancer and
outcomes.
Objectives: To examine the role of cognitive function and health literacy in adherence to deﬁnitive and adjuvant radiotherapy and chemoradiotherapy and disease-free and overall survival in patients with
head and neck cancer.
Methods: 149 patients who received either deﬁnitive or adjuvant
radiotherapy or chemoradiotherapy for squamous cell carcinoma of the
head and neck and were assessed by psycho-oncology provider before
initiating treatment were included. Patients between August 2017
through March 2020 were included. Patients were administered the
Montreal Cognitive Assessment (MoCA) and the Rapid Estimate of
Adult Literacy in Medicine (REALM-SF) by the psych-oncologist
before starting treatment. Cancer and treatment related variables,
including adherence, were obtained via chart review. Adherence was
deﬁned as having completed the treatment recommended by the Multidisciplinary Tumor Board.
Results: Patients were predominantly male (78%), white (73%), with an
average age of 62 years (SD = 9.1). The average years of education was
13.6 years (SD = 2.6). The mean health literacy score was 6.3 out of 7
(SD = 1.3, range 0-7), indicating reading at 7-8th grade level. The mean
cognitive function score was 23.8 out of 30 (SD = 3.6, range 10-30,
scores less than 26 are indicative of cognitive impairment). Sixteen
percent of patients were non-adherent to treatment recommendations
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and this was not associated with either health literacy or cognitive
function (P = 0.5 & 0.36, respectively). Lower health literacy was
associated with later stage at presentation (P < 0.05). Health literacy
was not associated with disease-free or overall survival (P = 0.66 &
0.11, respectively). However, cognitive function was associated with
overall survival (P < 0.0001) but not disease-free survival (P = 0.22).
Conclusions: Psychosocial variables such as health literacy and cognitive function are infrequently considered or studied in head and neck
cancer. However, there exists signiﬁcant evidence that patients with
head and neck cancer tend to have higher rates of cognitive impairment
and lower health literacy than the general population. Further, literacy
and cognitive function are known to contribute to health outcomes in
other populations. The current study found that cognitive impairment,
but not health literacy, is associated with overall survival, while not
being associated with treatment adherence. Further research is needed
into the pathways that cognitive function interacts with cancer care and
survival. This study highlights the need for assessment of cognitive
function in patients with head and neck cancer, as identiﬁcation and
intervention with these patients can aid in survival outcomes and quality
of life.

(P097) Survival of Mucosal Melanoma Patients in the
Immune Checkpoint Inhibitor Era
Charles Hsu, MD, PhD1, Jessica Xing, MD2, Baldassarre Stea, MD,
PhD3, Shona Dougherty, MB, ChB, PhD2, Montaser Shaheen, MD2, Le
Christopher, MD, FACS2, Jared Robbins, MD4; 1University of Arizona
Cancer Center, 2University of Arizona, Tucson, 3Banner/University of
Arizona/Dept. Radiation Oncology, 4University of Arizona
Background: Mucosal melanoma (MM) is an uncommon subtype of
melanoma with a poor prognosis due to its aggressive behavior,
typically arising in the head and neck, anorectal, and vulvovaginal
regions. Surgical resection with adjuvant radiation or deﬁnitive dose
radiation therapy for gross or residual disease have shown variable
local control with frequent distant metastatic disease, poor response
to cytotoxic chemotherapy, and generally worse survival than cutaneous melanoma (CM). The role of immune checkpoint inhibitors
(ICI) is well-established for CM, but the utility of radiation therapy
and ICI is poorly characterized for MM presenting with localized
disease.
Objectives: Our goal was to explore practice patterns of treatment and
examine survival of ICI and radiation therapy for MM presenting with
localized/locally advanced disease.
Methods: We reviewed cases with histologically conﬁrmed mucosal
melanoma without distant metastasis (DM) at presentation who were
treated with RT in the adjuvant or deﬁnitive setting at our institution
from 2010–2021. Rates of local control (LC), DM, and overall survival
(OS) were calculated with the Kaplan-Meier method and measured from
the end of radiation therapy. The log-rank test was used to assess differences in survival.
Results: Of 17 patients with MM treated with RT, primary sites were
N = 15 (88%) head and neck and N = 2 (12%) vagina with median
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follow-up of 19.2 months. 52.9% of patients were female, and mean
age at the time of RT was 68.2 years (11.8% <50 y and
47.1% > 70 y). At diagnosis, 23.5% of head and neck and 0% of
vaginal had nodal involvement. Surgical resection included partial
biopsy (5.9%), excisional biopsy (11.8%), wide local excision
(47.1%), and radical resection (35.3%), with 64.7% of patients having
gross or residual disease. Technique used included fractionated
IMRT/3D in N = 14 (82.4%, mean dose 60 Gy, mean fractions 28.6),
3D conformal (45 Gy/25fxns) with brachytherapy boost (15 Gy/5fxs)
in N = 1 (5.9%), brachytherapy alone (30 Gy/5) in N = 1 (5.9%), and
SBRT alone (30 Gy/5) in N = 1 (5.9%). Mean BED a/b = 2.5 was 110
(92.4-129.3) with mean EQD2 of 61.3 Gy (median 60.2 Gy, 51.4 Gy71.8 Gy). Of N = 12 with tumor sequencing, none were BRAF positive and N = 1(8.3%) PD-L1 positive. 94.1% of patients were treated
with ICI with N = 3 with CTLA-4 inhibitor alone (17.7%), N = 6 with
CTLA-4/PD-1 inhibitor (35.3%), and N = 7 with PD-1 inhibitor alone
(41.2%). N = 2 (12%) received ICI as initial treatment, N = 7 (41%)
adjuvant after surgery and/or RT, and N = 7 (41%) after recurrence.
Overall survival: As of last follow-up, 35.3% of patients were
deceased, and median OS was 50.2 months with 1-, 2-, and 5-year OS
of 92.9%, 71.6%, and 35.8%. Median OS was longer for those
without gross disease after surgery (91.1 mos vs. 32.1 mos) as well as
those treated to EQD2 > = 60 Gy (50.2 mos vs. 20.4 mos) but not
statistically signiﬁcantly different (log-rank P > 0.05). Local control:
N = 7 (41.2%) had local recurrence: 2 patients progressed locally
before completion of RT, another 5 progressed after completion of
RT with median local-recurrence free survival (LRFS) of 48.0 month
and 1-, 2- and 5-year LRFS of 76.2%, 76.2%, and 38.1%. Though
patients without gross disease had median LRFS of 60.9 months,
even those with gross disease treated with adjuvant or deﬁnitive dose
RT had fair LC with LRFS of median 48.0 months, log-rank P = 0.15.
Median LRFS was greater but not statistically signiﬁcantly different
for those treated to EQD2 > = 60 Gy ( > = 60 Gy 48.0 mos vs.
<60 Gy 11.3 mos, log-rank P = 0.81). Distant metastases: N = 13
(76.5%) of patients developed distant metastases. Median DM-free
survival (DMFS) was 13.2 months, with 1-, 2-, and 5-year DMFS of
53.7%, 30.7%, and 10.2%. Median DMFS did not differ by gross
residual tumor (none 13.2 vs. yes 15.2 mos, log-rank P = 0.77) or by
EQD2 > = 60 Gy (< 60 Gy 11.3 months vs. > = 60 Gy 17.2 months,
log-rank P = 0.16). OS, LRFS, and DMFS did not differ by type and
timing of ICI (log-rank P > 0.05).
Conclusions: Among patients treated with either adjuvant or deﬁnitive RT for localized mucosal melanoma of the vagina and nasal/
paranasal cavities, nearly all patients received ICI, though timing and
type of ICI was variable. Gross total resection and dose of radiation
seemed to inﬂuence OS, though these factors were not statistically
signiﬁcantly associated with outcomes due to the small number of
patients. Unfortunately, distant metastases affected the majority of
patients and appeared to drive outcomes. We were unable to determine how ICI administration inﬂuenced their survival as most
patients were treated with these drugs. Further prospective/randomized studies are necessary to better evaluate optimal methods and
sequencing of therapy to improve survival in this rare and deadly
disease (Figs. 1 and 2).

FIGURE 1. Overall survival for all patients, and by gross disease and RT dose.
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FIGURE 2. Local recurrence and distant metastasis free survival.

(P098) A Prospective Trial Evaluating Patient Reported
Outcomes (PROs) of Oral Stents Fabricated Using Intraoral
Scanning (IOS) and 3D Printing for Head and Neck Cancer
Patients Receiving Radiotherapy (RT)
Mohamed Zaid, MD1, Nimit bajaj, BDS, MPH2, Ryan Mathew, BS2,
Millicent Roach, BS2, Anshuman Agrawal, BS2, Christopher Wilke,
MD, PhD3, Caroline Chung, MD, MSc2, Clifton Fuller, MD, PhD1,
Gary Gunn, MD4, Jack Phan, MD, PhD4, William Morrison, MD1,
Adam Garden, MD4, Steven Frank, MD1, David Rosenthal, MD1,
Richard Cardoso, DDS, MS2, Ruth Aponte Wesson, DDS, MS2,
Adegbenga Otun, BDS2, Mark Chambers, DMD, MS2, Eugene Koay,
MD PhD5; 1MD Anderson Cancer Center, 2The University of Texas,
MD Anderson Cancer Center, 3University of Minnesota, 4The University of Texas M.D. Anderson Cancer Center, 5MD Anderson
Background: Oral stents can be useful in improving the therapeutic
index of RT in patients (pts) with head and neck cancer (HNC).
However, standard stents require extensive resources to fabricate, which
are less likely to exist outside academic institutions and therefore limit
their utilization in community practices.
Objectives: Previously we reported that 3D printed stents are noninferior to standard stents in terms of PROs and positioning reproducibility. Also, we showed that 3D printed stents require signiﬁcantly
less time and resources to fabricate (Zaid, et al Oral Oncology 2020).
Here, we report the interim results of the second cohort of this trial, in
which we utilize IOS and virtual articulating techniques to create
the stent.
Methods: Prospectively, we evaluated pts with HNC who were
dispatched to receive RT and prescribed mouth-opening tonguedepressing stents. Pts had their traditional impressions and bite
records acquired (∼2 cm mouth opening) to construct a stone model
that would be used to manually craft the traditional wax pattern for
simulation and the acrylic stent for RT. Then, we used IOS to scan
the patient’s upper and lower teeth, and the closed bite registration.
Scan ﬁles were imported to computer aided design (CAD) software,
where we used a home-developed virtual articulator to simulate the
2 cm mouth opening. Then, we designed and 3D printed the stents as
previously described (Zaid, et al RO 2019). Pts inserted the 3D
printed stent and the traditional stent for 5–10 minutes at 3 time
points (TP): 1) before simulation (wax pattern), 2) pre-treatment
(acrylic stent), and 3) mid-treatment (weeks 3–5 of RT, acrylic
stent). After each TP for each stent, pts were asked to ﬁll out a
questionnaire covering the design domains of oral stents that
included comfort, ease of insertion, gagging, jaw pain, roughness
and stability in treatment position (Kaanders, et al IJROBP 1992).
Each question was graded on a scale of 0 (best) to 10 (worst).
We used Matched-Pairs test for statistical analysis at signiﬁcance
level of <0.05.
Results: With a target of 10 evaluable pts, four pts fulﬁlled our
inclusion criteria, and completed the three TPs (age 26–73 years, 4

male, 3 oropharyngeal cancer and 1 nasopharyngeal cancer, median
RT dose = 68 Gy). At the ﬁrst TP, there was no signiﬁcant difference
between the 3D printed stent and the wax pattern scores (mean difference = − 2.3, 95%CI [5, − 10], P = 0.36). Similarly, there was no
signiﬁcant difference in the overall scores of the 3D printed (mean
difference = − 1.25, 95%CI [2, − 4], P = 0.3) and acrylic stents
combining TPs 2 and 3.
Conclusions: The interim results indicate that 3D printed stents
designed using IOS, virtual articulators and CAD are not superior, and
potentially not inferior to the traditional stent in terms of PROs. This
updated digital workﬂow can further expand the utilization of these
devices to radiation oncology practices that currently lack the support to
make these devices.

(P099) Compromising Care of Cervical Cancer Patients
Through Disincentivizing Brachytherapy: Exploring the
Impact of Reimbursement on Utilization and Outcomes
David Boyce-Fappiano, MD1, Kevin A. Nguyen, MS2, Mitchell
Kamrava, MD3, Olsi Gjyshi, MD, PhD1, Lauren Andring, MD4, Ann H.
Klopp, MD, PhD5, Catheryn Yashar, MD6, Peter F. Orio III, DO, MS7,
Nikhil G. Thaker, MD8, Albert Chang, MD, PhD9; 1MD Anderson
Cancer Center, 2David Geffen School of Medicine, University of California Los Angeles (UCLA), 3Cedars-Sinai Medical Center, 4UT MD
Anderson Cancer Center, 5The University of Texas MD Anderson
Cancer Center, 6UC San Diego School of Medicine, 7Dana-Farber
Cancer Institute, Brigham and Women’s Hospital, 8Arizona Oncology,
9
University of California Los Angeles
Background: Optimal management of locally advanced cervical
cancer (CC) involves multi-modality therapy with chemotherapy and
combined external beam radiation therapy (EBRT) and brachytherapy (BT). There are growing concerns regarding decreased BT
utilization despite evidence displaying compromised outcomes
without BT.
Objectives: We sought to explore patterns of BT utilization and
relate these ﬁndings to changes in reimbursement while exploring the
impact of the new radiation oncology alternative payment model
(RO-APM).
Methods: This study included a total of 21,153 patients from the
Surveillance, Epidemiology, and End Results registry with a diagnosis of cervical cancer between 1988 and 2015 who received
radiation therapy without any surgery to their primary site. Utilization patterns to be reﬂective of the RO-APM were conducted on
all patients. A sub-cohort of patients with locally advanced (stage
IB2-IVA) non-metastatic disease were utilized to determine utilization patterns and survival outcomes (n = 14,121). Overall (OS)
and disease-speciﬁc survival (DSS) were compared between
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FIGURE 1. Trends in radiation modality utilization for cervical cancer from 1988 to 2015.

radiation modalities within this sub-cohort. Medicare episodes and
reimbursement rates for EBRT and BT were obtained from
2009-2020. Reimbursement levels were compared using multiple
methodologies including MPFS, Ambulatory Payment Classiﬁcation (APC), comprehensive APC (C-APC) and the newly proposed
RO-APM.
Results: In total, 10,107 (47.8%) and 5,888 (41.7%) patients
received EBRT while 11,046 (52.2%) and 8,233 (58.3%) received
EBRT + BT in the overall and sub-cohort respectively. Overall from
1988-2015 BT utilization declined by 22.7%. Within the sub-cohort
median OS was 2.33 and 5.92 years while median DSS was 4.0 vs.
17.4 years for EBRT and EBRT + BT respectively (P < 0.0001). Treatment with BT was associated with improved OS (HR: 0.68, 95%CI:

0.65-0.71, P < 0.0001) and DSS (HR: 0.68, 95%CI: 0.64-0.71,
P < 0.0001). Black race, increasing age and higher stage disease were
associated with inferior outcomes. Medicare claims for BT declined by
42.1% from 2009-2020 with the steepest decline occurring in 2017
(42.2%) correlating with a 66.7% cut in reimbursement with C-APC
implementation. On comparison of payment methodology for 2018 ROAPM ﬁnal rule resulted in a 31.7% cut from the current C-APC model,
and a 51.5% reduction from the APC model.
Conclusions: Brachytherapy utilization continues to decline and closely
mirrors changes in reimbursement. In its present form, RO-APM will
amplify the already substantial reductions in reimbursement thus
threatening the sustainability of BT and compromising care for CC
patients (Figs. 1–3).

FIGURE 2. Kaplan Meier curves comparing (A) overall survival by receipt of radiation (B) disease-specific survival by receipt of radiation
for patients with locally advanced cervical cancer (stage IB2-IVA).
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FIGURE 3. Comparison of Medicare claims filed for cervical cancer brachytherapy and expected annual reimbursement utilizing the
ambulatory payment methodology for HOPDs (APC FFS from 2009-2016 and C-APC from 2017-2020).

(P100) Impact of Socioeconomic Status on Cervical Cancer
Prevention and Screening
Christine Hill-Kayser, MD1, Ronak Dave, BA2, Michael LaRiviere,
MD1, Carolyn Vachani, MSN, RN, AOCN1, Margaret Hampshire, RN,
BSN, OCN1, James Metz, MD1, Christina Bach, MSW, MBE, LCSW3,
Karen Arnold-Korzeniowski, BSN, RN1, Marisa Healy, BSN, RN1;
1
University of Pennsylvania, 2Augusta University/University of Georgia
Medical Partnership, 3Oncolink
Background: Cervical cancer (CC) screening effectively reduces rates
of CC, and is recommended by the U.S. Preventative Services Task
Force, American College of Gynecology, and American Cancer Society. (Curry S, et al, JAMA 2018; Practice Bulletin No. 168, Obstetrics
and Gynecology 2016, Fontham E, et al, A Cancer Journal for Clinicians 2020) Prior research has shown that over 50% of invasive CC in
countries with screening programs are in women who are
underscreened, and differences in CC screening are associated with
race, age, income, education, geography, and healthcare access. (Bos A,
et al, International Journal of Cancer 2006; Akers A, et al, Current
Problems in Cancer 2007).

TABLE 1. Effect of Income on Rates of Cervical Cancer Prevention
use and Risk Factor Avoidance in Higher vs. Lower Income
Patients, Stratified by Age

Results are presented with highest frequency user group (lower vs higher
income) listed in each age group and for each mechanism of prevention. Comparisons refer to higher income vs. lower income.

Objectives: We attempted to determine how income, family history,
and Medicaid expansion were related to utilization of CC screening and/
or vaccination and avoidance of risk factors.
Methods: A convenience sample was obtained from users voluntarily
completing an Internet-based survey designed to assess individual
cancer risk (oncolink.org).(LaRiviere M, et al, ASCO 2019) Analysis
was limited to users who self-identiﬁed as women living in the U.S.
Users were classiﬁed as lower income (LI) [annual household income
(AHHI) < $25,000] and higher income (HI, AHHI > $100,000) and
stratiﬁed by age ( ≤ 25 vs 26+). Comparisons of before vs. after Medicaid expansion were limited to users living in states that had implemented expansion of Medicaid. Due to the large number of comparisons, the 2-tailed P-value cutoff was set to 0.0026.
Results: Of eligible users, 1,774 identiﬁed as LI (64% ≤ 25 y, range
<18-80, 70% white), and 2,257 identiﬁed as HI (31% ≤ 25 y, range
<18-74, 84% white). With the exception of rates of vaccination in those
> 25y and pap smears in those ≤ 25y, HI patients tended to access
preventative services and avoid risk factors for CC at the highest rates
(Table 1). Further examination of LI group demonstrated that FH of CC
did not impact rates of vaccination against HPV or risky sexual activity

TABLE 2. Effect of Either a Family History of Cervical Cancer
(Stratified by Age) or Medicaid Expansion on Rates of Cervical
Cancer Prevention Use and Risk Factor Avoidance in Lower
Income Patients

Results for family history are presented as negative family history vs. positive
family history. Results for Medicaid expansion are presented as before expansion
vs. after expansion.
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(Table 2). Of LI users living in states with Medicaid expansion, 63
responses were submitted before expansion (46% ≤ 25 y, age range 1873, 75% white), and 75 responses were submitted after (45% ≤ 25 y,
age range 18-64, 61% white). Medicaid expansion did not signiﬁcantly
affect rates of adherence with pap smears or HPV vaccination (Table 2).
Conclusions: Individuals with greater income demonstrated better access to
preventative care and avoidance of risk factors associated with cervical cancer.
In the LI user group neither FH of CC nor Medicaid expansion impacted rates
of access to preventative services or avoidance of risk factors. These ﬁndings
point to need for education surrounding CC risk and prevention, particularly
for LI women, regardless of age, insurance status, or family history.

(P101) Your Cancer Journey: The Development of a Culturally Informed Patient Education Material to Improve
Willingness to Pursue Radiation Therapy in American
Indian & Alaska Native Individuals (View Study)
Sasha Ebrahimi, PhD1, Todd DeWees, PhD2, Farhia Omar, MPH2, Timothy
Mathews, FNP – BC3, Donald Northfelt, MD2, Samir Patel, MD2; 1Mayo
Clinic Arizona, 2Mayo Clinic, 3Phoenix Indian Medical Center
Background: Patients from American Indian and Alaska Native (AI/AN)
these communities are often diagnosed with advanced stage cancers and do
not complete guideline concordant cancer care. A recent study by our group
at the Mayo Clinic, in collaboration with the Phoenix Indian Medical Center
(PIMC), shows that many AI/AN patients are concerned about side effects of
radiation therapy (RT) and their concerns are directly associated with the
inability of their providers to explain their treatments adequately (Patel SH,
et al Cancer Control 2020). Studies show that standardized patient education
that use diverse cultural representation and simple language can lead to better
clinical outcomes – particularly in populations with low health literacy. Here
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we propose a project to address the communication barrier AI/AN patients
face by using a culturally informed brochure.
Objectives: 1. To design an educational aid that addresses concerns and
questions speciﬁc to the AI/AN population in a culturally informed
manner with input from all stakeholders. 2. To subsequently use this
material to assess improvements in patient anxiety, perception of information received, and RT completion rate in a randomized controlled trial.
Methods: Members of the PIMC staff and the AI/AN patient appearing
in the brochure served as community advisors and helped us reﬁne the
brochure’s language and images in an iterative process. 100 adult AI/
AN patients receiving cancer treatment at the PIMC will be recruited.
50 patients will receive the standard Mayo Clinic educational booklet
while the other 50 patients will also receive our educational brochure.
All patients will be surveyed twice, once at their clinical visit where
radiation therapy referral is made, and a subsequent visit 1-2 weeks later
to assess patient anxiety and perception of the information received.
Results: Community advisors identiﬁed the following key elements for the
brochure: 1. Graphic representation of native communities and Arizona
landscapes, 2. Employing motifs of windows and doorways to elaborate on
cultural themes of illness as a journey, 3. Depicting native patients and their
family in a story-telling manner, 4. Avoiding complex topics such as
fractionation, 5. Including reassuring verbiage, and 6. Highlighting importance of exercise, eating healthy, and family support. The prototype was
designed through an unique collaborative effort with the Phoenix Indian
Medical Center and the Mayo Clinic (Figs. 1 and 2). The project has
received IRB approval and is currently proceeding with activation.
Conclusions: Adapting medical educational literature to make the
language and imagery inclusive, accessible, and understandable may be
a powerful tool towards equitable care. This study serves as a prototype
that can be utilized in addressing underserved communities facing
communication barriers in other clinical contexts.

FIGURE 1. Bifold brochure, outside view.
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FIGURE 2. Bifold brochure, inside view.

(P102) Changing Landscape of Community Oncology Differential Delay in Cancer Diagnoses Due to the COVID 19
Pandemic

(P103) Worsening Disparities in Intensity-modulated
Radiotherapy Utilization Among Non-Hispanic Black
Patients

Mitchell Finkelstein, High School Student1, Kevin Healey, Medical
Student 1st year2, Steven Finkelstein, MD, DABR, FACRO1; 1FCA/US
Oncology Network, 2AUI
Background: In March 2020, the U.S. health-care system delayed
performing routine procedures secondary to the COVID-19 pandemic.
The number of cancer screenings plummeted according to data from
Medicare, insurers, and electronic medical records. It is unclear if this
delay effected all facets of community oncology equally.
Objectives: To test the hypothesis of a differential delay in cancer
diagnoses by disease subsite in some community oncology organizations due to the COVID 19 pandemic.
Methods: This is a retrospective review of prospectively collected data;
new patients referred to a large multispecialty community oncology
organization before COVID 19 (quarter 2 April-June 2019) were compared
with during COVID 19 (quarter 2 April-June 2020). Data was obtained
using Centricity and iKnowMed electronic medical records for completeness. Cancer disease subsites data (n = 24) were recorded and compared.
Results: As compared with previous year quarter 2 (analogous time
period before COVID 19 pandemic), there was an overall decrease
in new patients cancer referrals to a large multispecialty community
oncology organization. Out of twenty four different cancers subsites, 14 (58%) were decreased. Brain, carcinoid, and breast (DCIS)
were greatest decreased by 75%, 50%, and 40% respectively.
Common cancers skin, breast, and lung were decreased by 6.8%,
5.3%, and 11.7%. Interestingly, head and neck (unknown primary),
GI (upper), and multiple myeloma were increased by 150%, 52.6%,
and 45.4%.
Conclusions: The data suggest a differential delay in cancer diagnoses
by disease subsite in some community oncology organizations. Interestingly, head and neck (unknown primary) was increased by 150%
suggesting referral before complete staging. Further data over time will
assess if these changes persist into the future.

Ryan Hutten, MD1, Christopher Weil, MD2, David Gaffney, MD,
PhD1, Kristine Kokeny, MD3, Shane Lloyd, MD4, Charles Rogers,
PhD, MPH, MS, MCHES5, Gita Suneja, MD2; 1Huntsman Cancer
Institute at the University of Utah, 2University of Utah Huntsman
Cancer Institute, 3Huntsman Cancer Hospital, University of Utah,
4
University of Utah, Huntsman Cancer Institute, 5University of Utah
School of Medicine
Background: Across many cancer sites, intensity-modulated radiotherapy (IMRT) results in improved quality of life, decreased acute and
late toxicity, and opportunities for dose escalation compared with
standard 3D conformal radiotherapy (3DCRT). Sparse published

TABLE 1. Likelihood of IMRT Utilization in Non-Hispanic Black
Patients
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TABLE 2. Subset Analysis of IMRT Usage Based on Insurance in
Non-Hispanic Black Patients

literature from the early IMRT era suggests non-White patients had
lower rates of IMRT utilization, yet the magnitude IMRT-related disparities has not been reported as IMRT utilization has increased.
Objectives: To evaluate temporal trends in IMRT utilization when
stratifying by race and ethnicity.
Methods: The National Cancer Database was queried to identify 10
disease sites with the highest total number of cancer patients treated
with deﬁnitive-intent IMRT in 2017, the most recent year of available
data. Patients who were stage IV at diagnosis, <18 years of age, had
unknown insurance status or race, or treated with palliative intent
radiation were excluded. Race and ethnicity were classiﬁed as Asian,
Hispanic, Hawaiian/Paciﬁc islander, Native American/Eskimo, nonHispanic Black (NHB), and non-Hispanic White (NHW). Using clinical
and demographic covariates, multivariable logistic regression for IMRT
utilization was conducted for each disease site for both early (20042010) and contemporary (2011-2017) cohorts.
Results: Among 10 disease sites (see Table 1), 1,010,292 patients
received radiotherapy as part of deﬁnitive treatment with rates of IMRT
utilization increasing from 22.0% to 57.8% between 2004 and 2017.
When adjusting for clinical and sociodemographic covariates, NHB
patients were signiﬁcantly less likely to receive IMRT in 1 of 10 disease



Volume 44, Number 10, October 2021

sites in the 2004-2010 cohort, and 5 of 10 disease sites in the 2011-2017
cohort compared with NHW patients (see Table 1). Of 119,601 NHB
patients, 33.3% had private insurance, 46.3% had Medicare, 46.3% had
Medicaid, and 4.61% had no insurance. Compared with patients with
private insurance in the contemporary cohort, patients insured by
Medicare were more likely to receive treatment with IMRT in 6 of 10.
Subset analyses by insurance status revealed that NHB patients with
private insurance or Medicare were less likely to receive IMRT in 3 of
10 and 2 of 10 disease sites, respectively (see Table 2).
Conclusions: Despite greater awareness of racial disparities in cancer
care and outcomes, this study demonstrates that as IMRT utilization has
increased over time, the disparity in utilization of IMRT between NHB
and NHW patients has worsened. Compared with private insurance,
patients with Medicare appear to have higher likelihood of IMRT utilization on multivariate analysis, however disparities exist even when
stratifying by insurance type. Further investigation of the underlying
drivers of differential IMRT use—including the role of prior authorization for IMRT utilization in patients with private insurance and social
determinants of health such as insurance access—is warranted.

(P104) Design and Implementation of an Internet-Based
Cancer Risk Assessment Tool: Use over 10 Years
Michael LaRiviere, MD1, Ryan O’Keefe, BS1, Maribel Carpenter1,
Hann-Hsiang Chao, MD, PhD2, Isabella Amaniera1, Carolyn Vachani,
MSN, RN, AOCN1, Margaret Hampshire, RN, BSN, OCN1, Christina
Bach, MSW, MBE, LCSW3, Karen Arnold-Korzeniowski, BSN, RN1,
James Metz, MD1, Christine Hill-Kayser, MD1; 1University of Pennsylvania, 2Hunter Holmes McGuire Veterans Administration Medical
Center, 3Oncolink
Background: Prevention and early intervention can improve survival
and quality of life across cancers. Patient understanding of risk factors,
and associated actionable lifestyle changes and screening programs, is
not well understood by clinicians.
Objectives: We sought to understand individuals’ non-modiﬁable and
modiﬁable risk factors for the development of cancer.
Methods: An Internet-based tool, Reduce My Risk, was created in 2009
and made available on oncolink.org after beta testing and review by a
multidisciplinary advisory board. Users voluntarily completed a survey

FIGURE 1. Geographic location of respondents outside of North America (“Where have you spent the majority of your life?”).
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TABLE 1. Survey Questions

regarding demographics and cancer risk factors (Table 1), and received
information about their cancer risk. Research related to these data has
been IRB-approved.
Results: 28,001 surveys were completed from 2009-2019. Median age
among respondents was 26y (18-101); 60% were female, 87% lived in

North America (Fig. 1), 76% were White/Non-Hispanic, 37% had at
least a bachelor’s degree, and 22% had household income > $100,000/
y. Household size was 3 or less among 54% of respondents. Most lived
in a city/suburb (81%). Users reported on behavioral/modiﬁable risk
factors: 13% were current smokers, 23% previous smokers, 10% used
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TABLE 2. Reported Family History of Cancer by Primary
Cancer Type
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of men between 18-25y received the human papilloma virus (HPV)
vaccine. Among women surveyed, 36% reported performing breast selfexaminations monthly, and 50% reported receiving a breast examination by a clinician at least once every 3y. Sixty seven percent of men
between 55-75y reported undergoing screening prostate speciﬁc antigen
testing, and 50% of men in this age group annual digital rectal
examinations. Nonmodiﬁable risk factors included family cancer history (64%, Table 2) or genetic syndrome (3%), and cancer-predisposing
health condition (26%); 31% of women began menstruating <12y and
33% gave birth to a ﬁrst child > 30y.
Conclusions: This free, publicly accessible cancer risk assessment tool
has a large user population. Users have higher educational status and
smaller household than the general population. Not only did 97% of
users report behavioral risk factors, but 60% of all individuals reported
at least 4 modiﬁable risk factors. By understanding detailed characteristics of a large number of respondents, in-depth analysis of these data
has the potential to improve educational interventions to reduce cancer
risk through behavioral modiﬁcation and cancer screening across the
general public.

(P105) Trends in Diagnosis and Treatment of Metastatic
Cancer in the United States

cigars or pipe tobacco, 6% used oral snuff/chew/quid, and 29% reported
secondhand smoke exposure. Other substance use included marijuana
(22% former users, 10% current users), alcohol (52% current users, 8%
of those ≥ 14 drinks/week), and areca nut, betel leaf, or exotic smoking
(1%). Body mass index (BMI) was ≥ 30 in 19%; 74% of all surveys
reported dietary risks and 36% reported infrequent exercise. Intercourse
<18y and > 10 sexual partners were reported by 43% and 10%,
respectively. Excess UV exposure was reported by 19%, and exposure
to known carcinogens 14%. Sixty-two percent of respondents reported
having received the hepatitis B virus vaccine, 49% of women and 23%

Eric Lehrer, MD, MS1, Kelsey Stoltzfus, MPH2, Brianna Jones, MD1,
Niraj Gusani, MD, MS2, Vonn Walter, PhD3, Ming Wang, PhD2,
Daniel Triﬁletti, MD4, Shankar Siva, MBBS, PhD5, Alexander Louie,
MD, MSc, PhD6, Nicholas Zaorsky, MD, MS3; 1Icahn School of
Medicine at Mount Sinai, 2Penn State College of Medicine, 3Penn State
Cancer Institute, 4Department of Radiation Oncology, Mayo Clinic,
Jacksonville, FL, USA, 5Peter MacCallum Cancer Centre, 6Odette
Cancer Centre - Sunnybrook Health Sciences Centre
Background: Metastatic cancer has historically been considered fatal;
however, there is a paucity of evidence characterizing the epidemiology
of incidence, treatment, and outcomes.
Objectives: We aim to: (I) characterize the epidemiology of metastatic
cancer over time; (II) characterize treatment trends for metastatic

FIGURE 1. Age-adjusted incidence rates per 100,000 by primary cancer site and age at diagnosis. A) The y-axis depicts the age-adjusted
incidence rate of metastatic cancer per 100,000, and the x-axis depicts the age group at diagnosis in years. Age groups are divided into
5 year increments. The colors depict the primary cancer site. (B) The y-axis depicts the relative incidence rate of metastatic cancer per
100,000 compared with other metastatic cancer patients, and the x-axis depicts the age group at diagnosis in years. For patients under
age 25 soft tissue cancers, kidney, and liver cancers make up the plurality of cases. For patients ages 25 to 50, lung, colorectal, breast, and
ovarian cancers have the highest incidence rates. For patients over age 50, the plurality of cases are seen in lung, colorectal, pancreatic,
breast, and prostate cancers.
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FIGURE 2. Trends in the utilization of various treatment options in metastatic cancer patients. (Top row) The y-axis depicts the percent utilization
of the particular treatment (beam radiation, surgery, single-agent chemotherapy. The x-axis depicts the year, from 2004 to 2015. The colors depict
the primary cancer site. (Bottom row) The y-axis depicts the percent utilization of the particular treatment (multi-agent chemotherapy, hormone
therapy, immunotherapy). The x-axis depicts the year, from 2010 to 2015. The colors depict the primary cancer site.
disease; (III) evaluate if survival has improved for metastatic cancer
patients over time.
Methods: The Surveillance, Epidemiology, and End Results (SEER)
and the National Cancer Database (NCDB), 1998-2015 to determine
incidence rates, annual percent change (APC), descriptive epidemiological statistics, and odds ratios for survival.
Results: There were a total of 1,055,860 patients with metastatic cancer.
The most frequent primary cancers were lung (42.6%), colorectal
(9.5%), and ovarian (5.5%). Metastatic lung and colorectal cancer
incidence decreased, APC: − 1.57 (P < 0.001) and APC: − 1.48
(P < 0.001), respectively; metastatic pancreatic cancer incidence
increased, APC: 0.62 (P = 0.001). The use of local therapies decreased
for almost all sites, and the use of systemic therapies increased across
multiple sites: single-agent chemotherapy in kidney cancer (2.54%
increase/year), female breast cancer (1.14% increase/year) and prostate
(1.08% increase/year); multi-agent chemotherapy, most notably in pancreas (2.23% increase/year), uterus (1.81% increase/year), and colorectal
cancer (1.54% increase/year). Increased utilization of immunotherapy
was observed across the majority of sites, most notably in melanoma
(2.14% increase/year). Patients diagnosed from 2006-2010 had 17.4%
higher odds of surviving at least 60 months compared with 1998-2002.
Conclusions: Metastatic disease has been shown to have unique epidemiological patterns, and survival has improved. Continued research
on metastatic disease is important in understanding and addressing the
distinct health concerns of this population (Figs. 1 and 2).

(P106) Characterizing Geographic Isolation from RT Facilities
Sean Maroongroge, MD, MBA1, David Wallington, MD2, Paige Taylor, MS1, David Followill, PhD1, Diana Zhu, BA2, Beverly Guadagnolo, MD, MPH1, Benjamin Smith, MD1, James Yu, MD, MHS3,

Leslie Ballas, MD4; 1University of Texas MD Anderson Cancer Center,
2
Yale University, 3Yale School of Medicine, 4University of Southern
California Keck School of Medicine
Background: Across multiple contexts, travel distance has been shown
to impact the timing and type of care cancer patients receive. (Ambroggi
M, et al Oncologist 2015) Radiation therapy (RT) is no different, and in
fact, may be more prone to the effect of travel distance given the daily
treatments required. However, the current distribution of RT facilities in
the US is not well established. A comprehensive inventory of US RT
facilities was last assessed in 2005, based on data from state regulatory
agencies and international dosimetric quality assurance bodies. (Ballas
L, et al IJROBP 2006) We updated this database to characterize population-level measures of geographic access to RT in the US and
analyze changes over the past 15 years. We also sought to identify
characteristics of counties that were furthest from existing RT facilities
to better understand challenges faced by patients who are geographically isolated from RT resources.
Objectives: Our objectives include reﬁning our “gold standard” database of RT facilities in the US, mapping the data to allow for the
visualization of spatial and temporal trends in access over time, and
identifying characteristics of counties that face the greatest geographic
barriers to receiving RT.
Methods: We compiled data from state regulatory agencies and independent quality assurance bodies to identify US facilities that delivered
RT for human medical treatment in 2018-2020. Addresses were geocoded, mapped, and analyzed with Geographic Information Services
(GIS) software. Geographic isolation was deﬁned as a Euclidean distance of greater than 50 miles between a county centroid and the nearest
RT facility. We assessed changes in multiple measures of geographic
access over time. Univariate and multivariate logistic regression analyses (with a forward selection process) were performed at the county
level to identify features associated with geographic isolation.
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FIGURE 1. Service area map of RT facilities in the US. Salmon-colored regions represent areas more than 50 miles from the nearest RT
facility. Green circles represent areas with new coverage in the latest dataset (2020). Deep red circles represent areas that have lost
coverage since 2005. Blue shaded regions represent areas that have maintained coverage through both periods.
Results: In 2020, a total of 2,313 US RT facilities were reported
compared with 1,986 in 2005, representing a 16.5% growth in facilities
over nearly 15 years. 513 of 3,143 (16.9%) of counties met our deﬁnition for geographic isolation in the 2020 dataset compared with 589 of
3,143 (18.7%) in 2005. 233 counties are located more than 75 miles
from the nearest RT facility, which is notably the upper limit of distance
for which the Department of Health and Human Services allows for
local transportation reimbursement in its latest guidance regarding the
local transportation safe harbor (85 FR 77684). We also found that
increased distance to RT was signiﬁcantly associated with county
measures of rural status, less insurance coverage, older median age, and
lower rates of cancer death.
Conclusions: Based on a 50-mile threshold, we found that one-sixth of
counties in the US can be considered geographically isolated from RT
facilities. Further consideration should be given to policies and technologies that would support the rural patients most vulnerable to the
ﬁnancial toxicity of cancer care to address the health disparities they
face (Fig. 1).

(P107) Impact of the Early COVID-19 Pandemic on Sex
Participation in Academic Publishing in Radiation
Oncology
Robert Miller, MD1, Nancy Anabaraonye2, Jillian Tsai, MD, PhD3,
Hina Saeed, MD4, Fumiko Chino, MD5, Oscar Garcia, MPH6, Ekaete
Ekpo, BA7, Sudeep Ahuja, BA8, Christine Lauro, MD9; 1University of
Tennessee Medical Center Knoxville, 2University of Pennsylvania,
3
Memorial Sloan Kettering, 4University of Wisconsin, 5Memorial Sloan
Kettering Cancer Center, 6University of Southern California, 7Johns
Hopkins, 8University of Maryland Baltimore County, 9University of
Tennessee Knoxville
Background: There is a known sex gap in oncology publishing with
worse disparities within specialty ﬁelds such as radiation oncology.
There has been a dramatic increase in the number of manuscripts
submitted to academic journals during the pandemic. Several analyses
have suggested that the pandemic has had a disproportionate impact on
academic productivity of women in academia, as measured by manuscript publication rates.
Objectives: To determine if female authors published fewer manuscripts proportionally in the early months of the COVID-19 pandemic in
ASTRO Advances in Radiation Oncology.

Methods: A comparison of the sex of ﬁrst/co-ﬁrst and corresponding/
co-corresponding authors, as well as early career versus mid/late career
status and manuscript type, for all papers published by Advances from
its inception in December 2015 to the end of February 2020 was made
to those published after the spread of COVID-19 to North America from
March to the end of May 2020.
Results: This examination of papers published during COVID-19 did
not indicate a statistically signiﬁcant decrease in the overall proportion
of women publishing in Advances. For early career female authors, this
proportion fell just short of statistical signiﬁcance (39% vs. 19%,
P = 0.051). When only scientiﬁc manuscripts were considered, there
was a statistically signiﬁcant decrease in publications by early career
female ﬁrst authors during the early months of the pandemic (37% vs.
11%, P = 0.02).
Conclusions: In the early months of the pandemic, early career female
investigators published fewer manuscripts proportionally compared
with historical rates. Although the results of this study were inconclusive, they do shed light on the broader problem of sex inequality in
academia and raise questions regarding methods to remediate this issue.
A sex gap in academic publishing exists. It has been speculated that
family and parental obligations may affect the trajectory of careers
differently between women and men.

(P108) How Do Radiation Oncology Program Directors
Increase Diversity in Residency Training Programs?
Arif Musa, MS1, James Ninia, MS2, Julianne Flowers, BS1, Maysoon
Al-Hihi, MD3, Richard Jennelle, MD4, Eric Chang, MD4, Omar Ragab,
MD4; 1Wayne State University School of Medicine, 2Wayne State
University, 3Detroit Medical Center, 4University of Southern California
Keck School of Medicine
Background: Radiation oncology remains one of the least diverse
specialties in medicine. Despite attempts to increase the number of
females and under-represented minorities (URM), females make up
only 33.3% of residents and under-represented minorities (URMs) only
6.9% (1). Recently, an overall decline in the number of applicants
coincided with a decline in Black applicants to radiation oncology
residency (2). As a result, there has been a call to action to increase
diversity in radiation oncology residency programs by optimizing the
resident selection process (3).
Objectives: This cross-sectional study of residency training program
directors was performed to identify which strategies were most
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preferred to increase the number of female and URM radiation oncology residents.
Methods: An anonymous, electronic survey was submitted to a list of
residency training program directors in the specialty of radiation
oncology. The survey included questions about program characteristics,
demographic and representation data, and strategies to potentially
increase diversity. The level of agreement or disagreement for each
strategy was quantiﬁed based on a 5-point scale (1 = disagree,
2 = somewhat disagree, 3 = neutral, 4 = somewhat agree, 5 = agree). A
weighted average (WA) was calculated for each strategy. Data were
collected from March to May 2021. A lottery incentive was included.
Results: Responses were received from 15.4% of 91 residency program
directors from university and hybrid programs located in urban and
suburban regions of the United States. Program directors most supported increasing the number of female and URM faculty, recruiting
female and URM medical students directly, and promoting mentorship
among female and URM applicants (WA = 4.9) to increase diversity
followed by establishing a “safe space” to discuss workplace issues
(WA = 4.8). Other highly supported strategies included holistic application review, pipeline program establishment, and concrete measures
to track success of such initiatives (WA = 4.7). Supporting “Women in
Radiation Oncology” and similar groups was also believed to increase
diversity according to program directors (WA = 4.6). Respondents also
expressed somewhat less agreement towards establishing a mission
statement related to increasing diversity, unconscious bias training, and
forming a subcommittee dedicated to increasing diversity (WA = 4.4).
Similar levels of agreement were expressed for establishing an ofﬁce of
diversity, conducting research regarding diversity, cultural competence
training, and “Second Look Days” for applicants (WA = 4.3). In addition, program directors somewhat agreed that a webpage dedicated to
diversity (WA = 4.2), increasing funding for diversity initiatives
(WA = 4.2), and advertising the specialty at diverse medical schools
(WA = 4.0) could increase representation. By comparison, program
directors expressed less support for deemphasizing exam scores
(WA = 3.9), Grand Rounds presentations related to diversity (WA =
3.7), accepting a a minimum number of female, URM or international
applicants (WA = 3.4), and de-identifying applications (WA = 3.1).
Conclusions: Radiation oncology residency training program directors
that responded to our survey expressed varying levels of support for
several strategies to increase diversity. Principally endorsed strategies
included increasing the number of female and URM faculty, promoting
mentorship of female and URM residents, and direct recruitment of
interested female and URM applicants. Several diversity-related initiatives such as a dedicated website, mission statement, and resident
selection committee were also endorsed to a lesser degree. However,
deemphasizing exam scores, accepting a minimum number of applicants, and de-identifying applications garnered less support. These
strategies may be useful to residency program directors and selection
committees seeking to increase representation. Future research is
needed to determine which strategy or combination of strategies is
signiﬁcantly associated with increasing the percentage of female and
URM residents in radiation oncology training programs.

(P109) Impact of the Radiation Oncology Alternative Payment
Model (RO-APM) on Reimbursement for MRI-Guided
Radiotherapy and Adaptive Replanning
Russell Palm, MD1, Kurt Eicher2, Austin Sim, MD, JD3, Susan Peneguy1, Stephen Rosenberg, MD MS1, Stuart Wasserman1, Peter Johnstone, MD, FACR, FASTRO1; 1Mofﬁtt Cancer Center, 2Guidehouse
Consulting, 3Department of Radiation Oncology, H. Lee Mofﬁtt Cancer
Center & Research Institute
Background: The pending implementation of Radiation Oncology
Alternative Payment Model (RO-APM) has raised concerns regarding
the adoption and development of new technology in radiation oncology.
A novel technique that will be impacted by a deviation from a fee-forservice (FFS) model is MRI-guided adaptive radiotherapy (MRgART)
which is intensive of both physician and medical physicist time.
Objectives: We sought to model a typical patient load and distribution
for an MRI-Linac (MRL) and compare current reimbursement under
FFS (Model A) to the proposed RO-APM Final Rule as published on
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9/29/2020 (Model B). We then derived a new modiﬁer that could be
used in the RO-APM to account for the additional resources necessary
to provide this type of adaptive therapy (Model C).
Methods: A sample MRL patient load and distribution consisted of an
annual throughput of 200 patients with 5 primary cancer diagnoses:
breast (31%), lung (13%), colorectal (15%), pancreas/hepatobiliary
(28%), and prostate (13%). Online adaptive treatment planning was
utilized in both lung and pancreatic cancer, and MRI guidance without
adaptive planning was used for breast, colorectal, and prostate cancer.
All treatment regimens except colorectal cancer were hypofractionated.
We utilized nationwide average Truvian FFS Medicare reimbursement
for current procedural terminology (CPT) codes associated with the
technical fees for treatment planning and delivery (Model A) compared
with payment for the technical component of treatment associated with
the diagnosis in RO-APM (Model B). Within the framework of the ROAPM, we added a modiﬁer to account for the proportion of treatments
that were adapted across the total treatment course (Model C); this
retained standard reimbursement for MR guided treatments that did not
require adaptation.
Results: Reimbursement for all selected diagnoses were lower in Model B
compared with Model A, with the largest differences in the adaptive
treatments for lung cancer (− 89%) and pancreatic cancer (− 83%) and
more moderate differences for nonadaptive treatments (breast: − 75%;
colorectal: − 65%; prostate: − 51%). A total annual reimbursement discrepancy in Model B would amount to -79%. Without implementation of
adaptive replanning there was no difference in reimbursement in breast,
colorectal and prostate cancer between Model B and Model C. Accommodating online adaptive treatments in Model C would result in a difference from the FFS (Model A) of − 55% for lung cancer and − 53% for
pancreatic cancer with an overall difference of − 59%.
Conclusions: Without adjustment, the viability of MRgART as a new
treatment strategy is threatened under the RO-APM. Modiﬁcations that
allow for the proportion of adaptive fractions to be billed would allow
the evidence supporting this technique to grow while still allowing for
signiﬁcant cost-savings by encouraging high-value care.

(P110) To Biopsy or Not to Biopsy: Harnessing the NCDB
to Examine Overall Survival Differences as a Function of
Staging Method in Early-Stage Non-Small Cell Lung Cancer
Treated with SBRT
James Cantrell1, Pawan Acharya2, Sara Vesely2, Tyler Gunter1;
1
Department of Radiation Oncology/Stephenson Cancer Center/
OUHSC, 2Department of Biostatistics and Epidemiology/OUHSC
Background: The use of stereotactic body radiation therapy (SBRT) for
early-stage non-small cell carcinoma of the lung (ES-NSCLC) has been
increasing, and many patients are being treated with SBRT without
complete mediastinal staging, contrary to NCCN Guideline recommendations (NCCN 2021). There is a possibility that forgoing invasive
staging in these patients increases the risk of nodal recurrence, thereby
decreasing survival.
Objectives: This study aims to identify overall survival (OS) differences for ES-NSCLC depending on staging method, using the National
Cancer Database’s (NCDB) data set. Further, we intend to identify any
patient, tumor, or treatment characteristics associated with survival.
Methods: Using the NCDB, a retrospective observational cohort study
was performed investigating survival outcomes and prognostic indicators for ES-NSCLC patients receiving SBRT. Only those patients with
ES-NSCLC treated with SBRT (deﬁned as 1-5 fractions with allowable
dose of 3000-7000cGy) within 1 year of diagnosis were included.
Patients receiving any surgical or systemic therapy were excluded.
Kaplan Meier method, log-rank test, and Cox proportional hazards
regression were performed to determine characteristics associated
with OS.
Results: A total of 12,413 patients from 2010 to 2015 met inclusion
criteria for analysis with 876 (7.1%) receiving nodal sampling (NS) and
11537 (92.9%) receiving no nodal sampling (NNS) as part of their
staging work-up. Median survival (MS) for all ES-NSCLC patients
receiving SBRT was 35.8 months (95% CI 35.1-36.8 mo), with 2-year
and 5-year OS estimates of 66.2% and 28.6%. There was no difference
in OS between the NS and the NNS group on univariate or multivariate
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SBRT without nodal staging. These ﬁndings suggest similar OS
between patients with ES-NSCLC treated with SBRT who underwent
mediastinal nodal staging versus those without nodal staging. Furthermore, this study highlights numerous patient, disease, and treatment
related prognostic variables to consider when counseling and planning
therapy for similar patients. Prospective randomized controlled trials are
required to conﬁrm the lack of survival difference between staging
approaches, but these results support the NCCN Guidelines recommendation that certain tumors do not necessarily require invasive nodal
staging.

(P111) Utilization of a Modiﬁed Frailty Index in Predicting
Oncologic Outcomes and Toxicity for Patients with Early
Stage Non-small Cell Lung Cancer Treated with Hypofractionated Radiotherapy

analysis (MVA) (HR 0.99 (95% CI 0.9-1.09), P = 0.83) (Fig. 1,
Table 1). Negative prognostic factors on MVA include age greater than
75, male sex, Charlson-Deyo Score of 1 or greater, increasing tumor
size, and biological effective dose < 100 Gy. Positive prognostic factors
on MVA include Black or other non-white race, adenocarcinoma histology, and shorter interval from diagnosis to SBRT. On MVA there
was a 3% decrease in OS for every additional month from diagnosis to
start of SBRT (P = 0.0075).
Conclusions: The use of SBRT to treat ES-NSCLC continued to
increase over the period of this study, with most patients proceeding to

FIGURE 1. Overall survival comparison of NS and NNS groups.

Justin Cohen, MD1, Maria Sanchez, BS2, Kai Sun, MS3, Melissa
Vyfhuis, MD/PhD4, Akshar Patel, MD4, Sara Dudley, MD5, Pranshu
Mohindra, MD, MBBS6; 1University of Maryland Medical Center
Department of Radiation Oncology, 2University of Maryland School of
Medicine, 3University of Maryland School of Medicine Department of
Epidemiology and Public Health, 4Baltimore Washington Medical
Center Department of Radiation Oncology, 5Central Maryland Radiation Oncology, 6Department of Radiation Oncology, University of
Maryland School of Medicine
Background: Moderately hypofractionated regimens have emerged as
an alternative to stereotactic body radiotherapy for patients (pts) with
central/ultracentral non-small cell lung cancer (NSCLC) who are
medically inoperable due to age, poor performance status (PS) or
comorbidity and who may be at a higher risk of severe toxicity.
Objectives: Utilize a modiﬁed frailty index (mFI) to identify frail pts
and demonstrate that frailty could better stratify clinical outcomes in
these pts.
Methods: We retrospectively analyzed 41 consecutive previously unirradiated pts with stage I-IIB or recurrent NSCLC treated with deﬁnitive
hypofractionated (8-15 fractions) radiation therapy (RT) in our multisite practice. An 11 factor mFI score was calculated based on the following variables: ECOG score ≥ 2, impaired sensorium, diabetes,
chronic lung disease, myocardial infarction within 6 months, hospitalization within 6 months for heart failure, coronary/cardiac disease, HTN
on medication, history of transient ischemic attack, stroke with deﬁcits,
and peripheral vascular disease. Kaplan-Meier (KM) method was used
to estimate 1-year overall-survival (OS), local control (LC), freedom
from progression (FFP) and logistic regression for severe toxicity ( ≥
grade 3) with patients stratiﬁed by mFI score (0-3 vs ≥ 4), median age
(< 78 vs ≥ 78) and ECOG PS (0-1 vs ≥ 2).
Results: Most pts were elderly (median 78 y; range 58-94), White
(78%), with squamous cell carcinoma (43.9%). Twenty pts (48.8%) had
Stage I disease, 12 (29.2%) had Stage II, and 9 (30%) had recurrent
disease. Pts were treated with 8-15 fractions (fx) with a dose range of
50-70 Gy; 70 Gy in 10 fx was most common. At a median follow-up of
17 months, KM estimated 1-year OS for the whole cohort was 87%.
When stratiﬁed by mFI score (0-3 vs ≥ 4), there was no signiﬁcant
difference in 1-year LC (84.3% vs 100%), FFP (76.5% vs 76.5%), or
OS (86.5% vs 92.3%). When stratiﬁed by median age (< 78 vs ≥ 78),
there was no signiﬁcant difference in 1-year LC (82.1% vs 92.9%), FFP
(67.3% vs 84.8%), or OS (94.4% vs 80.7%). When stratiﬁed by ECOG
PS (0-1 vs ≥ 2), there was no signiﬁcant difference in 1-year LC
(89.3% vs 93.8%), FFP (80.7% vs 71.4%), or OS (86.5% vs 87.2%).
There were 4 instances of severe grade 3 toxicity (all cardiopulmonary),
all in the frailer group (mFI score ≥ 4) which was signiﬁcant on
multivariate analysis (P = 0.0136). Stratiﬁcation by median age and PS
was not signiﬁcant.
Conclusions: We found a strong association between higher frailty
score and toxicity outcomes in patients with early-stage NSCLC treated
with hypofractionated RT, a difference that was not predicted by age or
PS. Despite the toxicity risk, hypofractionated RT allowed even frail
patients to achieve comparable tumor control and survival when compared with non-frail patients. Future analyses in larger datasets could
explore the balance between the two competing end-points of toxicity
versus tumor control/survival in frail patients.
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(P112) Examining Outcomes and Toxicity When Using
Hypofractionated Radiotherapy to Early-Stage Tumors for
Patients with Non-Small Cell Lung Cancer
Abigail Copella, MD1, Karthik Devarajan, PhD1, Sameera Kumar,
MD1; 1Fox Chase Cancer Center
Background: Stereotactic Body Radiation Therapy (SBRT) is standard
of care for medically-inoperable, peripheral, non-small cell lung cancer
(NSCLC). While SBRT has been used in peripheral early-stage
NSCLC, the use of SBRT in central lesions is controversial. The most
high-risk central lesions are ultracentral, which come within 5mm or
less of the primary or secondary bronchi. Hypofractionated radiation
therapy (HFRT) for these tumors is a new paradigm that remains largely
unexplored. A prospective study of 47 patients with ultracentral tumors
looking at efﬁcacy and safety of a 6000 cGy in 12 fractions regimen
found 38% of patients experienced grade ≥ acute/late toxicity, with 1
patient experiencing grade 4 and 7 patients experiencing grade 5
hemoptysis (Tekatli H, et al JTO 2016). A second prospective study
demonstrated feasibility of accelerated radiation therapy for non-operable, early stage, NSCLC by using HFRT. This study delivered
6987cGy in 411cGy fractions, over 17 fractions, with toxicity comparable with conventionally fractionated radiation (Bogart J, et al
JCO 2010).
Objectives: The aim of this study is to present local progression free
survival (L-PFS), progression free survival (PFS), overall survival (OS)
and toxicity data for a single institution experience using an HFRT
regimen, 6987cGy in 17 fractions.
Methods: This is a retrospective review of patients with early stage (I or
II) NSCLC treated at a single institution between 2011 and 2019.
Kaplan-Meier curves, log-rank tests and Cox proportional hazards
models were used to analyze L-PFS and PFS. Toxicity rates were
evaluated for patients with ultra-central tumors based on presence of
bronchial stricture/necrosis (BSN), hemoptysis and/or pneumonitis after
treatment. IRB approval was obtained.
Results: A total of 35 patients with NSCLC were included in this study.
Twenty patients had ultra-central tumors, 7 had central tumors and 8
had peripheral tumors. Median age of patients was 79 years. Forty-six
percent of patients were female. Fifty-one percent had squamous histology while 49% had adenocarcinoma histology. One and 2 year
L-PFS were 81.6% (95% CI 0.68-0.98) and 73% (95% CI 0.54-0.97)
respectively. The PFS was 60% (95% CI 0.4-0.82) and 51% (95% CI
0.33–0.79) at 1 and 2 years respectively. The OS at 1, 2, and 3 years
was 62% (95% CI 0.48-0.81), 38% (95% CI 0.24-0.61) and 26% (95%
CI 0.13-0,49) respectively. In patients with ultra-central tumors, 4
patients (20%) experienced BSN and 2 patients (10%) experienced
pneumonitis. Hemoptysis occurred in 1 patient (5%) with an ultracentral
tumor in the setting of local recurrence.
Conclusions: This study demonstrates that the HFRT regimen 6987cGy
in 17 fractions is both safe and feasible, and thus, is an attractive
treatment option for central and ultra-central lung tumors. The toxicity
proﬁle is limited with early data demonstrating acceptable L-PFS
and PFS.

FIGURE 1. Impact of clinical and treatment factors on time to DF.
ITV volume, ITV mean, ITV min, GTV mean, and GTV volume were
the factors most strongly associated with DF. Levels of categorical
variables: Histology (squamous cell carcinoma, adenocarcinoma,
NSCC-NOS, and no biopsy / non-diagnostic biopsy); Delivery
type (IMRT and 3D); T stage (T1, T2, and T3); Lobe involved (LUL,
LLL, RUL, RML, and RLL); Abdominal compression (present or
absent). Units: Dose (Gy), Volume (cc).
Objectives: To identify clinical and dosimetric risk factors for DF in a
cohort receiving SBRT for early stage NSCLC to assist in risk
stratiﬁcation.
Methods: Using a prospectively maintained, IRB-approved registry,
patients with early stage NSCLC were reviewed for failure. DF was
deﬁned as new distant tumor focus on CT with evidence of viability by
biopsy or FDG PET. The following variables were recorded for each
case: GTV and ITV volume, target min/mean/max dose, BED (α/
β = 10), histology, clinical T stage, lobe, PET SUVmax, type of SBRT
delivery, and ± abdominal compression. ITV/GTV ratio was calculated
as a surrogate for respiratory motion. The effect of each factor on DF
was evaluated with the Hoeffding’s D statistic, and correlation between
factors was assessed with Pearson’s correlation coefﬁcient.

(P113) Impact of Dosimetric Factors on Distant Failure in
Early Stage Non-Small Cell Lung Cancer Patients Receiving Stereotactic Body Radiation Therapy
Shahed Badiyan, MD1, James Cordova, MD, PhD2, Randall Brenneman, MD PhD2, Yi Huang, MS2, Kylie Kang, MD2, Gregory Vlacich,
MD, PhD2, Clifford Robinson, MD2, Pamela Samson, MD, MPHS2,
Matthew Spraker, MD, PhD2, Aadel Chaudhuri, MD, PhD3; 1Washington University School of Medicine, 2Department of Radiation
Oncology, Washington University School of Medicine in St. Louis,
3
Washington University School of Medicine in St. Louis
Background: Stereotactic body radiation therapy (SBRT) has local
control (LC) rates of > 90% for early stage non-small cell lung cancer
(NSCLC) (Timmerman et al JAMA 2010). Despite excellent LC, distant failure (DF) is common with upwards of 31% of patients failing at
5 years (Timmerman et al IJROBP 2014). Identiﬁcation of risk factors
predictive of DF may help identify those who would beneﬁt from
adjuvant systemic therapy.

FIGURE 2. Probit regression curve for GTV volume versus DF.
Estimated baseline probability of DF was 22% while 50% predicted probability of DF (horizontal red dashed line) was seen
with GTV volume ≥ 130 cc (vertical black dashed line). Units:
Volume (cc).
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Uncorrelated variables associated with DF were evaluated using univariate and multivariate Cox regression. Probit regression was used to
build a continuous model predicting probability of DF. Signiﬁcance was
set at α < 0.05 for all comparisons.
Results: Of those treated between October 2005 and March 2015, 305
patients with complete dosimetric data were identiﬁed for analysis.
Median follow up time was 19.5 months (range, 0-168 mo), and DF was
noted in 25.2% of cases. The cohort consisted of 95.5%, 0.7%, and
3.8% T1, T2, and T3 tumors, respectively. Histology included squamous cell carcinoma (36.1%), adenocarcinoma (38.7%), and NSCLC
not otherwise speciﬁed (NSCC-NOS, 18.1%); 7.1% were treated
empirically. ITV volume, ITV mean and min, GTV mean, and GTV
volume were most strongly associated with DF (Fig. 1). ITV volume,
ITV mean, and ITV min were highly correlated with GTV volume and
GTV mean, and were omitted from regression analysis. On univariate
analysis, GTV volume was signiﬁcantly associated with DF (HR: 1.01,
P = 0.01). GTV volume remained signiﬁcant on multivariate analysis
(HR: 1.01, P = 0.01) when controlling for GTV mean and ITV/GTV
ratio in the model. Probit analysis estimated the baseline probability of
DF to be 22% (range, 17-28%) with 50% probability of DF at GTV
volume ≥ 130 cc (P = 0.02, Fig. 2).
Conclusions: In this early stage NSCLC cohort, larger GTV volume
was associated with a higher likelihood of DF following SBRT.
Baseline probability of DF exceeded 20% while a GTV ≥ 130 cc
(equivalent to a 6.3 cm spherical tumor) predicted a 50% probability of
DF. Larger studies evaluating the predictive capacity of dosimetric
quantities, including GTV volume, are warranted to validate models for
risk stratiﬁcation in early stage NSCLC.

(P114) A Novel STING Agonist in Combination with
Radiotherapy to Treat Local and Systemic PD1-resistant
Lung Adenocarcinoma
Hampartsoum Barsoumian, PhD1, Livia Cox2, Duygu Sezen, MD2,
Kewen He, MD2, Ethan Hsu, BA2, Yun Hu, PhD3, Nahum PueblaOsorio, PhD2, Maria Angelica Cortez, PhD2, James Welsh, MD1; 1MD
Anderson Cancer Center Welsh Lab, 2MD Anderson Cancer Center,
3
Welsh Lab Radiation Oncology MD Anderson Cancer Center
Background: Immunotherapy has revolutionized the oncological
landscape in recent years, proving to be an effective and minimally
toxic cancer therapeutic in the treatment of solid tumors. However,
resistance to immunotherapy remains a substantial challenge. In most
tumor types, immunotherapy treatment maintains a 20-40% response
rate, with one third of initial responders developing acquired resistance
to the immunotherapy (1). The combination of immunotherapy with
stereotactic body radiation therapy (SBRT) has become a powerful
clinical strategy in the treatment of solid tumors, as well as an effective
tool to combat immunotherapy resistance. This combination simultaneously regulates immune pathways, while promoting an abscopal
response in which treatment to the primary tumor site exposes the
immune system to antigens, propagating a vaccine-like response to nonirradiated metastatic sites (2). This study uses an innate agonist to
stimulator of interferon genes protein (STING). When co-administered
with checkpoint inhibitor(s) and SBRT, the STING agonist further
activates antigen presenting cells and subsequently T-cells to promote
abscopal antitumor responses (3, 4).
Objectives: This study uses a novel STING agonist in combination with
radiotherapy (RT) to overcome α-PD1 resistance and enhance abscopal
occurrence in murine models resembling non-small cell lung adenocarcinoma (NSCLC). By using this therapeutic combination, immunologically “cold” tumors convert to immunologically “hot” (5), therefore
restricting the growth of both primary and secondary metastatic tumors.
Methods: Bilateral tumor models were established in 129Sv/Ev mice
with either 344SQ-Parental (344SQ-P) or 344SQ α-PD1-Resistant
(344SQ-R) lung adenocarcinoma cells (6). Primary and secondary
tumors were implanted subcutaneously on right and left hind legs
respectively. When primary tumors reached around 7mm in diameter,
they were irradiated with a Cesium source with a dose of either 5 Gy x 3
fractions or 12 Gy x 3 fractions. Both primary and secondary tumors
were measured twice per week using digital calipers and mice were
euthanized when average tumor diameter reached 14mm. STING
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agonist (BMS-986301) was injected into primary tumors 3, 9, and
19 days after the last fraction of RT for the parental model; and 2, 7, and
16 days post-RT for the resistant model. Systemic anti-PD1 (200µg/IP
injection) was administered twice per week starting on day 5 postprimary tumor inoculation. At deﬁned endpoints, lungs were also harvested, stained with Bouin’s ﬁxative, and enumerated for lung lesions.
Log-Rank tests were used to compare survival curves, while two-way
ANOVA was used to compare tumor growth curves.
Results: When coupled with RT, the STING agonist and α-PD1 combination signiﬁcantly improved control of both the primary and secondary tumors in the 344SQ-P as well as 344SQ-R models. Moreover,
comparing the efﬁcacy of 5 Gyx3 + STING to 12 Gyx3 + STING, both
groups were equally capable to delay the growth of primary and secondary tumors in the 344SQ-P model (5 Gyx3 vs 5 Gyx3 + STING,
P < 0.0001; 12 Gyx3 vs 12 Gyx3 + STING, P < 0.0001). Therefore, we
selected the 5 Gy x 3 dose to proceed with the next set of experiments in
the resistant model and to reduce the chance of any potential toxicity. In
344SQ-R, the triple combination of RT + STING agonist + α-PD1
signiﬁcantly prolonged survival time relative to all other groups (5 Gyx3
median survival was 25 days vs 5 Gyx3 + STING 36 days vs triple
therapy 43 days; 5 Gyx3 vs 5 Gyx3 + STING P = 0.0210; 5 Gyx3 vs
triple therapy P = 0.0039). The triple therapy also achieved prominent
abscopal responses in 344SQ-R as measured by secondary tumor growth
curves (5 Gyx3 vs triple therapy, P < 0.0001). In addition, although the
dual treatment of RT and STING reduced lung metastases compared
with control or RT only, the triple combination of RT + STING agonist
+ α-PD1 led to signiﬁcantly lower lung metastasis counts compared with
RT alone (P = 0.0235) in the aggressively growing 344SQ-R model.
Conclusions: Based on these preclinical results, radiotherapy along
with local STING agonist may be a potent therapeutic approach to treat
NSCLC cases with anti-PD1 resistance, prolong survival, and maximize
abscopal responses.

(P115) Care Patterns for Stereotactic Radiosurgery in Small
Cell Lung Cancer Brain Metastases
Olsi Gjyshi, MD, PhD1, Steven H. Lin, MD, PhD1, Todd A. Pezzi, MD,
MBA1, Matthew Ning, MD, MPH1, Junsheng Ma, PhD1, Suyu Liu,
PhD1, Chad G Rusthoven, MD2; 1MD Anderson Cancer Center,
2
University of Colorado School of Medicine
Background: The historical standard of care for brain metastases
(BMs) from small cell lung cancer (SCLC) has been whole-brain
radiotherapy (WBRT). However, there is growing interest in upfront
stereotactic radiosurgery (SRS) for select SCLC patients.
Objectives: To determine the current practices and rate of SRS vs.
WBRT use in patients with SCLC BMs.
Methods: We invited United State-based Radiation Oncologists
(ROs) via email to answer an anonymous survey using a branching
logic system addressing their use of SRS and WBRT for SCLC BMs.
Wilcoxon rank-sum test and Fisher’s exact test were used to compare
differences in continuous and categorical variables, respectively. Multivariable logistic regression analyses were ﬁtted for outcome variables
including covariates with P < 0.10 obtained on univariable analysis.
Results: In total, 309 ROs completed the survey and 290 (95.7%)
reported that they would consider SRS for SCLC BMs under certain
clinical circumstances. Across patient characteristics, the number of
BMs was the most heavily weighted factor (mean 4.3/5 in importance),
followed by performance status, cognitive function, and response to
prior therapy. Fewer BMs was correlated with increased SRS use
(55.8% offered SRS ‘very frequently’ [ > 75% of cases] or ‘often’ [5175% of cases] for 1 BM vs. 1.1% for > 10 BM, P < 0.001). In situations
where WBRT was preferred, concern for rapid intracranial progression
(45.3%) and lack of high-level data (36.9%) were the most important
factors. The majority (60.6%) were aware of a large recent international
retrospective analysis (FIRE-SCLC) reporting similar OS between
upfront SRS and WBRT; awareness of this study was the only
respondent variable predictive of SRS use for limited BMs (19.2% of
those aware of the study preferring SRS for limited [ ≤ 4] BMs before
vs. 61% preferring SRS after the publication, P < 0.001). 88.2%
expressed a willingness to enroll patients on a recently opened cooperative group phase III trial of SRS vs. hippocampal-avoidance WBRT.
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Conclusions: In the ﬁrst survey of SRS for SCLC BMs, we observed a
high level of physician openness to upfront SRS in SCLC, particularly
for patients with limited numbers of BMs, as well as signiﬁcant interest
in generating prospective randomized data to clarify the role of SRS in
this population.

(P116) Cardiac Events Following Chemoradiotherapy for
Locally Advanced Non-Small Cell Lung Carcinoma with
Photon and Proton Beam Radiotherapy
Timothy Kegelman, MD, PhD1, Nikhil Yegya-Raman, MD1, Kristine
Kim, MD1, Steven Feigenberg, MD1, Srinath Adusumalli, MD1, Corey
Langer, MD1, Roger Cohen, MD1, Rupal O’Quinn, MD1, Bonnie Ky,
MD1, Michael Kallan, MS1, Srinivas Denduluri, PhD1, Keith Cengel,
MD, PhD1, Aditi Singh, MD1, Charu Aggarwal, MD, MPH1, Joshua
Bauml, MD1, William Levin, MD1, Abigail Berman, MD, MSCE1;
1
University of Pennsylvania
Background: Cardiac toxicity secondary to chemoradiotherapy (CRT)
for locally advanced non-small cell lung cancer (LA-NSCLC) is of
particular concern in a patient population with underlying cardiac risk
factors. Heart radiation dose correlates with adverse cardiovascular
events (CVEs) following CRT. A strategy to minimize this dose is to
utilize Proton Beam RT(PBRT).
Objectives: We aimed to test if type of radiation received correlated
with decreased risk of incurring a post-RT CVE, or with decreased
grade of post-RT CVE in a single-center retrospective study.
Methods: Between December 2008 and November 2016, 187 consecutive patients with LA-NSCLC were treated deﬁnitively with CRT
utilizing either PBRT or photon RT. No patient received adjuvant
immunotherapy as this cohort predates the results of the PACIFIC trial.
Clinical characteristics, RT details, and outcomes were collected. Using
the institutional electronic medical record, we conducted a screen for
ﬁrst instance of CVE, including myocardial infarction (MI), atrial
ﬁbrillation (AFIB), stroke, aortic aneurysm, coronary artery disease,
heart failure, and graded these events. Associations with these events
with RT type were calculated by using Fisher’s Exact test, and survival
by log-rank test from Kaplan-Meier analysis.
Results: All patients received CRT to a median dose in both groups of
66.6 Gy (range 52.2–74.0 Gy). 89 (47.6%) received photon RT, while
98 patients (52.4%) received PBRT. Median follow up was 29 months
(range 4–134). The photon cohort was signiﬁcantly younger, median
age 63.8 years compared with 69.4 years (P = 0.01) and had a less
extensive smoking history (median 30 vs 40 pack-years, P = 0.035).
Mean heart dose (MHD) was signiﬁcantly higher in the photon group
(median 15.0 vs 6.7 Gy, P < 0.001) as were the proportions of patients
receiving > 10 Gy (61.8% vs 28.6%, P < 0.001) and > 20 Gy MHD
(29.2% vs 7.1%, P <0.001). The photon cohort had a lower burden of
CVEs before RT, 34.8% compared with 54.1% of the PBRT group
(P = 0.012). After RT, overall CVEs recorded were similar, observed in
42.7% of the proton group compared with 40.8% of the PBRT group
(P = 0.88). Following treatment, more total (5.7%, n = 5 vs 1.1%, n = 1)
and grade 3+ (n = 3 vs n = 1) MIs occurred in the photon group compared with the PBRT group, although the association did not reach
statistical signiﬁcance (P = 0.88 and 1 respectively). Likewise, numerically more strokes occurred in the photon cohort compared with the
PBRT cohort (4.8%, n = 4 vs 0, P = 0.052). Median overall survival
was similar between the groups (29.2 vs 29.0 months, P = 0.6). Type of
radiation received did not correlate with occurrence of other CVEs or in
evaluating time to individual CVEs.
Conclusions: In our retrospective analysis of deﬁnitive treatment of LANSCLC, the use of PBRT lowered the mean radiation dose to the heart.
While we observed fewer total and grade 3+ MIs and strokes in the PBRT
group, the differences in CVEs did not reach statistical signiﬁcance.

(P117) Pulmonary Hemorrhage in Patients Treated with
Thoracic Stereotactic Ablative Radiotherapy and AntiAngiogenic Agents
Brianna Lau, BA1, Hyunsoo No, MD, CMD1, Yufan (Fred) Wu, MD2,
Max Devine, BS1, Ryan Ko, BS3, Billy Loo, MD, PhD1, Maximilian
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Diehn, MD, PhD1, Alex Chin, MD, MBA1, Lucas Vitzthum, MD,
MAS1; 1Stanford University Radiation Oncology, 2Stanford University,
3
Oakland University
Background: Hemoptysis is a rare but potentially fatal toxicity associated with thoracic stereotactic ablative radiotherapy (SABR). Prior
studies have suggested that vascular endothelial growth factor inhibitors
(VEGFI) may potentiate the risk for pulmonary hemorrhage in patients
treated with SABR for centrally located lung tumors. However, the
toxicity severity relative to timing or sequence of treatment delivery
between SABR and VEGFI, as well as location of the treated tumor, is
not well deﬁned.
Objectives: The purpose of this study is to evaluate the combined
toxicity of VEGFIs and SABR for peripheral, central, or ultra-central
tumors.
Methods: We retrospectively evaluated patients with primary or
metastatic lung tumors treated with SABR between 2008 and 2018 at a
single institution. Baseline patient, tumor and treatment characteristics
were evaluated. Pulmonary bleeding events were graded using CTCAE
version 5.0. Rates of a grade three or higher (G3+) or any ipsilateral
pulmonary hemorrhage at three years were estimated using the KaplanMeier method. We compared rates of bleeding by tumor location,
treatment with a VEGFI, sequence of therapy and VEGFI within
90 days of SABR using the log-rank test.
Results: This inclusion criteria identiﬁed a total of 925 pulmonary
tumors treated with SABR in 691 patients. Of this cohort, 44 patients
were treated with a VEGFI (bevacizumab, sorafenib, pazopanib, sunitinib or ramucirumab), with the majority receiving bevacizumab
(n = 38, 86.3%). Median follow-up was 32.2 months for the overall
cohort and 46.4 months for VEGFI patients. The rate of G3+ hemorrhage was signiﬁcantly higher in patients treated with a VEGFI (7.3 vs
0.8%, P < 0.01). The rate of any grade hemorrhage did not signiﬁcantly
vary between groups (9.4 vs 2.7%, P = 0.1). Among those treated with a
VEGFI, the median interval between VEGFI therapy and SABR was 16
weeks, ranging from zero days to 3.7 years, with 15 (34.0%) patients
treated within 90 days of SABR. Among patients treated with SABR
and VEGFI, there was no signiﬁcant difference in rates of hemorrhage
when the interval was > or ≤ 90 days (12.0 vs 0.0%, P = 0.17).
Similarly, there was no signiﬁcant difference between rates of G3+
hemorrhage when VEGFI was given before (12.9%), after (8.3%), or
before and after SABR (0.0%). Patients were treated with SABR to
peripheral (738, 79.8%), central (137, 14.8%) and ultra-central (50,
5.4%) locations with a median BED10 of 87.5 Gy. When stratiﬁed by
location, both central/ultra-central tumors (21.1 vs 3.2%, P = 0.03) and
peripheral tumors (3.4 vs 0.1%, P = 0.03) had increased rates of G3+
hemorrhage when treated with a VEGFI.
Conclusions: VEGFI therapy was associated with an increased rate of
high-grade hemorrhage in patients undergoing SABR to pulmonary
tumors. Rates of high-grade hemorrhage were increased with VEGFI
for both central/ultra-central and peripheral tumors although the absolute rate was low for peripheral tumors. While limited by low sample
size and event rate, there was no correlation observed between interval
or sequence of VEGFI and SABR and rate of high-grade hemorrhage.

(P118) Pulmonary Adverse Events After Real World
Adjuvant Immune Checkpoint Inhibitor (ICI) Therapy and
Its Impact on Survival for Locally Advanced Non-Small
Cell Lung Cancer
Zhongxing Liao, MD, FASTRO, FAAWR1, Lirong Wu, MD, PhD2,
Ting Xu, MD, PhD3, Saumil Gandhi, MD, PhD4, Steven H. Lin, MD,
PhD5, Wang Jing, MD, PhD6, Quynh-Nhu Nguyen, MD3, Aileen Chen,
MD3, Joe Chang, MD, PhD3, Mehmet Altan, MD3, Anne Tsao, MD3,
Roza Nurieva, PhD3, Ajay Sheshadri, MD4, James Welsh, MD7, Percy
Lee, MD3; 1The University of Texas MD Anderson Cancer Center,
2
Jiangsu Cancer Hospital, 3UT MD Anderson Cancer Center, 4UT M D
Anderson Cancer Center, 5MD Anderson Cancer Center, 6Shandong
Cancer Hospital, 7MD Anderson Cancer Center Welsh Lab
Background: In the PACIFIC trial, only lung cancer patients without
disease progression and who did not have symptomatic pneumonitis
from concurrent CRT were included in the randomization, excluding
many patients from the beneﬁt of ICI due to concern over severe
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FIGURE 1. Two-year disease outcomes in NSCLC patients developed TRPT stratified by completion of ICI treatment.
pulmonary adverse events. In real world practice, however, ICI is
commonly given to any patient after concurrent CRT, even though it is
not clear whether deviation from PACIFC patient selection for combining ICI with CRT will increase the risk of lung complications or not.
Objectives: 1) To assess the impact of adjuvant immune checkpoint
inhibitor (ICI) on the incidence of pulmonary adverse events (PAE),
and 2) to assess the impact of ICI and PAE on survival in locally
advanced non-small cell lung cancer (LA-NSCLC).
Methods: Patients with a diagnosis of LA-NSCLC who received concurrent chemotherapy with curative intention were included in this
study. Information on patient-, disease-, treatment-characteristics, and
outcomes (survival and toxicities) have been collected on an IRB
approved protocol for retrospective chart review and informed consents
has been waived. Characteristics were compared by t-test for continuous
variables and χ2 test for categorical variables. Survival and PAE were
calculated from the end of radiotherapy. PAEs included pneumonitis,
pneumonia, ﬁbrosis, and pleural effusion. Outcomes were compared
between patients who received ICI versus who did not by Cox proportional hazard regression and Kaplan-Meier analysis. The impact on
survival due to ICI interruption caused by pulmonary toxicities was also
assessed.
Results: Total 336 patients treated from July 2010 to November 2019
were included in this study, among them, 217 patients received standard
concurrent chemoradiation (CRT) and 119 patients treated after
December 2014 received additional ICI (CRTI). Patient- and diseasecharacteristics were similar between CRT and CRTI groups. The 2-year
survival rates were 62.7% and 86.6% for CRT and CRTI groups
respectively (P < 0.0001); and the survival curves starts to diverge at the
end of radiotherapy which was the beginning of OS assessment time
point. In multi-variable analysis, CRTI patients had statistically signiﬁcantly improved 2-year survival (HR = 0.43, 95% CI 0.24-0.76,
P = 0.004), adjusted for age, sex, race, smoking packyear, ECOG score,
histology, stages, gross tumor volume, tumor location, total radiation
dose, mean lung dose and radiation modality. ECOG score, smoking
pack-year, mean lung dose and adjuvant chemotherapy were also signiﬁcant independent factors for 2-year survival. Additionally, CRTI
patients had improved 2-year PFS with HR of 0.58 (95% CI 0.39-0.85,
P < 0.006). Incidence of ≥ grade 2 PAEs was 34.1% in CRT group
compared with 68.9% in CRTI group (CRT vs. CRTI: HR = 0.46, 95%
CI 0.34-0.64, P < 0.0001). Finally, compared with those who completed
ICI after developing PAEs, patients who had to discontinue ICI due to
severe PAEs had worse 2-year OS (68% vs 98%, P < 0.0001) and
higher rates of distant metastasis (69% vs 79%, P = 0.015) (Fig. 1).
Conclusions: Immune checkpoint immunotherapy has improved 2-year
survival and disease control of patients with LA-NSCLC treated with
concurrent chemoradiation. Patients who received CRTI were more
likely to develop PAEs compared with those who received CRT. The
ICI discontinuation due to PAEs negatively impacted 2-year overall and
distant metastasis free survival.

FIGURE 1. Steps of analytic dataset creation for stage 3 NSCLC
cohorts (durvalumab users and non-durvalumab users) in open
claims.
Background: The recommended treatment for patients with unresectable stage 3 NSCLC is deﬁnitive chemoradiation followed by 1 year of
maintenance durvalumab.
Objectives: To assess use of maintenance durvalumab based on patient
and physician characteristics among stage 3 NSCLC patients in the U.S.
Methods: Analyses were conducted in both open claims (IQVIA
pharmacy and medical claims data) and adjudicated closed claims
(IQVIA PharMetrics Plus Health Plan Claims Database). Patients were
ﬁltered with the following criteria: (1) ≥ 1 lung cancer diagnosis code
Nov 2017–Nov 2020, (2) retain any metastatic/advanced codes, (3)

(P119) Patterns of Care in Maintenance Therapy in U.S.
Patients Undergoing Deﬁnitive Chemoradiation for Stage 3
Non-Small Cell Lung Cancer (NCSLC)
Jason Liu, MD1, Emily Bratton, PhD2, Xinyan Yu, BS2, Colton Ladbury, MD1, Joseph Wagner, MPH2, Mackenzie Small, BS2, Arya
Amini, MD1; 1City of Hope National Medical Center, 2IQVIA

FIGURE 2. Steps of analytic dataset creation for stage 3 NSCLC
cohorts (durvalumab users and non-durvalumab users) in closed
claims.
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TABLE 1. Summary of NSCLC Patient Characteristics based on Open Claims (left) (Nov 2017- Nov 2020) and Closed Claims (right) (Nov
2017- Nov 2020)

1 – Maximum recorded age is 85 years for all patients to ensure protection of patient identity. 2 – If physician was afﬁliated with any academic institution, then
academic practice was coded as ‘yes’. 3 – Urban/rural status associated with chemoradiation claim. 4 – First adjuvant regimen following chemoradiation and within
90 days of treatment end date.

exclude SCLC patients, and (4) limit to single primary tumor looking
back to Nov 2015. Lastly, patients must have been ≥ 18 years, have no
lung cancer surgery codes during the observation period, and received
chemoradiation after the index date and before May 31, 2020. Logistic
regression was used to evaluate differences between patients who
received durvalumab following chemoradiation compared with those
who did not.
Results: N = 8071 NSCLC patients were included from the open claims
source; 1794 (22.2%) received maintenance durvalumab (Table 1).
Overall, distributions of baseline characteristics were similar between
durvalumab and non-durvalumab patients. Durvalumab patients had a
higher probability of older age ( ≥ 65 y) (odds ratio [OR] 1.2, 95% CI
1.1–1.3) and being treated in the Midwest (OR 1.2, 95% CI 1.0–1.4),
respectively. Among non-durvalumab users (N = 6277), chemotherapy
(n = 2785; 44.4%) and pembrolizumab (n = 2047; 32.6%) were most
commonly used, with combination chemotherapy treatment given to
n = 1629 (26.0%) patients. N = 357 NSCLC patients were included
from the closed claims source; 127 (35.6%) received maintenance
durvalumab (Table 1b). Overall, distributions of baseline characteristics
were similar between durvalumab and non-durvalumab patients. None
of the baseline characteristics differed between exposure groups (all
95% CIs crossed the null). Among non-durvalumab users (N = 230),
chemotherapy (n = 124; 53.9%) and pembrolizumab (n = 82; 35.6%)
were most commonly used, with combination chemotherapy treatment
given to n = 63 (27.4%) patients.
Conclusions: The rate of durvalumab utilization was overall low in
both the open and closed claims data sources (22.2% and 35.6%
respectively). In the open claims data source, durvalumab utilization
was higher for patients ≥ 65 years and treated in the Midwest; similar
trends were observed in the closed claims database but did not reach

signiﬁcance. Interesting ﬁndings include a higher rate of pembrolizumab utilization than expected. Future studies are needed to better
understand these current practice patterns in the U.S. (Figs. 1 and 2).

(P120) Multiple Primary Lung Cancers: Treatment Outcomes After Stereotactic Body Radiotherapy (SBRT)
Gyujae Choi, MD1, Angela Zhu, MD1; 1Baylor College of Medicine
Background: Patients with lung cancer may often present with multiple
primary lung cancers (MPLCs), whether found to have two primary foci
of disease at the same time (synchronous) or developing a second lesion
after treatment of their initial disease (metachronous). Surgery is considered the mainstay of treatment for patients with stage I-II non-smallcell lung cancer (NSCLC), with stereotactic body radiation therapy
(SBRT) an acceptable alternative for patients unﬁt for surgery or who
refuse surgery.
Objectives: We investigated our institutional treatment outcomes following SBRT for patients with early-stage MPLCs.
Methods: From June 2011 to March 2020, patients receiving SBRT for
MPLC were reviewed. Patients underwent review of imaging and
pathology at a multi-disciplinary tumor board before undergoing
deﬁnitive treatment. Dose and fractionation varied with the most
common prescriptions being 50 Gy/5 fractions, 56 Gy/4 fractions, and
55 Gy/5 fractions.
Results: A total of 38 patients were treated for 80 metachronous and
synchronous lesions, which were comprised of 68 T1 lesions and 12 T2
lesions. Median follow-up was 25.9 months, with local control (LC)
rates calculated per lesion to be 98.6%, 93.3%, and 88.2% at 1, 2, and
3 years. Median overall survival (OS) was 43.5 months, with OS rates at
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83.6%, 67.8%, and 52.3% at 1, 2, and 3 years. 62 of the 80 (77.5%)
treated lesions were not associated with any subsequent acute or late
toxicity. The 18 (22.5%) lesions associated with toxicity were comprised of 9 acute and 9 late events. All reported toxicity were grade 1
(13 of 18) or grade 2 (5 of 18).
Conclusions: SBRT for early-stage MPLC achieves high control rates
with limited toxicity. Patients deemed unﬁt for surgical management of
MPLC should be considered for deﬁnitive SBRT.
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TABLE 2. Number of Patients Who Failed Categorized

(P121) Single Institution Experience of Stereotactic Body
Radiation Therapy (SBRT) in Lung Cancer
Mary Nittala, DrPH1, Eswar Mundra, MD2, Satyaseelan Packianathan,
MD, PhD3, Maria Smith, MSN, NPC2, William Woods, MSN, NPC2,
rahul bhandari, MD4, Robert Allbright, MD2, Srinivasan Vijayakumar,
MD, MPH2; 1The University of Mississippi Medical Center, 2University
of Mississippi Medical Center, 3Univerity of Mississippi Medical Center, 4G.V. (Sonny) Montgomery VA Medical Center
Background: Stereotactic body radiation therapy [SBRT] is an effective treatment for early stage non- small cell cancer [NSCLC] patients
who do not undergo surgery, either medically inoperable or who decline
surgery. SBRT provides enhanced tumor control and overall survival
[OS] results in medically inoperable early stage NSCLC patients. In this
study, we investigated the effectiveness of two different radiation
fractions used and presented our institutional experience.
Objectives: To determine the clinical outcomes between two treatment
regiments (50 Gy vs. 55 Gy) among stage I NSCLC patients treated
with SBRT at a state academic medical center.
Methods: A retrospective analysis of 114 patients with stage I (T12N0M0) NSCLC lesions treated at a state academic medical center
between October, 2009 and April, 2019. Survival analysis with treatment regiments of 50 Gy and 55 Gy were conducted to evaluate the
signiﬁcant effect of scheduled fractionation. The primary endpoints of
this retrospective study included rates of OS, local control [LC] and
disease free survival [DFS]. Log rank test and the Kaplan-Meier method
was used to analyze the survival function between populations of two
treatment intervals. The SPSS v.24.0 was used for statistical analysis.
Results: The 114 early stage NSCLC patients (median age, 68 y; range
12-87 y) had a median follow- up of 23 months (range 2- 64). Number
of males (n = 72; 63.2%) were diagnosed and treated for NSCLC
compared with females (n = 42; 36.8 %). The majority of patients in this
study were Caucasians (n = 68; 59.6%) compared with AfricanAmericans (n = 46; 40.4%). The majority of patients (n = 76; 66.7%)
were treated with 50 Gy in 5 fractions, and 38 patients (33.3%) with
55 Gy in 5 fractions. The 1, 2 & 3-year OS and DFS rates were better
for the patients treated with 55 Gy group [OS, 81.7% vs. 72.8%; 81.7%
vs. 58.9%; 81.7% vs. 46.7% (P = 0.049)], [DFS, 69.7% vs. 69.7%;
61.9% vs. 55.7%; 61.9% vs. 52.0% (P = 0.842)] compared with the

patients treated with 50 Gy. Adenocarcinoma was the most common
pathology in both groups comprising (51.3% & 68.4%) lesions. A total
number of [39 (34.2%) vs. 12 (8.5%)] failed. Among these, 11 (9.6%)
vs. 6 (5.3%) local, 18 (15.8%) vs. 3 (2.6%) regional, and 10 (8.8%) vs.
3 (2.6%) distant failures were observed between two groups treated with
50 Gy vs.55 Gy.
Conclusions: Early stage NSCLC lesions treated with modiﬁed SBRT
fractionation group 55 Gy shows better local control, overall survival
and disease free survival rates compared with the interval group of
patients treated with 50 Gy (Tables 1, 2 and Fig. 1).

TABLE 1. 1-, 2-, and 3-year Overall Survival and Disease Free
Survival (%)

FIGURE 1. Overall survival and disease free survival years since
end of SBRT.
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(P122) Treatment Patterns for Isolated Nodal Recurrences
in Non-Small Cell Lung Cancer After Deﬁnitive Stereotactic
Ablative Radiotherapy
Hyunsoo No, MD, CMD1, Max Devine, BS1, Brianna Lau, BA1, Billy
Loo, MD, PhD1, Maximilian Diehn, MD, PhD1, Alex Chin, MD, MBA1,
Lucas Vitzthum, MD, MAS1; 1Stanford University Radiation Oncology
Background: Stereotactic ablative radiotherapy (SABR) results in high rates
of primary tumor control for early-stage non-small cell lung cancer (NSCLC)
1. However, medical literature notes up to 2-9% of patients may develop
isolated nodal recurrence (INR) after initial treatment2-6. An optimal treatment paradigm for those experiencing INR has not been well deﬁned.
Objectives: The objective of this study is to determine the rates of INR
after SABR for treatment of early-stage NSCLC and to analyze the
patterns of care and outcomes for early-stage NSCLC patients who
developed post-SABR INR.
Methods: This retrospective cohort study included patients with Stage
T1-3 N0 M0 NSCLC treated with deﬁnitive SABR from 2003-2018.
Exclusion criteria included synchronous primaries, ﬁrst-line systemic
therapy, and patients with <3 months follow up. We investigated the
incidence of INR and baseline factors between patients who did and did
not exhibit INR. Among patients who experienced INR, we described
treatment patterns and outcomes including overall (OS) and progression
free survival (PFS) from the time of nodal failure using the KaplanMeier method.
Results: A total of 342 patients met inclusion criteria for the study. The
median follow-up post-SABR was 3.3 years with a 3-year INR rate of
10.6% (95% CI, 6.6% –13.4%). The median OS for patients with INR
was 2.1 years with an estimated 3-year survival of 39.3% (95% CI,
24.4–63.3%). The median PFS was 1.4 years with an estimated 3-year
PFS of 26.7% (95% CI, 14.1–50.3%). Both OS and PFS differed by
treatment type. Thirty of the 34 patients exhibiting INR had known
salvage treatment courses, including chemoradiotherapy (CRT) (43.3
%, n = 13), RT alone (26.7 %, n = 8), chemotherapy alone (13.3%,
n = 4), and observation (16.7%, n = 5). Patients treated with CRT had
the best survival outcomes with an estimated 3-year OS and PFS of
81.5% (95% CI, 61.1–100.0%) and 63.9% (95% CI, 40.7–100.0%),
respectively. No patients treated with chemotherapy, RT alone, or
observation were alive without a censoring event at 3 years.
Conclusions: INR occurred in approximately 10% of patients treated with
SABR for early-stage NSCLC. The highest rates of survival among
patients with INR were observed in those treated with chemoradiotherapy.

(P123) Hypofractionated vs. Standard Radiotherapy for
Locally Advanced Limited-Stage Small Cell Lung Cancer
Nadia Saeed, BA1, Lan Jin, PhD, MSc2, Alexander Sasse, BA3, Arya
Amini, MD4, Vivek Verma, MD5, Nataniel Lester-Coll, MD6, Po-Han
Chen, MD, PhD7, Roy Decker, MD, PhD8, Henry Park, MD, MPH9;
1
Yale University School of Medicine, 2Yale School of Medicine,
Department of Surgery, 3Yale University, 4City of Hope National
Medical Center, 5University of Texas M.D. Anderson Cancer Center,
Department of Radiation Oncology, 6University of Vermont Larner
College of Medicine, Division of Radiation Oncology, 7Yale School of
Medicine, Department of Pathology, 8Yale School of Medicine,
Department of Therapeutic Radiology, 9Yale School of Medicine
Background: There is increasing interest in hypofractionated radiation
therapy (HFRT) in locally advanced limited-stage small cell lung cancer
(SCLC), particularly during the COVID-19 pandemic. HFRT with 4045 Gy in 15 fractions is preferred in many Western countries but not
used regularly in the U.S. HFRT is likely more convenient and less
expensive than standard radiation therapy (RT), and reduces exposure
during the pandemic. The real-world impact of deﬁnitive HFRT with
chemotherapy in this setting remains unclear.
Objectives: We sought to determine if: (1) HFRT is associated with
different patient characteristics & practice patterns but similar overall
survival (OS) compared with standard RT in locally advanced limitedstage SCLC; (2) the relationship between fractionation schedule and OS
is impacted by chemotherapy timing.
Methods: This retrospective cohort analysis included patients in the
National Cancer Database with unresected primary stage II-III SCLC
diagnosed in 2008-2016. All patients underwent chemotherapy initiated
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within six months of starting either HFRT (40-45 Gy in 15 fractions) or
standard RT (45 Gy in 30 fractions or 60-70 Gy in 30-35 fractions).
Associations among sociodemographic and clinicopathologic variables
with fractionation were assessed using χ2, Fisher’s exact test, ANOVA,
and multivariable logistic regression. Kaplan-Meier estimator, log-rank
test, and multivariable Cox proportional hazards regression modeling
were used to evaluate OS. Propensity score matching (PSM) analysis
was used to reduce confounding on OS. Subset analyses were performed to evaluate the effect of chemotherapy timing in relation to RT.
Results: Our analysis included 7,143 patients: 25.8% received 45 Gy in
30 fractions, 72.1% 60-70 Gy in 30-35 fractions, and 2.1% HFRT.
Median age was 64 years. 85.2% of patients had stage III disease and
71.9% underwent early concurrent chemotherapy (RT and chemotherapy initiated within 30 d of each other). In the PSM cohort
(N = 292), median OS was similar between standard RT (22.9 mo [95%
CI 18.2-30.4]) vs. HFRT (21.2 mo [CI 16.3-24.7]; P = 0.13). MVA on
the whole cohort (N = 7,143) also yielded comparable OS (HR for
HFRT 1.09, CI 0.90-1.32, P = 0.37). On PSM, OS was numerically
shorter with HFRT in the early concurrent chemotherapy subset (16.0
[CI 13.5-19.3] vs. 19.1 mo [CI 15.4-24.8], P = 0.20) and numerically
longer with HFRT in the non-early concurrent chemotherapy subset
(30.0 mo [CI 21.4-37.7] vs. 18.6 mo [CI 15.0-21.5], P = 0.075).
Conclusions: OS with HFRT appears similar to standard RT in locally
advanced limited-stage SCLC, although the timing of chemotherapy
may modify the effect of fractionation on OS. HFRT may be considered
over standard RT in select patients (particularly those unable to receive
early concurrent chemotherapy), which may offer certain advantages
both during and after the pandemic era. Given the limitations of this
retrospective analysis and lack of data on toxicity and tumor control,
further investigation is needed.

(P124) Hypofractionated vs Conventionally Fractionated
Radiation Therapy with Concurrent Chemotherapy for
Stage III Non-small Cell Lung Cancer
Alexander Sasse, BA1, Vikram Jairam, MD2, Nadia Saeed, BA3, Henry
Park, MD, MPH2; 1Yale University, 2Yale School of Medicine, 3Yale
University School of Medicine
Background: A standard deﬁnitive treatment option for locally
advanced non-small cell lung cancer (NSCLC) includes conventionally
fractionated radiation therapy (CFRT) with concurrent chemotherapy.
Moderately hypofractionated radiation therapy (HFRT), a potential
alternative, is frequently used outside the United States. HFRT has
increased convenience for patients and minimizes exposure to the
healthcare setting, which is particularly beneﬁcial during the COVID-19
pandemic.
Objectives: The aims of this study were to evaluate practice patterns
and compare overall survival (OS) between patients who received
concurrent chemoradiotherapy with HFRT vs CFRT for stage
III NSCLC.
Methods: The National Cancer Database (NCDB) was queried for
patients with stage III NSCLC diagnosed between 2004 and 2015 with
known vital status who received concurrent chemoradiation, deﬁned as
chemotherapy received within 30 days of radiation. CFRT was deﬁned
as delivery of 60 Gy in 30 fractions. HFRT was deﬁned as 55-60 Gy in
20-24 fractions with 2.5-3 Gy/fraction. Univariable and multivariable
logistic regression was used to identify factors associated with receipt of
HFRT. We evaluated the association between fractionation schedule
and OS using the Kaplan-Meier method, and signiﬁcance was determined using the log-rank test. Univariable and multivariable Cox proportional hazards regressions were used to identify predictors of OS.
Propensity score matching (PSM) was performed to account for known
confounders of OS. PSM was performed using the variables with a
P-value less than 0.1 after multivariable cox regression analysis.
Results: A total of 6,914 patients were included in this analysis, among
whom 6751 (97.6%) received CFRT and 163 (2.4%) received HFRT.
On χ2 analysis, HFRT was associated with lower vs. higher education
level (56% vs. 44%, P = 0.007) and a higher vs. lower T-stage (63% vs.
51%, P = 0.002), but was not associated with age, N-Stage, comorbidity
score, income, or insurance. In the whole cohort, HFRT was signiﬁcantly associated with decreased OS compared with CFRT on
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univariable (median 14.9 [CI 13.0-16.7] vs. 21.6 mo [CI 20.9-22.1],
P < 0.001) and multivariable (HR 1.39, 95% CI 1.14-1.69, P = 0.003)
analysis. After PSM, similar ﬁndings were noted on univariable analysis
but were no longer statistically signiﬁcant (median 15.2 [CI 12.8-17.1]
vs. 21.7 [15.1-27.1] months, P = 0.10).
Conclusions: Our ﬁndings suggest that moderately hypofractionated
radiotherapy with concurrent chemotherapy may not be a viable alternative to concurrent chemoradiotherapy with conventionally fractionated radiation therapy for routine utilization in stage III NSCLC, even
during the COVID-19 pandemic. Given that selection bias may affect
the observed outcomes after HFRT, prospective studies will be needed
to directly compare these regimens.

(P125) Residing in Food Priority Areas Correlates with
Unique Socioeconomic Demographics and Patterns-of-care
in Patients with Stage III Non-small Cell Lung Cancer
Bansi Savla, MD1, Muhammad Hamza, Medical Student2, Kanav
Markan, Medical Student3, Dan Yacubovich, Undergraduate Student4,
Stephen Cobbs, Undergraduate Student5, Katherine Scilla, MD6,
Whitney Burrows, MD7, Ranee Mehra, MD8, Robert Miller, MD,
MBA, FASTRO9, Christian Rolfo, MD, MBA8, Pranshu Mohindra,
MD, MBBS2, Melissa Vyfhuis, MD, PhD10; 1University of Maryland,
2
Department of Radiation Oncology, University of Maryland School of
Medicine, 3American University of Integrative Sciences, 4University of
Maryland Baltimore County, 5Stonehill College, 6University of Maryland Department of Medical Oncology, 7University of Maryland Division of Thoracic Surgery, 8University of Maryland Division of Medical
Oncology, 9Division of Radiation Oncology, University of Tennessee
Medical Center, 10Baltimore Washington Medical Center Department
of Radiation Oncology
Background: Nutritional deﬁciencies have been linked with poor
prognosis in multiple cancer sites. Patients living in food priority areas
(FPAs) may have limited access to healthy foods. To our knowledge,
there is no published data analyzing how residence in an FPA may
impact treatments rendered or outcomes for patients with locally
advanced non-small cell lung cancer (LA-NSCLC).
Objectives: We aim to characterize socioeconomic and cancer demographics of stage III NSCLC patients living in zip code-designated FPAs
treated with curable intent at a single institution. We hypothesize that
residence in an FPA will impact treatments rendered and cancer outcomes.
Methods: This is an IRB-approved single institution retrospective study
of 515 LA-NSCLC patients treated with curative intent from January
2000-January 2019. χ2 tests were done to compare variables stratiﬁed
by residence in FPAs. Mann-Whitney U-test was used to compare
differences between continuous variables. Kaplan-Meier analysis and
cox proportional hazard models were used to analyze overall survival
(OS) and freedom from recurrence (FFR). Cox regression with forward
model selection was used for multivariate analysis (MVA).
Results: Twenty-eight percent of our LA-NSCLC patients live in FPAs
(N = 144). Patients living in an FPA were more likely than patients not
living in an FPA to self-identify as black (86% vs 18.7%, P < 0.0001),
single (70.6% vs 39.5%, P < 0.001), younger than 60 (52.1% vs 35.7%,
P = 0.001), uninsured (13.9% vs 10.5% P < 0.0001), with lower
median income ($28548 vs. $66200, P < 0.001) and worse performance status compared with non-FPA patients (ECOG PS > 1.40%, P =
0.025). Patients in FPAs had lower pre-chemoradiation (CRT) albumin
(P = 0.006), took longer to ﬁnish RT [Avg. 48d (28-78) vs. 46d (1-77),
P = 0.044] and were less likely to undergo trimodality therapy (14% vs.
86%; P = < 0.001). Most patients received concurrent CRT (91%) with
deﬁnitive doses (82% of patients received ≥ 60 Gy) of RT. There was
no difference in OS (23.1m vs. 25m, P = 0.46) or FFR (15.4m vs
18.4m, P = 0.32) between the two groups. On MVA, insurance status
(HR: 0.38, 95% CI: 0.242-0.618, P < 0.001), consolidation chemotherapy receipt (HR: 0.556, 95% CI: 0.409-0.755, P < 0.0001), marital
status (HR: 1.37, 95%CI: 1.049-1.884, P = 0.037), pre-CRT albumin
(HR: 0.628, 95% CI: 0.507-0.765, P < 0.001) and post-CRT BMI (HR:
0.968, 95% CI: 0.943-0.994, P = 0.017) were all predictors of OS.
Conclusions: In this institutional analysis examining impact of FPAs in
patients with LA- NSCLC, we demonstrate a socioeconomic divide in
this population, where residing in FPAs reﬂects distinct patient
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demographics and receipt of less aggressive therapy (i.e. surgery).
Though cancer outcomes were not different between the groups,
important nutritional factors were predictive of OS in LA-NSCLC. To
overcome limitations of a retrospective analysis, we are currently
characterizing nutritional needs of our patients in a prospective study.

(P126) Integration of Anti-TIGIT and anti-Lag3 with
NBTXR3-mediated Immunoradiation Therapy Improves
Abscopal Effect and Induces Long-term Memory Against
Cancer
Yun Hu, PhD1, Lily Schuda2, Sébastien Paris, PhD3, Hampartsoum
Barsoumian, PhD4, Angelica Cortez, PhD4, James Welsh, MD4; 1Welsh
Lab Radiation Oncology MD Anderson Cancer Center, 2MD Anderson
Experimental Radiation Oncology Welsh Lab, 3Nanobiotix, 4MD
Anderson Cancer Center Welsh Lab
Background: TIGIT and Lag3 are inhibitory receptors expressed on
cytotoxic CD8+ T cells and NK cells and directly inhibit the activation
and proliferation of these cells. We proposed that blockade of TIGIT
and Lag3 could improve antitumor immune response in a mouse model
of anti-PD1-resistant mice.
Objectives: In this study, we aim to improve the therapeutic outcome of
radioimmunotherapy by combining a radio-enhancer (NBTXR3), radiation, anti-PD1, anti-LAG3, and anti-TIGIT.
Methods: 129Sv/Ev mice were inoculated with 50,000 anti-PD1-resistant 344SQR cells in the right leg on day 0 (primary tumor) and with
50,000 cells in the left leg on day 4 (secondary tumor). Primary tumors
were injected with NBTXR3 (radioenhancer nanoparticles) on day 7
and irradiated with 12 Gy on days 8, 9, and 10. Anti-PD1 (200 μg), antiLag3 (200 μg), and anti-TIGIT (200 μg) were given to mice by intraperitoneal injections on days 5, 8, 11, 14, 21, 28, 35, and 42. On day 21,
primary tumors, secondary tumors, and blood samples were harvested
and analyzed with ﬂow cytometry to evaluate changes in immune cell
populations. Mice in which tumors were completely eradicated were rechallenged with another 50,000 344SQR cells in the right ﬂank at least
two months post radiation; no further treatment was given to these mice,
and tumor growth was monitored.
Results: The addition of anti-TIGIT, anti-Lag3, or anti-TIGIT+antiLAG3 to NBTXR3+XRT+anti-PD1 therapy signiﬁcantly improved
control of both primary and secondary tumors, and the addition of
anti-TIGIT plus anti-LAG3 also led to fewer spontaneous lung
metastases. The addition of either anti-TIGIT or anti-Lag3 to
NBTXR3+XRT+anti-PD1 extended the mouse survival time relative
to NBTXR3+XRT+anti-PD1. None of the 8 mice in either the
NBTXR3+XRT+anti-PD1+anti-TIGIT group or the NBTXR3+XRT
+anti-PD1+anti-Lag3 group survived more than 32 days; in contrast,
3 of the 8 mice that received NBTXR3+XRT+anti-PD1+anti-TIGIT
+anti-Lag3 survived until the end of the experiment. These surviving
mice were found to have developed memory against 344SQR cells,
and no further tumor growth was observed after re-challenge. Flow
cytometry analysis showed that adding anti-TIGIT+anti-Lag3 to
NBTXR3+XRT+anti-PD1 increased the percentages of proliferating
CD8+ T cells in primary tumors, secondary tumors, and blood, and
increased the percentage of NK cells in the secondary tumors.
Conclusions: Blockade of TIGIT and Lag3 with NBTXR3+XRT+antiPD1 improved CD8+ T-cell proliferation, augmented the antitumor
response at both irradiated and unirradiated (abscopal) tumors, and
induced potent long-term antitumor memory in mice.

(P127) Radiotherapy Targeting One or Two Metastases in
the Setting of Oligoprogressive Lung Cancer
Rebecca Shulman, MD1, Mengying Deng1, Martin Edelman, MD1,
Sameera Kumar, MD1; 1Fox Chase Cancer Center
Background: Improved outcomes for metastatic lung cancer achieved
with immunotherapy and other innovative treatments have raised
expectations that progression-free survival of patients with oligoprogressive lung cancer may be prolonged with SBRT and hypofractionated
radiotherapy (RT).
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Objectives: This retrospective study tested the hypothesis that RT
targeting one or two metastases in patients with oligoprogressive lung
cancer will delay metastatic progression with little added toxicity.
Methods: A retrospective chart review was conducted for lung cancer
patients treated from 2018 to 2020 at a single institution. Covariates
examined included age, sex, length of illness, regimen of systemic treatment, sites of metastases, and toxic side effects. Oligoprogression before
RT was deﬁned as radiographic evidence of progression of one or two
metastases while all other metastases remained stable. The patients’ lung
cancer was considered to have progressed after RT if surveillance imaging
during a follow-up period ranging from 32 and 471 days demonstrated
extension of at least one metastasis, including any metastasis at a nonradiated site. Kaplan-Meier curves were calculated for PFS.
Results: Twenty ﬁve patients were identiﬁed who had received RT for
oligoprogressive lung cancer, including 24 patients with NSCLC (19
with adenocarcinoma, 4 with squamous cell, 1 with mixed adenocarcinoma and squamous) and one patient with small cell lung cancer.
One patient had not undergone surveillance imaging post-RT and was
excluded from further study. Sites of oligoprogression in the remaining
24 patients included lung (71%), mediastinal/supraclavicular lymph
nodes (21%), bone (4%), and adrenal gland (4%). The median progression free survival time for all patients was 9.5 months. After
receiving RT, 13 of 24 patients (54%) demonstrated no further disease
progression during the follow-up period. Of the 11 patients with progression post-RT, 9 involved extracranial lesions, 1 involved intracranial lesions and 1 involved both. Seven patients (64%) with progressive disease had received immunotherapy and four patients (36%)
had received a form of targeted systemic therapy. For all 25 study
patients receiving RT for oligoprogressive disease, toxicity was shortterm and no worse than grade 2, limited chieﬂy to cough and
dysphagia.
Conclusions: A retrospective chart review reveals that 54% of
patients who received RT targeting 2 or fewer metastases for oligoprogressive lung cancer showed no evidence of disease progression
during a follow-up period ranging from 32 to 471 days. The median
progression free survival time for all patients was found to be
9.5 months. Toxicity associated with RT for oligoprogressive disease
was mild and transient.

(P128) Radiation Therapy (RT) for Diffuse Large B-cell
Lymphoma (DLBCL) of the Orbit: A Single Institution’s
Cohort Experience
Jonathan Baron, BS1, Christopher Wright, MD1, Daniel Lee, BS1,
Maribel Carpenter1, Cesar Briceno, MD2, Amit Maity, MD PhD1, John
Plastaras, MD, PhD1, Ima Paydar, MD1; 1Department of Radiation
Oncology, University of Pennsylvania, 2Department of Ophthalmology,
University of Pennsylvania
Background: Orbital DLBCL can arise as a primary ocular adnexal
lymphoma or, more commonly, as a secondary manifestation of already
systemic disease. RT has been established as a potential treatment option,
but due to the limited number of patients presenting with orbital DLBCL,
the efﬁcacy and safety of this modality needs to be further characterized.
Objectives: Our purpose was to describe a single institution’s experience of treating patients with orbital DLBCL with RT, as well as to
assess the safety and outcomes in this population.
Methods: We retrospectively analyzed data from 10 patients with
orbital DLBCL treated with RT between May 2009 and January 2019 at
the University of Pennsylvania. Patient, tumor, radiation, and systemic
therapy details were retrospectively recorded from the patients’ medical
records. Acute (< 3 mo) and late ( > 3 mo) radiation toxicity were
graded by CTCAEv5. Follow-up time was deﬁned as time from start of
RT to event or last follow-up. Overall response was deﬁned as achieving a complete or partial response by clinical exam or imaging as
deﬁned by Deauville or RECIST criteria. Progression free survival was
estimated using the Kaplan-Meier method.
Results: Median follow-up time was 24.8 months (range 0.8-87.5). The
majority of the patients were male (70%), with a median age of 60 (2274). Nine patients presented with unilateral and 1 patient with bilateral
orbital involvement. Median maximum dimension of disease treated
was 26mm (range 15-52). Most patients (70%) had systemic
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FIGURE 1. Progression Free Survival.

lymphoma preceding secondary orbital involvement. Ocular muscles
were the most common orbital subsite involved (60%), while 4 patients
had lacrimal gland and eye lid involvement, and 3 patients had
extension of disease to bone. Five patients received rituximab before
RT, 2 patients after RT, and 3 patients did not receive systemic therapy. Median RT dose used was 17.5 Gy (range 3-36 Gy) in 1.5-2 Gy
fractions. Photon RT was used in 9 patients (IMRT in 6 patients &
3DCRT in 3 patients) and proton RT in 1 patient. Grade 1 (G1) and G2
acute RT toxicities were present in 7 patients and 2 patients, respectively. No G3 or higher acute toxicities occurred. Dry eye syndrome
occurred in two patients, one with G1 toxicity ﬁrst noted 3 months after
RT (treated with 10.5 Gy) and one with G2 toxicity ﬁrst noted 1 month
after RT (treated with 25 Gy); both patients developed chronic dry
eyes. No other long-term toxicities occurred. The overall response rate
was 90%, with 60% of patients achieving a complete response. No
patients had orbital disease recurrence, while 4 patients experienced
systemic progression (Fig. 1).
Conclusions: RT for the treatment of orbital DLBCL resulted in
favorable outcomes, with no local recurrence and with modest longterm toxicity. Future studies may be undertaken to further clarify the
dose and technique of RT to optimize local control and toxicity.

(P129) Radiation Therapy for Early Stage Low Grade
Follicular Lymphoma Is Associated with Improved Overall
Survival in the Rituximab Era
Jordan Fenlon, MD1, Ryan Hutten, MD1, Skyler Johnson, MD1, David
Gaffney, MD, PhD1, Randa Tao, MD1; 1Huntsman Cancer Institute at
the University of Utah
Background: National Comprehensive Cancer Network (NCCN)
treatment guidelines for early stage follicular lymphoma (FL) includes
involved-site radiation therapy (ISRT). Up to 50% of early stage FL
treated with radiation therapy (RT) remain relapse-free at 10 years and
are likely cured. Despite this, RT utilization has been decreasing.
Objectives: To compare overall survival (OS) for stage I and II, grade 1
and 2 FL between various treatment regimens, in the era that ISRT is
standard and rituximab became widely available. Secondary objectives
were to evaluate trends in national practice patterns over time, and
identify predictors for receipt or omission of RT.
Methods: The National Cancer Database (NCDB) was queried to
identify patients with stage I-II and grade 1-2 nodal or extranodal FL
diagnosed between 2011 and 2017. Patients were stratiﬁed by treatment group including observation, RT, rituximab, RT + rituximab,
and chemotherapy + rituximab. OS was calculated using a KaplanMeier estimator and analyzed with log rank testing. Multivariable
Cox proportional hazards modeling was utilized to evaluate associations between clinical variables and survival. Multivariable logistic
regression was used to identify predictors for recommendation and
receipt of RT vs. observation. The observation and RT groups were
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cohorts. Despite lack of evidence supporting a change in patterns of
care, RT utilization continues to decline and systemic therapy is
increasing (Figs. 1 and 2).

(P130) Clinical Outcomes for Patients with Diffuse Large
B-cell Lymphoma Treated with Radiation Therapy and
Lenalidomide

FIGURE 1. Survival by treatment group. Kaplan-Meier analysis for
patients by treatment group. All patients had stage I-II, grade 1-2 FL.
Abbreviations: RT, radiotherapy; FL, follicular lymphoma; R, rituximab.

propensity matched to mitigate confounding factors and again analyzed with multivariable Cox, Kaplan-Meier estimator, and log rank
testing.
Results: 11,645 patients were included in the analysis with a mean
follow up time of 45 months who underwent treatment with either RT
only (n = 2,399), observation (n = 5,214), rituximab (n = 808), RT +
rituximab (n = 242), or chemotherapy + rituximab (n = 1,165). Fiveyear OS was 90.6% for RT only, 81.1% for observation, 84.3% for
rituximab, 89.5% for RT + rituximab, and 87.3% for chemo + rituximab. Compared with RT alone, observation was associated with worse
OS outcomes (HR 1.41, P < .001), while the other treatment groups
were not signiﬁcantly different. Compared with patients with private
insurance, those with Medicaid had worse survival (HR 2.26, P < .001).
Patients who made > 46,000 dollars per year had better survival than
those who made < 30,000 (HR 0.75, P = .03). Treatment at an academic
center was predictive for both the recommendation (OR 1.30, P < .01)
and receipt (OR 1.39, P < .01) of observation instead of RT. Between
2011 and 2017, RT monotherapy decreased from 33.4% to 22.4%,
chemotherapy + rituximab increased from 0.5% to 15%, and rituximab
monotherapy increased from 0.6% to 10.2%. After propensity matching
the RT and observation groups, observation remained associated with
worse overall survival (HR 1.23, P = .02).
Conclusions: In early stage low-grade FL, RT was associated with
improved survival compared with observation in propensity matched

Sungjune Kim, MD, PhD1, Shreni Shah, Medical Student2, Su-Yuan
Yu, Medical Student3, Matthew Mills, MD1, Nicholas Figura, MD1,
Timothy Robinson, MD, PhD1; 1H. Lee Mofﬁtt Cancer Center and
Research Institute, Department of Radiation Oncology, 2USF Morsani
College of Medicine, 3University of South Florida, Morsani College of
Medicine
Background: First-line treatment for diffuse large B-cell lymphoma
(DLBCL) consists of combination immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Patients who develop relapsed or refractory (R/R) disease
following second-line salvage high-dose chemotherapy and autologous
stem cell transplantation have a dismal overall prognosis (Crump M,
et al, Blood 2017).
Objectives: Lenalidomide is an immunomodulatory agent that has been
shown to demonstrate efﬁcacy in the setting of R/R DLBCL; however,
there is currently minimal evidence on the role of combining lenalidomide with radiotherapy (RT).
Methods: This is a single institution retrospective review of DLBCL
patients who underwent RT within 3 months of lenalidomide
administration. Local control (LC), progression-free survival (PFS),
and overall survival (OS) were estimated using the Kaplan-Meier
method from the start date of RT and were compared with the logrank test.
Results: The study identiﬁed 10 DLBCL patients who received RT to
12 distinct disease sites within 3 months of lenalidomide administration.
Median clinical follow-up post-RT was 6.9 months (range, 0.1118.0 mo). The majority of patients were stage IV (n = 7, 70%) with a
median age of 69 years (range, 42-93 y). Three patients demonstrated
BCL2 rearrangement while one patient demonstrated MYC rearrangement; however, there were no cases of double- or triple-hit DLBCL.
The median number of systemic regimens before lenalidomide was 2.5
(range, 0-6). The 12 disease sites treated with RT received a median
dose of 36 Gy (range, 18-50 Gy) to a planned target volume of 553cc
(range, 16-4764 cc). The 12-month LC, PFS, and OS were 87.5%,
34.4%, and 62.5%, respectively. There were no episodes of acute nor
late grade ≥ 3 radiation-related toxicities.
Conclusions: The combination of radiotherapy with concurrent lenalidomide appears to be a well-tolerated treatment option for patients with
R/R DLBCL. While early outcomes data appear comparable with historical controls, further evaluation of long-term clinical outcomes and
toxicities remains warranted.

(P131) Upfront versus Delayed Stereotactic Radiosurgery
for Brain Metastases in Epidermal Growth Factor Receptor
(EGFR) Mutant Non-Small Cell Lung Cancer Treated with
EGFR Tyrosine Kinase Inhibitors

FIGURE 2. Treatment trends over time. Treatment trends over time
comparing observation, RT, R, RT + R, and chemo + R between
2011 and 2017. Abbreviations: RT, radiotherapy; R, rituximab.

Ammoren Dohm, MD1, Joseph Tang, BA1, Matthew Mills, MD1,
Bradford Perez, MD1, Timothy Robinson, MD, PhD2, Ben Creelan,
MD1, Jhanelle Gray, MD1, Arnold Etame, MD1, Michael Vogelbaum,
MD, PhD1, Peter Forsyth, MD1, Hsiang-Hsuan Michael Yu, MD1,
Daniel Oliver, MD1, Kamran Ahmed, MD3; 1H. Lee Mofﬁtt Cancer
Center & Research Institute, 2H. Lee Mofﬁtt Cancer Center and
Research Institute, Department of Radiation Oncology, 3Department of
Radiation Oncology, H. Lee Mofﬁtt Cancer Center & Research Institute
Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) and stereotactic radiosurgery (SRS) have shown
response in the management of non-small cell lung cancer (NSCLC)
brain metastases (BM). However, whether to withhold metastasis-
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directed therapy until progression of asymptomatic intracranial disease
while on EGFR-TKI or to treat with upfront SRS remains an area of
investigation, especially in the era of 3rd generation EGFR-TKI.
Objectives: We evaluated clinical outcomes in NSCLC BM treated
with SRS and EGFR-TKI to determine optimal management. Our primary objective was to evaluate the effect of SRS timing with EGFRTKI on distant intracranial control (DIC).
Methods: A total of 30 NSCLC BM patients, treated between 2015
and 2019, to a total of 110 intact (non-operative) BM over 43 single
fraction SRS sessions were included. EGFR-TKI therapies included
osimertinib (n = 10), afatinib (n = 3), erlotinib (n = 13), and geﬁtinib
(n = 4). Time-to-event analysis was conducted with the Kaplan-Meier
method, with log-rank testing to determine differences in outcomes
by subgroup. Outcomes included DIC and local control (LC) calculated from SRS and overall survival (OS) from the date of BM
diagnosis.
Results: Median follow-up from BM diagnosis was 11.0 months (1.153.1 mo) and 9.3 months from SRS (0.1-52.4 mo). SRS was conducted
before, concurrently, and after EGFR-TKI therapy in 15, 87, and 8
lesions, respectively. No signiﬁcant differences in age (P = 0.77), sex
(P = 0.07), presence of systemic metastasis (P = 0.07), SRS dose
(P = 0.40), KPS (P = 0.23) or EGFR-TKI generation (P = 0.45) were
noted between treatment groups. The median DIC was 26.2, 21.0, and
3.2 months (P = 0.086) for SRS upfront, concurrently, and after EGFRTKI, respectively; only SRS timing was signiﬁcant on univariate
analysis favoring upfront SRS (HR 0.13, P = 0.048). Median OS was
42.8, 11.9, and 4.0 months for SRS upfront, concurrently, and after
EGFR-TKI, respectively (P = 0.0009). No differences were noted in LC
(P = 0.58) based on timing of SRS. Rates of radiation necrosis did not
differ between treatment groups and were 0%, 3.5%, and, 0%,
for upfront, concurrent, and after EGFR-TKI groups, respectively,
P = 0.49.
Conclusions: In our analysis of NSCLC BM patients treated with SRS,
we demonstrate that upfront SRS before EGFR-TKI was associated
with a trend towards improved DIC and improved OS. Further evaluation of concurrent treatment with SRS and third-generation EGFRTKIs is warranted.

(P132) A Patient-level Data Meta-analysis of the Abscopal
Effect
Steven Hatten, Medical Student1, Eric Lehrer, Resident Physician2,
Jenn Liao, Medical Student1, Mike Sha, Medical Student1, Daniel
Triﬁletti, MD3, Shankar Siva, Physician4, Sean McBride, Physician5,
David Palma, Physician6, Sheldon Holder, Physician7, Nicholas Zaorsky, Physician8; 1Department of Radiation Oncology, Penn State
Cancer Institute, Hershey, PA, USA, 2Department of Radiation
Oncology, Icahn School of Medicine at Mount Sinai, New York, NY,
USA, 3Department of Radiation Oncology, Mayo Clinic, Jacksonville,
FL, USA, 4Sir Peter MacCallum Department of Oncology, University of
Melbourne, Melbourne, Australia, 5Department of Radiation Oncology,
Memorial Sloan Kettering Cancer Center, New York, NY, USA,
6
Department of Radiation Oncology, London Health Sciences Centre,
London, Ontario, Canada, 7Division of Hematology and Oncology,
Penn State Cancer Institute, Hershey, PA, USA, 8Department of Public
Health Sciences, Penn State College of Medicine, Hershey, PA, USA
Background: The abscopal effect is deﬁned by local therapy resulting
in response within a targeted tumor but also reducing tumor burden in
distant, untreated areas.
Objectives: Number one is to systematically review cases of the
abscopal effect. Number two is to perform a patient-level data analysis
for clinical predictors of duration of response and survival.
Methods: PICOS/PRISMA/MOOSE was used for articles published
before 09/2019 in MEDLINE/PubMed and Google Scholar. Inclusion
criteria were: (1) population: patients with reported abscopal response;
(2) intervention: documented treatment(s); (3) control: none; (4) outcomes: overall and progression-free survival; (5) setting: retrospective
case reports. Time from treatment until abscopal response and time
from abscopal response until progression or death were calculated.
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FIGURE 1. PRISMA flow diagram.

Univariate and multivariate analyses were conducted for survival
outcomes.
Results: 50 studies (n = 55) were included. Median age was 65 years,
(interquartile range, IQR: 58-70) and 62% were male. 54 (98%)
patients received radiotherapy; 34 (62%) received radiotherapy
alone, 5 (9.1%) underwent surgery, 4 (7.3%) received chemotherapy,
and 11 (20%) received immunotherapy. Median total dose was 32 Gy
(IQR: 25.5–48 Gy) and median dose per fraction was 3 Gy (IQR:
2-7.2). Median time until abscopal response was 4 months (IQR: 1-5,
min 0.5, max 24). At 5-years, overall survival was 63% and
distant progression-free survival was 45%. No variables had statistical signiﬁcance (all P > 0.05) in predicting duration of response or
survival.
Conclusions: Almost all reported cases of the abscopal response are
after radiation therapy; however, there are no known predictors of
duration of response or survival in this population (Figs. 1 and 2).

FIGURE 2. Outcome survival and progression free survival.
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(P133) Normalized Standardized Uptake Value Characterization of Adrenal Metastases for Biology-Guided Radiation
Therapy Utilizing FDG-PET
Calvin Huntzinger, MS1, Daniel Palmieri, BS2, Shervin Shirvani, MD1,
Ronald Lalonde, PhD2, Adam Olson, MD3; 1ReﬂeXion Medical, 2University
of Pittsburgh Medical Center, 3Department of Radiation Oncology, UPMC
Hillman Cancer Center, University of Pittsburgh School of Medicine
Background: Biology-guided radiation therapy (BgRT) is a tracked dose
delivery method utilizing positron emissions emanating from tumors to
deliver radiation to moving targets, while minimizing dose to adjacent normal
tissue. This novel approach may be beneﬁcial in the application of ablative
radiation to treat adrenal metastases in non-small cell lung cancer (NSCLC).
Because BgRT is predicated on detecting the SUV of active tumors, it
requires PET contrast between the surrounding tissue and the metastasis,
which is quantiﬁed as the normalized standardized uptake (NSUV).
Objectives: In this study, we reviewed various calculations of NSUV
for adrenal metastases, a common site of metastatic spread for nonsmall cell lung cancer (NSCLC), to determine optimal numerical
thresholds for BgRT delivery.
Methods: We measured NSUV values in a retrospective cohort of patients
at a single center who received an FDG PET-CT before SBRT for adrenal
metastases between January 1, 2007 and July 1, 2019. We excluded patients
who received systemic therapy between PET-CT and SBRT or whose PETCT was more than 180 days before SBRT. NSUV was calculated by
dividing max SUV within the gross tumor volume (GTV) by mean SUVs
in 5, 10, and 15-mm rings around the GTV. The liver area was cropped
from the rings surrounding right adrenal metastases while bowel and
stomach areas were cropped from rings surrounding left adrenal metastases.
All contouring was performed in an Eclipse treatment planning system. A
two-tailed T-test was used for any comparisons. A prespeciﬁed NSUV of 3
was assumed as the minimum NSUV for BgRT and potential factors
associated with NSUVs above this threshold were explored.
Results: Eighteen patients were ultimately included in the analysis. Ten
(56%) received SBRT for a right adrenal metastasis and 8 (44%) for a left
adrenal metastasis. The average age at time of treatment was 69 (range 4487) with 13 male (72%) and 5 female (28%) patients. The average time
elapsed between PET-CT and SBRT was 43 days (range 15-133). Ten
(56%) patients received systemic therapy in the year before their PET-CT
and 8 (44%) received no systemic therapy. The NSUVs are presented in the
following table: GTV Ring Size NSUV (Mean ± SD) NSUV Range 5 mm
3.95 ± 2.24 1.94-9.76 10 mm 4.66 ± 2.80 2.16-12.19 15 mm 5.03 ± 3.02
2.23-13.09. There was no signiﬁcant difference in NSUV ratio between the
5 mm and 15 mm ring method (P = 0.233). Tumor size was not associated
with a higher odds of an NSUV of 3 or greater (P = 0.3978 for 5 mm ring,
P = 0.7597 for 10/15 mm ring) nor was right vs. left adrenal metastasis
(P = 1.0 for 5 mm ring, P = 0.1176 for 10/15 mm rings).
Conclusions: Biology guided radiation therapy (BgRT) shows promise
in the treatment of adrenal metastases. Mean NSUVs increased as the
GTV ring size increased, but the difference between the smallest and
largest increase was not signiﬁcant. A 5 mm ring around the GTV could
provide a robust and simple method to calculate NSUVs to see whether
adequate contrast is present for BgRT. Assuming an NSUV of 3 is
required for optimal functioning of BgRT, most of the adrenal metastases would be BgRT candidates. This investigation will inform future
investigations of BgRT for NSCLC metastases in the upper abdomen.

FIGURE 1. Overall survival by radiation dose intensity.
referred to radiation oncology between October 2016 and December
2017. A survival estimate was calculated using the validated NEAT
model based on number of active tumors, ECOG performance status,
albumin, and primary tumor site. The consulting nurse and physician
were prospectively surveyed on whether the patient would survive a
longer or shorter duration than the NEAT estimate. Concurrent predictions made by the validated Chow and TEACHH models were used
as a control. Overall survival was calculated from time of enrollment.
The accuracy of predictions compared with observed survival between
groups was assessed using the McNemar’s χ2d test.
Results: The median survival for enrolled patients was 7.8 months. The
accuracy of nursing and physician predictions was similarly accurate (61.6%
vs. 60.3%, P = 0.85). The accuracy of the TEACHH model and Chow models
were also similar (49.3% vs. 48.0%, P = 0.74). The accuracy of human predictions was signiﬁcantly improved compared with the accuracy of computer
models alone (61.0% vs. 48.6%, P = 0.016). Radiation dose intensity was
informed by predicted survival and median survival was signiﬁcantly higher in
patients receiving an EQD2 ≥ 40 (17 mo vs. 2 mo, P < 0.001).
Conclusions: Experienced clinicians, both nurses and oncologists, have
insight that can modestly supplement the accuracy of validated models
to predict survival in patients with advanced cancer (Fig. 1).

(P135) Local Control of 1-5 Fraction Radiotherapy Regimens for Spinal Metastases: An Analysis of the Impacts of
Biologically Effective Dose and Primary Histology
Roman Kowalchuk, MD1, David Cousins, MD2, Kelly Spencer, MS3,
K. Richardson, MS3, James Larner, MD2, Timothy Showalter, MD2,
William McAllister, MD4, Jason Sheehan, MD, PhD2, C. Kersh, MD3,
Sunil Dutta, MD5; 1Mayo Clinic - Rochester, 2University of Virginia,
3
University of Virginia / Riverside, 4Riverside Regional Medical Center,
5
Emory University
Background: Ablative doses of radiotherapy for the treatment of oligometastatic disease can improve overall survival (OS). Despite this
beneﬁt, toxicity can be severe and patient selection is critical.

(P134) Improved Accuracy in Predicting Survival When
Supplementing a Predictive Model with Clinical Intuition
Johnny Kao, MD1, Amanda Zucker, DO2, Michelle Urso, RN1, Pawel
Karwowski, BA1, Giavanna Bustamante, RN1, Deborah Lugo, RN3,
LuAnn Rowland, RN, OCN, CNS1; 1Good Samaritan Hospital Medical
Center, 2New York College of Osteopathic Medicine, 3Memorial Sloan
Kettering Cancer Center Regional Care Network
Background: Neither clinical intuition or validated prognostic models
adequately predict survival for patients with advanced cancer.
Objectives: We hypothesized that experienced clinicians could predict
survival of patients with metastatic cancer better than validated models
alone thereby demonstrating the value of clinician intuition.
Methods: This prospective, single institution, cohort study conducted at
a community hospital recruited 73 patients with advanced cancer

FIGURE 1. The local control rates of the different primary histologies are shown.
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TABLE 1. Trends of Immunotherapy Over Time

FIGURE 2. Patients in RPA class 1 demonstrated improved local
control with BED ≥ 40 Gy (P = 0.05).
Objectives: This analysis evaluates the impacts of biologically effective
dose (BED) and primary histology on local control (LC) of spinal
metastases treated with highly conformal radiotherapy to moderately
escalated doses per fraction.
Methods: Patients were treated at two institutions with either stereotactic
body radiation therapy (SBRT) or tomotherapy for spinal metastases from
2010-2020, and at least one clinical or imaging follow-up was required.
Patients treated with less than 5 Gy per fraction or 8 Gy in 1 fraction were
excluded. The dataset was divided into three RPA classes predictive of
survival (Chao et al IJROBP 2012). Class 1 required > 30 months from
primary disease diagnosis and Karnofsky performance status (KPS) > 70;
class 2 included > 30 months from primary diagnosis and KPS ≤ 70 or
≤ 30 months from diagnosis and age < 70 years; class 3 involved ≤
30 months from diagnosis and age ≥ 70. The primary endpoint was LC;
secondary endpoints were toxicity and OS. Key statistical methods
included the Kaplan-Meier method and Cox hazards analysis. An alpha/
beta ratio of 10 Gy was used for BED calculations.
Results: 223 patients with 248 treatments met inclusion criteria. Patients
had a median KPS of 80, and common primary disease sites included
breast (29.4%), non-small cell lung cancer (15.7%), and prostate (13.3%).
Patients presented at a median age of 67.4 years at a median 42.8 months
after primary diagnosis. A median 24 Gy (6-36) was delivered in a median
3 fractions (1-5) to a median planning target volume (PTV) of 37.3 cc
(1.1-2436.0). Median BED was 38.4 Gy (9.6-79.2). At a median clinical
follow-up of 12.85 months, there were 44 local failures. 2-year LC was
75.7%, and 2-year OS was 42.1% via the Kaplan-Meier method. No
difference in LC was noted between SBRT and tomotherapy, but PTV >
30 cc was indicative of increased local failure (P = 0.01). LC was varied
among primary histology in the cohort (Fig. 1), and increased BED was
predictive of improved LC for primary prostate cancer (HR = 0.85 95% CI
[0.74–0.99]). When matched according to RPA class, patients with
favorable survival (class 1) had improved LC with BED ≥ 40 Gy
(P = 0.05, Fig. 2). This relationship was also shown using an ROC curve.
Patients in the intermediate and poor survival groups failed to show this
improvement. Toxicity was minimal, with only 6 total instances of grade 2
toxicity reported, and no grade 3-5 toxicities.
Conclusions: Treatment of spinal metastases with a range of moderately
escalated doses per fraction using modern radiation techniques was efﬁcacious and well-tolerated. BED ≥ 40 Gy may improve LC, particularly
for prostate cancer and patients with favorable survival; however, a multidisciplinary approach may be necessary for larger tumor volumes.

and targeted agents. Using the National Cancer Database (NCDB) we
examined the utilization of such treatments overtime and attempted to
identify potential barriers of use.
Objectives: The objective is to explore trends in the utilization of
immunotherapy/targeted therapy in the treatment of metastatic melanoma.
Methods: The NCDB was queried for patients with MM from 2004-2014.
Sociodemographic, treatment, and overall survival data was examined.
Results: The use of immunotherapy/chemotherapy in healthy patients
increased overtime to 54% in 2004 to 72.1% in 2014. Patients were less
likely to receive immunotherapy if they lacked insurance, were of older
age, and received care at a community practice as compared with

TABLE 2. Multivariate Analysis of Predictors of Receiving
Immunotherapy

(P136) Adoption of Immunotherapy in the Treatment of
Metastatic Malignant Melanoma
Todd A. Pezzi, MD, MBA1, Ashley Pezzi, MD2, Amanda Shreders,
MD3, William Hammond, MD3, Jennifer Crozier, MD3, Christopher
Pezzi, MD3; 1MD Anderson Cancer Center, 2Baylor College of Medicine Dermatology, 3Baptist MD Anderson Cancer Center
Background: Major advances have occurred in the treatment of
metastatic melanoma since 2011 leading to improvements in response
to therapy and overall survival–notably the usage of immunotherapy

Multivariate analysis of predictors of receiving immunotherapy for treatment
of metastatic melanoma in the National Cancer Data Base, 2004-2014.
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academic centers. Those who received immunotherapy had greater
overall survival.
Conclusions: Immunotherapy and targeted agents have become
standard of care in those with MM. Adoption of these new therapies has
been slow despite the improved response and survival compared with
other treatments (Tables 1 and 2).

(P137) Disparities in Survival and Surveillance Imaging in
Long-Term Survivors with Brain Metastasis Treated with
Stereotactic Radiosurgery
Benjamin Rich, MD1, Deukwoo Kwon, PhD2, Yash Soni3, Danny
John3, Jonathan Bell, MD, PhD1, Gregory Azzam, MD1, Eric Mellon,
MD1, Raphael Yechieli, MD1, Carolina Benjamin, MD4, Ronald Benveniste, MD4, Matthew Abramowitz, MD1, Ricardo Komotar, MD4,
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Michael Ivan4, Jacques Morcos4, Tejan Diwanji, MD1; 1University of
Miami/Sylvester Comprehensive Cancer Center, Department of Radiation Oncology, 2University of Miami/Sylvester Comprehensive Cancer
Center, 3University of Miami Miller School of Medicine, 4University of
Miami, Department of Neurosurgery
Background: Guidelines recommend surveillance magnetic resonance
imaging (MRI) every three months in asymptomatic patients with brain
metastasis following treatment based on the majority of patients with
central nervous system (CNS) disease-free survival (DFS) under one
year (Patel SH, et al Am J Clin Oncol. 2012). Patients with long-term
CNS DFS with brain metastasis treated with stereotactic radiosurgery
(SRS) are an increasingly important population, but survival disparities
and follow-up patterns are not established.
Objectives: Our objective is to evaluate disparities in survival and
follow-up surveillance imaging in patients with brain metastasis treated
with SRS with long-term CNS DFS.

TABLE 1. Patient Characteristics
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TABLE 2. Effect of Selected Variable on MRI Brain Frequency After One Year From SRS Treatment

Methods: We identiﬁed a cohort of 373 consecutive patients with brain
metastasis treated with SRS in the deﬁnitive or postoperative setting at
our institution from 9/2014 to 9/2019. Eligible patients had at least one
year of CNS DFS from SRS treatment for newly diagnosed brain
metastasis. Patient socioeconomic and disease characteristics were retrospectively collected. The MRI brain scans from one-year post-treatment during CNS DFS were collected with a Poisson regression univariable (UVA) and multivariable (MVA) analysis conducted to assess
impact of select factors on imaging follow-up. Overall survival (OS)
was calculated as time from SRS treatment to death. Survival was
censored at death or last follow-up. Kaplan-Meier univariate analysis
was conducted to assess impact of factors on OS. P-value of <0.05 was
used for signiﬁcance.
Results: 55 patients met eligibility criteria for inclusion in this study
(median follow-up 2.48 years, median age at treatment 60 y). The
median CNS disease-free survival and OS was not reached. 11 patients
(20.0%) had intracerebral progression at median time of 2.26 years. A
median of 4 MRIs were performed during CNS DFS after one year. On
UVA, males (RR 1.32, P = 0.034) had increased MRI frequency,
whereas increased income (middle income RR 0.67, P = 0.036; upper
income RR 0.65, P = 0.037) and more than 12 months between radiation oncology follow-ups (RR 0.65, P = 0.003) were associated with
lower MRI frequency. On MVA, there was a trend for radiation
oncology follow-ups and income (P < 0.10).
Conclusions: Patients with metastatic disease to the brain treated
deﬁnitively or postoperatively with SRS who have CNS DFS at one
year have a good prognosis. Factors that predict survival at time of
treatment do not appear to be associated with survival in this selective

population. A low level of income and regular follow-ups with a
radiation oncologist were associated with increased follow-up imaging
frequency on UVA. While these ﬁndings did not remain signiﬁcant on
MVA, the cohort may be underpowered to detect this difference. We
believe these ﬁndings warrant further investigation with a multi-institutional cohort (Tables 1 and 2).

(P138) Determining Factors of Salvage Radiation Therapy
Modality for Distant Brain Metastasis Failure After Initial
Stereotactic Radiosurgery
Yash Soni1, Benjamin Rich, MD2, Deukwoo Kwon, PhD3, Wei Zhao3,
Danny John1, Crystal Seldon, MD2, Carolina Benjamin, MD4, Ronald
Benveniste, MD4, Ricardo Komotar, MD4, Macarena De La Fuente,
MD5, Maria del Pilar Prieto, MD5, Gregory Azzam, MD2, Eric Mellon,
MD2, Matthew Abramowitz, MD2, Tejan Diwanji, MD2; 1University of
Miami Miller School of Medicine, 2University of Miami/Sylvester
Comprehensive Cancer Center, Department of Radiation Oncology,
3
University of Miami/Sylvester Comprehensive Cancer Center, 4University of Miami, Department of Neurosurgery, 5University of Miami/
Sylvester Comprehensive Cancer Center, Department of Neurology
Background: The likelihood of distant brain metastasis failure is
increased in patients initially undergoing stereotactic radiosurgery (SRS)
versus whole brain radiation therapy (WBRT) for brain metastasis
(LeCompte MC, et al J Neuroncol 2020). Although the factors inﬂuencing survival outcomes have been studied extensively, those used to
determine salvage reirradiation with SRS versus WBRT are unknown.
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TABLE 1. Baseline Patient Characteristics by Salvage
Therapy Type

TABLE 2. Effect of Selected Variable on Receipt of Salvage SRS or
Salvage WBRT (WBRT = Reference)

Objectives: To determine the clinical and demographic characteristics
associated with treating distant brain metastasis failure (DBF) with
salvage SRS vs. salvage WBRT after initial SRS treatment.

Methods: We identiﬁed a cohort of 374 consecutive patients with brain
metastases treated with SRS in the deﬁnitive or postoperative setting, at
a single institution, from August 2014 to September 2019. Eligible
patients received subsequent salvage radiation at our institution with
WBRT or SRS due to DBF at least one month after initial SRS. Clinical
and demographic characteristics were retrospectively recorded. Univariate (UVA) and stepwise multivariate analyses (MVA) were performed to determine if there was an association between these factors
and the use of salvage SRS versus WBRT. Odds ratios (ORs) and
corresponding P-values were estimated from a logistic regression
model. A survival analysis was also performed to assess the hazard ratio
(HR) of these factors on survival. All tests were two sided and P-value
of <0.05 was used for signiﬁcance.
Results: A total of 84 patients (median age 59.6, median time to salvage
radiation 5.4 months, median follow-up from initial treatment
1.45 years and 0.84 years from salvage treatment) met eligibility criteria
for inclusion in this study. 69 patients received SRS and 15 patients
received WBRT at the time of ﬁrst DBF. The following factors were
associated with decreased use of salvage SRS on UVA: ≥ 3 sites of
DBF (OR 0.06, P = 0.009) and brain metastasis velocity ≥ 4 (OR =
0.17, P = 0.025).On MVA, ≥ 3 sites of DBF was associated with
decreased use of salvage SRS (OR 0.07, P = 0.012). There were no
socioeconomic or other clinical factors associated with receipt of salvage SRS versus WBRT on UVA or MVA. Median overall survival
from retreatment was 21 months. On MVA, progressing extracranial
disease was associated with decreased survival (HR 2.96, P = 0.018)
and receipt of salvage SRS versus WBRT increased survival (HR 0.30,
P = 0.006).
Conclusions: In this analysis, the only factor independently associated with selection of salvage WBRT vs. SRS for DBF is the
number of new intracranial lesions. This is congruent with current
guidelines. No socioeconomic disparities were found to signiﬁcantly
inﬂuence modality of salvage therapy. In this cohort, salvage SRS
was associated with a statistically signiﬁcant improvement in OS;
however, this may represent a selection bias. We await results of the
accruing randomized trial NRG-BN009, which is evaluating these
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salvage treatment modalities, for further guidance in this patient
population (Tables 1 and 2).

Abstracts

TABLE 1. Rates of Procedural Complications and Treatmentrelated Toxicities Following CT-guided HDR Interstitial
Brachytherapy Ablation

(P139) CT-guided Interstitial HDR Brachytherapy Is a Safe
and Effective Treatment Option for Central and Ultracentral Lung Malignancies
Stephanie Yoon, MD1, Robert Suh, MD1, Fereidoun Abtin, MD1,
Mitchell Kamrava, MD2, Puja Venkat, MD1, Alan Lee, MD1, Albert
Chang, MD, PhD1; 1University of California Los Angeles, 2CedarsSinai Medical Center
Background: Central lung tumors lie in close proximity to critical
organs that, if untreated, can cause signiﬁcant morbidity. Effective
treatment options are limited with an increased risk for toxicity. CTguided interstitial high-dose rate (HDR) brachytherapy is a relatively
novel therapeutic option for lung malignancies, and has the potential to
overcome limitations faced with current therapeutic options, such as
image-guided thermal ablation or stereotactic body radiotherapy, for
central lung tumors. Few institutions globally offer HDR brachytherapy
for pulmonary malignancies with our institution, to our knowledge,
being the ﬁrst to offer this therapy in the United States.
Objectives: The aim of this investigation was to assess the long-term
safety and efﬁcacy of interstitial HDR brachytherapy for pulmonary
malignancies.
Methods: From September 2015 to August 2019, 25 patients with 37
pulmonary tumors were treated with interstitial HDR brachytherapy.
CT-guided placement of interstitial catheters was performed followed
by radiation delivery. Twenty-three patients received a median total
dose of 21.5 Gy (range, 15-27.5) in a single fraction. Two patients
received median total dose of 24.75 Gy (range 24-25.5 Gy) over 2-3
fractions. Patients were followed every 3 months with chest CT and
physical exam to assess tumor response and treatment-related toxicity.

Descriptive statistics were reported for patient demographics, clinical
features, procedural complications, and toxicity. Fisher’s exact test
assessed the association between LC and several covariates. KaplanMeier method estimated local tumor control (LC), progression-free
survival (PFS) and overall survival (OS).
Results: Of 37 treated tumors, 88% of patients had lung metastases.
24.3% and 54.1% of tumors were centrally and ultra-centrally located,
respectively. Average tumor volume was 11.6 cm3 (SD 12.4, range
0.57-62.8). Median follow-up was 19 months (range 3-48). Two and
3-year LC were 96.2% (Fig. 1). No clinical or treatment covariates were
associated with LC. Two and 3-year PFS were 29.7%. Two and 3-year
OS were 65.5%. Thirteen of 39 (33.3%) procedures were associated
with trace minor pneumothorax requiring no intervention, 4 (10.3%)
procedures were associated with major pneumothorax requiring chest
tube insertions, and 1 (2.5%) procedure with minor radiographic
pulmonary hemorrhage. All procedural complications resolved within
24 hours from treatment (Table 1). Four patients developed acute grade
1-2 toxicity. No patients developed late toxicity.
Conclusions: CT-guided interstitial HDR brachytherapy is a safe and
effective treatment. Brachyablation should be considered in the multidisciplinary management of centrally-located pulmonary tumors.

(P140) Psycho-social Impact of COVID-19 on Hematologic
Cancer Patients and Caregivers

FIGURE 1. Kaplan-Meier curve for local tumor control.

Isabella Amaniera1, Christina Bach, MSW, MBE, LCSW2, Carolyn
Vachani, MSN, RN, AOCN1, Karen Arnold-Korzeniowski, BSN, RN1,
James Metz, MD1, Christine Hill-Kayser, MD1, Margaret Hampshire,
RN, BSN, OCN1, Marisa Healy, BSN, RN1, Alexander Rodriguez1,
Courtney Misher, MPH,BSRT(T)1, Laura Kendrick, MHA, BSRT(T)1;
1
University of Pennsylvania, 2Oncolink
Background: Patients with hematologic cancers (HC) are at higher risk
for severe Covid-19 infection, due to the nature of their disease and
treatment. This risk is even higher for those undergoing transplant. At
baseline, the HC population is at risk for increased feelings of isolation,
psychosocial challenges, and ﬁnancial distress.
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Objectives: Further understand the impact of the COVID-19 pandemic
on feelings of isolation, psychosocial challenges, and ﬁnancial distress
in the HC population.
Methods: An Internet-based survey was available on Oncolink.org over
a 3-month period from April to June 2020. It was completed by a
convenience sample consisting of individuals diagnosed with cancer
over the age of 18 or their caregivers. Demographics, treatment-related
variables, practical needs (transportation, caregiving responsibilities)
ﬁnancial impact (costs of cancer treatment, loss of a job, insurance,
reduction in income) and factors surrounding access to food were
collected.
Results: There were 281 respondents. Caregivers and patients with HC
made up 37% of respondents (n = 104). Of these, 89% were patients
and 11% were caregivers. Age ranged from 28 to 81 (median 61). The
majority of participants were White (87%) and lived in the United
States (88%). Hematologic diagnoses included multiple myeloma
(66%), non-Hodgkin lymphoma (17%), acute leukemia (5%), Waldenstrom macroglobulinemia (5%), chronic leukemia (4%), and
Hodgkin lymphoma (2%). Most (76%) participants reported undergoing
active cancer treatment, with 96% receiving chemotherapy (alone or
combined with other therapies). In total, 37% of participants reported
that their treatments were changed or delayed during this time period.
Reasons for this change or delay of treatment included: decision by
oncology team (63%), worry about COVID exposure at treatment
center (13%), and worry about increased COVID risk related to treatment (11%). The majority of participants reported feeling increased
social isolation (81%) since the beginning of the COVID19 pandemic,
and reported that their mental health (worry, mood, sleep) was affected
by the pandemic (70%). Those reporting feeling more socially isolated
were also more likely to report negative impact on mental health
(P < 0.00001). Participants reporting that COVID-19 was affecting their
worry, mood and sleep were more likely to report an increase in
expenses (P = .003) and reduced access to food (P = .002). They were
also more likely to report COVID-19 impacting their ability to pay for
their monthly expenses (P < 0.005).
Conclusions: Patients and caregivers with HC represented the top user
group completing our survey. Our ﬁndings demonstrate that early in the
pandemic, patients experienced treatment delays and changes. These
patients reported feeling more socially isolated and this was related to
compromised mental health. Our results also illustrate the interconnectedness between mental health and practical needs. As we
emerge from the pandemic, oncology providers should be aware of the
lingering effects of social isolation and how this impacts mental health.

(P141) Standardization of PRISMA-Based Systematic
Review Practices for American Radium Society Appropriate Use Criteria Guidelines
Christopher Anker, MD1, Jonathan Beitler, MD, MBA2, Kristina
Novick, MD, MS3, Sue Yom, MD, PhD, MAS4, William Small, MD,
FACRO, FACR, FASTRO5, Karen Heskett, MSI6; 1University of
Vermont Larner College of Medicine, Division of Radiation Oncology,
2
Knox County Health Clinic, 3University of Pennsylvania, 4University
of California, San Francisco, 5Loyola University Chicago, Stritch
School of Medicine, Cardinal Bernardin Cancer Center, 6University of
California San Diego
Background: The American Radium Society (ARS) Appropriate Use
Criteria (AUC) Committees consist of disease-site expert panels that provide modiﬁed Delphi-derived treatment guidelines based on an rigorous
review of the literature. The Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines have established
methodologic standards for systematic reviews, including most recently via
the 2020 statement (Page, et al BMJ 2021) and accompanying explanation
and elaboration document (Page, et al BMJ 2021). However, adherence to
PRISMA guidelines is variable among publications noting their use.
Objectives: Standardize systematic review methodology to improve
reproducibility, quality, and transparency of the ARS AUC guideline
development process.
Methods: To tailor the PRISMA 2020 checklist to the ARS AUC
methodology, we performed an extensive analysis of resources
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TABLE 1. American College of Radiology (ACR) Study
Quality Rubric

available on the EQUATOR network (Enhancing the QUAlity and
Transparency Of health Research), assessing the PRISMA documents
as well as the The Cochrane handbook (https://training.cochrane.org/
handbook, accessed March 29, 2021).
Results: The essential elements of the PRISMA 2020 checklist that
pertain to ARS AUC procedures were deﬁned. A topic proposal
document based on PRISMA-P is submitted for approval to the
Disease-Site Committee Chair and the Steering Committee before
reference screening. Topic proposals will use the Cochrane FINER
Criteria (Feasible, Interesting, Novel, Ethical, and Relevant) to formulate focused PICOTS (Population, Intervention, Comparison,
Outcome, Timing, Study type) question(s). The search strategy must
be optimized through consultation with a librarian or information
specialist. The search must involve ≥ 1 databases, including Medline
(via Ovid or PubMed) and Embase (strongly recommended). To
conﬁrm the search’s sensitivity we suggest checking results against a
pre-selected validation set of articles. Article titles/abstracts must be
reviewed by ≥ 2 reviewers and full text by at least 1. Backward
citation searching (from references within the selected articles) and
forward citation searching (for papers that cite the selected articles)
is encouraged. Study quality rating using modiﬁed American College
of Radiology (ACR) deﬁnitions will be assigned by ≥ 2 reviewers
(Table 1). Certainty assessment will be deﬁned via ACR “Strength of
Evidence” and “Strength of Recommendation” categorization. The
ﬁnal publications are to include the search strategies reported in full,
the PRISMA 2020 ﬂowsheet detailing the record selection process,
and the PRISMA 2020 checklist.
Conclusions: We have redeﬁned the ARS AUC guideline development
process using PRISMA 2020 documents, including the checklist. The
resulting reproducibility and transparency will increase the quality of
ARS AUC guidelines.

(P142) Normal Pressure Hydrocephalus: A Reversible Late
Side-Effect of Whole Brain Radiation
Abigail Copella, MD1, Scott Shepard, MD2, Elizabeth Handorf, PhD1,
Shelly Hayes, MD1, Stephanie Weiss, MD1; 1Fox Chase Cancer
Center, 2Temple University Hospital
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TABLE 1. Response to Shunting Intervention

NA = not applicable; Dx = Diagnosis Sx = Symptoms; Mos = months.

Background: Whole brain radiotherapy (WBRT) remains widely used
despite the emergence of radiosurgery (SRS) for treatment of metastatic
disease to the brain (Barbour A, et al Advances in Radiation Oncology
2019; Modh A, et al IJROBP 2017). Attempts to minimize late effects
of WBRT typically involve alternative planning and dosing strategies.
Recently a signiﬁcant improvement in time to neurocognitive decline
was observed with hippocampal avoiding WBRT (HA-WBRT) but
surviving patients remain at risk for long term sequelae of treatment
(Gondi V, et al IJROBP 2018). High dose per fraction has long been
recognized as a predictor for a clinical syndrome hallmarked by “progressive dementia, ataxia and urinary incontinence” in long-term survivors (Deangelis L, et al Neurology 1989). Dementia, gait disturbance
and urinary incontinence are the classic triad associated with normal
pressure hydrocephalus (NPH), which can be diagnosed through a
lumbar drain trial (Williams M, et al Continuum 2016), and may be
reversible in up to 80% of patients through ventriculoperitoneal (VP)
shunting (Toma AK, et al Epub 2013). Because survival after diagnosis
of brain metastasis has improved signiﬁcantly over the past decade
(Sperduto P, et al JAMA Oncology 2017), interventions that reverse
long-term treatment-related toxicity are valuable.
Objectives: Describe value to patients of VP shunting for NPH after
receipt of WBRT for brain metastases.
Methods: Patients who underwent WBRT at an NCI Comprehensive
Cancer Center were retrospectively cross-matched to a list of patients
who underwent therapeutic VP shunt for NPH between January 1 2016
and January 31 2020. All patients were referred by a CNS specialist in
radiation oncology to a neurosurgeon for clinical suspicion of NPH
including new or progressive symptoms of magnetic gait (G), cognitive
changes (C), and/or new onset of urinary incontinence (U). NPH was
conﬁrmed via large volume lumbar drain in all patients before shunting.
Five patients were identiﬁed and constitute the subjects of this report.
All patients were scored as either having (Y) or not (N) symptoms of G,
C and U at diagnosis of NPH, and at post-shunting follow-ups. Time to
any symptom failure or last follow up was calculated.
Results: Median time from WBRT to presentation of symptoms suggesting
NPH was 40 months (Range, 7-148m). The majority of patients were found
to have improvement in all presenting symptoms. Patients 4 and 5 did not
achieve improvement in cognition with VP shunt. Two patients were found
to have durability of symptom improvement at time of analysis. Three
patients experienced relapse of symptoms after VP shunt placement with
median time to shunt failure being 7 months (Range, 1-8m).
Conclusions: NPH is a potentially reversible late side effect of. VP
shunting may achieve complete or partial relief of symptoms in these
patients and should be considered in the follow-up of long-term survivors with cognitive, gait and urinary changes after WBRT (Table 1).

(P143) Mixed Methods Evaluation of #NextGenBrachy: A
Targeted Mentorship Program to Increase Competence,
Comfort, and Representation in Brachytherapy
Idalid Franco, MD, MPH1, Daniel Petereit, MD2, Firas Mourtada,
PhD3, Lisa Singer, MD, PhD4; 1Harvard Radiation Oncology Program,
2
Monument Health Cancer Care Institute at Monument Health, 3Helen

F. Graham Cancer Center Christiana Care Health System, 4Department of Radiation Oncology, Brigham and Women's Hospital and
Dana-Farber Cancer Institute, Harvard Medical School
Background: Although brachytherapy (BT) plays a critical role in
cancer treatment (Holschneider CH, et al Brachytherapy 2019), recent
data shows a decline in utilization and underrepresentation of women
and early-career providers (Valle LF, et al JCO Oncol Pract 2021; Lu
DJ, et al Brachytherapy 2019). Resident surveys have cited lack of
exposure during training as a cause of decreased comfort, with an
interest in on-the job training (Marcrom S, et al Brachytherapy 2018).
These ﬁndings highlight the importance of a targeted approach toward
ensuring an adequate supply of brachytherapists.
Objectives: The purpose of this analysis is to describe the experiences
and obstacles to BT practice reported by mentees, before and within the
ﬁrst few months of participation, in a national mentorship program. We
hypothesize that structured access to experienced mentors for earlycareer practitioners can provide a venue to address obstacles and
increase BT exposure and comfort.
Methods: #NextGenBrachy was prospectively developed as a virtual
mentorship program to allow for ﬂexible communication and ongoing
collaborations between experienced BT mentors and early-career
mentees. The goal was to serve as an on-the-job virtual training platform, with a secondary goal of increasing representation of women and
early-career practitioners. An anonymous REDCap survey was sent to
mentees, within the ﬁrst few months of program initiation. A Linkerttype 5-point scale was used to measure initial BT comfort and conﬁdence. Free text responses provided additional descriptive data.
Results: A total of 13/17 mentees completed the survey (76%
response). Mentees were 82% female and 82% in their ﬁnal year of
residency or had completed training within the last 4 years. Comfort and
conﬁdence of participants was highest in performing gyn BT and least
in prostate BT, with prostate HDR having the lowest level of comfort or
conﬁdence among participants. For open ended questions regarding
obstacles, qualitative data analysis revealed multiple themes: difﬁculties
or lack of access in obtaining mentorship, obstacles with networking,
and lack of knowledge or awareness of available resources. In regards
to what participants hoped to gain, recurring themes included: the
ability to lead a BT program, comfort and competence with BT,
improved networking, and increased participation on a national level.
The majority (76%) reported feeling minimally connected to the BT
community and none reported a leadership position in a national BT
association.
Conclusions: Although the declining trends in BT use are multifactorial, targeted mentorship programs, such as #NextGenBrachy, can
serve as a catalyst to increase BT utilization and diversity. Future work
is needed to evaluate the overall impact of such programs and to
develop solutions to increase awareness regarding the impact of mentorship in creating and sustaining a representative workforce that provides standard of care to all patients.

(P144) Radiation Oncology Practice Size Consolidation
Brian Baumann, MD1, Jacob Hogan, BS2, Amit Roy, MD3, Jordan
Pollock, BS4, John Baumann, MD5, Hiram Gay, MD1, Carlos Perez,
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MD6; 1Department of Radiation Oncology, Washington University
School of Medicine in St. Louis, 2Washington University School of
Medicine, 3Washington University in St. Louis, 4Mayo Clinic,
5
Princeton Radiation Oncology, 6Washington University in St. Louis,
Department of Radiation Oncology
Background: In recent years, there has been evidence of practice
consolidation in US healthcare. To our knowledge, a detailed quantitative study of recent changes in radiation oncology practice size has not
been performed.
Objectives: We aim to evaluate radiation oncology practice size
changes between 2012 and 2020 in the US overall, for all regions, and
for both male and female physicians.
Methods: Using the Medicare Physician Compare Database, we identiﬁed practices employing radiation oncologists using their Taxpayer
Identiﬁcation Number and individual radiation oncologists using their
National Provider Identiﬁer. We assigned physicians with multiple
practice afﬁliations to the practice with the largest size. Practice size
includes the number of physicians of any specialty employed at that
practice, not just radiation oncologists. We compared the number of
individual radiation oncologists and the number of practices in each
practice size category between 2012 and 2020. Further analysis by US
census region and sex were performed. Cochran-Armitage test for trend
was used to detect signiﬁcant differences.
Results: Between 2012 and 2020, the total number of practicing radiation oncologists identiﬁed increased by 9% (4,300 to 4,679) while the
number of practices employing radiation oncologists decreased by
11.5% (1,606 to 1,422). The number of radiation oncologists in practices of size 1-2, 3-9, 10-24, and 25-49 decreased by 3.7%, 4.7%, 4.9%
and 2%, respectively, while the number of radiation oncologists in
practices of size 50-99, 100-499, and 500+ increased by 1.4%, 2.1%,
and 11.8%, respectively (all 500+ practices are multi-specialty groups).
The increase in practice size at both the individual and practice levels

FIGURE 1. Physician selection flowchart. Flowchart of physician
selection using the Physician Compare dataset (n = number in
2012, number in 2020).
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FIGURE 2. Bar plot of overall changes in group practice size. Bar
plot showing (A) the number of radiation oncologists and (B) the
number of group practices in each size category for 2012
and 2020.

was consistent in all regions and for both genders (FDR-adjusted P <
0.001 in all cases).
Conclusions: Our analysis provides objective evidence that practice
size consolidation is occurring within the US Radiation Oncology
workforce. The potential implications of practice consolidation for
physicians and patients should be considered by specialty leaders,
hospital administrators and government ofﬁcials when determining
future ﬁnancial policy (Figs. 1 and 2).

(P145) Feasibility of a Phase II Study Utilizing Spatially
Fractionated Radiation Therapy for Bulky or Radioresistant Tumors of the Head and Neck, Thorax, Abdomen,
Pelvis, and Extremities
Elizabeth Jeans, MEd, MD1, Michael Grams, PhD1, Randi Finley,
CMD1, William Breen, MD1, Dawn Owen, MD, PhD1, Sean Park, MD,
PhD1, Bradley Stish, MD2, Scott Lester, MD1, Ivy Petersen, MD1, Saﬁa
Ahmed, MD1, Kimberly Corbin, MD1, Mark Waddle, MD1, Michael
Haddock, MD1, Kenneth Merrell, MD1, Christopher Hallemeier, MD1,
Nadia Laack, MD1, Daniel Ma, MD1; 1Mayo Clinic, Rochester, 2Mayo
Clinic Rochester
Background: Spatially fractionated radiotherapy (SFRT), the modernday implementation of grid therapy, delivers a heterogenous dose,
consisting of high-dose distribution of “hotspots” interspersed with low
dose “valleys”, to a designated target volume.
Objectives: Bulky or radioresistant tumors have speciﬁc treatment
challenges. SFRT allows for high dose delivery with sparing of closely
approximated tissues and the potential to stimulate the radiationinduced bystander effect and non-speciﬁc immune system cells. This
study reports the feasibility of developing and accruing to a prospective
institutional protocol utilizing SFRT for curative or palliative purposes.
Methods: Patients are registered to a curative- or palliative-intent arm.
SFRT delivery options include a brass aperture to deliver a static ﬁeld or
lattice SFRT, utilizing VMAT. SFRT technique, dose, and optional consolidative radiotherapy dose/fractionation are prescribed at physician’s
discretion. The primary outcome is radiographic local control rate, utilizing
RECIST criteria, at 3 - 6 months. The secondary objectives include acute
and late adverse event proﬁle by assessment of grade 3 or higher adverse
events (NCI-CTCAE version 5 criteria), overall survival, regional progression, and distant disease control. An enrollment of 120 patients, 70
palliative and 50 deﬁnitive, is planned based on a 95% exact binomial
conﬁdence interval for local failure rate of ≤ 10% (curative), ≤ 30%
(palliative) and an estimation of adverse (grade 3+) events within 90 days
of ≤ 5%. Patient disease and treatment-related characteristics, as well as
follow-up details, including disease site-speciﬁc patient reported outcomes
are maintained in a prospective database.
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TABLE 1. Disease Site and Median Tumor Size

Results: From 01/2020 until 01/2021, 24 patients have been accrued
and received palliative (n = 19) or curative (n = 5) SFRT. Tumor location and size are listed in Table 1. Median dose of SFRT was 20 Gy in a
single fraction [range, 18 Gy–25 Gy]. Twenty-one patients received
VMAT SFRT and 3 patients received brass aperture SFRT. All curative
patients received consolidative RT 1-2 weeks following SFRT to a
median of 57.5 Gy in 25 fractions [35–62.5 Gy, 10–25 fractions], EQD2
median 58.9 Gy [39.4 Gy–65.1 Gy, α/β ratio 10]. Eleven palliative
patients (58%) received consolidative RT to a median of 30 Gy in 5
fractions [20–30 Gy, 3–5 fractions], EQD2 median 40.0 Gy [27.7 Gy–
40.0 Gy, α/β ratio 10]. For the patient’s enrolled to date, median followup is 4.1 months.
Conclusions: This ongoing prospective trial accruing patients with
radioresistant and bulky tumors for treatment with SFRT demonstrates
feasibility. Continued follow-up is necessary to determine efﬁcacy and
safety of SFRT. An understanding of appropriate selection for patients
undergoing SFRT is warranted. Co-enrollment on a sister study analyzing pre- and post-RT frozen biospecimens for immune cell subtypes
may help to elude underlying mechanisms of SFRT and appropriate
selection of patients, alongside sequencing of optimal adjunct therapies.

(P146) Global Health Opportunities in US Radiation Oncology
Programs
Amy Le, MD1, Jordan Holmes, MD, MPH1; 1Indiana University
Department of Radiation Oncology
Background: The incidence of cancer has increased in low- and middle-income countries (LMIC), however, many countries have limited
access to cancer care with inadequate resources (Jemal A, et al Cancer
Epidemiol Biomarkers Prev 2010). There is a need to train global
oncologists to work with colleagues in LMIC to assist with local
capacity-building efforts and develop sustainable infrastructure for
clinical oncology care, education, and research. There is growing
awareness of the beneﬁts formal training in global health provides
however formalized training and career pathways have been slow to
emerge in radiation oncology.
Objectives: The purpose of this study was to explore the extent of
online information on global health education available to potential US
radiation oncology residency program applicants. We hypothesized that
the majority of US radiation oncology programs do not have formal
training in global oncology or do not provide the information to prospective applicants in an accessible manner via internet resources.
Methods: Residency program websites were reviewed for 89 US
radiation oncology programs. The homepages and residency program
portion of the websites were examined for speciﬁc mention of international or global health initiatives, rotations, research collaborations, or
dedicated programs. Results were compared with prior report based on
data from the Association of Residents in Radiation Oncology (ARRO)
and the 2018 ARRO Global Health Resident Survey.
Results: Program websites for 76 programs (85.4%) had no information
available on global health education, 3 websites (3.4%) mentioned
potential for involvement in general global health initiatives, 5 websites
(5.6%) described international rotations (including 2 in non-LMIC), 1
website (1.1%) described international research collaborations, and 4
websites (4.5%) provided evidence of a global health track or program.
The websites for some residency programs did not include information on
the international opportunities they offered (5 websites, 5.6%), based on
comparison with report from ARRO and the 2018 ARRO Global Health
Resident Survey which identiﬁed 11 programs with global health initiatives
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based on active resident and faculty involvement in global health opportunities and focus on LMIC (Li BC, et al Glob Onco 2021).
Conclusions: A few radiation oncology residency programs had a dedicated global health track or program detailed on the program website,
while several others described international collaborations or rotations.
Some programs did not include information on the program website about
global health opportunities, running the risk of failing to attract global
health-minded applicants. Expansion of more formalized training would
allow for more radiation oncology residents to enrich their global health
perspective and gain experience for a career in global oncology.

(P147) Emergency Department Presentations for Radiation
Cystitis Among Patients with a History of Prostate Cancer
Victor Lee, BS1, James Yu, MD, MHS1, Henry Park, MD, MPH1,
Vikram Jairam, MD1; 1Yale School of Medicine
Background: Radiation therapy is often used to treat abdominopelvic
cancers such as prostate, cervical, uterine, and rectal cancer. Radiation
cystitis (RC) is a known complication of radiation therapy to the pelvic
area that can manifest years after initial treatment.
Objectives: We aim to shed light on the national burden of RC and
identify patients who at increased risk of requiring invasive measures to
manage this complication.
Methods: The Nationwide Emergency Department Sample was queried
for patients with prostate cancer who presented to the emergency
department (ED) from 2006 to 2015 for a primary diagnosis of radiation
cystitis. Visits associated with the use of an invasive procedure (transurethral procedures and cystectomies) were further identiﬁed. Baseline
demographic, socioeconomic factors, and hospital characteristics were
compared between patients receiving and not receiving invasive procedures using the χ2 test for categorical variables, and the MannWhitney U or analysis of variance tests for continuous variables.
Multivariable logistic regression was used to identify factors associated
with the receipt of invasive procedures. Weighted frequencies were
used to create national estimates for all data analysis.
Results: Between 2006 and 2015, a weighted total of 17,456 ED visits
occurred for RC among patients with a prostate cancer history, of which
5,925 (33.9%) were treated with an invasive procedure. ED visits
associated with invasive procedures were more likely to also be associated with hypertension (53.3% vs 48.9%), inpatient admission (98.7%
vs 86.2%), longer length of stay (6.6 d vs 4.6 d), and higher median total
charges compared with visits without an associated invasive procedure
($36,213.00 vs $19,166.70) compared with those without invasive
procedures. On adjusted analysis, factors associated with undergoing an
invasive procedure included hospital location in the Northeast compared with Midwest (odds ratio [OR], 1.34; 95% conﬁdence interval
[CI], 1.04-1.73), having metastatic cancer (OR, 1.46; 95% CI, 1.052.04), hypertension (OR, 1.31; 95% CI, 1.10-1.55), and a history of
prostatectomy (OR, 2.96; 95% CI, 1.86-4.70).
Conclusions: In conclusion, radiation cystitis can be a signiﬁcant
complication of prostate cancer among patients who undergo radiation
therapy. Approximately one third of ED visits for radiation cystitis are
treated with an invasive procedure, and patients with metastatic cancer,
hypertension, and a prior prostatectomy may be at particularly high risk.
While radiation remains a safe and effective treatment for patients with
prostate cancer, providers should be mindful of radiation cystitis as a
potential complication requiring procedural intervention, as severe cases
could lead to signiﬁcant bleeding or anemia. Patients at greatest risk for
this complication should be monitored closely in the outpatient setting.

(P148) Geospatial Disparities in Access to Proton Therapy
in the Continental United States
Luke Maillie1, Stanislav Lazarev, MD2, Charles Simone, MD,
FACRO3, Matthew Sisk, PhD4; 1Icahn School of Medicine at Mount
Sinai, 2Mount Sinai, 3New York Proton Center, 4University of Notre
Dame
Background: Proton therapy (PT) is increasingly recognized as an
important component of therapy for select cancers due to its negligible

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

www.amjclinicaloncology.com

Copyright r 2021 Wolters Kluwer Health, Inc. All rights reserved.

| S123

Abstracts

American Journal of Clinical Oncology



Volume 44, Number 10, October 2021

FIGURE 1. Time to the nearest PT center for children and adults. The boundary of each ZCTA in the mainland U.S. is shown.

exit dose and, as a result, improved normal tissue sparing and lower risk
of adverse effects compared with conventional photon-based radiotherapy techniques. It is often purported that due to the existence of
relatively few centers in the continental United States (US), inequities in
access to PT may be present, however no formal study of geospatial
access to proton centers has been conducted to date.
Objectives: This study examined access to PT in the continental US by
quantifying travel time to PT centers.
Methods: Population data from 2014-2018 were available for 320.7
million people in 32,644 zip code tabulation areas (ZCTAs) in the
continental US. Addresses for all PT centers in operation were geocoded. ArcGIS Pro Mapping software was used to determine travel time
from the center point of each ZCTA to the nearest PT center. Two
models were constructed, one for adults ( ≥ 18 y) and one for children
(< 18 y) due to one proton center being available only for children. Data
on age, race, health insurance status, household income, educational
attainment, and geographic area were also analyzed.
Results: A total of 36 proton centers were identiﬁed in the continental
US. The median travel time was 1.61 (IQR 0.67-3.36) hours for children and 1.64 (IQR 0.69-3.33) hours for adults. 35.7% of children and
34.7% of adults were found to live within one hour of the nearest PT

center, while 29.0% of children and 29.1% of adults were found to live
over three hours from the nearest PT center. Signiﬁcant variation in
travel time to the nearest PT center was observed between states, with
11 states having a median travel time of less than 1 hour and 20 states
having a median travel time of over 3 hours. Catchment, deﬁned as the
population located closest to a facility, varied widely between facilities
with a median of 5.71 (IQR 3.75-9.30) million per facility for adults and
1.45 (IQR 1.02-2.75) million per facility for children. The West has a
longer median travel time of 3.51 (IQR 1.15-7.13) hours when compared with the Midwest (1.70, IQR 0.79-2.69), South (1.60, IQR 0.613.12), and Northeast (1.04, IQR 0.57-2.01). Native Americans were
seen to live at further distances when compared with other races.
Households within the highest income quartile were observed to live
closer to PT centers when compared with lower income quartiles. Time
to nearest proton center did not differ signiﬁcantly based on insurance
status or education level.
Conclusions: Average travel time to the nearest PT center is high, and
travel times vary signiﬁcantly based on the state of residence. While
being from the West or being Native American confers a higher median
travel time and being in the highest income quartile confers a lower
median travel time, travel time does not signiﬁcantly vary based on
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FIGURE 2. Time to the nearest PT center by state for adults.
States are shown in order of increasing median travel time to
nearest PT center.

health insurance status or educational attainment. Disparities in geographic access for certain populations warrant further examination to
improve access to this important cancer treatment modality (Figs. 1, 2
and Table 1).

(P149) OncMonic: A Novel Visual Proprietary Study Paradigm
for the Oncologist-in-training
Gohar Manzar, MD PhD1; 1The University of Texas MD Anderson
Cancer Center

TABLE 1. Time to Nearest PT Center Based by Demographic
Variables

Abstracts

Background: In recent years, a new generation of visual mnemonic
learning devices has emerged to assist with medical education for
board licensure examinations. SketchyMedical↓ and Picmonic↓ have
revolutionized the study of pathophysiology, microbiology, and
pharmacology. The use of such memory anchor devices has demonstrated increased long-term memory retention by 331% and an
improvement in test scores after one week by 50% among medical
students in a randomized double-blind controlled study1. The basis
for this is a dual coding phenomenon whereby distinct verbal and
visual pathways to encode information diversiﬁes the basis for recall,
as well as the Von Restorff effect, whereby a potently stimulated
sensorium offers superior context for layering memory as compared
with plain bulleted texts. There is a general lack of embracement of
such pedagogical innovation among medical sub-specialties.
Oncology is an ideal candidate for supplementation of traditional study approaches with the exponential increase in data
and its meaningful utilization in multidisciplinary tumor boards to
guide clinical decision making, particularly in the space of clinical
trials.
Objectives: To develop and validate an assistive visual mnemonic
paradigm for the study of major clinical trials under the domain of
radiation oncology.
Methods: An IRB proposal will investigate the recall of landmark
clinical trials presented with the use of pictorial mnemonics among
clinical radiation oncology residents participating in a weekly didactic
seminar series. A separate clinical trial included within the same presentation by the same speaker without the visual assistive device will
serve as the internal control.
Results: A survey will be collected among consenting residents
immediately post-seminar, one week post-seminar, and eight weeks
post-seminar. Metrics for recall of speciﬁc symbolic cues will include
the study name or acronym, primary and/or secondary outcomes of the
trial, and clinical criteria the study generated. Statistical analysis will be
conducted using a Student’s t test.
Conclusions: Rich visual tools are transforming medical education with
less reliance of traditional lackluster memorization. Embracing such
pedagogical advances within radiation oncology by leveraging proven
research in memory recall will empower residents to better utilize the
vast array of data at their disposal and may potentially inﬂuence clinical
dispositions.

(P150) Optimizing Practical Implementation of Automated
Radiotherapy Treatment Planning Tool: A Survey

Comparison of access to PT by demographic and geographic characteristics
in the continental US.

Gwendolyn McGinnis, MD, MS1, Matthew Ning, MD, MPH2, Remigio
Makufa, MS3, Carlos Cardenas, PhD2, Surbhi Grover, MD4, Laurence
E. Court, PhD2, Grace Smith, MD MPH2; 1UT MD Anderson Cancer
Center, 2MD Anderson Cancer Center, 3Gaborone Private Hospital,
4
University of Pennsylvania
Background: Low-to-middle income countries (LMIC) have inequitable access to radiation treatment secondary to shortages in both
available technology and personnel training. The use of automated
planning software can lessen this disparity. The Radiation Planning
Assistant (RPA) is an automated treatment-planning tool designed for
limited resource environments. In anticipation of international deployment, understanding practical implementation of the RPA in LMIC is
critical to optimizing its value.
Objectives: We conducted a survey to better characterize the optimal
approach to RPA deployment in LMIC clinical settings.
Methods: Providers in three countries expressing interest in piloting
RPA were approached for survey participation, with 100% response.
Providers received an initial 1-hour remote, live videoconference
learning session supported by interactive learning using breast and head
and neck cancer dummy radiation plans. Providers were surveyed on
anticipated need for training and ongoing support.
Results: Five institutions were included with 25 total participants.
Countries included South Africa (n = 13), Tanzania (n = 1), and Guatemala (n = 12). Most commonly, participants were between the ages of
31-50 years old (72%) and in practice for > 5 years (68%). The
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distribution of included respondent roles were as follows: physician
(32%), dosimetry (24%), physicist (32%), resident/registrar (4%),
radiation therapist (4%), and administrator (4%). Most participants
reported they would ﬁnd printed materials (96%), on-site in-person
training (96%), off-site in-person training (92%), interactive online
training (100%), and online video tutorials (100%) helpful. When asked
to rate how helpful each of these resources would be on a scale of 1 to 5
(5 being most preferred), on-site in-person training (mean 4.25, SD =
0.9) scored the highest followed by interactive online training (mean
4.2, SD = 0.8), online video tutorials (mean 4.0, SD = 1.3), off-site inperson training (mean 3.74, SD = 1.1), and printed materials (mean
3.71, SD = 1.2). Only 44% of participants had previously used online
training to learn about software designed for radiation treatment planning. When asked how comfortable they would be using the RPA after
completing only an online training program on a scale of 1 to 5 (5 being
very comfortable), participants rated a mean score of 3.8 (SD = 1.3). In
terms of ongoing support for use of the RPA, participants reported that
they would ﬁnd telephone (88%), online chat (100%), email (92%), in
person (88%), scheduled online (96%), and online discussion (88%)
support helpful. Online chat (mean 4.1, SD = 1.1) was rated as the most
helpful on a scale of 1 to 5 (5 being the most helpful) followed by email
(mean 4.0, SD = 1.2), online discussion (mean 3.9, SD = 1.3) in person
(mean 3.9, SD = 1.4), scheduled online (mean 3.8, SD = 1.3), and telephone (mean 2.5, SD = 1.4) support.
Conclusions: This survey indicates various strategies may be effective
in training providers to use the RPA. However, these data provide early
signal that although many providers may not have had similar online
interactive training experiences, such an approach appears both
acceptable and effective for training the target users of the RPA. Online
training would be expected to be substantially less costly and have
potentially wider reach than in-person trainings globally. These data
help create a framework for global training to promote uptake and
proﬁciency in use of automated radiation therapy planning
technologies.

(P151) Diversity in Medical Physics Research Leadership:
Quantifying the Representation of Racial, Cultural, and Sex
Identity Minority Groups
Richard Castillo, PhD1, Jillian Rankin2, Brendan Whelan, PhD3,
Julianne Pollard-Larkin, PhD4, Matthew Scarpelli, PhD5, Keyvan Farahani, PhD6; 1Emory University, 2Emory University School of Medicine, 3University of Sydney, 4MD Anderson Cancer Center, 5Barrow
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Neurological Institute, 6National Cancer Institute, National Institutes of
Health
Background: The existence of disparities in the representation of
minority groups has been an ongoing, systemic issue in STEM ﬁelds.
Prior work has shown this is exacerbated for leadership positions and
awards recipients. However, a characterization of racial, ethnic, and sex
minority representation in medical physics research leadership has not
yet been established.
Objectives: The purpose of this study was to investigate the presence
and potential extent of disproportionate racial, ethnic, and sex representation in medical physics research leadership.
Methods: NIH grant funding was used as a proxy for research leadership. A list of AAPM members who received NIH grant funding as
principal investigator between 1985-2020 was generated using the
AAPM research database (Whelan B, et al Med. Phys. 2017). Anonymized demographics data for the group of NIH-funded AAPM members
(N = 416), as well as for all current AAPM members (N = 8690), was
provided by the AAPM. Fisher’s Exact test for independence was used
to test association between grant funding status and racial, ethnic, and
sex demographic factors. Two-sample z-tests were used to compare
proportions of individual demographic groups between the two study
populations. Member proﬁles for which race, ethnicity, or sex were not
reported were excluded from analysis.
Results: While not signiﬁcantly associated with ethnicity, relative
representation in research leadership was signiﬁcantly associated
with sex (P < 0.05) and had an association nearing signiﬁcance with
race (P = 0.055). Amongst demographic groups, women were signiﬁcantly underrepresented as research leaders relative to their
representation in the medical physics workforce (P < 0.05).
Although not statistically signiﬁcant due to low absolute representation in both groups, decreased relative representation amongst
grant recipients was observed for individuals identifying as Black or
African American, or as being of Hispanic, Latino, or Spanish origin. Within the group of research leaders, there were no individuals
who identiﬁed as American Indian, Alaskan Native, transgender, or
androgynous. Demographic data for AAPM was limited due to the
∼40% rate of members self-declaring a racial or ethnic identity
within membership proﬁles.
Conclusions: Our results suggest that the demographic makeup of the
pool of NIH-funded medical physicists is distinct from that of practicing
medical physicists in general, with signiﬁcant differences in sex
inclusivity observed. While we did not establish a statistically signiﬁcant association between race or ethnicity and grant funding, analysis was limited due to a severe lack of minority representation in
AAPM membership. Efforts to increase diversity and inclusion within

FIGURE 1. Gender identity demographic profiles of AAPM members and AAPM members with NIH grant funding. Relative representation in research leadership is significantly associated with sex (P < 0.05). Amongst AAPM members, women are underrepresented as
NIH grant recipients relative to their male counterparts. Individuals identifying as transgender or androgynous have little representation
in either group, but are notably absent from the NIH grant recipient group.
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FIGURE 2. Racial and ethnic demographic profiles of AAPM members and AAPM members with NIH grant funding. Minority racial and
ethnic groups are severely underrepresented in both the all-AAPM member population and AAPM member-NIH grants recipients
population. Decreased relative representation amongst grant recipients is observed for individuals identifying as Black or African
American, or as being of Mexican, Mexican American, Chicano, Cuban, Puerto Rican, or other Hispanic, Latino, or Spanish origin. Within
the group of research leaders, there are no individuals who identify as American Indian or Alaskan Native.
AAPM will help yield more meaningful results. Further investigation is
necessary to inform actionable policy to ensure diverse, equitable, and
inclusive representation, both in research funding and within the professional body at large (Figs. 1 and 2).

(P152) Decision Making Process and Operations for Irradiation of COVID-19 Positive Patients
Quynh-Nhu Nguyen, MD1, Julius Weng, MD2, Bouthaina Dabaja,
MD2, Prajnan Das, MD, MS, MPH3, Albert Koong, MD, PhD2, Elizabeth Bloom, MD2, Gary Gunn, MD4, Cody Wages, BS, CMD2,
Gregory Chronowski, MD2, Ryan Ritchey, RT (R) (T)2, Ann H. Klopp,
MD, PhD5, Kham Nguyen, BS, CMD, RT (T)2, Andrew Bishop, MD2,
Danna Fullen, RT3, Ivy Robinson, RT (R) (T)2, Denise Zaebst, RN,
MSN2, Jared Brokaw, RT (R) (T)2, Greg Swiedom, RT (R), MR2,
Christopher Sanders, BS, RT (R) (T)2, Zhongxing Liao, MD, FASTRO,
FAAWR5, Mary McAleer, MD5; 1UT MD Anderson Cancer Center,
2
MD Anderson Cancer Center, 3MD Anderson, 4The University of
Texas M.D. Anderson Cancer Center, 5The University of Texas MD
Anderson Cancer Center
Background: During the COVID-19 pandemic, patients who test positive
experience unique challenges of risking a treatment break in their radiation
therapy course which can affect their clinical outcome. Many cancer centers
quickly adopted policies and CDC guidelines into their daily operations to
ensure continued patient care and treatment during the pandemic. It is
important to develop and operationalize a safe process involving clinical
leaders and teams to deliver safe and effective radiation treatments for oncologic emergencies and deﬁnitive radiation courses. Treatment of COVID-19
positive patients for both routine and urgent RT indications requires careful
consideration and modiﬁcation of workﬂow to balance potential therapeutic
beneﬁts and risk of transmission to other patients and staff.
Objectives: To report decision making process and workﬂow to irradiate COVID-19 positive patients at a tertiary cancer center from 4
treatment locations.
Methods: The Radiation Oncology Covid-19 committee (RO COVID
RT) developed an integrated process to triage, provide consensus
treatment recommendations, and safely deliver radiation therapy to
patients who could not have a 21-day treatment break and patients who

needed emergent RT. Radiation oncology speciﬁc COVID policies
were created for each center by physicians, nurses, and radiation
therapists, which was then approved by the institution’s COVID committee. All COVID-19 positive patients were presented to the RO
COVID RT group, evaluated for clinical urgency, beneﬁt with radiation, and life expectancy, and, if deemed necessary, a limited planned
break, modiﬁcation of radiation dose, and hypofractionated course was
recommended. To minimize risk to staff and other vulnerable oncology
patients, inpatients were treated at our hospital’s main radiation facility
and outpatients were treated at three of our six ambulatory centers. We
conducted a retrospective review of patients treated with these COVID
policies between June 2020 to July 2021.
Results: A total of 20 patients were treated using COVID precautions
due to testing positive (n = 12, 60%) or for exposure/suspected COVID
(n = 8, 40%). Six (30%) patients received treatment for an emergent
indication (spinal cord compression, symptomatic leptomeningeal disease, cauda equina syndrome, and gastrointestinal bleeding). The
remaining patients were already receiving RT at the time of their positive COVID test and underwent treatment breaks for 7-14 days.
Thirteen (65%) patients were asymptomatic and were tested for routine
pre-radiation screening or due to concerns of COVID exposure. All
treatments were successfully completed without known spread of
COVID to staff. Sixteen patients (80%) were alive at last follow up.
Conclusions: In this study, COVID positive patients were effectively
treated with radiation therapy without signiﬁcant delays in access or
COVID transmission. We found that prospective review of cases at
COVID Operations Leadership meetings was essential in determining
urgency of RT, recommending hypofractionated regimens, and optimizing operational workﬂow of treating COVID patients.

(P153) ESAS Based Palliative Care Intervention in a Radiation
Oncology Clinic
Ronica Nanda, MD1, Alexandra Owens, MD2, Heather Jim, PhD1,
Roberto Diaz, MD, PhD3, Sunny Raiker, BS2, Nicholas Figura, MD4,
Peter Johnstone, MD, FACR, FASTRO3; 1H. Lee Mofﬁtt Cancer Center
and Research Institute, 2Morton Plant Hospital, 3Mofﬁtt Cancer
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Center, 4H. Lee Mofﬁtt Cancer Center and Research Institute,
Department of Radiation Oncology
Background: Symptom palliation as a component of routine cancer
care has been proven to improve overall survival and quality of life for
patients with advanced cancer. However, acute palliative care resources
are limited at many cancer centers, especially in the outpatient setting;
therefore, strategies to optimize the identiﬁcation and selection of
patients who require palliative care (PC) services are needed. We
piloted a program at our institution in March 2018 to provide outpatient
palliative care for cancer patients undergoing radiotherapy (RT) with
referral based on high Edmonton Symptom Assessment Scale (ESAS)
scores to divert resources toward patients in greatest need.
Objectives: To prospectively determine the impact of a palliative care
consultation and follow up care on patient for radiation oncology
patients with symptoms exceeding predetermined thresholds. We
piloted a program at our institution to reﬂexively refer patients for
outpatient palliative care should they report high symptom burden, as
measured by the clinically validated Edmonton Symptom Assessment
Scale (ESAS) score to divert resources toward patients in greatest need
in a community-based cancer center.
Methods: The Radiation Oncology clinic established use of a modiﬁed
ESAS tool (clinically validated in the outpatient oncology setting) in
2017, assessing 12 symptom domains on a 10-point scale. Higher scores
indicate higher symptom burden. Each patient was asked to complete
the modiﬁed ESAS at each consult, follow up, or weekly visit, and total
scores were calculated. Patients with either a high cumulative ESAS
score or a high score ( > 6) on a single symptom domain were referred
to the palliative care physician. Demographic and individual patient
data were obtained from the electronic medical record. Individual
domain and total scores were recorded in a deidentiﬁed database. The
net change between highest and lowest total scores as well as net
change in total scores from initial encounters and last follow up were
calculated to determine the effect of a standard symptom-based palliative care referral. Patients without a subsequent clinical encounter and
accompanying ESAS score following the palliative care consult were
excluded from ﬁnal analysis.
Results: Between March 2018 and January 2021, a total of 91 patients
consulted with outpatient palliative care at least once. A total of 75
patients met the criteria for ﬁnal analysis. ECOG performance status for
all patients was 0-2. Mean total score from initial radiation oncology
encounter was 49.4 +/- 22.3 (range 0 to 97); at initial PC consultation,
mean total score was 53.2 +/- 22.9 (standard deviation) (range 1-101).
At time of last follow up, mean total scores was 45.1 +/- 25.6 (range
0-103). The mean lowest total score was 30.0 +/- 22.1. (range 0-88) and
highest total scores mean was 66.6 +/- 21.7 (range 13-107). Mean
change in total scores from initial radiation oncology visit to last follow
up was -4.28 points +/- 25.6 (range -86 to 61) and from initial PC
consult to last follow up was -8.03 points +/- 22.1 (range -88 to 40).
84% of patients had improvement in the highest individual score by at
least one point, and of those who had an improvement, 70% had an
individual score improve from severe ( > 6) to not severe (< = 6). Of
the 21 patients who passed away during this interval, twelve had lower
or stable total ESAS scores at last follow up.
Conclusions: Radiation oncology patients referred to outpatient palliative care have high symptom burden at baseline. Palliative care
consultation and follow up were correlated with a decrease in total
ESAS scores of 8 points. Previous literature suggests that improvement
in ESAS scores is associated with improved quality of life and decrease
in total scores of 3-4 points is clinically meaningful. Patients at end of
life in this cohort appeared to have stable ESAS scores suggesting a
signiﬁcant beneﬁt from early palliative care intervention.

(P154) Malignant Cord Compression and Timing of Postoperative Radiotherapy
April Vassantachart, MD1, Phillip Bonney, MD1, Eugene Lin, MD,
MS2, Shelly Bian, MD2; 1LAC+USC Medical Center, 2Keck School of
Medicine of USC
Background: Malignant spinal cord compression (MSCC) can result in
permanent neurologic injury and often requires prompt neurosurgical
decompression followed by radiation therapy (RT). Post-surgical care
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FIGURE 1. Forest plot of relative risk for impaired ambulation
based on time to treatment initiation of radiation. RR = relative
risk. CI = confidence interval.

can include rehabilitation and time for wound healing which can lead to
delays in post-operative RT.
Objectives: This study aims to retrospectively review the time to initiation (TTI) of RT after surgical intervention for MSCC and its association with ambulatory status at 3 months. We also compare TTI in
patients discharged to home, versus inpatient rehabilitation, or a skilled
nursing facility.
Methods: Our institutional database was queried for patients with solid
malignancies and spinal metastases with Bilsky 2 or 3 MSCC who
underwent surgical intervention from 2015-2020 and postoperative RT.
In patients who were ambulatory peri-operatively, we computed the
relative risk of decreased ambulation at 3 month follow up using different TTI cutoff values of 30, 42, and 56 days. P values were generated
using a 1-sided Fisher’s Exact Test. TTI was also evaluated in all
patients who underwent post-operative RT based on their discharge to
either home, inpatient rehabilitation, or a skilled nursing facility.
Results: We found 85 patients with MSCC who underwent surgery.
Within this group, 56 received post-operative RT with known TTI. For
our TTI analysis, we excluded 14 patients who were not peri-operatively ambulatory and 10 patients who did not have at least 3 months
of follow up. Three-month ambulatory rates for TTI of ≤ 30 vs
> 30 days, ≤ 42 vs > 42 days, and ≤ 56 vs > 56 days were 86% vs
78% (P = 0.460), 87% vs 67% (P = 0.203), and 89% vs 40%
(P = 0.034), respectively. For all patients who received post-operative
RT without wound complications causing delays in RT, TTI based on
discharge to home (n = 35), a skilled nursing facility (n = 4), or inpatient
rehab (n = 16) was 28 days (IQR 19-41), 28 days (IQR 16-41), and
35 days (IQR 24-53), respectively. Six patients were found to have
locally recurrent disease causing cord compression—only one recurred
after post-operative RT while ﬁve recurred before post-operative RT.
Three had TTI > 100 days due to recurrent disease at 33 days and
56 days requiring two re-resections, transportation difﬁculties from
skilled nursing facility, and continued oncologic care at an outside
hospital who did not refer the patient for RT. The other three patients
received RT within 30 days, however two recurred before RT and one
recurred at 465 days.
Conclusions: Initiation of post-operative radiation more than 56 days
after surgical resection for MSCC showed lower ambulatory rates at
3 months. Further studies evaluating the optimal timing of post-operative RT and causes for delay are needed (Fig. 1).

(P155) Prisoner of the Heart – Primary Unresectable Cardiac
Angiosarcoma in an African American Man
Jehan Yahya, MD1, David Henkin, MD2, Joseph Montecalvo, MD3,
Rami Khoury Abdulla, MD3; 1OHSU: Oregon Health & Science
University, 2UT Health, 3Henry Ford Hospital
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FIGURE 1. (A) CT axial showing mass centered in right atrioventricular groove with extension into the right atrium and ventricle,
pericardial effusion. (B) CT showing right lower lobe 14 mm pulmonary nodule. (C) Cardiac MRI Proton Density Black Blood images
showing the mass is heterogeneous in signal with areas of isointense signal and hyperintense signal compared with normal myocardium.
There is a moderate pericardial effusion along the left ventricle (no signal). (D) Cardiac MRI T2 Weight, Fat Saturated, Black Blood
demonstrating a heterogeneous T2 hyperintense signal within the 7 x 7.8 cm mass. The pericardial effusion along the left ventricle
demonstrates high signal. (E) Cardiac MRI Phase Sensitive Inversion Recovery images obtained after the administration of intravenous
contrast showing a heterogeneous enhancement within the mass. There is no signal in the pericardial effusion.
Background: One-quarter of cardiac tumors are malignant [Centofanti
P, et al Ann Thorac Surg 1999] and present with metastasis [Patel S,
et al Med Sci Mon 2014]. The most common malignant primary cardiac
tumor is sarcoma, of which 30% is angiosarcoma [Patel S, et al Med Sci
Mon 2014]. From all histologic subtypes, primary cardiac angiosarcoma
(PCA) has the statistically lowest medial overall survival of 7 months
with no associated improvement over the last decade [Yin K, et al J
thorac cardiovasc Surg 2019]. Given this, the outcomes of interventions
are controversial. Eleven percent of PCAs are found in AfricanAmericans [Yin K, et al J thorac cardiovasc Surg 2019]. We contribute
a report of unresectable PCA in an African-American imprisoned man
who faced numerous obstacles, resulting in partial completion of
radiotherapy.
Objectives: • Cardiac angiosarcoma has a higher incidence within the
White population. • The presenting symptoms include dyspnea and

hemorrhagic pericardial effusion. • Delay in diagnosis prolongs
hemodynamic instability and patient discomfort. • This case offers
value for future male African American epidemiologic studies. • There
are no radiotherapy guidelines in treating patients diagnosed with any
cardiac sarcoma • Radiation therapy provided symptom free in a
metastatic setting • The COVID-19 pandemic complicates disposition,
especially relating to prisons.
Methods: Case Description A 42-year-old imprisoned African-American man with no relevant history presented to an outside hospital with
chest pain, dyspnea, tachycardia, mufﬂed heart sounds and jugular
venous distention without hypotension secondary to a large hemorrhagic pericardial effusion with tamponade. The subxiphoid approach
pericardiocentesis was unsuccessful. The subsequent pericardial
window via left mini thoracotomy with pericardial biopsy removed
1500 cc of bloody pericardial effusion status post chest tube placement,

FIGURE 2. (A) HE stained cardiac mass specimen. (B) Specimen stained with ERG. (C) Specimen stained with CD31. Specimen had a
negative sarcoma fusion panel.
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resulting in symptomatic improvement. Transthoracic echocardiogram
(TTE) revealed 62% ejection fraction, pericardial effusion and hyperdynamic biventricular systolic functions with right ventricular diastolic
collapse. The pericardial biopsy showed poorly differentiated malignant
epithelial neoplasm. Computed tomography (CT) chest showed a 6 x
5.8 x 8 cm mass of the right heart border extending into both right atrial
and ventricular lumens with abutment into the superior vena cava,
lymphadenopathy, and 14 mm pulmonary right lower lobe nodule
suspicious for metastasis (Fig. 1). The patient was transferred to our
hospital. Repeat CT chest revealed an interval decrease in pericardial
effusion and new left pleural effusion, and Pleur-x catheter was placed.
Increased dyspnea prompted CTPE, which was negative, with repeat
TTE showing reaccumulation of pericardial effusion. CT abdomen
pelvis was negative for metastasis. Cardiac MRI revealed a 7 x 7.8 cm
mass originating from the atrioventricular groove extending into the left
atrium, the lateral atrial recess, the right atrial posterior and lateral free
walls, and the pericardium with right coronary artery encasement.
Another 2.5 x 3 cm heterogeneous mass was found involving the right
superior and inferior pulmonary veins. Cardiac biopsy pathology
revealed positivity for ERG and CD31 stains (Fig. 2), consistent with
angiosarcoma. His course was complicated by an unstable arrhythmia
and a new 1400 cc hemorrhagic effusion requiring thoracentesis. TTE
demonstrated interval decrease to 4.9 x 4.1 cm after six of the 30
fractions prescribed to 60 Gray (Gy). The prevalence of COVID-19 in
both our hospital and Michigan prisons complicated disposition. Thus,
he enrolled in hospice after 12 fractions of radiotherapy and expired in
jail 5 months from initial symptom onset.
Results: N/A
Conclusions: The rarity of primary cardiac tumors [Reynen K, Am J
Cardol 1996] makes randomized trials investigating outcomes difﬁcult.
An evaluation of primary cardiac sarcomas within the United States, not
exclusively PCA, using the SEER database found 24% of patients
received radiotherapy with no association to better outcomes [Yin K,
et al J thorac cardiovasc Surg 2019]. It is unclear what percentage of
patients with the angiosarcoma histology (43% of their study population) received radiotherapy. Additionally, the database did not
include the timing of interventions. Our patient’s tumor decreased by
half after receiving a total of 12 Gy with moderate symptom relief.
There was no additional interval imaging to trend tumor size after
receiving 24 Gy. Currently, there are no radiotherapy guidelines in
treating patients diagnosed with any cardiac sarcoma. The risk of
contracting COVID-19 while admitted was high. Thus, he only received
24 Gy, enrolled into hospice and transferred back to his jail hospital and
expired. Did the partial radiation provide beneﬁt? The radiotherapy he
did receive had no effect on his overall survival given he expired within
the expected timeframe, however he did not complete his prescription.
Isambert et al found that radiotherapy was associated with improved
progression-free survival, retrospectively [Isambert N, et al Journal of
General Internal Medicine 2017] . However, our patient is not wellrepresented in their study cohort encompassing all histologies and only
patients with non-metastatic disease received radiotherapy. For the
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entire cohort, about 19% received radiotherapy as monotherapy. The
mean age of PCA diagnosis is 47.2 years old [Yin K, et al J thorac
cardiovasc Surg 2019], which aligns closely to that of our patient’s.
PCAs arise in the right atrium [6] causing cardiac encasement, pericardial involvement, pericardial effusion, and cardiac tamponade
[Reynen K, Am J Cardol 1996]. The most common site of metastasis is
the lungs [Patel S, et al Med Sci Mon 2014, Abdel-Rahman Z et al
Journal of General Internal Medicine 2017], as most likely seen here.
All of the above factors made achieving disease control or patient
comfort a challenge. PCA must be in the differential for pericardial
effusion. The need to further evaluate the role of radiotherapy is greatly
needed. Given the rarity of PCA, it is unlikely that clinical trials will
investigate the role of radiotherapy or other interventions. This report
chronicles interval tumor size decrease and symptom relief. Lastly,
more investigations on PCA in African-American men [Galven D, et al
Oncoscience 2018] are needed.

(P156) Sequential Diffusion Tensor Imaging and Magnetic
Resonance Spectroscopy in Patients Undergoing Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma
Julianna Bronk, MD, PhD1, Ping Hou, PhD1, Mark J. Amsbaugh, MD1,
Soumen Khatua, MD1, Anita Mahajan, MD2, Leena Ketonen, MD1,
Susan McGovern, MD, PhD3; 1University of Texas MD Anderson
Cancer Center, 2Mayo Clinic, 3The University of Texas MD Anderson
Cancer Center
Background: Diffusion tensor imaging (DTI) for evaluation of white
matter tracts is used with magnetic resonance spectroscopy (MRS) to
improve management of diffuse intrinsic pontine glioma (DIPG).
Changes in apparent diffusion coefﬁcient (ADC), fractional anisotropy
(FA), and tumor metabolite ratios have been reported after initial
radiation for DIPG, but these markers have not been studied sequentially in patients undergoing re-irradiation for progressive DIPG.
Objectives: We evaluated quantitative changes in FA, ADC, and tumor
metabolites and qualitative changes in white matter tracts in patients
who received re-irradiation for progressive DIPG on a prospective
clinical trial.
Methods: Four patients with progressive DIPG treated with re-irradiation on a prospective trial had DTI and MRS before and after reirradiation. Median re-irradiation dose was 25.2 Gy (24-30.8 Gy). Fiber
tracking was performed using standard tractography analysis. FA and
ADC values were calculated pre- and post-reirradiation. Multivoxel
MRS was performed. Findings were correlated with clinical features
and conventional MRI of tumors.
Results: All patients had an initial response to re-irradiation as shown
by a decrease in tumor size. FA increased with disease response and
decreased with progression while ADC decreased with disease response
and increased with progression. At second progression, the FA fold
change relative to pre-re-irradiation values decreased (median fold
change -0.15). Visualization of tracts demonstrated robust reconstitution

FIGURE 1. Sequential DTI tractography during disease response and progression. DTI tractography of the medial lemniscus tracts in
Patient 2 (A) and Patient 3 (B) are shown before re-irradiation, during treatment response and at second progression.
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FIGURE 2. Quantitative measurements of FA, ADC, and metabolites before and after re-irradiation and at second progression. A.
Absolute values for FA and ADC for the corticospinal and medial lemniscus tracts at first progression, after reRT, and at second progression
in patients who underwent reRT for progressive DIPG. B. Median fold change in FA and ADC during disease response and at second
progression for patients with serial imaging following re-irradiation. C and D. Median Chol:Cr (C) and Chol:NAA (D) ratios at first
progression (n = 1 scan), during response to re-irradiation (n = 6 scans), and at second progression (n = 3 scans).
of previously disrupted paths during tumor response; conversely, there
was increased ﬁber tract disruption and inﬁltration during tumor progression. MRS analysis revealed a decrease in Chol:Cr (median 2.5) and
Chol:NAA ratios (median 1.4) during tumor response and increase
during progression (median 3.6 for Chol:Cr, median 2.1 for Chol:
NAA).
Conclusions: This study is the ﬁrst to prospectively examine changes in
white matter tracts and tumor metabolism in DIPG patients undergoing
re-irradiation. Changes related to tumor response and progression are
observed even after only 24-30.8 Gy re-irradiation (Figs. 1 and 2).

(P157) MRI Radiomics Features Correlate with Histologic
Tumor Necrosis Following Neoadjuvant Radiation Therapy
in Extremity Soft Tissue Sarcoma
Crystal Seldon, MD1, James Grosso, MD, PhD2, Ty Subhawong, MD3,
Gautam Shrivastava, ScM1, Melanie Fernandez, BS1, Raphael Yechieli,
MD1, Matthew Mason, BS4; 1University of Miami/Sylvester Comprehensive Cancer Center, Department of Radiation Oncology, 2University
of Miami, Department of Diagnostic Radiology, 3University of Miami,
Departmentof Diagnostic Radiology, 4Univerisity of Miami, Department of Diagnostic Radiology
Background: Radiomics has become a new method of extracting data
from radiographic images for quantifying pixelated data far beyond
what the human eye can perceive. Unique differences at the pixel level
between subsets of patients can help radiologists interpret radiographic
images in a clinically meaningful way to predict response to oncologic
treatments, predict prognosis, and help in diagnosis of tumor types.
Objectives: The purpose of this study is to identify MRI radiomic
features of sarcomas treated neoadjuvantly with radiation that correlate
with excised tumor histologic necrosis.
Methods: Patients with intermediate- or high-grade extremity soft tissue
sarcomas who underwent neoadjuvant radiation therapy, and who had
post-treatment MRI scans were included. We employed MINT Lesion
radiomics software for extraction of quantitative imaging data from contrast-enhanced sequences. The lesion Regions of Interest (ROIs) were
manually contoured on a single slice demonstrating largest tumor crosssecitonal areas; 3 ROIs were analyzed as replicates within each scan, and
averaged before ﬁnal analysis. Following neoadjuvant treatment, tumors
were excised and histologic tumor necrosis was determined. Using Pearson
correlation statistics, the percent necrosis was compared with radiomic
features of post treatment scans. Only radiomic features with a P value
<0.05 were considered statistically signiﬁcant which correlated with a
Pearson value of less than -0.25 or greater than 0.25.
Results: 11 patients, treated between 2013 and 2019 were included in the
study. The clinical characteristics were: male–(45%) and female- (55%); type
of sarcomas included Synovial, Spindle, Liposarcoma, and Myxoﬁbrosarcoma. The average necrosis on ﬁnal pathology was 71% +/- 38%
std. A total of 42 radiomic features were extracted from the ROIs. 12 of the

delta-radiomics parameters were signiﬁcantly correlated with necrosis
(P-value < 0.05). The signiﬁcantly correlated radiomic features includes
ﬁrst and second order values representing the distribution of voxel intensities within the segmented image regions and the statistical interrelationships between neighboring voxels, respectively. The highest correlated radiomic features included(names directly from Mint lesion):
secondorder.Information_correlation_1, secondorder.Dissimilarity, and
secondorder.Difference_average.
Conclusions: Radiomics features, including both ﬁrst and second order
features, are associated with histologic necrosis in neoadjuvantly treated
extremity soft tissue sarcomas. This data supports multi-parametric
image texture mapping in the development of prediction models for
neoadjuvant treatment response in sarcoma.

(P158) Vertebral Body Growth Retardation Following
Proton Craniospinal Radiation
Shannon MacDonald, MD1, Myrsini Ioakeim-Ioannidou1, Andrzej
Niemierko, PhD1, Drosoula giantsoudi, PhD1, Roshan Sethi, MD1,
Daniel Kim, MD MBA1, joseph Simeone, MD1; 1Massachusetts General Hospital
Background: Craniospinal irradiation (CSI) is a standard component of
curative therapy for several childhood brain tumors. Long-term survivors are at risk of late complication from CSI. A known side-effect of
CSI is growth impairment of the vertebral column resulting in decreased
sitting height for survivors

FIGURE 1. Growth retardation as a function of follow-up time.
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(P159) Survival Disparities Among the Adolescent and
Young Adult (AYA) Sarcoma Population

FIGURE 2. The effect of age at CSI on expected growth retardation at age 15.

Objectives: We determined the rate and amount of vertebral body (VB)
growth retardation after proton craniospinal irradiation (CSI) compared
with patients that did not receive spinal irradiation.
Methods: We performed a retrospective outcome data analysis of 87
patients < 16 years old with central nervous system (CNS) tumors who
received proton radiotherapy (PRT) at our institution between 2002 and
2010 with available spinal MRI imaging. Fifty-ﬁve patients received
CSI, while 32 brain tumor patients that received focal cranial irradiation
served as controls. Vertebral body height was measured midline using
sagittal T1-weighted contrast or non-contrast enhanced MRI images of
the spine. Measurements were repeated at multiple levels (C3, C3-C4,
T4, T4-T5, C3-T6, T4-T7, L3, L1-L5) on available scans for the
duration of follow-up. Data were ﬁtted using a mixed- effects regression
multivariable model, including follow-up time, CSI dose, age at CSI,
and pre-treatment VB percentile as parameters.
Results: Median follow-up was 70 months for patients treated with
proton CSI and 52.9 months for the control group. There was a signiﬁcant association of CSI dose, age at treatment, and pre-treatment
percentile with VB growth retardation. Growth retardation was shown
to be independent of sex or growth hormone deﬁciency.
Conclusions: Although the current practice of PRT CSI delivery allows
for sparing of the organs anterior to the spine, the vertebral column
receives radiation therapy (RT) due to its close proximity to the targeted
spinal canal. In growing children, the whole vertebral body is generally
included so that growth impairment is even across the VB. We present a
quantitative model predicting the growth retardation of patients treated
with PRT CSI based on age at treatment, CSI dose, follow-up time, and
pre-treatment growth percentile (Figs. 1–3).

Crystal Seldon, MD1, Gautam Shrivastava, ScM2, Abdurrahman AlAwady, BS3, David Asher, MD3, Stephen Ramey, MD3, Melanie Fernandez, BA3, Sarah Dooley, MD3, Wei Zhao, MS4, Deukwoo Kwon,
PhD2, Tejan Diwanji, MD1, Jonathan Trent, MD, PhD3, Ty Subhawong,
MD3, Raphael Yechieli, MD1; 1University of Miami/Sylvester Comprehensive Cancer Center, Department of Radiation Oncology, 2University
of Miami/Sylvester Comprehensive Cancer Center, 3University of
Miami/Sylvester Comprehensive Cancer, Department of Radiation
Oncology, 4University of Miami/Sylvester Comprehensive Cancer Center, Biostatistics and Bioinformatics Shared Resource
Background: Soft tissue sarcomas (STS) are rare in the adult population, however, occur more frequently in the adolescent and young
adult population (AYA) (Bleyer, et al Nat Rev Cancer 2008). Notably,
survival rates among AYAs are similar to those of children and higher
than in adults, however, this is not seen in STS (American Cancer
Society, Cancer Facts & Figures 2020). Poorer prognosis is attributed to
numerous factors including more aggressive clinical characteristics of
STS in the AYA population compared with those diagnosed in children,
poor clinical trial participation of AYAs, and lack of data regarding
prognostic factors in this age group (Bleyer, et al Cancer 2005).
Objectives: In this retrospective study, we sought to determine survival
disparities and variables associated with poor prognosis among AYAs
as compared with older patients with extremity STS in the National
Cancer Database (NCDB).
Methods: The NCDB was utilized to identify patients (pts) 18 and older
with extremity STS diagnosed between 2004-2014 and treated deﬁnitively with limb-sparing surgery (LSS) or amputation. Multivariable
analyses used logistic regressions for patterns of treatment and their
correlation with demographic factors (sex, race, ethnicity, insurance
status, income, education, and distance from hospital) and tumor
characteristics (primary site, grade, size, clinical stage, depth of
extension, and surgical margins).
Results: 8,201 patients were included in the study of which 1,141 were
AYA (13.9%). At the time of the analysis, 5,465 patients were alive with an
overall survival of 9.6 years. Patients aged 40-64 years old (HR 1.37, 95% CI
1.18-1.59, P < 0.001) and those 65 and older (HR 2.85, 95% CI 2.47-3.28,
P < 0.001) had signiﬁcantly worse survival when compared with the AYA
population as identiﬁed on Kaplan-Meier plot for OS. On multivariable
analysis, there were no factors associated with increased survival in the AYA
population. Two comorbidities (HR 6.82, 95% CI 1.77-26.3, P = 0.005),
location in a small metro area (HR 1.52, 95% CI 1.05-2.18, P = 0.025), tumor
size greater than 5 cm (HR 3.53, 95% CI 1.99-6.27, P < 0.001), and positive
surgical margins (HR 1.89, 95% CI 1.06-3.47, P = 0.031) were associated
with worse survival in this age group. Living in a smaller metro location was
a unique factor for poor prognosis among AYAs that was not seen in the
older age groups.
Conclusions: Survival disparities exist among the age groups of
patients diagnosed with extremity STS. Further study is warranted to
identify the impact of these survival disparities.

(P160) Impact of Radiation Therapy on Survival of Pediatric Metastatic Neuroblastoma: Analysis of the National
Cancer Database

FIGURE 3. The effect of CSI dose on expected growth retardation
at age 15.

Sherif Shaaban, MD1, Kathryn Dusenbery, MD1, Emily Greengard, MD1,
Stephanie Terezakis, MD1; 1University of Minnesota Medical Center
Background: Radiation therapy (RT) has been incorporated in treatment of pediatric metastatic neuroblastoma (MNB) with demonstrated
local control beneﬁt. Although the impact on overall survival is still
unknown.
Objectives: We identify the impact of RT on overall survival among
MNB patients.
Methods: The NCDB was queried for patients aged ≤ 18 years diagnosed with neuroblastoma between 2004-2016. Patients with metastatic
disease were included with exclusion of patients with 4S/MS disease
aged ≤ 12 months. Univariable logistic regression was used to evaluate
factors associated with the delivery of RT. Overall survival (OS) analysis
was performed using Kaplan-Meier and log-rank test. Cox hazards
modeling were used to ascertain variables associated with OS.
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FIGURE 1. Overall Survival of all study population (A) and stratified by radiotherapy treatment (B).
Results: 504 patients met the study criteria; 257 patients (51%) received
RT and 247 (49%) did not. Surgery was performed more frequently
among RT group (88%) versus the non-RT group (32%). The number
of patients who underwent autologous bone marrow transplant (ABMT)
in the RT group was signiﬁcantly higher than those in the non-RT group
(73% versus 26%, P = 0.0001). The most common utilized RT
modalities were 3D CRT (50%) and IMRT (34%). The most common
used RT dose was 2,160 cGy (58%) and the most frequent boost dose
was 1,440 cGy. Logistic regression analysis conﬁrmed that surgery with
positive surgical margins, use of ABMT and immunotherapy covariates
were associated with increased likelihood of receiving RT. After
stratiﬁcation by RT receipt, the median OS was signiﬁcantly higher
among the RT group, 67 months (95% CI, 62.53-71.4 mo) versus
56 months among the non-RT group (95% CI, 51.64-61.38 mo) (P =
0.008). Cox hazards modeling conﬁrmed that non-receipt of RT was
associated with poorer OS on univariate (HR 1.51, 95% CI 1.11- 2.05,
P = 0.009) and multivariate (HR 1.52, 95% CI 1.115- 2.07, P = 0.008)
analysis. Presence of bone metastases was signiﬁcantly associated with
worse OS on univariate analysis (HR 1.80, 95% CI 1.08- 2.97,
P = 0.022). ABMT receipt was associated with better OS on univariate
(HR 0.333, 95% CI, 0.145- 0.763, P = 0.009) and multivariate (HR
0.234, 95% CI, 0.147- 0.897, P = 0.002) analysis.
Conclusions: Impact of RT on OS has not been widely investigated. Our
study demonstrated that RT was signiﬁcantly associated with improved
OS. Future prospective studies are warranted to identify the impact RT on
survival in high risk and metastatic neuroblastoma (Fig. 1).

(P161) Impact of Strict Brainstem Dosimetric Parameters
on Symptomatic Brainstem Injury and Survival After
Proton Beam Radiation in Pediatric Brain Tumors
Rituraj Upadhyay, MD1, David Grosshans, MD, PhD1, Susan
McGovern, MD, PhD1, Mary McAleer, MD1, Kristina Woodhouse,
MD1, Waﬁk Zaky, MD1, Murali Chintagumpala, MD2, Anita Mahajan,
MD3, Arnold Paulino, MD1; 1The University of Texas MD Anderson
Cancer Center, 2Texas Children's Cancer Center, Baylor College of
Medicine, 3Mayo Clinic
Background: Brainstem toxicity after radiation is a devastating complication and is a particular concern with protons, given the biological
differences and range uncertainties. Dosimetric predictors of brainstem

injury are not well deﬁned and the prescription dose is often decreased
to limit the risk, especially in tumors involving the posterior fossa.
Objectives: To investigate the difference in survival and risk of
brainstem injury in pediatric brain tumors treated with proton therapy
when using strict brainstem dosimetric.
Methods: All patients < 18 years with infratentorial brain and pineal
tumors, treated with proton beam radiation at our institution from
2007–2019, with a brainstem Dmean of > 30 Gy and/or Dmax >
50.4 Gy were included. We excluded patients with primary brainstem
tumors. In 2014, our institution started using strict brainstem dose
constraints of Dmax ≤ 57 Gy, Dmean ≤ 52.4 Gy and V54 ≤ 10% to
decide ﬁnal dose to the target(s). We analyzed Symptomatic brainstem
injury (SBI) and survival before and since incorporation of these
guidelines. SBI was deﬁned as any new or progressive cranial neuropathy, bulbar weakness, ataxia, dysmetria and/or motor weakness with
corresponding radiographic abnormality within the brainstem. KaplanMeier test was used for survival analysis.
Results: A total of 595 patients were reviewed and 362 (medulloblastoma = 209, ependymoma = 86, ATRT = 43, pineoblastoma = 9,
others = 15) met our inclusion criteria. Median age at RT was 5 years
(range 0.7–17.9 y) and median prescribed RT dose was 54 CGyE (range
39.6–59.4 CGyE). About 32% patients were prescribed > 54 Gy before
2014, compared with only 9% since 2014. Median follow up was
40 months (range 1–152). 2-year progression free survival in patients
treated before and since 2014 was 70.3% and 70.6% (P = 0.649), while
overall survival was 80.8% and 86.1% (P = 0.77) respectively. Ten
patients (2.7%) developed SBI, at a median of 4 months after radiation
(range 1-6). Asymptomatic imaging changes within brainstem were
seen in 47 patients (13%) at a median of 4 months after RT, with most
common ﬁndings being increased T2 ﬂair, focal enhancement and
encephalomalacia. The incidence of SBI decreased from 4.2% (20072013) to 0.7% (2014-2019) (P = 0.047) while asymptomatic imaging
changes remained similar (11.6% vs 15.1%, P = 0.33). On univariate
analysis, only timing of radiation (before/since 2014) was an independent predictor of SBI (P = 0.028), while no signiﬁcant association
was observed with extent of resection, number of resections, age at
radiation, prescribed RT dose, cone down and systemic treatment.
Conclusions: Although our study is limited given the heterogenous
population and different time-period of comparison, our results suggest
that the use of strict brainstem dose constraints to determine ﬁnal dose
to the tumor/ tumor bed results in a lower incidence of SBI, without
compromising the survival.
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TABLE 2. Univariable and Multivariable Predictors of Receipt of
Proton Radiotherapy

Christopher Weil, MD1, Lew Felicia, DVM2, Vonetta Williams, MD/
PhD3, Ralph Ermoian, MD3, Matthew Poppe, MD1; 1University of Utah
Huntsman Cancer Institute, 2Washington State University Elson S.
Floyd College of Medicine, 3University of Washington
Background: Proton radiotherapy (PR) is well established in the
treatment of pediatric malignancies in the central nervous system (CNS)
given established dosimetric advantages that may reduce the late effects
of radiotherapy.
Objectives: In this analysis, we sought to update our 2016 published
patterns of care data on the receipt of PR in children with primary CNS
malignancies since both the number of proton centers and availability
have signiﬁcantly increased in the interim. We aimed to evaluate the
utilization of PR in this population and characterize the clinical and
sociodemographic factors predictive of receipt of PR.

TABLE 1. Baseline Patient Characteristics Between Photon and
Proton Radiotherapy Groups

Methods: The National Cancer Data Base (NCDB) was queried to
identify all pediatric patients with primary CNS malignancies treated
with radiotherapy (RT) with curative intent from 2004 to 2017. Clinical
characteristics and demographics were analyzed using standard T and
χ2 testing. Predictors of receipt of PR were identiﬁed with univariable
and multivariable logistic regression.
Results: We identiﬁed 9,126 patients age ≤ 18 years treated with RT
between 2004 and 2017, of which 1,045 (11.5%) received PR. PR usage
continued to increase signiﬁcantly, from <1% in 2004 to 28% in 2017.
This increase was most striking for ependymoma and medulloblastoma,
where PR was utilized in 45% and 47% of cases, respectively, in 2017.
The proportion of White and Asian patients receiving PR for non-high
grade glioma and non-meningioma CNS malignancies over the study
period rose from <1% for both to 35% and 44%, respectively, while in
Black patients the proportion rose from <1% to 26%. Multivariable
predictors of receipt of PR include year of diagnosis, age under 6 years,
income level, distance from PR facility, and histology; multivariable
predictors of receipt of non-proton radiotherapy include Black race,
rural residence and Medicaid insurance. These factors remained signiﬁcant when isolating the most recent ﬁve years of data.
Conclusions: The usage of PR for CNS malignancies continues to
increase and has doubled over the last four years. Despite the potential
clinical advantages to PR for pediatric primary CNS malignancies, there
are notable socioeconomic, geographic and racial disparities in the
receipt of PR that have persisted despite the increased availability and
accessibility over the study period. Further study is warranted to
identify how to address the disparities and better support these patients
(Tables 1–3).
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TABLE 3. Univariable and Multivariable Predictors of Receipt of Proton
Radiotherapy Limited to Low Grade Glioma, Ependymoma, Medulloblastoma, Primitive Neural Ectodermal Tumors, Craniopharyngiomas,
Germ Cell Tumors and Atypical Teratoid/Rhabdoid Tumors

(P163) A Dose Accumulation Assessment of Alignment
Errors During Spatially Fractionated Radiation Therapy
John Ginn, PhD1, Sai Duriseti, MD, PhD1, Thomas Mazur, PhD1,
Matthew Spraker, MD, PhD1, James Kavanaugh, PhD2; 1Department of
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Radiation Oncology, Washington University School of Medicine in St.
Louis, 2Washington University School of Medicine
Background: Spatially-fractionated radiotherapy (SFRT) treatment
techniques produce high-dose peaks and low-dose valleys by interweaving a matrix of high- and low-dose spheres through a technique
termed Lattice. Due to the highly localized spatial dose gradients
associated with SFRT, it is critical for patients be aligned correctly for
treatment.
Objectives: Here we report the dosimetric impact of daily alignment
setup uncertainty through a dose accumulation study.
Methods: Dose accumulation was retrospectively performed for ten
patients enrolled on a completed prospective trial evaluating Lattice for
large tumors (NCT04133415). SFRT was completed in 5 fractions with
20 Gy prescribed to the entire tumor volume and 66.7 Gy prescribed to
the high-dose spheres of 1.5cm diameter. Daily alignment error was
quantiﬁed through a landmark analysis with paired landmarks manually
selected in both the planning computed tomography (CT) scan and the
registered daily cone beam CT image. The dosimetric impact of
alignment errors was quantiﬁed by translating the isocenter in the
treatment planning system by the daily average alignment error for each
fraction. To understand the effect of varying magnitude and frequency
of alignment errors, we also performed a simulated error analysis by
translating isocenter by 5 mm and 10 mm for one and two fractions,
with alignment errors separately assessed for the superior-inferior and
axial dimensions. We hypothesized misalignment errors will reduce the
volume of tumor receiving both 66.7 Gy and 20 Gy while also blurring
the dose gradient between the high- and low-dose spheres. Therefore,
we quantiﬁed the ratio of the mean dose in the high-dose and adjacent
low-dose spheres (DR) as well as the mean dose (Dmean) and standard
deviation of the mean in the 1.5 cm ring surrounding the high-dose
spheres.
Results: The total average and standard deviation alignment error was
1.8 mm and 0.6 mm across all patients. Visual inspection revealed
alignment errors tend to blur the edges of the high- and low-dose distributions. Quantitatively, mean DR decreased from 3.42 to 3.32 in the
dose accumulation study. On average Dmean in the 1.5 cm ring was
35.5 Gy in both the initial plans and accumulated dose, while the
standard deviation of the dose in this region decreased by 25.5 cGy
from the initial plan to 10.7 Gy. The simulated worst case was an
inferior-superior shift of 10 mm for two fractions. In this case average
DR decreased to 2.72, and the Dmean and standard deviation of the
dose in the surrounding ring decreased 24.5 cGy and 148.0 cGy,
respectively.
Conclusions: The dose accumulation study revealed on average DR
only decreased from 3.42 to 3.32. However, setup errors > 5 mm result
in larger dosimetric degradation than those observed clinically. As
indicated by our simulation study, even a single large setup error can
substantially reduce the DR and overall SFRT plan quality,

FIGURE 1. Example of a spatially fractionated dose distribution. A coronal view of a spatially fractionated dose distribution showing the
high- and low-dose spheres dispersed throughout the target.
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FIGURE 2. Relative change in mean dose ratio. The change in
mean dose ratio relative to the initial plan. The results are
displayed for the dose accumulation study utilizing the alignment errors from the landmark analysis (black), the axial
simulated shifts (red) and superior-inferior simulated shifts
(blue).
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simulation and ﬁrst treatment was 1.9 days (range 0-5 d). The mean
change in tumor volume was 22.64% smaller in the diagnostic CT scan
plan. The D1 was an average 1% hotter in the hypothetical plans
(P = 0.16).
Conclusions: In hospitalized patients with an indication for palliative
radiation, treatment planning on a pre-existing recent diagnostic CT
scan produces comparable dose distributions without increases in dose
to OARs when compared with the use of CT simulation scans, particularly for treatment of the spine or when a very recent diagnostic CT is
available. Bypassing CT simulation in select cases allows for earlier
delivery of radiation with less patient and logistical burden. In combination with daily image-guidance, this may translate to more timely
delivery of radiation, less cost and burden to critically ill patients, and
improved palliative beneﬁt.

(P165) Assessment and Development of Plan Quality Metrics for Spatially Fractionated Radiation Therapy
emphasizing the importance of accurate daily alignment during fractionated SFRT (Figs. 1 and 2).

(P164) Dosimetry Comparison of Palliative Radiation Plans
Generated from Available Diagnostic CT Images versus
Dedicated CT Simulation for Inpatients
Quoc-Anh Ho, MD1, Lexie Smith-Raymond, MAdm, BS, RT(R)(T),
CMD2, Angela Locke, BS, RT(T), CMD2, Jared Robbins, MD3; 1The
University of Arizona, 2Banner Health, 3The University of Arizona
College of Medicine - Tucson
Background: The morbidity sequelae of advanced cancer are often
irreversible. Early palliative radiation can prevent, delay, and even
improve these consequences. Treatment may be delayed due to a
packed CT (computed tomography) simulation schedule or other
logistics including the cost and burden of arranging ambulance transportation when radiation centers are off-site.
Objectives: The primary objective was to determine the feasibility of
using a recent diagnostic CT scan in lieu of a dedicated simulation CT
to generate an adequate plan without sacriﬁcing dosimetric goals and
subsequent efﬁcacy or tolerability. Secondary objectives included how
much the lesion has grown, and how much earlier treatment could start
if planned on a diagnostic CT scan.
Methods: For each inpatient treated with palliative radiation, a prior
recent diagnostic CT scan was imported into the RayStation (RaySearch
Laboratories, Stockholm, Sweden) planning system. From these diagnostic scans, planning treatment volumes (PTV) and organs at risk
(OAR) were contoured using the same technique as the patient’s actual
treatment. The primary outcome was to compare both the PTV coverage
and OAR dose between the plan generated from the diagnostic CT
compared with that from the simulation CT. Our secondary outcomes
include mean time between CT simulation and ﬁrst treatment, change in
tumor volume between diagnostic scan and CT simulation, and the
hottest 1% of each plan (D1).
Results: Between May and August 2019, a total of 22 inpatients were
treated palliatively. Of those 22 patients, 10 patients (ages 32-92 y,
median 64.5 y, 50% spine ) met study criteria and had a diagnostic CT
scan that was obtained within 14 days of simulation CT that was also
compatible with our planning software. In the plans that were delivered, a mean of 98.8% (range 94.4-100%) of PTV was covered by at
least 95% prescription dose. In the diagnostic CT plans, a mean of
95.4% (range 84.5-100%) of PTV was covered by at least 95% prescription dose. The difference between plans trended towards signiﬁcance (P = 0.061). When looking at patients receiving treatment to
the spine or having a diagnostic CT within 4 days of the simulation CT,
there was no statistically signiﬁcant difference between the two plans
(P = 0.032 and 0.030, respectively). The OARs received on average,
1.4% less mean radiation dose in the hypothetical plans (P = 0.911).
All OAR constraints were met in both groups. The mean time between
diagnostic CT and CT simulation was 5.9 days, and between CT

James Kavanaugh, PhD1, John Ginn, PhD2, Sai Duriseti, MD PhD2,
Thomas Mazur, PhD2, Matthew Spraker, MD, PhD2; 1Washington
University School of Medicine, 2Department of Radiation Oncology,
Washington University School of Medicine in St. Louis
Background: Spatially fractionated radiation therapy (SFRT) delivers
highly heterogeneous dose distributions (100-30% variation) within a
tumor and has been shown to be an effective treatment for large solid
tumors (Amendola, et al Radiation Research 2020, Wu, et al Radiation
Research 2020). Modern SFRT can be delivered with volumetric
modulated radiation therapy (VMAT) via a technique known as Lattice,
in which the internal dosimetric gradients are achieved using optimization structures (high- and low-dose spheres) placed within the
tumor. Standard plan quality metrics used to deﬁne dose to the target are
insufﬁcient in assessing the quality and consistency of the dose distributions of SFRT.
Objectives: This study investigated several potential metrics to quantify the heterogeneous SFRT dose within the gross tumor volume
(GTV) using existing evaluation tools within modern planning
systems.
Methods: Plan quality metrics were assessed using 23 Lattice treatment plans delivered as part of a Phase I clinical trial
(NCT04133415). The periphery of the high-dose spheres received a
prescription of 66.7 Gy and the low-dose spheres and periphery of the
PTV received a prescription of 20 Gy delivered in 5 fractions (Duriseti, et al, Advances in Radiation Oncology, 2021). Metrics included
EUDa = -10, ratio of the mean dose within the high-dose and lowdose spheres (DR), and ratio of the mean and standard deviation dose
within a 1.5cm ring surrounding the high-dose spheres (DR_1.5)
(Fig. 1). For each metric, outliers were deﬁned as individual values
that were above/below the ﬁrst/third quartile by at least 1.5 times the
interquartile range. The plan quality, including dosimetric gradients
within the GTV, for outliers for each metric were compared with the
plan quality of the entire patient cohort to determine if any observable
dosimetric difference existed. Dosimetric proﬁles comparing outlier
cases to non-outlier cases of comparable GTV volume were
evaluated.
Results: Two DR outliers (plan #11 and #12 in Fig. 2) and a single
DR_1.5 outlier (plan #11 in Fig. 2) were identiﬁed, with no outliers
identiﬁed for the EUDa = -10. Dosimetric proﬁles comparing plan #11
(GTVvol = 3714cc) to plan #21 (GTVvol = 3616cc) were taken through
the center of aligned high- and low-dose spheres in the axial plan, with
a representative example shown in Figure 1. The achieved dose gradients within plan #11 visibly broader, with doses > 20 Gy extending
into the low-dose spheres. Both plan #11 and #12 were for the same
patient and represented one of the ﬁrst set of plans from a newly trained
dosimetrist.
Conclusions: The review of three quantiﬁable metrics (EUDa = -10,
DR, and DR_1.5) within 23 Lattice plans indicates that both DR and
DR_1.5 are sensitive to gradient difference within the GTV. These
metrics offer the potential for translation of Lattice planning experience
to include easy-to-quantify metrics as surrogates for consistency in the
achieved GTV dose heterogeneity.
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FIGURE 1. Dose distribution and profile comparison for two lattice cases. Comparison of dose distribution and gradients for outlier case
(patient #11) and similar volume abdominal patient (patient #21). Broader dose gradients in the outlier case correspond to the DR and
DR_1.5cm metrics.

(P166) IMRT Treatment Planning Study for the First
Clinical Biology-guided Radiotherapy System

FIGURE 2. Computed DR and DR_1.5 metrics for 23 patient
population. Ratios for both the DR and DR_1.5 metrics across the
23 patient population. Outliers for both metrics are shown in the
red circles.

Nataliya Kovalchuk, PhD1, Daniel Pham, MS1, Dylan Breitkreutz,
PhD1, Eric Simiele, PhD1, Dante Capaldi, PhD1, Lucas Vitzthum, MD,
MAS2, Daniel Chang, MD3; 1Stanford Radiation Oncology, 2Stanford
University Radiation Oncology, 3Stanford University
Background: The ﬁrst clinical biology-guided radiotherapy (BgRT)
system–ReﬂeXion X1 - is installed and being commissioned for clinical
use at our institution. ReﬂeXion X1 is a 6MV-FFF linac mounted on a
ring gantry rotating at 60 rpm while the couch advances in 2.1mm
increments. The modulation is achieved via 50 ﬁring positions with 64
binary MLCs (6.25mm at 85cm SAD) with either 1cm or 2cm jaws.
Objectives: This study was conducted to compare the treatment plan
quality for IMRT cases without PET-guidance.
Methods: Nineteen patients previously treated with VMAT on C-arm
linacs were selected for this retrospective study including 8 prostate
cancer patients (80 Gy/40fx), 6 lung cancer patients (66 Gy/30fx) and 5
post-surgical parotid cancer patients (60 Gy–66 Gy/30fx). For each
VMAT plan, a corresponding plan was generated on the ReﬂeXion
treatment planning system (TPS) using our institutional planning constraints. All clinically relevant metrics in this study, including plan PTV
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TABLE 1. Comparison of Average Dosimetric Indices for Head and Neck, Lung, and Prostate Cases

Colors signify ReﬂeXion plan superiority (green) or inferiority (red).

D95%, PTV D1%, Conformity Index (CI), and organs at risk constraints were analyzed and compared between the VMAT and
ReﬂeXion plans using paired t-tests.
Results: Clinically acceptable plans were obtained with both techniques. For the prostate, lung, and head and neck sites, no statistically
signiﬁcant difference was observed in PTV D95%, PTV D1%, or CI
between the VMAT and ReﬂeXion treatment plans. Due to inherent
OAR dose penalties in the ReﬂeXion optimizer, dose reduction to
certain critical structures was observed in ReﬂeXion plans: brainstem
Dmax (-4.8 Gy, P < 0.008), contralateral cochlea Dmean (-4.8 Gy,
P < 0.01), lips Dmax (-3.5 Gy, P < 0.007) for head and neck cases;
esophagus Dmean (-2.3 Gy, P < 0.039), spinal cord Dmax (-3.6 Gy,
P < 0.001) for lung cases; femurs left and right Dmax (-4.8 Gy,
P < 0.003 and -5.0 Gy, P < 0.01) and rectum V75% (-1.6%, P < 0.01)
for prostate cases.
Conclusions: The ReﬂeXion TPS provided comparable plan quality to
VMAT plans (Table 1).

(P167) Lower Baseline Apparent Diffusion Coefﬁcient
Values Associated with Poor Prognosis in Locally Advanced
Pancreatic Cancer
Anna Laucis, MD, MPhil1, Yilun Sun, PhD1, Yue Cao, PhD1, Theodore
Lawrence, MD, PhD, FASTRO1, Mahmoud Al-Hawary, MD2, Thomas
Chenevert, PhD2, Kyle Cuneo, MD1; 1University of Michigan
Department of Radiation Oncology, 2University of Michigan Department of Radiology
Background: A challenge in locally advanced pancreatic cancer is the
difﬁculty in obtaining adequate tumor tissue to personalize therapy.
Non-invasive diffusion magnetic resonance imaging (dMRI) has the
potential to tell us about the biology of a tumor and its responsiveness to
therapy. Our prior work found a signiﬁcant association between pretreatment apparent diffusion coefﬁcient (ADC) and pathological
response in patients with resectable pancreatic cancer undergoing preoperative chemoradiation.
Objectives: The goal of the current study was to prospectively investigate the relationship between dMRI characteristics and outcomes after
chemoradiation in locally advanced pancreatic cancer patients.
Methods: Patients with locally advanced pancreatic cancer were
prospectively enrolled onto an IRB-approved clinical trial investigating dMRI characteristics at multiple time points before and
during chemoradiation. Each pancreatic tumor was delineated by two
radiation oncologists on T1-weighted MRI and dMRI images.
Baseline and mid-treatment ADC values were then analyzed and
compared with clinical outcomes including time to local failure
(TTLF), time to distant failure (TTDF), progression free survival
(PFS), and overall survival (OS). Additionally, CA-19-9 values were
obtained for each patient pre-radiation and at four months post-

radiation and compared with clinical outcomes. Univariable Cox
proportional hazard models, Student’s t-tests, and Kaplan Meier
methods were used for statistical analysis.
Results: A total of 23 MRI scans were obtained in nine patients
receiving gemcitabine-based chemoradiation. There were six male
and three female patients, with median age of 64 years (range 52-73).
The median PFS was 18 months and median OS was 25.3 months
from diagnosis for the cohort. Pre-treatment baseline MRIs were
obtained a median of 25 days (range 1–35) before radiation. We
found a signiﬁcant association between lower baseline ADC values
and several clinical outcomes. Speciﬁcally, lower mean baseline
tumor ADC values were associated with lower OS, lower PFS, shorter
TTLF, and shorter TTDF. The difference between baseline and midtreatment ADC values were also found to be signiﬁcantly different
between patients with and without distant failure (Fig. 1, P = 0.049).
In comparison, there was no signiﬁcant relationship between CA-19-9
lab values or mid-treatment ADC with any clinical outcome. Table 1
summarizes the baseline and mid-treatment ADC value results.
Conclusions: Lower baseline tumor ADC values were found to signiﬁcantly correlate with clinical outcomes including worse survival in
locally advanced pancreatic cancer patients. This is concordant with
prior studies showing poor pathological responses in resectable pancreatic cancer patients with lower baseline ADC values. Further
research is needed in a larger cohort of patients to study how this noninvasive imaging biomarker may help with clinical decision-making
and treatment planning.

FIGURE 1. Difference between baseline and mid-radiation (midRT) ADC values were significantly different for patients with and
without distant failure (DF), P = 0.049.
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TABLE 1. Cox Proportional Hazards Model of Mean Pancreatic
Tumor ADC

(P168) A Diode-based 64X64 X-ray Detector for Cancer
Radiotherapy
Mekhail Anwar1, Kyoungtae Lee2, Bruce Faddegon1, Jessica Scholey1,
Kavita Mishra1, Michel Maharbiz2; 1UCSF, 2UC Berkeley
Background: The ability to monitor radiation dose delivered in real time
to the tumor and organs at risk (OAR), is critical for radiotherapy quality
and safety, particularly for targets subject to motion or near critical OARs.
A highly sensitive in vivo microdosimeter (IVµD) implanted within the
tumor and OAR via biopsy needle solves this problem by monitoring and
relaying the dose delivered within the patient in real time. We have
developed a real time millimeter IVµD [1]. We hypothesize that the device
is capable of measuring photons via secondary electrons generated by pair
production and Compton scattering. Here we present the ﬁrst results for
photon detection: the IVµD is capable of counting the number of secondary
electrons generated by x-ray photons with the form factor and power
consumption compatible with in vivo implantation.
Objectives: An IVµD must satisfy the following requirements: 1)
measure and relay dose in real-time, 2) be millimeter scale for
implantation through a core biopsy needle, 3) high sensitivity, and 4)
low power (to minimize battery size or wireless power transfer
requirements). To accomplish these requirements, we exploit CMOS
fabrication technology (i.e. ‘computer chip technology’) that enables
direct integration of complex circuitry with highly sensitive sensing
elements in a small form factor.
Methods: A P-N diode was used to detect the secondary electrons generated from a photon interacting with the silicon. About ⅓ of the energy
deposited in the depletion region creates electron-hole pairs (EHPs), which
are then integrated on a nearby capacitor, transforming to a voltage pulse.
Because the voltage pulse amplitude is inversely proportional to the parasitic capacitance, a nearly minimum size of 1X1µm2 P-type diode was
used to maximize the signal. To readily detect photons while preserving
sensor sensitivity, the diodes are arrayed in a 64X64 structure. Each pixel
has its own amplifying circuit resulting in a total detection area of 512X512
µm2 with the ﬁll factor of 1/64. The duration of the voltage pulse (PW pulse width) is quantized by a 10-bit digital converter, the PW and pixel
location on chip are conveyed off chip. The device was tested under
Siemens Avant-Garde clinical 6 MeV X-ray linear accelerator. The total
radiated dose was 5 Gy with 3 Gy/min dose rate.
Results: At baseline, the ﬂux (0 Gy/min) is 0 counts/sec. At 3 Gy/min,
the response is near instantaneous, and measured ﬂux was 4,097 counts/
seconds/mm2. The standard deviation of the ﬂux when the beam is on is
32.9 counts/sec/mm2.
Conclusions: A new diode based 64X64 X-ray detector was developed
and veriﬁed under the clinical beam setting. We envision that the
proposed work can be used to improve the effectiveness of the cancer
radiotherapies.

(P169) Normal Tissue and Tumor Segmentation Using
V-Net Regularized by YOLO
John Lucas, K:1, Chih-Yang Hsu, PhD1; 1St. Jude Childrens Research
Hospital
Background: Automated tumor segmentation from Fluorodeoxyglucose (18FDG)-positron emission tomography and computed
tomography (18FDG-PET/CT) has the potential to aid diagnosis and
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treatment response evaluation in multiple tumor systems. Manual
delineation is time consuming and subject to human bias. Conventional
segmentation methods are often obscured by radiotracer uptake from
normal tissues, including brain, heart, liver, bilateral kidneys, and
bladder. Speciﬁcally, heart, liver, and kidneys are variably avid on
routine 18FDG-PET examinations, imposing additional challenge for
accurate segmentation.
Objectives: In this work, we propose a semantic segmentation network
based on autoencoder architecture reinforced by an object detection
branch for segmenting normal tissue and tumor from 3D 18FDG-PET/
CT. The autoencoder network consists of symmetrical encoder and
decoder with ResNet blocks and skip connections. The object detection
branch is derived from You only look once (YOLO) -real time object
detection which is added at the end of the encoder. Our hypothesis is
that the object detection branch not only regularizes the network but
also imposes location constraints based on anatomy.

TABLE 1. Encoder and Decoder Structure

The encoder starts with a 1x1x1 convolution and uses ResNet blocks [12]
where each block consists of three convolutions with ReLU activation followed
by identity skip connection. After skip connection, the image dimensions are
downsampled using convolutions with strides of 2 and kernel size 3x3x3. We
repeat the process four times and reach an encoder output size of 8x8x16. All
convolutions are 3x3x3 in kernel size and 32 ﬁlters. Table 1 outlines the encoder
structure. The number of convolutions at each level of the decoder and is thus
symmetrical to the encoder. Each level begins with upsampling by a factor of 2
using transpose convolution followed by concatenation from matching encoder
level. ResNet blocks with three convolutions and ReLU is then applied and the
process is repeated four times. A dropout layer with rate of 0.5 is connected
before the ﬁnal convolution layer of 1x1x1 kernel size for dense inference of eight
classes with softmax activation. Table 2 outlines the encoder structure.
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FIGURE 3. Proposed network structure. The proposed approach utilizes autoencoder based convolutional neural network (CNN)
architecture with a symmetrical encoder and decoder. The object detection branch is added at the end of the encoder.

FIGURE 4. Shows the average F1 score for each class in the validation set throughout training.

Methods: We test our hypothesis in a limited cohort consists of 34
pediatric patients with Hodgkin lymphoma with pre-treatment PET/CT
images. We used F1 score and Hausdorff distance at 95th percentile to
quantify segmentation accuracy and compare the results with established networks.
Results: The proposed method achieved the overall best segmentation
accuracy and improved the average F1 score by 0.19 in normal tissues
and tumor segmentation compared with V-Net. The overall Hausdorff
distance improved by 83% compared with V-Net.
Conclusions: Automatic detection and segmentation of normal tissues
and tumors by combining segmentation and regularization networks
substantially improves the clinical detection and treatment response
evaluation of PET and CT images relative to existing models (Table 1
and Figs. 3, 4).

(P170) Large Random Sporadic Patient-Speciﬁc Stereotaxic
Uncertainties Demand a New Workﬂow for Frame-Based
Intracranial Radiosurgery
LIJUN MA, PhD1, Nam Woo Cho, MD, PhD1, Benjamin Ziemer,
PhD1, Lauren Boreta, MD2, Penny Sneed, MD1, Steve Braunstein, MD,
PhD1; 1UCSF School of Medicine, 2UCSF
Background: Frame-based MR-imaging-only stereotaxy has been the
gold standard for single-fraction intracranial radiosurgery. With advent
of integrated online 3D stereotactic imaging such as voxel-by-voxel

mapped Gamma Knife Icon platform, small patient-speciﬁc uncertainties associated with rigid frame-based MR-imaging-only stereotactic
deﬁnition can now be promptly quantiﬁed before treatment delivery.
Objectives: In this study, we investigated patient-speciﬁc uncertainties
associated with classic rigid metal frame-based MR-imaging-only
stereotactic deﬁnitions speciﬁc to single-fraction stereotactic radiosurgery.
Methods: Pre-treatment phantom-based stereotactic deﬁnition measurements as well as pre-treatment patient-speciﬁc stereotactic deﬁnition
measurements were performed for a randomly sampled patients
undergoing brain radiosurgery (N = 16) treated since 2016 at our
institution, with the most common indication of trigeminal neuralgia,
with voxel-by-voxel stereotactic mapping available with use of a stereotactic CBCT (sCBCT) unit. Independent patient-speciﬁc measurements were performed with sCBCT scans as well as stereotactic serial
CT (ssCT) scans in conjunction with the classic frame-based MRimaging-only stereotactic deﬁnitions. The phantom measurements were
performed via a Elekta grid phantom as previously reported. Pretreatment patient-speciﬁc measurements were performed via comparing
identical MR imaging studies that mapped stereotactic coordinates via
(1) stereotactic localizer box attached to the frame for conventional
stereotactic MR scans with a slice thickness of 0.6 mm to 1.5 mm, (2)
stereotactic localizer box attached to the frame for independent ssCT
scans, and (3) sCBCT scans acquired immediately before the treatment
delivery. For each case, 6-12 anatomical and/or device landmarks were
ﬁrst identiﬁed via auto-segmentation of the same window/level/
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thresholding, and the stereotactic coordinates of these landmarks were
then compared across the different stereotactic deﬁnition methods.
Results: Pre-treatment phantom measurements produced < 0.8 mm
deviations among all three stereotactic deﬁnition methods in agreement
with our previous studies. However, discrepancy among three stereotactic deﬁnitions ranged from 0.2 to 2.5 mm (0.81 ± 0.67 mm) among
patient cases studied. Large shifts > 1.0 mm were predominately
observed in the peripheral brain region and mostly along the longitudinal z-axis. These shifts were random and sporadic acrossMR
scanning sequences, slice thickness, target sizes, isocenter locations,
and the patient head-tilt angles for the setups. Of note, such shifts were
within 1.0 mm when only comparing ssCT and sCBCT based measurements for the studied cases.
Conclusions: Sporadic patient-dependent uncertainties exceeding 2 mm
were observed with conventional frame-based MR-imaging-only stereotactic deﬁnitions. Such a result is alarming and demands further
investigations toward independent validations of stereotaxy, review of
clinical outcomes and possible revision of the workﬂow for the current
frame-based brain radiosurgery.

(P171) GammaKnife Auto-planning Using Artiﬁcial Intelligence: A Preliminary Comparison of ML and DL Treatment Planning Parameters for Vestibular Schwannoma
Lijun, MA, PhD1, Tom Nano, PhD2, Christopher Pang, MSc3, Yannet
Interian, PhD3, Gilmer Valdes, PhD4, Olivier Morin, PhD4; 1UCSF
School of Medicine, 2University of California San Francisco, 3USF,
4
UCSF
Background: Gamma Knife treatment planning is a manual and iterative approach that is tedious, time-consuming and produces highly
variable plans which depends on planner patients and experience.
Consequently, automatic and inverse planning techniques have been
previously developed. However, automatic planning methods are not
clinical implemented due to poor performance. The purpose of this
work is to develop artiﬁcial intelligence models that predict treatment
planning parameters for vestibular schwannoma cases.
Objectives: The objectives of this work are to develop and compare
machine learning (ML) and deep learning (DL) models for predicting
treatment planning parameters (number of shots, shot coordinates, shot
weights and collimator settings) and the dosimetry impact of prediction
errors.
Methods: A total of 223 vestibular schwannoma cases treated on
Leksell Gamma Knife Icon with a frame setup were used to build ML
and DL models. Each case consisted of a single target prescribed to
12.5 Gy to the 50% isodose line. The range of target sizes was 0.7–6.1
cc and the range of shots used were 1–61, varying in weight and collimator settings that were manually planned by three experienced
physicist. MR images, target masks and organs-at-risk masks (cochlea
and brainstem) were used as model inputs. A linear regression ML
model with Lasso regularization was trained on radiomic image features
extracted from MR images multiplied by the target mask. A 3D convolutional neural network (ResNet-34 architecture) was trained on
3-channel inputs containing MR image, target mask and OAR masks.
An 80/20 data split was used for training and testing subsamples and
mean-squared error (MSE) and R2-score was used to evaluate model
predictions.
Results: The ML model has a MSE mean of 53.77 and 31.48 in the
training and test datasets respectively for all treatment planning
parameters predicted. The R2 score in the test dataset was 0.63,
showing a good-ﬁt for our ML regression model. The DL model has a
MSE mean of 0.15 and 75.21 in the training and test datasets respectively for all treatment planning parameters predicted. The R2 score in
the test dataset was 0.42, showing a worst correlation in the DL model
predictions relative to ML predictions.
Conclusions: We have developed ML and DL model for predicting
Gamma Knife treatment planning parameters (number of shots, shot
coordinates, shot weights and collimator settings). Model predictions
from ML are more generalizable to out-of-sample performance than DL
predictions, indicating that ML models are superior than DL for automatic Gamma Knife treatment planning. Vestibular schwannoma cases
were chosen because of their simplicity (single target, average number
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of shots less than 20). We will evaluate the dosimetric impact (target
coverage, gradient index, selectivity, beam-on time) of ML and DL
prediction uncertainties relative to clinical plans. In the future, this
method will be expanded to multi-target lesions.

(P172) Generation of Synthetic X-ray Images Using Deep
Learning for Evaluation of Real-time Tracking
Tom Nano, PhD1, Sicheng Zhou, MSc2, Yannet Interian, PhD2, Gilmer
Valdes, PhD3, Olivier Morin, PhD3, Martina Descovich, PhD2; 1University of California San Francisco, 2USF, 3UCSF
Background: Real-time tracking using projection x-ray images during
stereotactic-body radiation therapy (SBRT) requires accurate identiﬁcation of targets relative to planning computed tomography (CT).
Target localization is highly dependent on co-registration of digitally
reconstructed radiographs (DRRs) that are generated from planning CT.
However, current DRRs do not contain the same ﬁne-detail as projection x-rays and are ultimately limited in tracking accuracy of sharp
edges in ﬁducials and bony-spine anatomy. The purpose of this work is
to develop a deep learning model that generates synthetic x-ray that can
be used to improve real-time tracking accuracy.
Objectives: The objective of this work is to develop a deep learning
model that will convert DRRs into synthetic x-ray images which will be
a more accurate representation of real-time patient x-ray images. The
model will be trained on image-to-image domain transformation (DRR
to x-ray image domains) rather than pixel-to-pixel mapping which will
allow for synthetic x-rays to be generated from multiple treatment sites
(intracranial, lung, abdomen and pelvis).
Methods: DRR-to-x-ray image pairs were extracted from 128 CyberKnife patient treatments of lung cases. For each case, the best coregistered image pair during the entire treatment for each orthogonal
view (camera A and B) were chose for model building from 256 image
pairs as it provides the most stationary case. The "processed DRR" and
“processed x-ray” images as provided by the CyberKnife system (and
used to determine tracking parameters) consisted of a 512 by 512 matrix
for our model input and output respectively. A 2D convolutional neural
network using cycle-consistent generative adversarial networks
(CycleGANs) was trained on 80% of the data and testing on a 20%
hold-out set. All images (synthetic x-rays, real x-rays, and DRRs) were
z-score normalized for fair a comparison removing mean pixel value
and gain variations between image domains. The mean-squared error
(MSE), maximum absolute error MAE) and structural similarity index
metric (SSIM) was used to compare synthetic x-ray accuracy to real
x-ray images.
Results: Mean and standard deviation between DRR and real x-ray
images was 0.23 +/- 0.17, 0.35 +/- 0.14 and 0.96 +/- 0.03 for MSE,
MAE and SSIM respectively. Mean and standard deviation between
CycleGAN synthetic x-ray predictions to real x-ray images was 0.09 +/0.08, 0.13 +/- 0.10 and 0.99 +/- 0.01 for MSE, MAE and SSIM
respectively. CycleGAN synthetic x-rays contain more ﬁne detail at
bone edges, and appear shaper with less blurring, then DRRs which
fundamentally cannot contain this information because they are generated from CT.
Conclusions: We have developed a method of generating synthetic
x-rays using deep learning that are more similar to real-time x-ray
projections than conventional DRRs. Synthetic x-rays that more accurately match with real x-rays provide more accurate real-time tracking.
We will evaluate registration performance with synthetic x-rays and
evaluate synthetic x-ray generation for other treatment sites (intracranial, lung, abdomen and pelvis).

(P173) Prediction of 3D Dose Distribution in Head and Neck
Cancer with Convolutional Neural Network
Simeng Zhu, MD1, Zhenzhen Dai, MS1, Ning (Winston) Ning, PhD,
MBA1; 1Henry Ford Cancer Institute
Background: Intensity-modulated radiation therapy (IMRT) is a commonly used technique for head and neck cancer, but the treatment
planning process can be time-consuming due to the inherent complexity
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of the iterative optimizations. Knowledge-based planning (KBP) has
been proposed as a solution to expedite the process. The currently
commercially available method uses regression-based machine learning
approach to predict dose-volume histograms to drive the optimizer in
the inverse planning.
Objectives: In this study, we aim to show the efﬁcacy of convolutional
neural network in predicting the 3-dimensional (3D) radiation dose
distribution directly as part of KBP in head and neck cancer.
Methods: We obtained the data of 340 patients with head and neck
cancer from a public dataset as part of the 2020 OpenKBP challenge
hosted by the American Association of Physicists in Medicine. The data
for each patient consists of downsampled computed tomography (CT)
images (128 x 128 x 128 voxels, with voxel size of approximately
3.5mm x 3.5mm x 2mm), binary masks for planning target volumes
(prescribed to 70, 63, and 56 Gy) and 7 organs-at-risk (OAR), and the
3D radiation dose distribution delivered by IMRT technique with 9
equispaced coplanar beams. A 3D U-Net with encoder-decoder architecture was used as the model for prediction. The inputs to the model
consisted of the simulation CT image with normalized Hounsﬁeld units,
masks for the PTVs, and a combined mask for the OARs. Based on the
input information, the model predicted a 3D (128 x 128 x 128 voxels)
radiation dose distribution in Gy. Three hundred cases were randomly
selected as the training set, and the rest of 40 patients were used for
testing only. Ten-fold cross validation was used during training, with
mean absolute error (MAE) between the predicted and real doses within
the body as the loss function. Adam was used as the optimizer with a
learning rate of 0.0001. The algorithm was implemented in Python 3.8
with Tensorﬂow 2.2 as the framework. The network training was performed on both Google Colab and NVIDIA Tesla V100 GPU. The
model performance was assessed by comparing the MAE between the
predicted and real dose distributions.
Results: The model was trained for 200 epochs, and model convergence
was conﬁrmed based on the validation loss (MAE < 3.0 Gy for the last
10 epochs). On the independent test set consisting of 40 patients, the
mean MAE for the predicted 3D dose distribution was 2.62 Gy per
voxel (range, 1.00–6.67 Gy), 3.8% of the prescribed dose of 70 Gy.
Conclusions: We showed that, with the CT images and contours of the
PTVs and OARs as input, convolutional neural networks are excellent
at predicting the radiation dose distributions that are similar to clinically
delivered doses.

(P174) Relative Incidence of Emergency Department Visits
After Treatment for Localized Prostate Cancer with Different Modalities of Radiation Therapy or Prostatectomy
Jes Alexander1; 1Department of Radiation Oncology, University of
California, San Francisco
Background: Side effect proﬁles play an important role in treatment
decisions for localized prostate cancer. Many datasources do not
directly capture side effects, but emergency department visits (EDVs)
can be measured in structured electronic health record (EHR) data.
EDVs during or shortly after treatment may be due to side effects or
psychological distress from treatment or comorbidities. There is limited
evidence examining EDVs associated with treatment for prostate
cancer.
Objectives: Determine whether treatment for prostate cancer is associated with EDVs using a self-controlled cohort study (SCCS) to control
for comorbidities within indivdiduals.
Methods: The cohort included patients treated with a single course of
radiation therapy (RT) or radical prostatectomy (RP) for prostate cancer
between 2011 and 2021, who had ≥ 6 months (mo) of lead-up and ≥ 6
mo of follow-up time documented in the EHR surrounding treatment
and ≥ 1 EDV in this period. Relative incidence (RI) of EDVs was
determined using the SCCS R package, which employs a Cox proportional hazards model, with the risk period for EDV events consisting
of the time between start of treatment and 1 month after completion, and
the baseline period consisting of all other time in the lead-up and follow-up periods. Associations with EDV events were analyzed with a
Woolf test for homogeneity followed by a Cochran-Mantel-Haenszel χ2
test or Fisher’s exact test, for patients treated with RT or RP,
respectively.
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Results: Among 211 patients with RP, the median age was 66 years
(range: 42 to 79) and among 179 patients with RT, the median age was
69 years (range: 47 to 87). After adjusting for age and, in the case of
RT, hormone therapy, there were higher rates of EDVs after RP (RI
19.5, 95% conﬁdence interval [CI]: 14.7 to 25.9, P < 0.001) and RT
overall (RI 2.5, 95% CI: 1.8 to 3.5, P < 0.001). There were higher rates
of ED visits for conventionally fractionated (CF) intensity modulated
radiation therapy (IMRT) with high-dose rate brachytherapy (HDR)
boost or stereotactic body radiation therapy (SBRT) boost or for HDR
alone: RI 3.2 (95% CI: 1.6 to 6.4, P = 0.001), RI 6.9 (95% CI: 3.3 to
14.3, P < 0.001), and RI 15.7 (95% CI: 6.9 to 35.5, P < 0.001),
respectively. In contrast, there were not higher rates of EDVs after
SBRT alone, low-dose rate brachytherapy alone or CF or hypofractionated IMRT alone compared with baseline. Genitourinary and gastrointestinal diagnoses were more likely for EDVs in the risk period as
compared with the baseline period for both RT (odds ratio (OR): 4.3,
95% CI: 1.6 to 11.3, P = 0.002) and RP (OR: 3.4, 95% CI: 1.4 to 8.0,
P = 0.004). However, admissions from EDVs were not signiﬁcantly
more likely during the risk period for RT or RP.
Conclusions: The relative rates of EDVs during or within 1 mo of
completion of RT for prostate cancer varies by modalities used, suggesting differing severities of side effects or psychological distress.
These data may aid in selecting treatments for patients.

(P175) Measure What Matters: Total Patients Under
Treatment No Longer a True Indicator of Radiation
Oncology Clinic Patient Volume
Joshua Asper, PA-C1, Travis Corwin2, William Nordwick, RTT,
MBA2, Ruben Mesa, MD2, Timothy Wagner, MD1, Mark Bonnen,
MD2; 1UT Health San Antonio, 2UT Health San Antonio Mays Cancer
Center
Background: In an era deﬁned by measuring what matters Radiation
Departments are still being held to outdated metrics that may or may not
be the best indicators of productivity and revenue. Frequently, total
number of patients under treatment is tracked as the leading indicator
for Radiation Oncology department productivity and revenue. The
popularity of hypofractionated regimens has decreased total number of
patients on treatment even when clinic and planning activities are on
the rise.
Objectives: Our data demonstrates the effects of these shorter courses
of treatment on the traditional metrics used as leading indicators for
productivity and revenue. We will also propose new metrics that our
data suggests more closely tracks both revenue and whole department
productivity.
Methods: Using EPIC EMR we collected service date information for
services rendered during ﬁscal years 2015 to 2020. One ﬁscal year was
deﬁned as the 12 months, September to August. Collected Data
included: total new patients, total treatments, average number of treatments per patient, and total clinical treatment plans (CTP), total charges
(indicated in millions) and total RVU (in thousands). We utilized CTP
to indicate unique patient new starts. The charge master remained
unchanged throughout the years reported. We compared the utilization
of conventional treatment options to SRS treatments with hope to
demonstrate increasing use of higher value treatment options.
Results: The total new patients seen were 1030 (FY15), 1091 (FY16),
1097 (FY17), 1123, (FY18), 1238 (FY19), 1191 (FY20). The total
number of treatments per year were 16358, 18338, 18086, 17021,
18263, 17754 respectively. The total number of CPT (new starts) per
year were 908, 967, 999, 1023, 1120, 1154. Dividing the total treatments delivered by the new starts resulted in the average number of
treatments per patient, 18, 19, 18, 17, 16, 15. Total charges (in millions)
by FY were: 23.5, 27.4, 25.1, 22.2, 27.1, 26.7. Total RVU (in thousands) by FY 41.8, 48.8, 48.8, 46.9, 52.7, 53.4. The total number of
new patients and new starts both continued to rise each year. The ratio
of new patients to new starts were 88, 88, 91, 92, 89, and 86 percent.
When comparing conventional to other short treatment options, the
most dramatic growth was demonstrated in SRS, with total treatments
39, 39, 37, 50, 108, 114 respectively.
Conclusions: Traditional methods of total number of patients under
treatment is no longer the best predictor of volume of work being done.
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Given the current trend of shorter course higher value treatments the
average number of patients on treatment and total treatments no longer
are best indicators of treatment value. We suggest using new treatments
starts as the new indicator as a predictor of value of work being done.
Secondly, we suggest that clinics should follow the ratio of new patients
to new starts to ensure that new patients being seen in clinic result in
new starts. Total patients on treatment at any given point is a measurement of the past.
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TABLE 1. Summary of National Clinical Trials Network Radiotherapy
Randomized Controlled Trials Included in This Analysis

(P176) Proton Therapy at the End of Life: A Retrospective
Review
Mina Bakhtiar, BA1, Anish Butala, MD2, Neil Taunk, MD, MS3, John
Nicholas Lukens, MD3, Joshua Jones, MD, MA3, Ima Paydar, MD4;
1
Perelman School of Medicine, University of Pennsylvania, 2Department of Radiation Oncology, Perelman School of Medicine, University
of Pennsylvania, 3Hospital of the University of Pennsylvania,
4
Department of Radiation Oncology, University of Pennsylvania
Background: Cancer patients often receive proton beam radiotherapy
(PBT) to reduce side-effects and in the re-irradiation setting. A proportion of patients receive radiotherapy near the end of life. The indications for and acute toxicities associated with proton beam therapy
near the end of life are poorly understood.
Objectives: To identify the characteristics, treatment indications, and
acute toxicities among patients who received PBT in the ﬁnal year of
life at a tertiary academic medical center.
Methods: A retrospective review of 175 patients treated with PBT
within the last year of life was performed. Electronic medical records
were reviewed for patient and treatment details. Follow-up was calculated from start of PBT until death. Acute (< 3 mo) and chronic
( > 3 mo) toxicities were graded using the CTCAE v5.0. Simple logistic
regression was used to evaluate factors associated with acute toxicity
and grade (G) 3 or 4 toxicity.
Results: Mean age was 66 years (19-94 y), with 57% male and 43%
female patients. The most common cancers were non-small cell lung
cancer (31%), hepatocellular carcinoma (13%), and small cell lung
cancer (7%). Concurrent systemic therapy was delivered to 47%.
Median dose was 4988 cGy (180-7388 cGy), with 38% receiving <
50 Gy. Mean treatment time was 38 days (1-189 d). Median time from
ﬁrst fraction to death was 185 days (1-363 d). On average, patients spent
27% of the remaining days of life receiving PBT. The most common
indications were LC (67%) and pain (24%), along with other clinical
symptoms including bleeding and dysphagia (9%). Forty-six percent
received PBT for reirradiation. Of 56 patients treated for symptoms,
69%, 27%, and 4% had partial/complete resolution, stable symptoms, or
progression of symptoms. Acute toxicity of any grade was noted in 87%
of patients (55% G1, 39% G2, 6% G3). The G3 toxicities included
dyspnea, fatigue, and dermatitis. Seven patients (4%) experienced
chronic toxicity; the most severe was a tracheo-esophageal ﬁstula (G4).
Among patients who received PBT for re-irradiation, 6 patients (8%)
experienced acute and 1 patient (< 1%) experienced chronic G3 or
greater toxicity. In the simple logistic regression model, higher dose
was positively associated with concurrent systemic therapy (B = 0.026,
P = 0.025). Higher dose was also positively associated with any grade
acute toxicity (B = 0.09, P < 0.001). No patient or treatment factors
were associated with > G3 toxicity.
Conclusions: Patients receiving PBT at the end of life have high rates
of symptom control. However, some patients spend a large portion of
their remaining days on treatment. Also, toxicities are moderate and
associated with higher dose. Therefore, further research is needed to
identify the best candidates for PBT at the end of life.

CNS indicates central nervous system; PRO, patient-reported outcome.

Background: The use of patient-reported outcomes (PROs) in
randomized clinical trials (RCTs) improves the sensitivity of adverse
event detection and enhances the appreciation of patient quality of
life concerns. However, PRO data collection is often incomplete—
for reasons varying from logistical obstacles to patient death, exit
from trials, and refusal—and the statistical analysis of these
incomplete data sets so as to minimize bias and maintain conclusion
integrity imposes a formidable challenge to trialists (Chowdhry et al,
Int. J. Radiat. Oncol. Biol. Phys., 2021). The Setting International
Standards in Analyzing Patient-Reported Outcomes and Quality of
Life Endpoints Data Consortium (SISAQOL) was formed to establish PRO analysis recommendations, including guidance for anticipating and addressing missing PRO data (Coens, et al, Lancet
Oncol., 2020).

TABLE 2. Summary of Relevant Patient-reported Outcome (PRO)
Data Analysis Recommended Statements Established by Setting
International Standards in Analyzing Patient-Reported Outcomes
and Quality of Life Endpoints Data Consortium (SISAQOL) and a
Survey of These Features in the Trial Set Analyzed in This Work
(Coens, et al, Lancet Oncol., 2020)

(P177) Analysis of Approaches to Missing Patient-Reported
Data in Radiotherapy Trials
Jackson Howell1, Jordan Kharofa, MD2, Christopher Anker, MD3;
1
University of Cincinnati College of Medicine, 2University of Cincinnati
College of Medicine, Department of Radiation Oncology, 3University of
Vermont Larner College of Medicine, Division of Radiation Oncology
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Objectives: Survey recently completed radiotherapy (RT) RCTs
that utilized PROs to evaluate how they approached the challenge
of missing PRO data and compare their methods to SISAQOL recommendations to identify speciﬁc areas for improvement in future
trials.
Methods: In prior work, a survey of all RT RCTs initiated by the
National Cancer Institute’s National Clinical Trials Network organizations between 2000 and 2020 was performed (Howell et al, Int. J.
Radiat. Oncol. Biol. Phys., 2021). Trial protocols were acquired from
the Cancer Trial Support Unit, and published manuscripts presenting
the trials’ data were collected. Only completed trials from this set that
published PRO data in manuscript form were considered. The protocols
and manuscripts produced by these trials were carefully examined, with
the data analysis methods and presentation of results compared with the
SISAQOL recommendations for the assessment of missing PRO data
(Coens, et al, Lancet Oncol., 2020).
Results: Twelve trials met these criteria (Table 1), and evaluation
objectives are summarized in Table 2. Only 75% speciﬁed a clear
strategy for addressing missing PRO data in the protocol, and 78% of
those trials adhered to the a priori strategy. Saliently, 67% of trials
analyzed recorded reasons for incomplete PRO data collection, which is
important when designing imputation methods for estimating missing
data. Importantly, 67% of trials at least partially incorporated a listwise
deletion strategy into their PRO data analysis, which can weaken the
analysis.
Conclusions: Areas for improvement in planning future RCTs
include increasing speciﬁcity of and adherence to a priori strategies
for analyzing PRO data, collecting reasons for missing data, and
utilizing data imputations methods, rather than listwise deletion
methods, when missing data arises. These methods will improve the
quality of PRO data analysis by utilizing the maximum amount of
collected data and decreasing the role of assumptions regarding
missing data.

(P178) The Impact of the Clinical and Translational
Research Infrasturcture Network (CTR-IN) Program on
Oncology Research in the Mountain West (MW) Region
Parvesh Kumar, MD1, Chad Cross, Associate Professor1, tony Ward,
Professor2, Curtis Noonan, Professor2; 1University of Nevada Las
Vegas, 2University of Montana
Background: The MW CTR-IN grant is a U-54 Institutional Development Award (IDeA) funded by the NIH / NIGMS to increase and
enhance research capacity. The CTR-IN Program (ctrin.unlv.edu) is
only one of 12 clinical and translational research centers funded by
NIGMS in the US. The CTR-IN involves a partnership with the 13
major public universities in the MW region (i.e., Nevada, New Mexico,
Wyoming, Montana, Idaho, Alaska and Hawaii) that covers 1/3rd of the
US land mass and almost 1/3rd of all IDeA states. Of the 13 CTR-IN
partner public universities, only 4 have schools of medicine (SOM). To
increase and enhance research capacity, the CTR-IN Program initiated a
pilot grant (PG) program for eligible research faculty of the 13 MW
University partners in 2013 that is now in its 8th year with a very
successful track record of producing independent extramural grant
funding.
Objectives: We conducted a retrospective review of our CTR-IN PGs
to determine their impact on oncology research in the Mountain West
region. All of our PGs undergo a rigorous “NIH-like” review process
and our funding percentile is typically in the 25th - 30% range. The
typical funding range for our PGs is usually $60 - $66k each with a
duration of one year.
Methods: During the initial grant cycle (2013 - 2017), a total of 83 PGs
were funded for approximately $60 - $66k each in many different areas
including cancer. Eight (9.6%) of the 83 PGs had a cancer focus. We
analyzed and compared various major outcome metrics such as the
Journal Impact Factor (JIF) of the published manuscripts, the Extramural Grant Funding (EMGF) and Return on Investment (ROI = total
EMGF amount/total awarded PG amount x 100%) for the cancer
focused PGs (n = 8) vs. the non-cancer PG awards (n = 75). Exact
comparisons of the means of the major outcomes (i.e., JIF, EMGF,
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ROI) between the cancer focused PGs vs. the non-cancer PGs were
conducted.
Results: Of the 8 pilot grants funded in cancer research, only 2 were
funded for faculty at a SOM while the others were funded at other
schools (i.e., Biological Sciences, Allied Health, Social Work,
Nursing and Computer/Mathematical Sciences) at our 13 partner
universities. The major outcomes for the cancer focused PGs vs. the
non-cancer focused PGs were as follows, respectively: (1) Mean
JIF = 3.94 (SD = 4.83) for 24 publications for the cancer focused PGs
vs. Mean JIF = 3.05 (SD = 1.69) for 126 publications for the noncancer focused PGs, P = 0.102; (2) Mean Amount of EMGF =
$1,255,913 (SD = $294,931) for a total EMGF amount of
$2,511,826 involving 4 grants (all from faculty at non-SOM Universities) vs. Mean Amount of EMGF = $2,317,870 (SD =
$3,669,986) for a total EMGF amount of $46,358,174 involving 43
grants, P = 0.765; (3) ROI was 2,002% (SD = 792%) vs. 3,644 %
(SD = 6,643%), P = 0.789.
Conclusions: Despite not having medical schools at majority of our
13 partner institutions, our comparative analysis of major scholarship
outcomes (i.e., JIF, EMGF and ROI) reveals that our cancer focused
PG awardees were just as successful as our non-cancer focused PG
awardees. The MW CTR-IN Program has been instrumental in
seeding a culture of investigator initiated clinical and translational
research through its pilot grant program including oncology research
despite the sparsity of medical schools in the MW region.

(P179) Radiotherapy Patients’ Procedural Stress and Anxiety:
A National Survey Study of Radiation Therapists’ Experience
in Daily Treatment
Nina Mayr, MD1, Daniel Hippe, MS2, Dean Baraba, RTT2, Simon Lo,
MB, ChB, FACR, FASTRO2, Jamie Bartalamay, MBA, RTT2, William
Yuh, MD, MSEE2, Kai Borm, MD3, Stephanie Combs, MD3, Alexandra Chadderdon, Psy D4; 1Nina A. Mayr, 2University of Washington,
3
Technische Universitaet Muenchen, 4University of Colorado
Background: Patients’ anxiety and stress towards radiation therapy
have been well recognized. However, little is known about their effects
on daily treatment delivery/workﬂow and about anxiety management in
the radiotherapy environment.
Objectives: We sought to assess prevalence, impact and management of
patient anxiety/stress in external radiotherapy from the perspective of
the radiation therapists (RTTs) who have the closest daily interactions
with patients.
Methods: A national survey of RTTs was conducted to collect their
experiences regarding prevalence and perceived importance of patients’
anxiety/stress, impact on their daily workﬂows, approaches to evaluation and management, and responsibilities for anxiety management in
radiotherapy patients.
Results: Among 739 responders, the importance of managing radiotherapy-associated patient anxiety/stress in the RTT’s practice was
judged as high by 97% (extremely important: 61%; very important:
36%). Anxiety-related interferences were reported by 89% for conventional and by 87% for advanced/complex (SBRT/IGRT/breathhold)
radiotherapy procedures. Interferences consisted predominately of
delays in fraction completion, need for re-imaging, patients’ inability to
cooperate and increased pain. Anxiety was assessed most commonly
through unstructured verbal discussion (82%). Assessment was most
commonly performed by nurses (83%), followed by RTT’s and radiation oncologists. The majority reported that RTTs carried the most
responsibility for anxiety management in their clinics. Management was
variable. Methodically unstructured measures including empathic
attention and patient education prevailed (Fig. 1). Requests for pharmacological anxiolytic therapy were common (72%), while most integrative health approaches, with the exception of breathing exercises,
were rare.
Conclusions: Patients’ procedural anxiety/stress has profound impact
on daily external radiotherapy delivery and workﬂows. Anxiety management varies widely and relies heavily on RTTs. Integrative health
approaches that are used in radiology and other medical procedures
appear underrepresented. Our observations may help inform strategies
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FIGURE 1. Method(s) used to manage radiation oncology patients’ procedural anxiety. Methods for the management of patient anxiety
used by responders are shown in descending frequency. Multiple choices were permitted.

to advance patient anxiety management within the radiation oncology
care team, decrease its interfering effects on radiotherapy delivery, and
improve patient experience.

(P180) Dosimetric Parameters Associated with Long-Term
Patient-Reported Quality of Life Following Deﬁnitive
Chemoradiation for Anal Cancer
Michael Rooney, MD1, Brian De, MD1, Kelsey Corrigan, MD, MPD1,
Graciela Nogueras Gonzalez, MS1, Prajnan Das, MD, MS, MPH2,
Cullen Taniguchi, MD, PhD2, Grace Smith, MD MPH1, Bruce Minsky,
MD1, Albert Koong, MD, PhD1, Eugene Koay, MD PhD2, Ethan
Ludmir, MD1, Craig Messick, MD1, Nancy You, MD MHSc1, George
Change, MD1, Ouida Westney, MD1, Van Morris, MD1, Emma Holliday, MD1; 1MD Anderson Cancer Center, 2MD Anderson
Background: Data describing long-term patient-reported outcomes
(PROs) following intensity-modulated radiation therapy (IMRT)-based
chemoradiation (CRT) for the treatment of squamous cell carcinoma of
the anus (SCCA) remain scarce.1 Furthermore, clinical and dosimetric
risk factors associated with adverse PROs are unknown.
Objectives: To identify dosimetric parameters which may be associated
with patient-reported quality of life after treatment with chemoradiation
for SCCA.
Methods: We identiﬁed 248 patients with SCCA treated at our institution from 2010-2018 who were alive and without recurrence. We
requested that all patients complete ﬁve validated PRO instruments:
Fecal Incontinence QOLScale (FIQOL), Low Anterior Resection Syndrome Score (LARS), International Consultation on Incontinence
Questionnaire (ICIQ) male and female lower urinary tract symptoms
(MLUTS and FLUTS, respectively), International Index of Erectile
Function (IIEF), and Female Sexual Function Index (FSFI). For those
completing surveys, we retrospectively segmented pelvic organs at risk

using published atlases and calculated prespeciﬁed dosimetric parameters (anal PTV D1, bowel bag V30(cc)/V35/V40/V45/D1, small bowel
V30(cc)/V35/V40/V45/D1, bladder V40(%)/V45/V50, vagina V40
(%)/V45/V50/mean dose(Gy), external genitalia V30/V20, penile bulb
mean dose, and prostate mean dose) using approved treatment plans.
After selecting factors with intuitive potential causal relations with
PROs and those with association on univariate analysis (P <0.05), we
generated multiple regression models to identify factors independently
associated with PROs.
Results: One-hundred eight (44%) patients completed surveys. Eighty
percent of respondents were female, mean (standard deviation) age was
60 (8.9) years, and 23% had T3/T4 disease. Mean bowel bag D1 was
49.9 Gy (3.3), and mean small bowel D1 was 48.1 Gy (4.6). Average
vaginal mean dose was 47.0 Gy (6.3), average penile bulb mean dose
was 49.2 Gy (7.1), and average prostate mean dose was 49.3 Gy (6.5).
Median [IQR] time from CRT to the completion of the PRO survey was
51 [37-84] months. Multiple regression modeling revealed that
increasing bowel bag D1 was signiﬁcantly associated with lower
FIQOL score (P = 0.001) and higher LARS score (P = 0.003), both
signifying worse bowel function. Higher bladder V40 was associated
with increased ICIQ score (P = 0.001), indicating worse urinary
function. Increasing vaginal V40 was associated with lower FSFI
(P = 0.011), correlating with worse sexual function. There were no
signiﬁcant dosimetric relationships detected with IIEF or PROMIS
scores.
Conclusions: Multiple dosimetric parameters are associated with
patient-reported quality of life across multiple symptomatic domains
following receipt of IMRT-based chemoradiation for the treatment of
SCCA. Minimizing hotspots in the bowel as well as V40 of the bladder
and vagina may improve long-term bowel, urinary and sexual function
for patients undergoing deﬁnitive chemoradiation. The dosimetric
parameters from this study could potentially be used to develop radiotherapy planning constraints that optimize patient reported quality
of life.
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